

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 9
SEPTEMBER 2016**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2016

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Cumulative Supplement 9

September 2016

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	viii
1.5 Availability of the Edition	ix
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend	x
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

**CUMULATIVE SUPPLEMENT 09
September 2016**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 36th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

BD RX INC
(BD RX)

FRESENIUS KABI USA LLC
(FRESENIUS KABI USA)

CITRON PHARMA LLC
(CITRON PHARMA LLC)

CASPER PHARMA LLC
(CASPER PHARMA LLC)

PROSAM LABS LLC
(PROSAM LABS)

OXFORD PHARMACEUTICALS LLC
(OXFORD PHARMS)

HIKMA MAPLE LTD
(HIKMA MAPLE)

EUROHEALTH INTERNATIONAL SARL
(EUROHLTH INTL SARL)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2015</u>	<u>MAR 2016</u>	<u>JUN 2016</u>	<u>SEP 2016</u>	<u>DEC 2016</u>
DRUG PRODUCTS	17151	17251	17528	17765	
LISTED SINGLE	2664	2693	2664	2665	
SOURCE	(15.5%)	(15.6%)	(15.2%)	(15%)	
MULTISOURCE	14487	14558	14864	15100	
	(84.5%)	(84.4%)	(84.8%)	(85%)	
THERAPEUTICALLY	14366	14434	14731	14968	
EQUIVALENT	(83.8%)	(83.7%)	(84%)	(84.3%)	
NOT THERAPEUTICALLY	121	124	133	132	
EQUIVALENT	(0.7%)	(0.7%)	(0.8%)	(0.7%)	
EXCEPTIONS ¹	73	73	73	73	
	(0.4%)	(0.4%)	(0.4%)	(0.4%)	
NEW MOLECULAR	28	9	20	8	
ENTITIES APPROVED					
NUMBER OF	1011	1007	1023	1027	
APPLICANTS					

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action.

The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ABACAVIR SULFATE

		SOLUTION;ORAL					
>A>		ABACAVIR SULFATE					
>A>	AA	HETERO LABS LTD III	EQ 20MG BASE/ML	A201107	001	Sep 26, 2016	Sep NEWA
		ZIAGEN					
>D>	+	VIIV HLTHCARE	EQ 20MG BASE/ML	N020978	001	Dec 17, 1998	Sep CFTG
>A>	AA	+	EQ 20MG BASE/ML	N020978	001	Dec 17, 1998	Sep CFTG

ABACAVIR SULFATE; LAMIVUDINE

		TABLET;ORAL					
>A>		ABACAVIR SULFATE AND LAMIVUDINE					
>A>	AB	TEVA PHARMS USA	EQ 600MG BASE;300MG	A079246	001	Sep 29, 2016	Sep NEWA
		EPZICOM					
>D>	+	VIIV HLTHCARE	EQ 600MG BASE;300MG	N021652	001	Aug 02, 2004	Sep CFTG
>A>	AB	+	EQ 600MG BASE;300MG	N021652	001	Aug 02, 2004	Sep CFTG

ACAMPROSATE CALCIUM

		TABLET, DELAYED RELEASE;ORAL						
		ACAMPROSATE CALCIUM						
	AB	+	GLENMARK GENERICS	333MG	A202229	001	Jul 16, 2013	May CRLD

ACETAMINOPHEN

		SOLUTION;IV (INFUSION)					
		ACETAMINOPHEN					
AP		PADDOCK LLC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	May NEWA
AP		SANDOZ INC	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Mar NEWA
		OFIRMEV					
AP	+	MALLINCKRODT IP	1GM/100ML (10MG/ML)	N022450	001	Nov 02, 2010	Mar CFTG

ACETAMINOPHEN; BUTALBITAL

		TABLET;ORAL					
		BUTALBITAL AND ACETAMINOPHEN					
AA		CNTY LINE PHARMS	325MG;50MG	A205120	001	Oct 30, 2015	Aug CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

		CAPSULE;ORAL					
		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
	+	MAYNE PHARMA INC	325MG;50MG;40MG	A089007	001	Mar 17, 1986	Aug CAHN
	+	METRIC	325MG;50MG;40MG	A089007	001	Mar 17, 1986	Jun CAHN
		TABLET;ORAL					
		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
	@	INGENUS PHARMS NJ	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Jan CAHN
	@	SUN PHARM INDS	325MG;50MG;40MG	A040601	001	Jul 29, 2005	Jan CAHN
		FIORICET					
AA		ACTAVIS LABS UT INC	325MG;50MG;40MG	A088616	001	Nov 09, 1984	May CMFD

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

		CAPSULE;ORAL					
		FIORICET W/ CODEINE					
AB	+	ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N020232	001	Jul 30, 1992	Jul CAHN
AB	+	ALLERGAN SALES LLC	325MG;50MG;40MG;30MG	N020232	001	Jul 30, 1992	Apr CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

		TABLET;ORAL					
>A>		ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE					
>A>		LARKEN LABS INC	325MG;30MG;16MG	A204209	001	Sep 30, 2016	Sep NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

		TABLET;ORAL					
		ACETAMINOPHEN AND CODEINE PHOSPHATE					
>A>	@	FRONTIDA BIOPHARM	300MG;15MG	A089671	001	Feb 10, 1988	Sep CAHN
>A>	@		300MG;30MG	A089672	001	Feb 10, 1988	Sep CAHN
	@		300MG;60MG	A089673	001	Feb 10, 1988	Jul CAHN
>D>	@	MUTUAL PHARM	300MG;15MG	A089671	001	Feb 10, 1988	Sep CAHN
>D>	@		300MG;30MG	A089672	001	Feb 10, 1988	Sep CAHN
	@	SUN PHARM INDS	300MG;60MG	A089673	001	Feb 10, 1988	Mar CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

ZYFREL

AA	CYPRESS PHARM INC	325MG/15ML; 7.5MG/15ML	A090468	001	Apr 14, 2016	Apr	NEWA
----	-------------------	------------------------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	ACTAVIS LABS FL INC	300MG; 5MG	A206470	001	Jun 02, 2016	May	NEWA
AA		300MG; 7.5MG	A206470	002	Jun 02, 2016	May	NEWA
AA		300MG; 10MG	A206470	003	Jun 02, 2016	May	NEWA
	@ ALLERGAN SALES LLC	500MG; 10MG	A040148	002	Feb 14, 1997	Jun	CAHN
AA	AMNEAL PHARMS NY	325MG; 7.5MG	A040746	002	May 10, 2016	Apr	NEWA
AA	LARKEN LABS INC	325MG; 5MG	A202935	002	Jun 15, 2016	Jun	NEWA
AA		325MG; 7.5MG	A202935	003	Jun 15, 2016	Jun	NEWA
AA		325MG; 10MG	A202935	004	Jun 15, 2016	Jun	NEWA
AA	PAR PHARM	300MG; 5MG	A205001	001	Jul 05, 2016	Jun	NEWA
AA		300MG; 7.5MG	A205001	002	Jul 05, 2016	Jun	NEWA
AA		300MG; 10MG	A205001	003	Jul 05, 2016	Jun	NEWA
AA	RHODES PHARMS	325MG; 5MG	A202991	001	Apr 12, 2016	Mar	NEWA
AA		325MG; 7.5MG	A202991	002	Apr 12, 2016	Mar	NEWA
AA		325MG; 10MG	A202991	003	Apr 12, 2016	Mar	NEWA
AA	TRIS PHARMA INC	300MG; 5MG	A202214	004	Mar 15, 2016	Jun	NEWA
AA		300MG; 7.5MG	A202214	005	Mar 15, 2016	Jun	NEWA
AA		300MG; 10MG	A202214	006	Mar 15, 2016	Jun	NEWA

NORCO

AA	ALLERGAN SALES LLC	325MG; 2.5MG	A040148	004	Jul 07, 2014	Jun	CAHN
AA	+	325MG; 5MG	A040099	001	Jun 25, 1997	Jun	CAHN
AA		325MG; 5MG	A040148	005	Jul 07, 2014	Jun	CAHN
AA	+	325MG; 7.5MG	A040148	003	Sep 12, 2000	Jun	CAHN
AA	+	325MG; 10MG	A040148	001	Feb 14, 1997	Jun	CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	+	MALLINCKRODT INC	325MG/5ML; 5MG/5ML	A040680	001	Sep 29, 2006	Aug	CRLD
AA			325MG/5ML; 5MG/5ML	A040680	001	Sep 29, 2006	May	CMFD

ROXICET

@ ROXANE

325MG/5ML; 5MG/5ML

A089351	001	Dec 03, 1986	Aug	DISC
---------	-----	--------------	-----	------

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ALVOGEN MALTA	325MG; 5MG	A202677	003	Mar 08, 2016	Feb	NEWA
AA		325MG; 7.5MG	A202677	001	Jul 26, 2012	Jan	CAHN
AA		325MG; 10MG	A202677	002	Jul 26, 2012	Jan	CAHN
AA	AMNEAL PHARMS NY	325MG; 7.5MG	A040778	002	Jun 27, 2014	Apr	NEWA
AA	MAYNE PHARMA INC	325MG; 2.5MG	A090177	001	Oct 20, 2008	Feb	CAHN
AA		325MG; 5MG	A090177	002	Oct 20, 2008	Feb	CAHN
AA		325MG; 7.5MG	A090177	003	Oct 20, 2008	Feb	CAHN
AA		325MG; 10MG	A090177	004	Oct 20, 2008	Feb	CAHN
	@	500MG; 7.5MG	A090177	005	Oct 20, 2008	Feb	CAHN
	@	650MG; 10MG	A090177	006	Oct 20, 2008	Feb	CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	ATLAS PHARMS LLC	325MG; 37.5MG	A202076	001	Mar 30, 2012	May	CAHN
----	------------------	---------------	---------	-----	--------------	-----	------

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

AB	NOSTRUM LABS INC	500MG	A204691	001	Mar 29, 2016	Mar	NEWA	
>A>	AB	NOVAST LABS LTD	500MG	A203434	001	Sep 30, 2016	Sep	NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

>D>	AP	EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A040089	001	Feb 28, 1995	Sep	CAHN
>A>	AP	WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A040089	001	Feb 28, 1995	Sep	CAHN

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS
ACETYLCYSTEINE

AP	AUROBINDO PHARMA LTD	6GM/30ML (200MG/ML)	A207358	001	Feb 29, 2016	Feb NEWA
>A> AP	FRESENIUS KABI USA	6GM/30ML (200MG/ML)	A200644	001	Nov 07, 2012	Sep CAHN
>D> AP	INNOPHARMA LICENSING	6GM/30ML (200MG/ML)	A200644	001	Nov 07, 2012	Sep CAHN

TABLET, EFFERVESCENT;ORAL
CETYLEV

ARBOR PHARMS LLC

500MG

N207916 001 Jan 29, 2016 Jan NEWA

+

2.5GM

N207916 002 Jan 29, 2016 Jan NEWA

ACITRETIN

CAPSULE;ORAL

ACITRETIN

AB IMPAX LABS INC

10MG

A202552 001 Dec 23, 2015 Aug CAHN

AB

17.5MG

A202552 002 Dec 23, 2015 Aug CAHN

AB

22.5MG

A202552 003 Dec 23, 2015 Aug CAHN

AB

25MG

A202552 004 Dec 23, 2015 Aug CAHN

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

SEMPREX-D

+ AUXILIUM PHARMS INC

8MG; 60MG

N019806 001 Mar 25, 1994 Mar CAHN

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

@ RANBAXY

200MG

A074975 001 Sep 30, 1998 Feb DISC

AB

ZYDUS PHARMS USA INC

200MG

A204313 001 Mar 25, 2016 Mar NEWA

OINTMENT;TOPICAL

ACYCLOVIR

AB

FOUGERA PHARMS INC

5%

A206633 001 May 11, 2016 Apr NEWA

TABLET;BUCCAL

SITAVIG

+ CIPHER PHARMS US

50MG

N203791 001 Apr 12, 2013 Jan CAHN

TABLET;ORAL

ACYCLOVIR

@ SUN PHARM INDS LTD

400MG

A074980 001 Sep 30, 1998 Feb DISC

@

800MG

A074980 002 Sep 30, 1998 Feb DISC

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

@ AMPHASTAR PHARMS INC

EQ 500MG BASE/VIAL

A074596 002 Apr 22, 1997 Jun CAHN

@

EQ 1GM BASE/VIAL

A074596 001 Apr 22, 1997 Jun CAHN

@ BEDFORD

EQ 500MG BASE/VIAL

A074596 002 Apr 22, 1997 Feb DISC

@

EQ 1GM BASE/VIAL

A074596 001 Apr 22, 1997 Feb DISC

AP

+

EQ 1GM BASE/VIAL

A074596 001 Apr 22, 1997 Feb CTEC

@ EUROHLTH INTL SARL

EQ 500MG BASE/VIAL

A074596 002 Apr 22, 1997 Apr CAHN

@

EQ 1GM BASE/VIAL

A074596 001 Apr 22, 1997 Apr CAHN

AP

HIKMA PHARMS LLC

EQ 500MG BASE/VIAL

A205771 001 Feb 29, 2016 Feb NEWA

+

EQ 1GM BASE/VIAL

A205771 002 Feb 29, 2016 Feb CRLD

AP

EQ 1GM BASE/VIAL

A205771 002 Feb 29, 2016 Feb NEWA

ADAPALENE

GEL;TOPICAL

ADAPALENE

AB

TARO

0.3%

A208322 001 Jun 23, 2016 Jun NEWA

SOLUTION;TOPICAL

ADAPALENE

>A> AB

CALL INC

0.1%

A203981 001 Sep 23, 2016 Sep NEWA

>D>

+

0.1%

A204593 001 Jan 05, 2016 Sep CTEC

>A> AB

+

0.1%

A204593 001 Jan 05, 2016 Sep CTEC

ADENOSINE

INJECTABLE;INJECTION

ADENOSINE

AP

EUROHLTH INTL SARL

3MG/ML

A076404 001 Jun 16, 2004 Apr CAHN

SOLUTION; IV (INFUSION)									
ADENOSINE									
AP	+	TEVA PHARMS USA	60MG/20ML (3MG/ML)	A077425	001	Aug 29, 2013	Apr	CRLD	
AP	+		90MG/30ML (3MG/ML)	A077425	002	Aug 29, 2013	Apr	CRLD	
<u>ALBUTEROL SULFATE</u>									
SOLUTION; INHALATION									
ALBUTEROL SULFATE									
AN	+	@ HI TECH PHARMA	EQ 0.083% BASE	A075063	001	Feb 09, 1999	Mar	DISC	
		@ LANDELA PHARM	EQ 0.083% BASE	A077569	001	Apr 04, 2006	Mar	DISC	
		NEPHRON	EQ 0.083% BASE	A074880	001	Sep 17, 1997	Mar	CRLD	
		@ TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999	Mar	DISC	
		@ WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003	Mar	DISC	
TABLET; ORAL									
ALBUTEROL SULFATE									
AB		SUN PHARM INDS	EQ 2MG BASE	A072637	002	Dec 05, 1989	Mar	CAHN	
AB			EQ 4MG BASE	A072637	001	Dec 05, 1989	Mar	CAHN	
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE</u>									
SOLUTION; INHALATION									
DUONEB									
		@ MYLAN SPECLT	EQ 0.083% BASE; 0.017%	N020950	001	Mar 21, 2001	Jun	DISC	
<u>ALENDRONATE SODIUM</u>									
SOLUTION; ORAL									
ALENDRONATE SODIUM									
	+	ROXANE	EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013	Aug	CRLD	
		FOSAMAX							
		@ MERCK	EQ 70MG BASE/75ML	N021575	001	Sep 17, 2003	Aug	DISC	
TABLET; ORAL									
ALENDRONATE SODIUM									
AB		IMPAX LABS INC	EQ 5MG BASE	A075710	001	Feb 06, 2008	Aug	CAHN	
AB			EQ 10MG BASE	A075710	002	Feb 06, 2008	Aug	CAHN	
AB			EQ 35MG BASE	A075710	003	Feb 06, 2008	Aug	CAHN	
AB			EQ 40MG BASE	A075710	004	Feb 06, 2008	Aug	CAHN	
AB			EQ 70MG BASE	A075710	005	Feb 06, 2008	Aug	CAHN	
AB		JUBILANT CADISTA	EQ 5MG BASE	A090557	001	Feb 18, 2010	Jun	CAHN	
AB			EQ 10MG BASE	A090557	002	Feb 18, 2010	Jun	CAHN	
AB			EQ 35MG BASE	A090557	003	Feb 18, 2010	Jun	CAHN	
AB			EQ 70MG BASE	A090557	004	Feb 18, 2010	Jun	CAHN	
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL</u>									
TABLET; ORAL									
FOSAMAX PLUS D									
		MERCK	EQ 70MG BASE; 2,800 IU	N021762	001	Apr 07, 2005	Aug	CMFD	
	+		EQ 70MG BASE; 5,600 IU	N021762	002	Apr 26, 2007	Aug	CMFD	
<u>ALFUZOSIN HYDROCHLORIDE</u>									
TABLET, EXTENDED RELEASE; ORAL									
ALFUZOSIN HYDROCHLORIDE									
AB		UNICHEM LABS LTD	10MG	A203192	001	Jan 28, 2016	Jan	NEWA	
<u>ALLOPURINOL</u>									
TABLET; ORAL									
ALLOPURINOL									
AB		INDOCO REMEDIES	100MG	A204467	001	Jul 28, 2016	Jul	NEWA	
AB			300MG	A204467	002	Jul 28, 2016	Jul	NEWA	
AB		SUN PHARM INDS	300MG	A071450	001	Jan 09, 1987	Mar	CAHN	
ZYLOPRIM									
AB		SEBELA IRELAND LTD	100MG	N016084	001		Jan	CAHN	
AB	+		300MG	N016084	002		Jan	CAHN	
<u>ALMOTRIPTAN MALATE</u>									
TABLET; ORAL									
ALMOTRIPTAN MALATE									
AB		AJANTA PHARMA LTD	EQ 6.25MG BASE	A205523	001	Mar 03, 2016	Feb	NEWA	
AB			EO 12.5MG BASE	A205523	002	Mar 03, 2016	Feb	NEWA	

ALOSETRON HYDROCHLORIDETABLET; ORAL
LOTRONEX

AB	SEBELA IRELAND LTD	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Feb CAHN
AB	+	EQ 1MG BASE	N021107	001	Feb 09, 2000	Feb CAHN

ALPRAZOLAMTABLET, EXTENDED RELEASE; ORAL
ALPRAZOLAM

@	ACTAVIS LABS FL INC	0.5MG	A077198	001	May 13, 2010	Jan DISC
@		1MG	A077198	002	May 13, 2010	Jan DISC
@		2MG	A077198	003	May 13, 2010	Jan DISC
@		3MG	A077198	004	May 13, 2010	Jan DISC
@	COREPHARMA	0.5MG	A077996	001	Jan 31, 2007	Mar DISC
@		1MG	A077996	002	Jan 31, 2007	Mar DISC
@		2MG	A077996	003	Jan 31, 2007	Mar DISC
@		3MG	A077996	004	Jan 31, 2007	Mar DISC
@	IMPAX LABS	0.5MG	A077968	004	May 24, 2007	Jan DISC
@		1MG	A077968	003	May 24, 2007	Jan DISC
@		2MG	A077968	002	May 24, 2007	Jan DISC
@		3MG	A077968	001	May 24, 2007	Jan DISC

ALPROSTADILINJECTABLE; INJECTION
ALPROSTADIL

>D>	AP	EUROHLTH INTL SARL	0.5MG/ML	A074815	001	Jan 20, 1998	Sep CAHN
>A>	AP	WEST-WARD PHARMS INT	0.5MG/ML	A074815	001	Jan 20, 1998	Sep CAHN
		EDEX					
	@	AUXILIUM PHARMS INC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Mar CAHN
	AP		0.01MG/VIAL	N020649	002	Jun 12, 1997	Mar CAHN
	+		0.01MG/VIAL	N020649	005	Jul 30, 1998	Mar CAHN
	AP		0.02MG/VIAL	N020649	003	Jun 12, 1997	Mar CAHN
	+		0.02MG/VIAL	N020649	006	Jul 30, 1998	Mar CAHN
	AP		0.04MG/VIAL	N020649	004	Jun 12, 1997	Mar CAHN
	+		0.04MG/VIAL	N020649	007	Jul 30, 1998	Mar CAHN
		SUPPOSITORY; URETHRAL					
		MUSE					
	+	MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996	Jan CRLD
	+		0.25MG	N020700	002	Nov 19, 1996	Jan CRLD
	+		0.5MG	N020700	003	Nov 19, 1996	Jan CRLD

AMANTADINE HYDROCHLORIDECAPSULE; ORAL
AMANTADINE HYDROCHLORIDE

AB	BIONPHARMA INC	100MG	A078720	001	May 29, 2008	Jan CAHN	
>A>	AB	NEWGEN PHARMS LLC	100MG	A207570	001	Sep 30, 2016	Sep NEWA
AB	ZYDUS PHARMS USA INC	100MG	A208278	001	May 31, 2016	May NEWA	

AMIKACIN SULFATEINJECTABLE; INJECTION
AMIKACIN SULFATE

AP	+	EMCURE PHARMS LTD	EQ 250MG BASE/ML	A204040	001	Dec 12, 2013	May CRLD	
>D>	AP	EUROHLTH INTL SARL	EQ 50MG BASE/ML	A063313	001	Apr 11, 1994	Sep CAHN	
>D>	AP		EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	Sep CAHN	
AP			EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	May CRLD	
AP		SAGENT PHARMS	EQ 250MG BASE/ML	A203323	001	May 12, 2016	Apr NEWA	
>A>	AP	+	WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A063313	001	Apr 11, 1994	Sep CAHN
>A>	AP		EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	Sep CAHN	

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	002	Mar 26, 1997	Mar CMS1
---	-----------------	--	---------	-----	--------------	----------

CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	005	Mar 26, 1997	Mar CMS1
---	-----------------	--	---------	-----	--------------	----------

CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 5GM/100ML;	N020678	001	Mar 26, 1997	Mar CMS1
---	-----------------	-------------------------------	---------	-----	--------------	----------

INJECTABLE; INJECTION

CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER						
51MG/100ML;261MG/100ML;217MG/100ML ;112MG/100ML						
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	009	Mar 26, 1997	Mar CMS1
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	011	Mar 26, 1997	Mar CMS1
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	012	Mar 26, 1997	Mar CMS1
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	008	Mar 26, 1997	Mar CMS1
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	016	Mar 26, 1997	Mar CMS1
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	017	Mar 26, 1997	Mar CMS1
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	018	Mar 26, 1997	Mar CMS1
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	019	Mar 26, 1997	Mar CMS1
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	021	Mar 26, 1997	Mar CMS1

AMINOLEVULINIC ACID HYDROCHLORIDE

GEL; TOPICAL

AMELUZ

+	BIOFRONTERA	10%	N208081	001	May 10, 2016	May NEWA
---	-------------	-----	---------	-----	--------------	----------

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

@ IDT AUSTRALIA LTD

100MG

A085261 003

May CAHN

@

100MG

A085262 002

May CAHN

@

200MG

A085261 002

May CAHN

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB AUROBINDO PHARMA LTD

200MG

A204742 001 Jun 03, 2016 May NEWA

>A> AB MURTY PHARMS

100MG

A077069 003 Oct 04, 2016 Sep NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

>A> @ ANI PHARMS INC

10MG

A085031 002 Sep CMS1

>A> @

50MG

A085031 003 Sep CMS1

>A> @

75MG

A085031 004 Sep CMS1

@ SUN PHARM INDS INC

10MG

A040816 002 Jun 27, 2008 Mar DISC

@

10MG

A089399 002 Jul 14, 1987 Mar DISC

AB @

10MG

A089399 002 Jul 14, 1987 Mar CAHN

@

25MG

A040816 001 Jun 27, 2008 Mar DISC

@

25MG

A089399 001 Jul 14, 1987 Mar DISC

AB @

25MG

A089399 001 Jul 14, 1987 Mar CAHN

@

50MG

A040816 003 Jun 27, 2008 Mar DISC

@

50MG

A089399 003 Jul 14, 1987 Mar DISC

AB @

50MG

A089399 003 Jul 14, 1987 Mar CAHN

@

75MG

A040816 004 Jun 27, 2008 Mar DISC

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

	@	75MG	A089399	004	Jul 14, 1987	Mar	DISC
AB		75MG	A089399	004	Jul 14, 1987	Mar	CAHN
	@	100MG	A040816	005	Jun 27, 2008	Mar	DISC
	@	100MG	A089399	005	Jul 14, 1987	Mar	DISC
AB		100MG	A089399	005	Jul 14, 1987	Mar	CAHN
	@	150MG	A040816	006	Jun 27, 2008	Mar	DISC
	@	150MG	A089399	006	Jul 14, 1987	Mar	DISC
AB		150MG	A089399	006	Jul 14, 1987	Mar	CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

@	FRONTIDA BIOPHARM	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Jul	CAHN
@		EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Jul	CAHN
@	SUN PHARM INDS	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Mar	CAHN
@		EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Mar	CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

@	SUN PHARM INDS	10MG;2MG	A071077	001	Nov 12, 1986	Mar	CAHN
@		10MG;4MG	A071078	001	Nov 12, 1986	Mar	CAHN
@		25MG;2MG	A070297	001	Nov 12, 1986	Mar	CAHN
@		25MG;4MG	A071079	001	Nov 12, 1986	Mar	CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	CHINA RESOURCES	EQ 2.5MG BASE	A090752	003	May 16, 2016	May	NEWA
AB	INVAGEN PHARMS	EQ 2.5MG BASE	A206367	001	Dec 10, 2015	Feb	CAHN
AB		EQ 5MG BASE	A206367	002	Dec 10, 2015	Feb	CAHN
AB		EQ 10MG BASE	A206367	003	Dec 10, 2015	Feb	CAHN
AB	POLYGEN PHARMS	EQ 2.5MG BASE	A207821	001	Jul 11, 2016	Jun	NEWA
AB		EQ 5MG BASE	A207821	002	Jul 11, 2016	Jun	NEWA
AB		EQ 10MG BASE	A207821	003	Jul 11, 2016	Jun	NEWA
	@ SUN PHARM INDS	EQ 2.5MG BASE	A078081	001	Jan 31, 2008	Mar	CAHN
	@	EQ 5MG BASE	A078081	002	Jan 31, 2008	Mar	CAHN
	@	EQ 10MG BASE	A078081	003	Jan 31, 2008	Mar	CAHN

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	AUROBINDO PHARMA LTD	EQ 5MG BASE;160MG	A206512	001	Apr 22, 2016	Apr	NEWA
AB		EQ 5MG BASE;320MG	A206512	002	Apr 22, 2016	Apr	NEWA
AB		EQ 10MG BASE;160MG	A206512	003	Apr 22, 2016	Apr	NEWA
AB		EQ 10MG BASE;320MG	A206512	004	Apr 22, 2016	Apr	NEWA
>A> AB	INVAGEN PHARMS	EQ 5MG BASE;160MG	A205137	001	Sep 16, 2016	Sep	NEWA
>A> AB		EQ 5MG BASE;320MG	A205137	003	Sep 16, 2016	Sep	NEWA
>A> AB		EQ 10MG BASE;160MG	A205137	002	Sep 16, 2016	Sep	NEWA
>A> AB		EQ 10MG BASE;320MG	A205137	004	Sep 16, 2016	Sep	NEWA

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	MA GENERAL HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A207025	001	Feb 03, 2016	Jan	NEWA
AP	MIDWEST MEDCL	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204457	001	Nov 18, 2015	Jan	NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB	+ PERRIGO NEW YORK	EQ 12% BASE	A075774	001	May 01, 2002	Apr	CRLD
	LAC-HYDRIN						
	@ RANBAXY	EQ 12% BASE	N020508	001	Aug 29, 1996	Apr	DISC
	LOTION; TOPICAL						
	AMMONIUM LACTATE						
AB	+ PERRIGO NEW YORK	EQ 12% BASE	A075570	001	Jun 23, 2004	Apr	CRLD
	LAC-HYDRIN						
	@ RANBAXY	EQ 12% BASE	N019155	001	Apr 24, 1985	Apr	DISC

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD

250MG

A065016 001 Apr 08, 1999 Feb DISC

@

500MG

A065016 002 Apr 08, 1999 Feb DISC

TABLET;ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD

500MG

A065059 001 Nov 24, 2000 Feb DISC

@

875MG

A065059 002 Nov 24, 2000 Feb DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD

125MG

A065021 001 Dec 23, 1999 Feb DISC

@

250MG

A065021 002 Dec 23, 1999 Feb DISC

TABLET, EXTENDED RELEASE;ORAL

MOXATAG

+ VERNALIS R AND D LTD

775MG

N050813 001 Jan 23, 2008 Jan CAHN

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

>A> AB

CITRON PHARMA LLC

500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/
A,30MG

A206006 001 Oct 07, 2016 Sep NEWA

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB AUROBINDO PHARMA LTD

200MG/5ML;EQ 28.5MG BASE/5ML

A201090 001 Dec 20, 2011 Feb CDFR

AB

400MG/5ML;EQ 57MG BASE/5ML

A201090 002 Dec 20, 2011 Feb CDFR

AB

600MG/5ML;EQ 42.9MG BASE/5ML

A201091 001 Dec 20, 2011 Feb CDFR

@ SUN PHARM INDS LTD

200MG/5ML;EQ 28.5MG BASE/5ML

A065132 001 Mar 19, 2003 Feb DISC

@

400MG/5ML;EQ 57MG BASE/5ML

A065132 002 Mar 19, 2003 Feb DISC

@

600MG/5ML;EQ 42.9MG BASE/5ML

A065207 002 Jan 30, 2007 Feb DISC

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB HIKMA PHARMS

875MG;EQ 125MG BASE

A203824 001 Aug 23, 2016 Aug NEWA

@ SUN PHARM INDS LTD

875MG;EQ 125MG BASE

A065102 001 Sep 17, 2002 Feb DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SANDOZ

200MG;EQ 28.5MG BASE

A065065 001 Apr 18, 2002 Jul DISC

@

400MG;EQ 57MG BASE

A065065 002 Apr 18, 2002 Jul DISC

@ SUN PHARM INDS LTD

200MG;EQ 28.5MG BASE

A065161 001 Dec 03, 2003 Feb DISC

@

400MG;EQ 57MG BASE

A065161 002 Dec 03, 2003 Feb DISC

AUGMENTIN '125'

@ DR REDDYS LABS INC

125MG;EQ 31.25MG BASE

N050597 001 Jul 22, 1985 Jul DISC

125MG;EQ 31.25MG BASE

N050597 001 Jul 22, 1985 Mar CTEC

AUGMENTIN '250'

@ DR REDDYS LABS INC

250MG;EQ 62.5MG BASE

N050597 002 Jul 22, 1985 Jul DISC

+

250MG;EQ 62.5MG BASE

N050597 002 Jul 22, 1985 Mar CRLD

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

ADZENYS XR-ODT

NEOS THERAPS

EQ 3.1MG BASE

N204326 001 Jan 27, 2016 Jan NEWA

EQ 6.3MG BASE

N204326 002 Jan 27, 2016 Jan NEWA

EQ 9.4MG BASE

N204326 003 Jan 27, 2016 Jan NEWA

EQ 12.5MG BASE

N204326 004 Jan 27, 2016 Jan NEWA

EQ 15.7MG BASE

N204326 005 Jan 27, 2016 Jan NEWA

+

EQ 18.8MG BASE

N204326 006 Jan 27, 2016 May CRLD

EQ 18.8MG BASE

N204326 006 Jan 27, 2016 Jan NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB IMPAX LABS

1.25MG;1.25MG;1.25MG;1.25MG

A076852 001 Feb 16, 2016 Feb NEWA

AB

2.5MG;2.5MG;2.5MG;2.5MG

A076852 002 Feb 16, 2016 Feb NEWA

AB

3.75MG;3.75MG;3.75MG;3.75MG

A076852 003 Feb 16, 2016 Feb NEWA

AB

5MG;5MG;5MG;5MG

A076852 004 Feb 16, 2016 Feb NEWA

AB

6.25MG;6.25MG;6.25MG;6.25MG

A076852 005 Feb 16, 2016 Feb NEWA

AB

7.5MG;7.5MG;7.5MG;7.5MG

A076852 006 Feb 16, 2016 Feb NEWA

AB

TEVA

1.25MG;1.25MG;1.25MG;1.25MG

A077488 001 Apr 29, 2013 Feb CTNA

AB

2.5MG;2.5MG;2.5MG;2.5MG

A077488 002 Apr 29, 2013 Feb CTNA

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013	Feb CTNA
AB		5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013	Feb CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013	Feb CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013	Feb CTNA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A206340	001	Feb 05, 2016	Jan NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A206340	002	Feb 05, 2016	Jan NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206340	003	Feb 05, 2016	Jan NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A206340	004	Feb 05, 2016	Jan NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206340	005	Feb 05, 2016	Jan NEWA
AB		5MG;5MG;5MG;5MG	A206340	006	Feb 05, 2016	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206340	007	Feb 05, 2016	Jan NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX;INJECTION

AMPHOTEC

@	ALKOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996	Apr DISC
@		100MG/VIAL	N050729	002	Nov 22, 1996	Apr DISC

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP	MYLAN LABS LTD	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Aug CAHN
AP		EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Aug CAHN
AP		EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Aug CAHN
AP		EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Aug CAHN

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

@	SANDOZ	1MG	A079007	001	Jun 28, 2010	Aug DISC
---	--------	-----	---------	-----	--------------	----------

ARGATROBAN

INJECTABLE;INJECTION

ARGATROBAN

>A>	AP	HOSPIRA INC	250MG/2.5ML (100MG/ML)	A204120	001	Sep 21, 2016	Sep NEWA
-----	----	-------------	------------------------	---------	-----	--------------	----------

ARIPIPRAZOLE

INJECTABLE;INTRAMUSCULAR

ABILIFY

@	OTSUKA	9.75MG/1.3ML (7.5MG/ML)	N021866	001	Sep 20, 2006	Jun DISC
---	--------	-------------------------	---------	-----	--------------	----------

SOLUTION;ORAL

ARIPIPRAZOLE

AA	+	AMNEAL PHARMS	1MG/ML	A203906	001	Aug 14, 2015	Feb CRLD
----	---	---------------	--------	---------	-----	--------------	----------

TABLET;ORAL

ARIPIPRAZOLE

AB		AJANTA PHARMA LTD	2MG	A206174	001	Sep 12, 2016	Aug NEWA
AB			5MG	A206174	002	Sep 12, 2016	Aug NEWA
AB			10MG	A206174	003	Sep 12, 2016	Aug NEWA
AB			15MG	A206174	004	Sep 12, 2016	Aug NEWA
AB			20MG	A206174	005	Sep 12, 2016	Aug NEWA
AB			30MG	A206174	006	Sep 12, 2016	Aug NEWA
AB		AMNEAL PHARMS	2MG	A204838	001	Jun 17, 2016	Jun NEWA
AB			5MG	A204838	002	Jun 17, 2016	Jun NEWA
AB			10MG	A204838	003	Jun 17, 2016	Jun NEWA
AB			15MG	A204838	004	Jun 17, 2016	Jun NEWA
AB			20MG	A204838	005	Jun 17, 2016	Jun NEWA
AB			30MG	A204838	006	Jun 17, 2016	Jun NEWA
>A>	AB	MACLEODS PHARMS LTD	2MG	A204111	001	Oct 07, 2016	Sep NEWA
>A>	AB		5MG	A204111	002	Oct 07, 2016	Sep NEWA
>A>	AB		10MG	A204111	003	Oct 07, 2016	Sep NEWA
>A>	AB		15MG	A204111	004	Oct 07, 2016	Sep NEWA
>A>	AB		20MG	A204111	005	Oct 07, 2016	Sep NEWA
>A>	AB		30MG	A204111	006	Oct 07, 2016	Sep NEWA
>A>	AB	SCIEGEN PHARMS INC	2MG	A206383	001	Sep 29, 2016	Sep NEWA
>A>	AB		5MG	A206383	002	Sep 29, 2016	Sep NEWA
>A>	AB		10MG	A206383	003	Sep 29, 2016	Sep NEWA
>A>	AB		15MG	A206383	004	Sep 29, 2016	Sep NEWA
>A>	AB		20MG	A206383	005	Sep 29, 2016	Sep NEWA

TABLET;ORAL						
ARIPIPIRAZOLE						
>A> AB	30MG	A206383	006	Sep 29, 2016	Sep	NEWA
TABLET, ORALLY DISINTEGRATING;ORAL						
ABILIFY						
@ OTSUKA	10MG	N021729	002	Jun 07, 2006	May	DISC
@	15MG	N021729	003	Jun 07, 2006	May	DISC
ARIPIPIRAZOLE						
+ ALEMBIC PHARMS LTD	10MG	A202102	001	Apr 28, 2015	May	CRLD
	15MG	A202102	002	Apr 28, 2015	May	CTEC
<u>ARMODAFINIL</u>						
TABLET;ORAL						
ARMODAFINIL						
AB	MYLAN PHARMS INC	50MG	A200043	001	Jun 01, 2012	Apr CMFD
AB		150MG	A200043	002	Jun 01, 2012	Apr CMFD
AB		250MG	A200043	003	Jun 01, 2012	Apr CMFD
NUVIGIL						
AB	CEPHALON	50MG	N021875	001	Jun 15, 2007	Apr CTEC
AB		150MG	N021875	003	Jun 15, 2007	Apr CTEC
AB	+	250MG	N021875	004	Jun 15, 2007	Apr CTEC
<u>ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E</u>						
INJECTABLE;INJECTION						
M.V.I.-12 LYOPHILIZED						
@ TELIGENT PHARMA INC	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985	Jan	CAHN
<u>ASENAPINE MALEATE</u>						
TABLET;SUBLINGUAL						
SAPHRIS						
FOREST LABS LLC	EQ 2.5 BASE	N022117	003	Mar 12, 2015	Mar	NEWA
<u>ASPIRIN; BUTALBITAL; CAFFEINE</u>						
CAPSULE;ORAL						
BUTALBITAL, ASPIRIN AND CAFFEINE						
@ NOSTRUM LABS INC	325MG;50MG;40MG	A078149	001	Jun 13, 2007	Jan	CAHN
FIORINAL						
AA	+ ALLERGAN SALES LLC	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Apr CAHN
TABLET;ORAL						
BUTALBITAL, ASPIRIN AND CAFFEINE						
>A> AA	PHARMACEUTICS INTL	325MG;50MG;40MG	A204195	001	Sep 22, 2016	Sep NEWA
FIORINAL						
@ ALLERGAN SALES LLC	325MG;50MG;40MG	N017534	003	Apr 16, 1986	Apr	CAHN
<u>ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE</u>						
CAPSULE;ORAL						
BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE						
AB	MAYNE PHARMA INC	325MG;50MG;40MG;30MG	A203335	001	Oct 30, 2015	Aug CAHN
FIORINAL W/CODEINE						
AB	+ ALLERGAN SALES LLC	325MG;50MG;40MG;30MG	N019429	003	Oct 26, 1990	Apr CAHN
<u>ASPIRIN; CARISOPRODOL</u>						
TABLET;ORAL						
CARISOPRODOL AND ASPIRIN						
AB	+ HERITAGE PHARMS INC	325MG;200MG	A089594	001	Mar 31, 1989	Jun CRLD
AB	INGENUS PHARMS NJ	325MG;200MG	A040832	001	Jan 07, 2010	Jan CAHN
SOMA COMPOUND						
@ MEDA PHARMS	325MG;200MG	N012365	005	Jul 11, 1983	Jun	DISC
<u>ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE</u>						
TABLET;ORAL						
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE						
AB	INGENUS PHARMS NJ	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Mar CMFD
@		325MG;200MG;16MG	A040860	001	Jan 07, 2010	Jan CAHN
AB	+ SANDOZ	325MG;200MG;16MG	A040118	001	Apr 16, 1996	Mar CTEC
+		325MG;200MG;16MG	A040118	001	Apr 16, 1996	Jan CRLD

TABLET;ORAL

SOMA COMPOUND W/ CODEINE

@ MEDA PHARMS	325MG;200MG;16MG	N012366	002	Jul 11, 1983	Jan DISC
---------------	------------------	---------	-----	--------------	----------

>A> ASPIRIN; OMEPRAZOLE

>A> TABLET, DELAYED RELEASE;ORAL

>A> YOSPRALA

>A>	ARALEZ PHARMS	81MG;40MG	N205103	001	Sep 14, 2016	Sep NEWA
-----	---------------	-----------	---------	-----	--------------	----------

>A>	+	325MG;40MG	N205103	002	Sep 14, 2016	Sep NEWA
-----	---	------------	---------	-----	--------------	----------

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

AA	MAYNE PHARMA INC	325MG;4.8355MG	A091670	001	Mar 16, 2011	Aug CAHN
----	------------------	----------------	---------	-----	--------------	----------

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL

OXYCODONE AND ASPIRIN

@ SUN PHARM INDS	325MG;4.5MG;0.38MG	A040260	001	Jul 17, 1998	Mar CAHN
------------------	--------------------	---------	-----	--------------	----------

@	325MG;4.5MG;0.38MG	A087794	001	May 26, 1982	Mar CAHN
---	--------------------	---------	-----	--------------	----------

ATENOLOL

TABLET;ORAL

ATENOLOL

AB	ALVOGEN MALTA	25MG	A073646	001	Jul 31, 1992	Jan CAHN
----	---------------	------	---------	-----	--------------	----------

AB		50MG	A072303	001	Jul 15, 1988	Jan CAHN
----	--	------	---------	-----	--------------	----------

AB		100MG	A072304	001	Jul 15, 1988	Jan CAHN
----	--	-------	---------	-----	--------------	----------

@ NORTHSTAR HLTHCARE	25MG	A078254	001	Sep 25, 2009	Aug DISC
----------------------	------	---------	-----	--------------	----------

@	50MG	A078254	002	Sep 25, 2009	Aug DISC
---	------	---------	-----	--------------	----------

@	100MG	A078254	003	Sep 25, 2009	Aug DISC
---	-------	---------	-----	--------------	----------

TENORMIN

AB	ALVOGEN MALTA	25MG	N018240	004	Apr 09, 1990	Jan CAHN
----	---------------	------	---------	-----	--------------	----------

AB		50MG	N018240	001		Jan CAHN
----	--	------	---------	-----	--	----------

AB	+	100MG	N018240	002		Jan CAHN
----	---	-------	---------	-----	--	----------

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB	ALVOGEN MALTA	50MG;25MG	A072301	001	May 31, 1990	Jan CAHN
----	---------------	-----------	---------	-----	--------------	----------

AB		100MG;25MG	A072302	001	May 31, 1990	Jan CAHN
----	--	------------	---------	-----	--------------	----------

AB	SUN PHARM INDS	100MG;25MG	A073582	001	Apr 29, 1993	Mar CAHN
----	----------------	------------	---------	-----	--------------	----------

TENORETIC 100

AB	+	ALVOGEN MALTA	100MG;25MG	N018760	001	Jun 08, 1984	Jan CAHN
----	---	---------------	------------	---------	-----	--------------	----------

TENORETIC 50

AB		ALVOGEN MALTA	50MG;25MG	N018760	002	Jun 08, 1984	Jan CAHN
----	--	---------------	-----------	---------	-----	--------------	----------

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	SCIEGEN PHARMS INC	EQ 10MG BASE	A205519	001	May 19, 2016	May NEWA
----	--------------------	--------------	---------	-----	--------------	----------

AB		EQ 20MG BASE	A205519	002	May 19, 2016	May NEWA
----	--	--------------	---------	-----	--------------	----------

AB		EQ 40MG BASE	A205519	003	May 19, 2016	May NEWA
----	--	--------------	---------	-----	--------------	----------

AB		EQ 80MG BASE	A205519	004	May 19, 2016	May NEWA
----	--	--------------	---------	-----	--------------	----------

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

>A>	AP	NANJING KING-FRIEND	10MG/ML	A091489	001	Feb 17, 2012	Sep CAHN
-----	----	---------------------	---------	---------	-----	--------------	----------

>D>	AP	SAGENT PHARMS	10MG/ML	A091489	001	Feb 17, 2012	Sep CAHN
-----	----	---------------	---------	---------	-----	--------------	----------

ATRACURIUM BESYLATE PRESERVATIVE FREE

>D>	AP	+	EUROHLTH INTL SARL	10MG/ML	A074900	001	Jul 18, 1997	Sep CAHN
-----	----	---	--------------------	---------	---------	-----	--------------	----------

>A>	AP	NANJING KING-FRIEND	10MG/ML	A091488	001	Feb 17, 2012	Sep CAHN
-----	----	---------------------	---------	---------	-----	--------------	----------

>D>	AP	SAGENT PHARMS	10MG/ML	A091488	001	Feb 17, 2012	Sep CAHN
-----	----	---------------	---------	---------	-----	--------------	----------

>A>	AP	+	WEST-WARD PHARMS INT	10MG/ML	A074900	001	Jul 18, 1997	Sep CAHN
-----	----	---	----------------------	---------	---------	-----	--------------	----------

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@ SUN PHARM INDS	0.025MG;2.5MG	A085506	001		Mar CAHN
------------------	---------------	---------	-----	--	----------

LONOX

@ SANDOZ	0.025MG;2.5MG	A085311	002		Aug DISC
----------	---------------	---------	-----	--	----------

AURANOFINCAPSULE;ORAL
RIDAURA

+ SEBELA IRELAND LTD 3MG N018689 001 May 24, 1985 Jan CAHN

AXITINIBTABLET;ORAL
INLYTAPF PRISM CV 1MG N202324 001 Jan 27, 2012 Apr CAHN
+ 5MG N202324 002 Jan 27, 2012 Apr CAHNAZACITIDINEINJECTABLE;INTRAVENOUS, SUBCUTANEOUS
AZACITIDINEAP MYLAN INSTITUTIONAL 100MG/VIAL A204949 001 Apr 28, 2016 Apr NEWA
>A> AP SHILPA MEDICARE 100MG/VIAL A207518 001 Sep 29, 2016 Sep NEWA
POWDER;IV (INFUSION), SUBCUTANEOUS
AZACITIDINE
ACTAVIS LLC 100MG/VIAL N208216 001 Apr 29, 2016 Apr NEWAAZATHIOPRINETABLET;ORAL
IMURAN@ SEBELA IRELAND LTD 25MG N016324 002 Jan CAHN
AB + 50MG N016324 001 Jan CAHNAZATHIOPRINE SODIUMINJECTABLE;INJECTION
AZATHIOPRINE SODIUM>D> + EUROHLTH INTL SARL EQ 100MG BASE/VIAL A074419 001 Mar 31, 1995 Sep CAHN
>A> + WEST-WARD PHARMS INT EQ 100MG BASE/VIAL A074419 001 Mar 31, 1995 Sep CAHN
IMURAN
@ SEBELA IRELAND LTD EQ 100MG BASE/VIAL N017391 001 Jan CAHNAZILSARTAN KAMEDOXOMILTABLET;ORAL
EDARBIARBOR PHARMS LLC EQ 40MG MEDOXOMIL N200796 001 Feb 25, 2011 Jan CAHN
+ EQ 80MG MEDOXOMIL N200796 002 Feb 25, 2011 Jan CAHNAZILSARTAN KAMEDOXOMIL; CHLORTHALIDONETABLET;ORAL
EDARBYCLORARBOR PHARMS LLC EQ 40MG MEDOXOMIL;12.5MG N202331 001 Dec 20, 2011 Jan CAHN
+ EQ 40MG MEDOXOMIL;25MG N202331 002 Dec 20, 2011 Jan CAHNAZITHROMYCINFOR SUSPENSION;ORAL
AZITHROMYCINBX LUPIN LTD EQ 100MG BASE/5ML A065488 001 May 15, 2015 Apr CTEC
BX EQ 200MG BASE/5ML A065488 002 May 15, 2015 Apr CTECAZTREONAMINJECTABLE;INJECTION
AZTREONAM>D> @ EUROHLTH INTL SARL 1GM/VIAL A065286 001 Mar 23, 2011 Sep CAHN
@ 1GM/VIAL A065286 001 Mar 23, 2011 Mar DISC
>D> @ 2GM/VIAL A065286 002 Mar 23, 2011 Sep CAHN
@ 2GM/VIAL A065286 002 Mar 23, 2011 Mar DISC
>A> @ WEST-WARD PHARMS INT 1GM/VIAL A065286 001 Mar 23, 2011 Sep CAHN
>A> @ 2GM/VIAL A065286 002 Mar 23, 2011 Sep CAHNBACLOFENINJECTABLE;INTRATHECAL
BACLOFENAP SINTETICA SA 0.05MG/ML A091193 001 May 03, 2016 Apr NEWA
AP 0.5MG/ML A091193 002 May 03, 2016 Apr NEWA
AP 2MG/ML A091193 003 May 03, 2016 Apr NEWA
LIORESAL
AP + SAOL THERAPS RES LTD 0.05MG/ML N020075 003 Nov 07, 1996 May CAHN
AP + 0.5MG/ML N020075 001 Jun 17, 1992 May CAHN

INJECTABLE; INTRATHECAL
LIORESAL

AP + 2MG/ML N020075 002 Jun 17, 1992 May CAHN

TABLET; ORAL
BACLOFEN

AB NORTHSTAR HLTHCARE 10MG A078401 002 Sep 18, 2009 Jan NEWA

BARIUM SULFATE

FOR SUSPENSION; ORAL
E-Z-HD

+ BRACCO 334GM/BOTTLE

N208036 001 Jan 11, 2016 Jan NEWA

SUSPENSION; ORAL

READI-CAT 2

+ BRACCO 2% (9GM/450ML)

N208143 001 Jan 15, 2016 Jan NEWA

READI-CAT 2 SMOOTHIES

BRACCO 2% (9GM/450ML)

N208143 002 Jan 15, 2016 Jan NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

@ ACTAVIS LABS FL INC 5MG

A076267 001 Feb 11, 2004 Jan DISC

@ 10MG

A076267 002 Feb 11, 2004 Jan DISC

@ 20MG

A076267 003 Feb 11, 2004 Jan DISC

@ 40MG

A076267 004 Feb 11, 2004 Jan DISC

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ ACTAVIS LABS FL INC 5MG; 6.25MG

A076342 001 Feb 11, 2004 Jan DISC

@ 10MG; 12.5MG

A076342 002 Feb 11, 2004 Jan DISC

@ 20MG; 12.5MG

A076342 003 Feb 11, 2004 Jan DISC

@ 20MG; 25MG

A076342 004 Feb 11, 2004 Jan DISC

@ IVAX SUB TEVA PHARMS 5MG; 6.25MG

A076348 001 Feb 11, 2004 Mar DISC

@ 10MG; 12.5MG

A076348 002 Feb 11, 2004 Mar DISC

@ 20MG; 12.5MG

A076348 003 Feb 11, 2004 Mar DISC

@ 20MG; 25MG

A076348 004 Feb 11, 2004 Mar DISC

@ SUN PHARM INDS LTD 5MG; 6.25MG

A077483 001 Sep 08, 2005 Mar DISC

@ 10MG; 12.5MG

A077483 002 Sep 08, 2005 Mar DISC

@ 20MG; 12.5MG

A077483 003 Sep 08, 2005 Mar DISC

@ 20MG; 25MG

A077483 004 Sep 08, 2005 Mar DISC

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP ACCORD HLTHCARE 25MG/VIAL

A205574 001 May 19, 2016 May NEWA

AP 100MG/VIAL

A205574 002 May 19, 2016 May NEWA

AP GLENMARK PHARMS LTD 25MG/VIAL

A204771 001 Mar 24, 2016 Mar NEWA

AP 100MG/VIAL

A204771 002 Mar 24, 2016 Mar NEWA

AP HOSPIRA INC 25MG/VIAL

A204086 001 May 20, 2016 May NEWA

AP 100MG/VIAL

A204086 002 May 20, 2016 May NEWA

AP INNOPHARMA LICENSING 25MG/VIAL

A205476 001 Mar 24, 2016 Mar NEWA

AP 100MG/VIAL

A205476 002 Mar 24, 2016 Mar NEWA

TREANDA

AP + CEPHALON 25MG/VIAL

N022249 002 May 01, 2009 Mar CFTG

AP 100MG/VIAL

N022249 001 Mar 20, 2008 Mar CFTG

SOLUTION; IV (INFUSION)

BENDEKA

>D> EAGLE PHARMS 100MG/4ML (25MG/ML)

N208194 001 Dec 07, 2015 Sep CRLD

>A> + 100MG/4ML (25MG/ML)

N208194 001 Dec 07, 2015 Sep CRLD

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA BIONPHARMA INC 100MG

A081297 001 Jan 29, 1993 Jan CAHN

AA 200MG

A081297 002 Oct 30, 2007 Jan CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB TOLMAR 5%; 1.2%

A203688 001 Aug 25, 2016 Aug NEWA

BENZOYL PEROXIDE; ERYTHROMYCIN

	GEL; TOPICAL								
>A>	AKTIPAK								
>A>	+ CUTANEA	5%;3%		N050769	001	Nov 27, 2000	Sep	CTNA	
>D>	BENZAMYCIN PAK								
>D>	+ CUTANEA	5%;3%		N050769	001	Nov 27, 2000	Sep	CTNA	
	+	5%;3%		N050769	001	Nov 27, 2000	Feb	CAHN	

BENZPHETAMINE HYDROCHLORIDE

	TABLET; ORAL								
	BENZPHETAMINE HYDROCHLORIDE								
	@ IMPAX LABS	50MG		A040845	001	Nov 18, 2008	Mar	DISC	

BENZTROPINE MESYLATE

	TABLET; ORAL								
	BENZTROPINE MESYLATE								
AA	ASPEN GLOBAL INC	0.5MG		A204713	001	Apr 14, 2015	Jul	CAHN	
AA		1MG		A204713	002	Apr 14, 2015	Jul	CAHN	
AA		2MG		A204713	003	Apr 14, 2015	Jul	CAHN	
>A>	@ FRONTIDA BIOPHARM	1MG		A081264	001	Jan 23, 1992	Sep	CAHN	
	@	2MG		A081265	001	Jan 23, 1992	Jul	CAHN	
>D>	@ MUTUAL PHARM	1MG		A081264	001	Jan 23, 1992	Sep	CAHN	

BETAMETHASONE DIPROPIONATE

	SPRAY; TOPICAL								
	SERNIVO								
	+ PROMIUS PHARMA LLC	EQ 0.05% BASE/SPRAY		N208079	001	Feb 05, 2016	Feb	NEWA	

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

	CREAM; TOPICAL								
	CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE								
AB	GLENMARK PHARMS	EQ 0.05% BASE;1%		A202894	001	Oct 30, 2015	Mar	CAHN	

BETAXOLOL HYDROCHLORIDE

	SOLUTION/DROPS; OPHTHALMIC								
	BETAXOLOL HYDROCHLORIDE								
AT	TELIGENT PHARMA INC	EQ 0.5% BASE		A075630	001	Apr 12, 2001	Jan	CAHN	

BETHANECHOL CHLORIDE

	TABLET; ORAL								
	BETHANECHOL CHLORIDE								
	@ IMPAX LABS	5MG		A040739	001	Nov 01, 2006	Mar	DISC	
	@	10MG		A040741	001	Nov 01, 2006	Mar	DISC	
	@	25MG		A040740	001	Nov 01, 2006	Mar	DISC	
	@	50MG		A040721	004	Nov 01, 2006	Mar	DISC	
	DUVOID								
AA	BI-COASTAL PHARMA	10MG		A086262	001		Jul	CAHN	
AA		25MG		A086263	001		Jul	CAHN	
AA		50MG		A085882	003		Jul	CAHN	

BIMATOPROST

	SOLUTION/DROPS; TOPICAL								
	BIMATOPROST								
AT	SANDOZ INC	0.03%		A202719	001	Apr 19, 2016	Apr	NEWA	

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

	TABLET, CHEWABLE, TABLET, CAPSULE; ORAL								
	HELIDAC								
	@ SEBELA IRELAND LTD	262.4MG, N/A, N/A, N/A, 250MG, N/A, N/A, N/A, 500MG		N050719	001	Aug 15, 1996	Jan	CAHN	

BISOPROLOL FUMARATE

	TABLET; ORAL								
	BISOPROLOL FUMARATE								
	@ FRONTIDA BIOPHARM	5MG		A075474	001	Oct 25, 2002	Jul	CAHN	
	@	10MG		A075474	002	Oct 25, 2002	Jul	CAHN	
AB	+ MYLAN	10MG		A075831	002	Dec 14, 2005	Aug	CRLD	
	@ SUN PHARM INDS	5MG		A075474	001	Oct 25, 2002	Mar	CAHN	
	@	10MG		A075474	002	Oct 25, 2002	Mar	CAHN	
	ZEBETA								
	@ TEVA WOMENS	5MG		N019982	002	Jul 31, 1992	Aug	DISC	

TABLET;ORAL
ZEBETA

@ 10MG N019982 001 Jul 31, 1992 Aug DISC

BLEOMYCIN SULFATE

INJECTABLE;INJECTION
BLEOMYCIN SULFATE

>D> AP EUROHLTH INTL SARL EQ 15 UNITS BASE/VIAL A065042 002 Oct 17, 2001 Sep CAHN
>D> AP EQ 30 UNITS BASE/VIAL A065042 001 Oct 17, 2001 Sep CAHN
>A> AP WEST-WARD PHARMS INT EQ 15 UNITS BASE/VIAL A065042 002 Oct 17, 2001 Sep CAHN
>A> AP EQ 30 UNITS BASE/VIAL A065042 001 Oct 17, 2001 Sep CAHN

BOCEPREVIR

CAPSULE;ORAL
VICTRELIS

@ MERCK SHARP DOHME 200MG N202258 001 May 13, 2011 Jun DISC

>D> BRETYLIUM TOSYLATE
>D> INJECTABLE;INJECTION
>D> BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER
>D> + B BRAUN 100MG/100ML N019121 001 Apr 29, 1986 Sep DISC
>A> @ 100MG/100ML N019121 001 Apr 29, 1986 Sep DISC
>D> + 200MG/100ML N019121 002 Apr 29, 1986 Sep DISC
>A> @ 200MG/100ML N019121 002 Apr 29, 1986 Sep DISC
>D> + 400MG/100ML N019121 003 Apr 29, 1986 Sep DISC
>A> @ 400MG/100ML N019121 003 Apr 29, 1986 Sep DISC

BRIVARACETAM

SOLUTION;INTRAVENOUS
BRIVIACT

+ UBC INC 50MG/5ML (10MG/ML) N205837 001 Feb 18, 2016 Feb NEWA
+ UCB INC 50MG/5ML (10MG/ML) N205837 001 May 12, 2016 May CMS1

SOLUTION;ORAL
BRIVIACT

+ UCB INC 10MG/ML N205838 001 May 12, 2016 May CMS1
+ 10MG/ML N205838 001 Feb 18, 2016 Feb NEWA

TABLET;ORAL
BRIVIACT

UCB INC 10MG N205836 001 May 12, 2016 May CMS1
10MG N205836 001 Feb 18, 2016 Feb NEWA
25MG N205836 002 May 12, 2016 May CMS1
25MG N205836 002 Feb 18, 2016 Feb NEWA
50MG N205836 003 May 12, 2016 May CMS1
50MG N205836 003 Feb 18, 2016 Feb NEWA
75MG N205836 004 May 12, 2016 May CMS1
75MG N205836 004 Feb 18, 2016 Feb NEWA
+ 100MG N205836 005 May 12, 2016 May CMS1
+ 100MG N205836 005 Feb 18, 2016 Feb NEWA

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC
BROMSITE

+ INSITE VISION INC EQ 0.075% ACID N206911 001 Apr 08, 2016 Apr NEWA
+ SUN PHARMA GLOBAL EQ 0.075% ACID N206911 001 Apr 08, 2016 Jul CAHN

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

BROMOCRIPTINE MESYLATE

AB + MYLAN EQ 5MG BASE A077226 001 Apr 04, 2005 Jan CRLD

TABLET;ORAL

BROMOCRIPTINE MESYLATE

AB + PADDOCK LLC EQ 2.5MG BASE A077646 001 Oct 01, 2008 Jan CRLD
AB SANDOZ INC EQ 2.5MG BASE A074631 001 Jan 13, 1998 Feb CAHN

PARLODEL

AB US PHARMS HOLDINGS I EQ 2.5MG BASE N017962 001 Apr CMFD
@ EQ 2.5MG BASE N017962 001 Jan DISC

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

>A>	AA	ACELLA PHARMS LLC	2MG/5ML;10MG/5ML;30MG/5ML	A203375	001	Sep 20, 2016	Sep NEWA
-----	----	-------------------	---------------------------	---------	-----	--------------	----------

BUDESONIDE

CAPSULE;ORAL

BUDESONIDE

AB		ACTAVIS ELIZABETH	3MG	A206623	001	Apr 08, 2016	Mar NEWA
AB		MAYNE PHARMA	3MG	A206623	001	Apr 08, 2016	Aug CAHN
ENTOCORT EC							
AB	+	ELAN PHARMA INTL LTD	3MG	N021324	001	Oct 02, 2001	Jan CAHN
AB	+	PERRIGO PHARMA INTL	3MG	N021324	001	Oct 02, 2001	May CAHN

SUSPENSION;INHALATION

BUDESONIDE

AN		APOTEX INC	0.25MG/2ML	A078202	001	Mar 30, 2009	Jun CMFD
AN			0.5MG/2ML	A078202	002	Mar 30, 2009	Jun CMFD
AN		IMPAX LABS INC	0.25MG/2ML	A078404	001	Jul 31, 2012	Aug CAHN
AN			0.5MG/2ML	A078404	002	Jul 31, 2012	Aug CAHN
AN		TEVA PHARMS USA	1MG/2ML	A204548	001	Mar 08, 2016	Feb NEWA

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

AP	+	AMPHASTAR PHARMS INC	0.25MG/ML	A074441	001	Jan 27, 1995	Jun CAHN
AP	+	EUROHLTH INTL SARL	0.25MG/ML	A074441	001	Jan 27, 1995	Apr CAHN

BUPIVACAINE

INJECTABLE, LIPOSOMAL;INJECTION

EXPAREL

>D>		@ PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011	Sep CMFD
>A>	+		133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011	Sep CMFD

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	0.25%	A207183	001	May 13, 2016	May NEWA
AP			0.5%	A207183	002	May 13, 2016	May NEWA

INJECTABLE;SPINAL

BUPIVACAINE HYDROCHLORIDE

AP		CLARIS	0.75%	A207266	001	Jul 25, 2016	Jul NEWA
----	--	--------	-------	---------	-----	--------------	----------

BUPRENORPHINE HYDROCHLORIDE

IMPLANT;IMPLANTATION

PROBUPHINE

+		BRAEBURN PHARMS INC	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	Jun CAHN
+		TITAN PHARMS	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	May NEWA

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 2MG BASE	A201760	001	Jan 29, 2016	Jan NEWA
AB			EQ 8MG BASE	A201760	002	Jan 29, 2016	Jan NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

>A>	AB	KREMERS URBAN PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A205022	001	Sep 19, 2016	Sep NEWA
>A>	AB		EQ 8MG BASE;EQ 2MG BASE	A205022	002	Sep 19, 2016	Sep NEWA
	AB	SUN PHARM INDS LTD	EQ 8MG BASE;EQ 2MG BASE	A201633	002	Aug 05, 2016	Jul NEWA
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE							
	AB	SUN PHARM INDS LTD	EQ 2MG BASE;EQ 0.5MG BASE	A201633	001	Aug 05, 2016	Jul NEWA
ZUBSOLV							
		OREXO US INC	EQ 1.4MG BASE;EQ 0.36MG BASE	N204242	001	Jul 03, 2013	Jul CAHN
			EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Jul CAHN
	+		EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jul CAHN
			EQ 8.6MG BASE;EQ 2.1MG BASE	N204242	003	Dec 11, 2014	Jul CAHN
			EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jul CAHN

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

>D>	AB	APOTEX INC	100MG	A076143	002	Jan 17, 2006	Sep CRLD
>A>	AB	+	100MG	A076143	002	Jan 17, 2006	Sep CRLD
	AB	HERITAGE PHARMA	75MG	A206975	001	Aug 19, 2016	Aug NEWA
	AB		100MG	A206975	002	Aug 19, 2016	Aug NEWA
>D>		WELLBUTRIN					
>D>	AB	GLAXOSMITHKLINE	75MG	N018644	002	Dec 30, 1985	Sep DISC
>A>	@		75MG	N018644	002	Dec 30, 1985	Sep DISC
>D>	AB	+	100MG	N018644	003	Dec 30, 1985	Sep DISC
>A>	@		100MG	N018644	003	Dec 30, 1985	Sep DISC

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB1		INVAGEN PHARMS	100MG	A206674	001	Feb 09, 2016	Jan NEWA
AB3			150MG	A206556	001	Aug 26, 2016	Aug NEWA
AB1			150MG	A206674	002	Feb 09, 2016	Jan NEWA
AB1			200MG	A206674	003	Feb 09, 2016	Jan NEWA
AB3			300MG	A206556	002	Aug 26, 2016	Aug NEWA
AB1		SCIEGEN PHARMS INC	100MG	A205794	001	Mar 01, 2016	Feb NEWA
AB1			150MG	A205794	002	Mar 01, 2016	Feb NEWA
AB2			150MG	A206122	001	Aug 17, 2016	Aug NEWA
AB1			200MG	A205794	003	Mar 01, 2016	Feb NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CONTRAVE

+		OREXIGEN	90MG; 8MG	N200063	001	Sep 10, 2014	Apr CAHN
---	--	----------	-----------	---------	-----	--------------	----------

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB		HERITAGE PHARMA	5MG	A204582	001	Sep 18, 2015	Jun CAHN
AB			10MG	A204582	002	Sep 18, 2015	Jun CAHN
AB			15MG	A204582	003	Sep 18, 2015	Jun CAHN
AB			30MG	A204582	004	Sep 18, 2015	Jun CAHN
AB		IMPAX LABS INC	5MG	A074253	001	Mar 28, 2001	Aug CAHN
AB			10MG	A074253	002	Mar 28, 2001	Aug CAHN
AB			15MG	A074253	003	Mar 13, 2002	Aug CAHN

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

AP		LUITPOLD PHARMS INC	6MG/ML	A202259	001	Dec 22, 2015	Mar CAHN
----	--	---------------------	--------	---------	-----	--------------	----------

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

@		PERRIGO PHARMA INTL	2%	N019881	001	Feb 07, 1997	Jun CAHN
---	--	---------------------	----	---------	-----	--------------	----------

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

@		CLARIS	2MG/ML	A075697	001	Oct 23, 2001	Jan CAHN
AP		EUROHLTH INTL SARL	2MG/ML	A075046	001	Aug 12, 1998	Apr CAHN
		BUTORPHANOL TARTRATE PRESERVATIVE FREE					
@		CLARIS	1MG/ML	A075695	001	Oct 23, 2001	Mar CAHN
@			2MG/ML	A075695	002	Oct 23, 2001	Mar CAHN
AP		EUROHLTH INTL SARL	1MG/ML	A075045	001	Aug 12, 1998	Apr CAHN
AP			2MG/ML	A075045	002	Aug 12, 1998	Apr CAHN

SPRAY, METERED; NASAL

BUTORPHANOL TARTRATE

>A>	AB	APOTEX INC	1MG/SPRAY	A075499	001	Dec 04, 2002	Sep CAHN
>D>	AB	NOVEX	1MG/SPRAY	A075499	001	Dec 04, 2002	Sep CAHN

CABERGOLINE

TABLET; ORAL

CABERGOLINE

@		IMPAX LABS INC	0.5MG	A077843	001	Jul 03, 2007	Mar DISC
---	--	----------------	-------	---------	-----	--------------	----------

CABOZANTINIB S-MALATE

TABLET; ORAL

CABOMETYX

EXELIXIS INC	EQ 20MG BASE	N208692	001	Apr 25, 2016	Apr NEWA
	EQ 40MG BASE	N208692	002	Apr 25, 2016	Apr NEWA
+	EQ 60MG BASE	N208692	003	Apr 25, 2016	Apr NEWA

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFCIT

>D> AP	+	EUROHLTH INTL SARL	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Sep CAHN
>A> AP	+	WEST-WARD PHARMS INT	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Sep CAHN

SOLUTION; ORAL

CAFCIT

>D> AA	+	EUROHLTH INTL SARL	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Sep CAHN
>A> AA	+	WEST-WARD PHARMS INT	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Sep CAHN

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

MIGERGOT

+	HORIZON PHARMA	100MG; 2MG	A086557	001	Oct 04, 1983	Jan CAHN
---	----------------	------------	---------	-----	--------------	----------

CALCIFEDIOL

CAPSULE, EXTENDED RELEASE; ORAL

RAYALDEE

+	OPKO IRELAND GLOBAL	0.03MG	N208010	001	Jun 17, 2016	Jun NEWA
---	---------------------	--------	---------	-----	--------------	----------

CALCIPOTRIENE

CREAM; TOPICAL

CALCIPOTRIENE

AB		GLENMARK PHARMS	0.005%	A205772	001	Jun 09, 2015	Mar CAHN
----	--	-----------------	--------	---------	-----	--------------	----------

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED; NASAL

FORTICAL

>D>							
>D>	+	UPSHER SMITH	200 IU/SPRAY	N021406	001	Aug 12, 2005	Sep DISC
>A>	@		200 IU/SPRAY	N021406	001	Aug 12, 2005	Sep DISC

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL

AB		BIONPHARMA INC	0.25MCG	A091174	001	May 24, 2013	Jan CAHN
AB			0.5MCG	A091174	002	May 24, 2013	Jan CAHN

INJECTABLE; INJECTION

CALCITRIOL

AKORN

		AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	Feb CTEC
--	--	-------	------------	---------	-----	--------------	----------

@	ROCKWELL MEDCL	0.001MG/ML	A076206	001	Sep 17, 2003	Feb DISC
---	----------------	------------	---------	-----	--------------	----------

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB		LOTUS PHARM CO LTD	EQ 169MG CALCIUM	A203298	001	Jul 26, 2016	Jul NEWA
----	--	--------------------	------------------	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	002		Feb DISC
---	-----------------	---	---------	-----	--	----------

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@	FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	003		Feb DISC
---	-----------------	---	---------	-----	--	----------

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@	FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	007	Jun 24, 1988	Feb DISC
---	-----------------	---	---------	-----	--------------	----------

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@	FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	001		Feb DISC
---	-----------------	--	---------	-----	--	----------

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	004	Jul 07, 1982	Feb DISC
---	-----------------	---	---------	-----	--------------	----------

SOLUTION;INTRAPERITONEAL

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	005	Jul 07, 1982	Feb DISC
--------------------	---	---------	-----	--------------	----------

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	008	Jun 24, 1988	Feb DISC
--------------------	---	---------	-----	--------------	----------

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	006	Jul 07, 1982	Feb DISC
--------------------	--	---------	-----	--------------	----------

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	010	Nov 18, 1985	Feb CTEC
-----------------	---	---------	-----	--------------	----------

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985	Feb CTEC
-----------------	---	---------	-----	--------------	----------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP + BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N016682	001		Aug CRLD
----------------------	---	---------	-----	--	----------

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

>A>	INVOKAMET XR				
>A>	JANSSEN PHARMS	50MG;500MG	N205879	001	Sep 20, 2016 Sep NEWA
>A>		50MG;1GM	N205879	002	Sep 20, 2016 Sep NEWA
>A>		150MG;500MG	N205879	003	Sep 20, 2016 Sep NEWA
>A>		150MG;1GM	N205879	004	Sep 20, 2016 Sep NEWA

CANGRELOR

POWDER;IV (INFUSION)

KENGREAL

+ CHIESI USA INC	50MG/VIAL	N204958	001	Jun 22, 2015	Jul CAHN
------------------	-----------	---------	-----	--------------	----------

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB ROXANE	150MG	A200483	001	Jul 14, 2016	Jul NEWA
AB	500MG	A200483	002	Jul 14, 2016	Jul NEWA

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

@ APOTEX	12.5MG	A074737	001	Oct 28, 1998	Mar DISC
@	25MG	A074737	002	Oct 28, 1998	Mar DISC
@	50MG	A074737	003	Oct 28, 1998	Mar DISC
@	100MG	A074737	004	Oct 28, 1998	Mar DISC
AB HIKMA INTL PHARMS	12.5MG	A074505	001	Feb 13, 1996	Jun CAHN
AB	25MG	A074505	002	Feb 13, 1996	Jun CAHN
AB	50MG	A074505	003	Feb 13, 1996	Jun CAHN
AB	100MG	A074505	004	Feb 13, 1996	Jun CAHN
AB PRINSTON INC	12.5MG	A074477	001	Feb 13, 1996	Jul CMFD
AB	25MG	A074477	002	Feb 13, 1996	Jul CMFD
AB	50MG	A074477	003	Feb 13, 1996	Jul CMFD
AB	100MG	A074477	004	Feb 13, 1996	Jul CMFD
@ SANDOZ	12.5MG	A074363	001	Nov 09, 1995	Jan DISC
@	25MG	A074363	002	Nov 09, 1995	Jan DISC
@	50MG	A074363	003	Nov 09, 1995	Jan DISC
@	100MG	A074363	004	Nov 09, 1995	Jan DISC
@ STASON	12.5MG	A074677	004	May 30, 1997	Mar DISC
@	25MG	A074677	002	May 30, 1997	Mar DISC
@	50MG	A074677	001	May 30, 1997	Mar DISC
@	100MG	A074677	003	May 30, 1997	Mar DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB MYLAN IRELAND LTD	100MG	A076697	001	May 20, 2011	Jan CAHN
AB	200MG	A076697	002	May 20, 2011	Jan CAHN
AB	300MG	A076697	003	May 20, 2011	Jan CAHN

CARBIDOPATABLET; ORAL
CARBIDOPA

AB	EDENBRIDGE PHARMS	25MG	A205304	001	Feb 17, 2016	Feb	NEWA
----	-------------------	------	---------	-----	--------------	-----	------

CARBIDOPA; LEVODOPATABLET; ORAL
CARBIDOPA AND LEVODOPA

	@ IDT AUSTRALIA LTD	10MG;100MG	A073586	001	Jun 29, 1995	May	CAHN
	@	25MG;100MG	A073587	001	Jun 29, 1995	May	CAHN
	@	25MG;250MG	A073620	001	Jun 29, 1995	May	CAHN
AB	MAYNE PHARMA	10MG;100MG	A073618	001	Aug 28, 1992	Aug	CAHN
AB		25MG;100MG	A073589	001	Aug 28, 1992	Aug	CAHN
AB		25MG;250MG	A073607	001	Aug 28, 1992	Aug	CAHN

CARBINOXAMINE MALEATETABLET; ORAL
CARBINOXAMINE MALEATE
MIKART INC

6MG	A207484	001	May 31, 2016	May	NEWA
-----	---------	-----	--------------	-----	------

CARBOPLATININJECTABLE; IV (INFUSION)
CARBOPLATIN

	@ ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Apr	DISC
	@	150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Apr	DISC
	@	450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Apr	DISC
	@	600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Apr	DISC
AP	SANDOZ INC	50MG/5ML (10MG/ML)	A078280	001	May 08, 2008	Feb	CAHN
AP		150MG/15ML (10MG/ML)	A078280	002	May 08, 2008	Feb	CAHN
AP		450MG/45ML (10MG/ML)	A078280	003	May 08, 2008	Feb	CAHN
AP	SANJA PHARMS CO	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Mar	NEWA
AP		150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Mar	NEWA
AP		450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Mar	NEWA

CARFILZOMIBPOWDER; INTRAVENOUS
KYPROLIS

ONYX THERAP

+

30MG/VIAL	N202714	002	Jun 03, 2016	Jun	NEWA
60MG/VIAL	N202714	001	Jul 20, 2012	Feb	CAHN

CARISOPRODOLTABLET; ORAL
CARISOPRODOL

AA	INGENUS PHARMS NJ	350MG	A040823	001	Oct 22, 2008	Jan	CAHN
AB	STRIDES PHARMA	250MG	A205513	001	Nov 12, 2015	May	CAHN
AA		350MG	A205513	002	Nov 12, 2015	May	CAHN

CARVEDILOLTABLET; ORAL
COREG

AB	SMITHKLINE BEECHAM	3.125MG	N020297	004	May 29, 1997	May	CAHN
AB		6.25MG	N020297	003	Sep 14, 1995	May	CAHN
AB	+	12.5MG	N020297	002	Sep 14, 1995	May	CAHN
AB		25MG	N020297	001	Sep 14, 1995	May	CAHN

CARVEDILOL PHOSPHATECAPSULE, EXTENDED RELEASE; ORAL
COREG CR

SMITHKLINE BEECHAM

10MG	N022012	001	Oct 20, 2006	May	CAHN
20MG	N022012	002	Oct 20, 2006	May	CAHN
40MG	N022012	003	Oct 20, 2006	May	CAHN
80MG	N022012	004	Oct 20, 2006	May	CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATEFOR SUSPENSION; ORAL
CEFADROXIL

@ SUN PHARM INDS LTD

@

@

EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Feb	DISC
EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Feb	DISC
EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Feb	DISC

CEFAZOLIN SODIUMINJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A201654	001	Feb 03, 2016	Jan NEWA
----	-------------	------------------	---------	-----	--------------	----------

CEFDITOREN PIVOXILTABLET; ORAL
SPECTRACEF

@	VANSEN PHARMA	200MG	N021222	001	Aug 29, 2001	Apr DISC
@		400MG	N021222	002	Jul 21, 2008	Apr DISC

CEFEPIME HYDROCHLORIDEINJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

AP	QILU PHARM CO LTD	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan NEWA
AP		EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan NEWA
AP		EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan NEWA

CEFOTAXIME SODIUMINJECTABLE; INJECTION
CEFOTAXIME SODIUM

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016	Feb NEWA
AP		EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016	Feb NEWA
CLAFORAN						
AP	+ US PHARM HOLDINGS	EQ 500MG BASE/VIAL	N050547	001		Jan CAHN
AP	+	EQ 1GM BASE/VIAL	N050547	002		Jan CAHN
AP	+	EQ 2GM BASE/VIAL	N050547	003		Jan CAHN
AP	+	EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan CAHN
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER						
@	US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jun DISC
@		EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jun DISC
+		EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan CAHN
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
@	US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan CAHN
@		EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan CAHN

CEFOTETAN DISODIUMINJECTABLE; INJECTION
CEFOTAN

@	TELIGENT PHARMA INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	Jan CAHN
AP		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb CMFD
	@	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Jan CAHN
	@	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	Jan CAHN
AP		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb CMFD
	@	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Jan CAHN
	@	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Jan CAHN
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER						
+	B BRAUN	EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007	Jun CMS2
+		EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007	Jun CMS2

CEFOXITIN SODIUMINJECTABLE; INJECTION
CEFOXITIN

AP	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011	May CAHN
AP		EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011	May CAHN
AP		EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011	May CAHN
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER						
AP	+ B BRAUN	EQ 1GM BASE/VIAL	N065214	001	Mar 10, 2006	Aug CRLD
AP	+	EQ 2GM BASE/VIAL	N065214	002	Mar 10, 2006	Aug CRLD

CEFPODOXIME PROXETILFOR SUSPENSION; ORAL
CEFPODOXIME PROXETIL

@	SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Feb DISC
@		EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Feb DISC

TABLET; ORAL

CEFPODOXIME PROXETIL

@	SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Feb DISC
@		EQ 200MG BASE	A065083	002	Aug 20, 2003	Feb DISC

CEFTIBUTEN DIHYDRATE

CAPSULE;ORAL

CEDAX

@ PERNIX THERAP

EQ 400MG BASE

N050685 002 Dec 20, 1995 Jun DISC

FOR SUSPENSION;ORAL

CEDAX

@ PERNIX THERAP

EQ 90MG BASE/5ML

N050686 001 Dec 20, 1995 Jun DISC

@

EQ 180MG BASE/5ML

N050686 002 Dec 20, 1995 Jun DISC

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

@ HOSPIRA INC

EQ 1GM BASE/VIAL

A065231 001 Aug 02, 2005 Apr DISC

@

EQ 1GM BASE/VIAL

A202563 001 Aug 20, 2012 Apr DISC

@

EQ 2GM BASE/VIAL

A065231 002 Aug 02, 2005 Apr DISC

@

EQ 2GM BASE/VIAL

A202563 002 Aug 20, 2012 Apr DISC

ROCEPHIN

@ HOFFMANN LA ROCHE

EQ 500MG BASE/VIAL

A063239 002 Aug 13, 1993 Apr DISC

@

EQ 1GM BASE/VIAL

A063239 003 Aug 13, 1993 Apr DISC

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

@ BEDFORD

EQ 250MG BASE/VIAL

A065465 001 Aug 18, 2008 Jun DISC

@

EQ 500MG BASE/VIAL

A065465 002 Aug 18, 2008 Jun DISC

@

EQ 1GM BASE/VIAL

A065465 003 Aug 18, 2008 Jun DISC

@

EQ 2GM BASE/VIAL

A065465 004 Aug 18, 2008 Jun DISC

AP QILU PHARM CO LTD

EQ 250MG BASE/VIAL

A203702 001 Jun 29, 2016 Jun NEWA

AP

EQ 500MG BASE/VIAL

A203702 002 Jun 29, 2016 Jun NEWA

AP

EQ 1GM BASE/VIAL

A203702 003 Jun 29, 2016 Jun NEWA

AP

EQ 2GM BASE/VIAL

A203702 004 Jun 29, 2016 Jun NEWA

CEFUROXIME AXETIL

FOR SUSPENSION;ORAL

CEFTIN

GLAXOSMITHKLINE

EQ 125MG BASE/5ML

N050672 001 Jun 30, 1994 Feb CTEC

+

EQ 250MG BASE/5ML

N050672 002 Apr 29, 1997 Feb CTEC

CEFUROXIME AXETIL

@ SUN PHARM INDS LTD

EQ 125MG BASE/5ML

A065323 001 Feb 05, 2008 Feb DISC

@

EQ 250MG BASE/5ML

A065323 002 Feb 05, 2008 Feb DISC

TABLET;ORAL

CEFUROXIME AXETIL

@ SUN PHARM INDS LTD

EQ 125MG BASE

A065118 001 Apr 25, 2003 Feb DISC

@

EQ 250MG BASE

A065118 002 Apr 25, 2003 Feb DISC

@

EQ 500MG BASE

A065118 003 Apr 25, 2003 Feb DISC

CEFUROXIME SODIUM

INJECTABLE;INJECTION

ZINACEF

AP + IGI LABS INC

EQ 1.5GM BASE/VIAL

N050558 003 Oct 19, 1983 Jan CAHN

AP

+

EQ 7.5GM BASE/VIAL

N050558 004 Oct 23, 1986 Jan CAHN

ZINACEF IN PLASTIC CONTAINER

@ IGI LABS INC

EQ 15MG BASE/ML

N050643 001 Apr 28, 1989 Jan CAHN

+

EQ 30MG BASE/ML

N050643 002 Apr 28, 1989 Jan CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

ZINACEF

AB + IGI LABS INC

EQ 750MG BASE/VIAL

N050558 002 Oct 19, 1983 Jan CAHN

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB AUROBINDO PHARMA LTD

50MG

A206827 001 Feb 01, 2016 Jan NEWA

AB

100MG

A206827 002 Feb 01, 2016 Jan NEWA

AB

200MG

A206827 003 Feb 01, 2016 Jan NEWA

AB

400MG

A206827 004 Feb 01, 2016 Jan NEWA

AB

MACLEODS PHARMS LTD

50MG

A204590 001 Mar 16, 2016 Feb NEWA

AB

100MG

A204590 002 Mar 16, 2016 Feb NEWA

AB

200MG

A204590 003 Mar 16, 2016 Feb NEWA

AB

400MG

A204590 004 Mar 16, 2016 Feb NEWA

CEPHALEXIN

	CAPSULE;ORAL						
	CEPHALEXIN						
	@ SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Feb	DISC
	@	EQ 500MG BASE	A065007	002	Sep 16, 1999	Feb	DISC
	KEFLEX						
AB	PRAGMA PHARMS LLC	EQ 250MG BASE	N050405	002		Jul	CAHN
	@	EQ 333MG BASE	N050405	004	May 12, 2006	Jul	CAHN
AB		EQ 500MG BASE	N050405	003		Jul	CAHN
AB	+	EQ 750MG BASE	N050405	005	May 12, 2006	Jul	CAHN
	FOR SUSPENSION;ORAL						
	KEFLEX						
	@ PRAGMA PHARMS LLC	EQ 100MG BASE/ML	N050406	003		Mar	CAHN
	@	EQ 125MG BASE/5ML	N050406	001		Mar	CAHN
	@	EQ 250MG BASE/5ML	N050406	002		Mar	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL						
CETIRIZINE HYDROCHLORIDE						
AA	NOSTRUM LABS INC	5MG/5ML	A090191	001	Nov 12, 2009	Mar CAHN
AA	+ PERRIGO R AND D	5MG/5ML	A078398	001	Jun 17, 2008	Aug CRLD
	@ WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009	Apr DISC
ZYRTEC						
	@ J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Aug DISC

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL					
LIBRAX					
+	VALEANT PHARMS	5MG;2.5MG	N012750	001	Jul NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL							
PERIOGARD							
AT	COLGATE-PALMOLIVE CO	0.12%	A203212	001	Jan 28, 2016	Jan	NEWA

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION									
CHLOROPROCAINE HYDROCHLORIDE									
>D>	AP	EUROHLTH INTL SARL	2%	A040273	001	Sep 09, 1998	Sep	CAHN	
>D>	AP		3%	A040273	002	Sep 09, 1998	Sep	CAHN	
>A>	AP	WEST-WARD PHARMS INT	2%	A040273	001	Sep 09, 1998	Sep	CAHN	
>A>	AP		3%	A040273	002	Sep 09, 1998	Sep	CAHN	

CHLOROQUINE PHOSPHATE

TABLET;ORAL						
CHLOROQUINE PHOSPHATE						
@ IMPAX LABS	EQ 150MG BASE	A080880	001			Mar DISC
@	EQ 300MG BASE	A040516	001	Aug 29, 2003		Mar DISC

CHLORPHENIRAMINE MALEATE

TABLET;ORAL						
CHLORPHENIRAMINE MALEATE						
@	AUROLIFE PHARMA LLC	4MG	A080961	001		Mar CAHN
@	SUN PHARM INDS	4MG	A080700	001		Jun CAHN

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE;ORAL						
CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE						
@ SPRIASO LLC	8MG;54.3MG	N206323	001	Jun 22, 2015	Jun DISC	

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL						
HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE						
AA	MAYNE PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A205657	001	Aug 03, 2015	Feb CAHN

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ AUROLIFE PHARMA LLC

100MG

A088725 001 Aug 31, 1984 Mar CAHN

@

250MG

A088726 001 Aug 31, 1984 Mar CAHN

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB MYLAN

25MG

A086831 002 Jan CTEC

AB SUN PHARM INDS

25MG

A089286 002 Jul 21, 1986 Jan NEWA

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

@ AUROLIFE PHARMA LLC

250MG

A089852 001 May 04, 1988 Feb CAHN

@

500MG

A089853 001 May 04, 1988 Feb CAHN

+ MIKART

750MG

A040861 002 Jun 01, 2010 Apr CRLD

+ MIKART INC

250MG

A207483 001 Jun 24, 2016 Jun NEWA

@ SUN PHARM INDS

500MG

A089970 001 Sep 27, 1990 Mar CAHN

AA + WATSON LABS

500MG

A089859 001 May 04, 1988 Jul CRLD

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

AB IMPAX LABS INC

EQ 45MG FENOFIBRIC ACID

A200264 001 Sep 07, 2016 Aug NEWA

AB

EQ 135MG FENOFIBRIC ACID

A200264 002 Sep 07, 2016 Aug NEWA

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

+ TAKEDA GMBH

0.08MG/INH

N021658 002 Jan 10, 2008 Jan CRLD

CILASTATIN SODIUM; IMIPENEM

POWDER; INTRAMUSCULAR

PRIMAXIN

@ MERCK

EQ 500MG BASE/VIAL; 500MG/VIAL

N050630 001 Dec 14, 1990 May DISC

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

@ FRONTIDA BIOPHARM

50MG

A077208 002 Mar 29, 2006 Jul CAHN

@

100MG

A077208 001 Mar 29, 2006 Jul CAHN

@ SUN PHARM INDS

50MG

A077208 002 Mar 29, 2006 Jun CAHN

@

100MG

A077208 001 Mar 29, 2006 Jun CAHN

AB + TEVA

50MG

A077027 001 Nov 24, 2004 Jun CRLD

AB

+

100MG

A077027 002 Nov 24, 2004 Jun CRLD

PLETAL

@ OTSUKA

50MG

N020863 001 Jan 15, 1999 Jun DISC

@

100MG

N020863 002 Jan 15, 1999 Jun DISC

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

AT TELIGENT PHARMA INC

EQ 0.3% BASE

A076754 001 Jun 09, 2004 Jul CAHN

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@ IDT AUSTRALIA LTD

EQ 100MG BASE

A075939 001 Mar 03, 2005 May CAHN

@

EQ 250MG BASE

A075939 002 Jun 09, 2004 May CAHN

@

EQ 500MG BASE

A075939 003 Jun 09, 2004 May CAHN

@

EQ 750MG BASE

A075939 004 Jun 09, 2004 May CAHN

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

SOLUTION/DROPS; OTIC

OTOVEL

+ LABORATORIOS SALVAT

EQ 0.3% BASE; 0.025%

N208251 001 Apr 29, 2016 Apr NEWA

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
CIPROFLOXACIN EXTENDED RELEASE

@ ACTAVIS LABS FL INC	212.6MG;EQ 287.5MG BASE	A077417	001	Nov 30, 2010	Jan DISC
@	425.2MG;EQ 574.9MG BASE	A077809	001	Nov 30, 2010	Jan DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CITALOPRAM HYDROBROMIDE

@ SUN PHARM INDS	EQ 10MG BASE	A077052	001	Jul 03, 2006	Mar CAHN
@	EQ 20MG BASE	A077052	002	Jul 03, 2006	Mar CAHN
@	EQ 40MG BASE	A077052	003	Jul 03, 2006	Mar CAHN

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL
CLARITHROMYCIN

AB	ALLIED PHARMA INC	500MG	A203243	001	Feb 29, 2016	Feb NEWA
	@ IDT AUSTRALIA LTD	500MG	A065250	001	Aug 25, 2005	May CAHN
AB	+ MAYNE PHARMA	500MG	A065154	001	May 18, 2005	Aug CAHN

CLEVIDIPINE

EMULSION; INTRAVENOUS
CLEVIPREX

+	CHIESI USA INC	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008	Aug CAHN
+		50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008	Aug CAHN
+		125MG/250ML (0.5MG/ML)	N022156	003	Nov 08, 2013	Aug CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL
CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	MYLAN PHARMS INC	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	May NEWA
----	------------------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL
CLINDESSE

+	PERRIGO PHARMA INTL	EQ 2% BASE	N050793	001	Nov 30, 2004	Jun CAHN
---	---------------------	------------	---------	-----	--------------	----------

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

AP	EUROHLTH INTL SARL	EQ 150MG BASE/ML	A065206	001	Sep 24, 2004	Apr CAHN
----	--------------------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL
VELTIN

BX	+ AQUA PHARMS LLC	1.2%; 0.025%	N050803	001	Jul 16, 2010	Jan CAHN
----	-------------------	--------------	---------	-----	--------------	----------

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL
CLOBETASOL PROPIONATE

AB	+ FOUGERA PHARMS	0.05%	A074407	001	Feb 23, 1996	Mar CRLD
----	------------------	-------	---------	-----	--------------	----------

TEMOVATE

@ FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Mar DISC
------------------	-------	---------	-----	--------------	----------

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
ANAFRANIL

AB	+ MALLINCKRODT LLC	25MG	N019906	001	Dec 29, 1989	Jan CRLD
AB		50MG	N019906	002	Dec 29, 1989	Jan CRLD

CLONIDINE

FILM, EXTENDED RELEASE; TRANSDERMAL
CLONIDINE

AB	MAYNE PHARMA	0.1MG/24HR	A079090	001	Aug 20, 2010	Aug CAHN
AB		0.2MG/24HR	A079090	002	Aug 20, 2010	Aug CAHN
AB		0.3MG/24HR	A079090	003	Aug 20, 2010	Aug CAHN

CLONIDINE HYDROCHLORIDE

TABLET; ORAL							
CLONIDINE HYDROCHLORIDE							
	@ AUROLIFE PHARMA LLC	0.1MG	A070887	001	Aug 31, 1988	Feb	CAHN
	@	0.2MG	A070886	001	Aug 31, 1988	Feb	CAHN
	@	0.3MG	A071294	001	Aug 31, 1988	Feb	CAHN
AB	FRONTIDA BIOPHARM	0.1MG	A070925	001	Sep 04, 1987	Jul	CAHN
AB		0.2MG	A070924	001	Sep 04, 1987	Jul	CAHN
AB		0.3MG	A070923	001	Sep 04, 1987	Jul	CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL							
CLOPIDOGREL BISULFATE							
	@ ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001	May 28, 2013	Jun	DISC
AB	SUN PHARM INDS	EQ 75MG BASE	A078133	001	Jun 10, 2013	Mar	CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL							
CLORAZEPATE DIPOTASSIUM							
	@ AUROLIFE PHARMA LLC	3.75MG	A072219	001	Aug 26, 1988	Apr	CAHN
	@	7.5MG	A072220	001	Aug 26, 1988	Feb	CAHN
	@	15MG	A072112	001	Aug 26, 1988	Feb	CAHN
TABLET; ORAL							
CLORAZEPATE DIPOTASSIUM							
	@ AUROLIFE PHARMA LLC	3.75MG	A072512	001	May 11, 1990	Mar	CAHN
	@	7.5MG	A072513	001	May 11, 1990	Mar	CAHN
	@	15MG	A072514	001	May 11, 1990	Feb	CAHN
TRANXENE							
	@ RECORDATI RARE	3.75MG	N017105	006		Jun	DISC

CLOZAPINE

TABLET; ORAL							
CLOZAPINE							
AB	MAYNE PHARMA	25MG	A203807	001	Sep 17, 2015	Aug	CAHN
AB		100MG	A203807	002	Sep 17, 2015	Aug	CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL							
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE							
AA	NOSTRUM LABS INC	10MG/5ML; 6.25MG/5ML	A090180	001	Mar 17, 2010	Feb	CAHN

COLCHICINE

CAPSULE; ORAL							
MITIGARE							
	+ HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	Mar	CRLD
TABLET; ORAL							
COLCRYS							
>D>	+ TAKEDA PHARMS USA	0.6MG	N022352	001	Jul 29, 2009	Sep	CFTG
>A>	AB +	0.6MG	N022352	001	Jul 29, 2009	Sep	CFTG

COLCHICINE; PROBENECID

TABLET; ORAL							
PROBENECID AND COLCHICINE							
AB	INGENUS PHARMS NJ	0.5MG; 500MG	A040618	001	May 13, 2008	Jan	CAHN

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC							
COLY-MYCIN S							
	+ ENDO PHARMS INC	EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG BASE/ML; 0.5MG/ML	N050356	001		Feb	CAHN

CORTICOTROPIN

INJECTABLE; INJECTION							
PURIFIED CORTROPHIN GEL							
	@ ANI PHARMS	40 UNITS/ML	N008975	001		Feb	CAHN
	@	80 UNITS/ML	N008975	002		Feb	CAHN

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE;INJECTION
CORTROPHIN-ZINC

@ ANI PHARMS 40 UNITS/ML N009854 001 Feb CAHN

CROFELEMER

TABLET, DELAYED RELEASE;ORAL
FULYZAQ

+ NAPO PHARMS INC 125MG N202292 001 Dec 31, 2012 Jun CAHN

CROTAMITON

LOTION;TOPICAL
CROTAN

AT MARNEL PHARMS 10% A087204 001 Aug CAHN

CYANOCOBALAMIN

INJECTABLE;INJECTION
CYANOCOBALAMIN

AP SOMERSET THERAPS LLC 1MG/ML A206503 001 Dec 11, 2015 Mar CAHN

SPRAY, METERED;NASAL
NASCOBAL

+ ENDO PHARMS INC 0.5MG/SPRAY N021642 001 Jan 31, 2005 Feb CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

AB FRONTIDA BIOPHARM 5MG A073541 002 Apr 06, 2006 Jul CAHN

AB 10MG A073541 001 May 23, 1995 Jul CAHN

CYCLOPHOSPHAMIDE

INJECTABLE;INJECTION
CYTOXAN (LYOPHILIZED)

@ BAXTER HLTHCARE 500MG/VIAL N012142 003 Mar DISC

@ 1GM/VIAL N012142 004 Aug 30, 1982 Mar DISC

@ 2GM/VIAL N012142 005 Aug 30, 1982 Mar DISC

CYCLOSPORINE

CAPSULE;ORAL
CYCLOSPORINE

AB1 MAYNE PHARMA 25MG A065044 002 Dec 20, 2000 Aug CAHN

AB1 100MG A065044 001 Dec 20, 2000 Aug CAHN

INJECTABLE;INJECTION
CYCLOSPORINE

>D> AP EUROHLTH INTL SARL 50MG/ML A065004 001 Oct 29, 1999 Sep CAHN

>A> AP WEST-WARD PHARMS INT 50MG/ML A065004 001 Oct 29, 1999 Sep CAHN

SOLUTION;ORAL
CYCLOSPORINE

AB1 MAYNE PHARMA 100MG/ML A065054 001 Dec 18, 2001 Aug CAHN

CYPROHEPTADINE HYDROCHLORIDE

TABLET;ORAL
CYPROHEPTADINE HYDROCHLORIDE

AA INGENUS PHARMS NJ 4MG A205087 001 Sep 23, 2015 Jan CAHN

CYTARABINE

INJECTABLE;INJECTION
CYTARABINE

>D> AP EUROHLTH INTL SARL 100MG/VIAL A071471 001 Aug 02, 1989 Sep CAHN

>D> AP 500MG/VIAL A071472 001 Aug 02, 1989 Sep CAHN

>D> AP 1GM/VIAL A074245 001 Aug 31, 1994 Sep CAHN

>D> AP 2GM/VIAL A074245 002 Aug 31, 1994 Sep CAHN

AP MYLAN PHARMS INC 20MG/ML A200915 001 Dec 13, 2011 Mar CAHN

AP 20MG/ML A200916 001 Dec 13, 2011 Mar CAHN

>A> AP WEST-WARD PHARMS INT 100MG/VIAL A071471 001 Aug 02, 1989 Sep CAHN

>A> AP 500MG/VIAL A071472 001 Aug 02, 1989 Sep CAHN

>A> AP 1GM/VIAL A074245 001 Aug 31, 1994 Sep CAHN

>A> AP 2GM/VIAL A074245 002 Aug 31, 1994 Sep CAHN

DACLATASVIR DIHYDROCHLORIDETABLET; ORAL
DAKLINZA

BRISTOL-MYERS SQUIBB EQ 90MG BASE

N206843 003 Apr 13, 2016 Apr NEWA

DACTINOMYCININJECTABLE; INJECTION
DACTINOMYCIN

@ EUROHLTH INTL SARL 0.5MG/VIAL

A090304 001 Mar 16, 2010 Feb DISC

DALBAVANCIN HYDROCHLORIDEPOWDER; IV (INFUSION)
DALVANCE

+ DURATA THERAPS INTL EQ 500MG BASE/VIAL

N021883 001 May 23, 2014 Jan CDFR

DANAZOLCAPSULE; ORAL
DANAZOL>A> AB LANNETT 50MG
>A> AB 100MGA077246 002 Apr 19, 2007 Sep NEWA
A077246 003 Apr 19, 2007 Sep NEWADANTROLENE SODIUMFOR SUSPENSION; INTRAVENOUS
RYANODEX

+ EAGLE PHARMS 250MG/VIAL

N205579 001 Jul 22, 2014 Jun CRLD

INJECTABLE; INJECTION
DANTROLENE SODIUM

AP MYLAN INSTITUTIONAL 20MG/VIAL

A205239 001 Feb 18, 2016 Feb NEWA

DAPSONEGEL; TOPICAL
ACZONE

+ ALLERGAN INC 7.5%

N207154 001 Feb 24, 2016 Feb NEWA

TABLET; ORAL
DAPSONEAB ALVOGEN 25MG
AB 100MG
AB NORTH CREEK PHARMS 25MG
AB 100MG
AB NOSTRUM LABS INC 25MG
AB 100MGA205429 001 Jan 07, 2016 Mar CAHN
A205429 002 Jan 07, 2016 Mar CAHN
A204074 001 May 10, 2016 Apr NEWA
A204074 002 May 10, 2016 Apr NEWA
A203887 001 May 06, 2016 Apr NEWA
A203887 002 May 06, 2016 Apr NEWADAPTOMYCINPOWDER; INTRAVENOUS
CUBICIN

AP + CUBIST 500MG/VIAL

N021572 002 Sep 12, 2003 Jan CDFR

AP + CUBIST PHARMS LLC 500MG/VIAL
CUBICIN RF

N021572 002 Sep 12, 2003 Aug CAHN

+ CUBIST PHARMS LLC 500MG/VIAL
DAPTOMYCIN

N021572 003 Jul 06, 2016 Aug NEWA

AP CRANE PHARMS LLC 500MG/VIAL

A206005 001 Jun 15, 2016 Jun NEWA

AP HOSPIRA INC 500MG/VIAL

A202857 001 Sep 12, 2014 Jan CDFR

AP TEVA PARENTERAL 500MG/VIAL

A091039 001 Mar 25, 2016 Mar NEWA

POWDER; IV (INFUSION)
CUBICIN

@ CUBIST 250MG/VIAL

N021572 001 Sep 12, 2003 Jan CDFR

@ CUBIST PHARMS LLC 250MG/VIAL

N021572 001 Sep 12, 2003 Aug CAHN

DARIFENACIN HYDROBROMIDETABLET, EXTENDED RELEASE; ORAL
DARIFENACIN HYDROBROMIDE>A> AB AUROBINDO PHARMA LTD EQ 7.5MG BASE
>A> AB EQ 15MG BASE
AB CIPLA LTD EQ 7.5MG BASE
AB EQ 15MG BASEA206743 001 Sep 19, 2016 Sep NEWA
A206743 002 Sep 19, 2016 Sep NEWA
A207664 001 Sep 01, 2016 Aug NEWA
A207664 002 Sep 01, 2016 Aug NEWA

ENABLEX

AB APIL EQ 7.5MG BASE

N021513 001 Dec 22, 2004 Jan CAHN

AB + EQ 15MG BASE

N021513 002 Dec 22, 2004 Jan CAHN

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET, EXTENDED RELEASE; ORAL
VIEKIRA XR

+ ABBVIE INC EQ 200MG BASE; 8.33MG; 50MG; 33.33MG N208624 001 Jul 22, 2016 Jul NEWA

DASATINIB

TABLET; ORAL
DASATINIB

AB	APOTEX INC	20MG	A202103	001	Jun 10, 2016	May NEWA
AB		50MG	A202103	002	Jun 10, 2016	May NEWA
AB		70MG	A202103	003	Jun 10, 2016	May NEWA
AB		100MG	A202103	004	Jun 10, 2016	May NEWA
	SPRYCEL					
AB	BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006	May CFTG
AB		50MG	N021986	002	Jun 28, 2006	May CFTG
AB		70MG	N021986	003	Jun 28, 2006	May CFTG
AB	+	100MG	N021986	004	May 30, 2008	May CFTG

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION
DAUNOXOME

@ GALEN (UK) EQ 2MG BASE/ML N050704 002 Apr 08, 1996 May DISC

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
CERUBIDINE

>D>	AP	+	EUROHLTH INTL SARL	EQ 20MG BASE/VIAL	A064103	001	Feb 03, 1995	Sep CAHN
>A>	AP	+	WEST-WARD PHARMS INT	EQ 20MG BASE/VIAL	A064103	001	Feb 03, 1995	Sep CAHN
			DAUNORUBICIN HYDROCHLORIDE					
>D>	AP	+	EUROHLTH INTL SARL	EQ 5MG BASE/ML	N050731	001	Jan 30, 1998	Sep CAHN
>A>	AP	+	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	N050731	001	Jan 30, 1998	Sep CAHN

DEFERASIROX

TABLET, FOR SUSPENSION; ORAL
DEFERASIROX

AB	ACTAVIS ELIZABETH	125MG	A203560	001	Jan 26, 2016	Jan NEWA
AB		250MG	A203560	002	Jan 26, 2016	Jan NEWA
AB		500MG	A203560	003	Jan 26, 2016	Jan NEWA
	EXJADE					
AB	NOVARTIS	125MG	N021882	001	Nov 02, 2005	Jan CFTG
AB		250MG	N021882	002	Nov 02, 2005	Jan CFTG
AB	+	500MG	N021882	003	Nov 02, 2005	Jan CFTG

DEFIBROTIDE SODIUM

SOLUTION; IV (INFUSION)
DEFITELIO

+	GENTIUM SPA	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016	Mar NEWA
+	JAZZ PHARMS INC	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016	Aug CAHN

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL
DEMECLOCYCLINE HYDROCHLORIDE

@	IMPAX LABS	150MG	A065094	001	Mar 22, 2004	Mar DISC
@		300MG	A065094	002	Mar 22, 2004	Mar DISC

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	10MG	A208105	001	Mar 17, 2016	Mar NEWA
AB		25MG	A208105	002	Mar 17, 2016	Mar NEWA
AB		50MG	A208105	003	Mar 17, 2016	Mar NEWA
AB		75MG	A208105	004	Mar 17, 2016	Mar NEWA
AB		100MG	A208105	005	Mar 17, 2016	Mar NEWA
AB		150MG	A208105	006	Mar 17, 2016	Mar NEWA
AB	HERITAGE PHARMS INC	10MG	A207433	001	May 05, 2016	Jun CAHN
AB		25MG	A207433	002	May 05, 2016	Jun CAHN
AB		50MG	A207433	003	May 05, 2016	Jun CAHN
AB		75MG	A207433	004	May 05, 2016	Jun CAHN
AB		100MG	A207433	005	May 05, 2016	Jun CAHN
AB		150MG	A207433	006	May 05, 2016	Jun CAHN
AB	INDICUS PHARMA	10MG	A207433	001	May 05, 2016	Apr NEWA

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

AB		25MG	A207433	002	May 05, 2016	Apr	NEWA
AB		50MG	A207433	003	May 05, 2016	Apr	NEWA
AB		75MG	A207433	004	May 05, 2016	Apr	NEWA
AB		100MG	A207433	005	May 05, 2016	Apr	NEWA
AB		150MG	A207433	006	May 05, 2016	Apr	NEWA

NORPRAMIN

AB	US PHARM HOLDINGS	10MG	N014399	007	Feb 11, 1982	Jan	CAHN
AB		25MG	N014399	001		Jan	CAHN
AB		50MG	N014399	003		Jan	CAHN
AB		75MG	N014399	004		Jan	CAHN
AB	+	100MG	N014399	005		Jan	CAHN
AB		150MG	N014399	006		Jan	CAHN

DESLORATADINE

SOLUTION;ORAL

DESLORATADINE

AA	TARO	0.5MG/ML	A202936	001	May 26, 2016	May	NEWA
----	------	----------	---------	-----	--------------	-----	------

DESMOPRESSIN ACETATE

SPRAY, METERED;NASAL

STIMATE (NEEDS NO REFRIGERATION)

+	CSL BEHRING	0.15MG/SPRAY	N020355	002	Oct 24, 2007	Aug	CPOT
---	-------------	--------------	---------	-----	--------------	-----	------

TABLET;ORAL

DESMOPRESSIN ACETATE

	@ FERRING	0.1MG	N021795	001	May 08, 2008	Jun	DISC
	@	0.2MG	N021795	002	May 08, 2008	Jun	DISC
AB	IMPAX LABS INC	0.1MG	A077122	001	Jan 25, 2006	Aug	CAHN
AB		0.2MG	A077122	002	Jan 25, 2006	Aug	CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

>D>	AB	DURAMED PHARMS BARR	0.15MG;0.03MG	A075256	002	Aug 12, 1999	Sep	CRLD	
>A>	AB	+	0.15MG;0.03MG	A075256	002	Aug 12, 1999	Sep	CRLD	
	AB	MAYNE PHARMA	0.15MG,N/A;0.02MG,0.01MG	A076916	001	Dec 29, 2008	Aug	CAHN	
	AB		0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	A077182	001	Jan 24, 2006	Aug	CAHN	
>D>		ORTHO-CEPT							
>D>	AB	+	JANSSEN PHARMS	0.15MG;0.03MG	N020301	002	Dec 14, 1992	Sep	DISC
>A>		@	0.15MG;0.03MG	N020301	002	Dec 14, 1992	Sep	DISC	
		VOLNEA							
	AB	SANDOZ INC	0.15MG,N/A;0.02MG,0.01MG	A202689	001	Sep 09, 2016	Aug	NEWA	

DESONIDE

CREAM;TOPICAL

DESONIDE

AB	G AND W LABS INC	0.05%	A074027	001	Sep 28, 1992	Jan	CAHN
----	------------------	-------	---------	-----	--------------	-----	------

DESOXIMETASONE

GEL;TOPICAL

DESOXIMETASONE

AB	GROUPE PARIMA INC	0.05%	A204675	001	Aug 12, 2016	Aug	NEWA
----	-------------------	-------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL

DESOXIMETASONE

AB	NOVEL LABS INC	0.25%	A206792	001	May 10, 2016	Apr	NEWA
AB	PERRIGO ISRAEL	0.25%	A077770	001	Apr 20, 2015	May	CAHN
AB	TELIGENT PHARMA INC	0.25%	A208101	001	Feb 25, 2016	Feb	NEWA

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB	ACTAVIS LABS FL INC	EQ 25MG BASE	A204065	001	Jul 29, 2016	Jul	NEWA
AB		EQ 50MG BASE	A204065	002	Jul 29, 2016	Jul	NEWA
AB		EQ 100MG BASE	A204065	003	Jul 29, 2016	Jul	NEWA
AB	ROXANE	EQ 50MG BASE	A204082	001	Feb 16, 2016	Feb	NEWA
AB		EQ 100MG BASE	A204083	001	Feb 16, 2016	Feb	NEWA
	PRISTIQ						
AB	WYETH PHARMS INC	EQ 25MG BASE	N021992	003	Aug 20, 2014	Jul	CFTG

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

@	IDT AUSTRALIA LTD	0.75MG	A080399	001		May	CAHN
@	SUN PHARM INDS	0.25MG	A084013	001		Mar	CAHN
@		0.25MG	A084764	001		Mar	CAHN
@		0.5MG	A084084	001		Mar	CAHN
@		0.5MG	A084766	001		Mar	CAHN
@		0.75MG	A084081	001		Mar	CAHN
@		0.75MG	A084765	001		Mar	CAHN
@		1.5MG	A084086	001		Mar	CAHN
@		1.5MG	A084763	001		Mar	CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP	+	FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A040491	001	Apr 11, 2003	Mar	CTNA
----	---	--------------------	----------------------	---------	-----	--------------	-----	------

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; ORAL

DEXILANT SOLUTAB

+	TAKEDA PHARMS USA	30MG	N208056	001	Jan 26, 2016	Jan	NEWA
---	-------------------	------	---------	-----	--------------	-----	------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		ACCORD HLTHCARE INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204023	001	Feb 09, 2016	Jan	NEWA
AP		AUROBINDO PHARMA LTD	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205867	001	Mar 17, 2016	Mar	NEWA
AP		SANDOZ INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A091465	001	Jun 14, 2016	May	NEWA
		PRECEDEX						
+		HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Feb	CRLD

DESMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DESMETHYLPHENIDATE HYDROCHLORIDE

AB		IMPAX LABS INC	5MG	A079108	001	Aug 05, 2015	Aug	CAHN
AB			10MG	A079108	002	Aug 05, 2015	Aug	CAHN
AB			15MG	A079108	003	May 19, 2014	Aug	CAHN
AB			20MG	A079108	004	Dec 21, 2015	Aug	CAHN
AB			30MG	A079108	005	Nov 21, 2013	Aug	CAHN

TABLET; ORAL

DESMETHYLPHENIDATE HYDROCHLORIDE

AB		SUN PHARM INDS	2.5MG	A201231	001	Sep 24, 2015	Feb	CAHN
AB			5MG	A201231	002	Sep 24, 2015	Feb	CAHN
AB			10MG	A201231	003	Sep 24, 2015	Feb	CAHN
AB		TRIS PHARMA INC	2.5MG	A207901	001	Aug 26, 2016	Aug	NEWA
AB			5MG	A207901	002	Aug 26, 2016	Aug	NEWA
AB			10MG	A207901	003	Aug 26, 2016	Aug	NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

TOTECH

+	CLINIGEN HLTHCARE	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Mar	CAHN
---	-------------------	--------------------	---------	-----	--------------	-----	------

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMPHETAMINE SULFATE

AB		MAYNE PHARMA	5MG	A076137	001	Jan 18, 2002	Aug	CAHN
AB			10MG	A076137	002	Jan 18, 2002	Aug	CAHN
AB			15MG	A076137	003	Jan 18, 2002	Aug	CAHN
AB		MYLAN PHARMS INC	5MG	A206735	001	Jan 27, 2016	Jan	NEWA
AB			10MG	A206735	002	Jan 27, 2016	Jan	NEWA
AB			15MG	A206735	003	Jan 27, 2016	Jan	NEWA

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

>D>	AA	COREPHARMA	5MG	A090652	001	Mar 07, 2014	Sep	DISC
>A>		@	5MG	A090652	001	Mar 07, 2014	Sep	DISC
>D>	AA		10MG	A090652	002	Mar 07, 2014	Sep	DISC

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

>A>	@	10MG	A090652	002	Mar 07, 2014	Sep DISC
	@ IDT AUSTRALIA LTD	5MG	A085370	001		Aug CAHN
AA	NESHER PHARMS	5MG	A206588	001	Mar 28, 2016	Mar NEWA
AA		10MG	A206588	002	Mar 28, 2016	Mar NEWA
AA	NOVEL LABS INC	5MG	A204330	001	Mar 16, 2016	Feb NEWA
AA		10MG	A204330	002	Mar 16, 2016	Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

@ ANI PHARMS	15MG/5ML;6.25MG/5ML	N011265	002	Apr 02, 1984	Feb CMS1
--------------	---------------------	---------	-----	--------------	----------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

>D>	HOSPIRA	5GM/100ML;53MG/100ML;100MG/100ML;100MG/100ML;180MG/100ML;280MG/100ML;16MG/100ML	N019515	001	May 08, 1986	Sep DISC
>A>	@	5GM/100ML;53MG/100ML;100MG/100ML;100MG/100ML;180MG/100ML;280MG/100ML;16MG/100ML	N019515	001	May 08, 1986	Sep DISC

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;31MG/100ML;141MG/100ML;20MG/100ML;12MG/100ML;260MG/100ML	N017484	001		Feb CMS1
-----------------	--	---------	-----	--	----------

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	5GM/100ML;205MG/100ML;100MG/100ML;120MG/100ML;220MG/100ML	N018840	001	Jun 29, 1983	Feb CMS1
-------------------	---	---------	-----	--------------	----------

DIAZEPAM

INJECTABLE;INJECTION

DIAZEPAM

@ EUROHLTH INTL SARL	5MG/ML	A070313	001	Dec 16, 1985	Jan CAHN
----------------------	--------	---------	-----	--------------	----------

SOLUTION;ORAL

DIAZEPAM

AA	LANNETT HOLDINGS INC	5MG/5ML	A206477	001	Jun 24, 2016	Jun NEWA
AA	+ ROXANE	5MG/5ML	A070928	001	Apr 03, 1987	Jun CFTG

TABLET;ORAL

DIAZEPAM

	DAVA PHARMS INC	2MG	A070228	002	Sep 26, 1985	Jan NEWA
		5MG	A070228	003	Sep 26, 1985	Jan NEWA
AB	MAYNE PHARMA	2MG	A071134	001	Feb 03, 1987	Aug CAHN
AB		5MG	A071135	001	Feb 03, 1987	Aug CAHN
AB		10MG	A071136	001	Feb 03, 1987	Aug CAHN

DICLOFENAC POTASSIUM

CAPSULE;ORAL

DICLOFENAC POTASSIUM

AB	BIONPHARMA INC	25MG	A204648	001	Feb 23, 2016	Feb NEWA
----	----------------	------	---------	-----	--------------	----------

ZIPSOR

AB	+ DEPOMED INC	25MG	N022202	001	Jun 16, 2009	Feb CFTG
----	---------------	------	---------	-----	--------------	----------

FOR SOLUTION;ORAL

CAMBIA

AB	+ DEPOMED INC	50MG	N022165	001	Jun 17, 2009	Apr CFTG
----	---------------	------	---------	-----	--------------	----------

DICLOFENAC POTASSIUM

AB	PAR FORM	50MG	A202964	001	May 02, 2016	Apr NEWA
----	----------	------	---------	-----	--------------	----------

TABLET;ORAL

CATAFLAM

	@ NOVARTIS	50MG	N020142	002	Nov 24, 1993	Mar DISC
	DICLOFENAC POTASSIUM					
AB	+ MYLAN	50MG	A075463	001	Jul 26, 1999	Mar CRLD
	@ SUN PHARM INDS	50MG	A075470	001	Feb 21, 2002	Jun CAHN

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AB	AMNEAL PHARMS	1%	A208077	001	Mar 18, 2016	Mar NEWA
AB	GLENMARK PHARMS LTD	3%	A208301	001	Sep 13, 2016	Aug NEWA
AB	TARO	3%	A206298	001	Apr 28, 2016	Apr NEWA

VOLTAREN

AB	+ GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Mar CFTG
----	------------------------	----	---------	-----	--------------	----------

SOLUTION;TOPICAL

DICLOFENAC SODIUM

AT	AMNEAL PHARMS	1.5%	A206116	001	Sep 02, 2016	Aug NEWA
AT	TELIGENT PHARMA INC	1.5%	A202769	001	Jul 08, 2015	May CAHN

SOLUTION/DROPS;OPHTHALMIC

DICLOFENAC SODIUM

AT	RISING PHARMS INC	0.1%	A078553	001	Dec 28, 2007	Jan CAHN
----	-------------------	------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

AB	+ ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002	Feb CRLD
----	---------------------	-------	---------	-----	--------------	----------

VOLTAREN-XR

@ NOVARTIS 100MG

N020254	001	Mar 08, 1996	Feb DISC
---------	-----	--------------	----------

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

AB	EXELA PHARMA SCS LLC	50MG;0.2MG	A200540	001	Mar 14, 2014	Mar CAHN
AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Mar CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

DICYCLOMINE HYDROCHLORIDE

@ SUN PHARM INDS 10MG

A084505	001	Oct 21, 1986	Mar CAHN
---------	-----	--------------	----------

INJECTABLE;INJECTION

DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)

>D> AP	EUROHLTH INTL SARL	10MG/ML	A040465	001	Jun 30, 2003	Sep CAHN
AP		10MG/ML	A040465	001	Jun 30, 2003	Mar CMS1
>A> AP	WEST-WARD PHARMS INT	10MG/ML	A040465	001	Jun 30, 2003	Sep CAHN

SYRUP;ORAL

DICYCLOMINE HYDROCHLORIDE

+ MIKART 10MG/5ML

A040169	001	Mar 24, 2005	Jan CRLD
---------	-----	--------------	----------

TABLET;ORAL

DICYCLOMINE HYDROCHLORIDE

@ SUN PHARM INDS 20MG

A084600	001	Jul 29, 1985	Mar CAHN
---------	-----	--------------	----------

DIENOGEST; ESTRADIOL VALERATE

TABLET;ORAL

ESTRADIOL VALERATE AND DIENOGEST

AB	WATSON LABS INC	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M G, N/A	A202349	001	May 06, 2016	Apr NEWA
----	-----------------	---	---------	-----	--------------	----------

NATAZIA

AB	+ BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M G, N/A	N022252	001	May 06, 2010	Apr CFTG
----	------------------	---	---------	-----	--------------	----------

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

DIETHYLPROPION HYDROCHLORIDE

@ COREPHARMA 25MG

A040828	001	Nov 05, 2008	Mar DISC
---------	-----	--------------	----------

TENUATE

AA	+ ACTAVIS LABS UT INC	25MG	N011722	002		Apr CAHN
AA	+ ALLERGAN SALES LLC	25MG	N011722	002		Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

TENUATE DOSPAN

AB	+ ACTAVIS LABS UT INC	75MG	N012546	001		Apr CAHN
AB	+ ALLERGAN SALES LLC	75MG	N012546	001		Mar CAHN

DIFLUNISAL

TABLET;ORAL

DIFLUNISAL

@ IDT AUSTRALIA LTD 500MG

A074604	001	Jun 10, 1996	May CAHN
---------	-----	--------------	----------

DIGOXIN

INJECTABLE;INJECTION
LANOXIN

AP	+	COVIS PHARMA SARL	0.25MG/ML	N009330	002		Jun	CAHN
		LANOXIN PEDIATRIC						
	+	COVIS PHARMA SARL	0.1MG/ML	N009330	004		Jun	CAHN

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION
DIHYDROERGOTAMINE MESYLATE

AP		EUROHLTH INTL SARL	1MG/ML	A040453	001	Jun 09, 2003	Apr	CAHN
----	--	--------------------	--------	---------	-----	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DILACOR XR

	@	ALLERGAN SALES LLC	120MG	N020092	001	May 29, 1992	Jul	CAHN
	@		180MG	N020092	002	May 29, 1992	Jul	CAHN
	@		240MG	N020092	003	May 29, 1992	Jul	CAHN
		DILTIAZEM HYDROCHLORIDE						
	@	ACTAVIS LABS FL INC	120MG	A074852	001	Oct 10, 1997	Jan	DISC
	@		180MG	A074852	002	Oct 10, 1997	Jan	DISC
	@		240MG	A074852	003	Oct 10, 1997	Jan	DISC
AB3		VALEANT PHARMS NORTH	120MG	A075116	001	Dec 23, 1999	Jan	CAHN
AB3			180MG	A075116	002	Dec 23, 1999	Jan	CAHN
AB3			240MG	A075116	003	Dec 23, 1999	Jan	CAHN
AB3			300MG	A075116	004	Dec 23, 1999	Jan	CAHN

INJECTABLE;INJECTION
DILTIAZEM HYDROCHLORIDE

AP	+	AMPHASTAR PHARMS INC	5MG/ML	A074617	001	Feb 28, 1996	Jun	CAHN
AP	+	EUROHLTH INTL SARL	5MG/ML	A074617	001	Feb 28, 1996	Apr	CAHN

DINOPROSTONE

INSERT, EXTENDED RELEASE;VAGINAL
CERVIDIL

	+	FERRING PHARMS INC	10MG	N020411	001	Mar 30, 1995	Jan	CAHN
--	---	--------------------	------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL
DIPHENHYDRAMINE HYDROCHLORIDE

	@	HIKMA INTL PHARMS	50MG	A083567	001		Jul	CAHN
	@	HIKMA PHARMS	50MG	A083567	001		Feb	CAHN
	@	SUN PHARM INDS	25MG	A089488	001	Jan 02, 1987	Mar	CAHN
	@		50MG	A089489	001	Jan 02, 1987	Jun	CAHN

DIPYRIDAMOLE

INJECTABLE;INJECTION
DIPYRIDAMOLE

AP	+	AMPHASTAR PHARMS INC	5MG/ML	A074939	001	Apr 13, 1998	Jun	CAHN
AP	+	EUROHLTH INTL SARL	5MG/ML	A074939	001	Apr 13, 1998	Apr	CAHN

TABLET;ORAL

DIPYRIDAMOLE

	@	IDT AUSTRALIA LTD	25MG	A086944	002	Apr 16, 1991	May	CAHN
	@		50MG	A087562	001	Feb 25, 1992	May	CAHN
	@		75MG	A087561	001	Feb 25, 1992	May	CAHN
	@	LANNETT	25MG	A040898	001	Apr 23, 2008	Aug	DISC
	@		50MG	A040898	002	Apr 23, 2008	Aug	DISC
	@		75MG	A040898	003	Apr 23, 2008	Aug	DISC
	@	PUREPAC PHARM	25MG	A089425	001	Jul 12, 1990	Jul	DISC

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL
DISOPYRAMIDE PHOSPHATE

	@	AUROLIFE PHARMA LLC	EQ 100MG BASE	A070470	001	Dec 10, 1985	Feb	CAHN
	@		EQ 150MG BASE	A070471	001	Dec 10, 1985	Feb	CAHN
AB		MAYNE PHARMA	EQ 100MG BASE	A070173	001	May 31, 1985	Aug	CAHN
AB			EQ 150MG BASE	A070174	001	May 31, 1985	Aug	CAHN
	@	SUN PHARM INDS	EQ 100MG BASE	A070351	001	Dec 17, 1985	Mar	CAHN
	@		EQ 150MG BASE	A070352	001	Dec 17, 1985	Mar	CAHN

DISULFIRAMTABLET; ORAL
DISULFIRAM

AB	ALVOGEN MALTA	250MG	A091681	001	Aug 08, 2013	Jan CAHN
----	---------------	-------	---------	-----	--------------	----------

DIVALPROEX SODIUMTABLET, EXTENDED RELEASE; ORAL
DIVALPROEX SODIUM

@	IMPAX LABS	EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009	Feb DISC
@		EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009	Feb DISC

DOBUTAMINE HYDROCHLORIDEINJECTABLE; INJECTION
DOBUTAMINE HYDROCHLORIDE

>D>	AP	EUROHLTH INTL SARL	EQ 12.5MG BASE/ML	A074277	001	Oct 31, 1994	Sep CAHN
		@ TELIGENT PHARMA INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995	Jan CAHN
>A>	AP	WEST-WARD PHARMS INT	EQ 12.5MG BASE/ML	A074277	001	Oct 31, 1994	Sep CAHN

DOCETAXELINJECTABLE; INJECTION
DOCETAXEL

HOSPIRA INC	20MG/ML (20MG/ML)	N022234	004	Jun 23, 2016	Jun NEWA
	80MG/4ML (20MG/ML)	N022234	005	Jun 23, 2016	Jun NEWA
	120MG/6ML (20MG/ML)	N022234	006	Jun 23, 2016	Jun NEWA

SOLUTION; IV (INFUSION)
DOCETAXEL

EAGLE PHARMS	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Jan CAHN
	80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Jan CAHN
	160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Jan CAHN

DOFETILIDECAPSULE; ORAL
DOFETILIDE

AB	TIGER PHARMS LLC	0.125MG	A207058	001	Jun 06, 2016	May NEWA
AB		0.25MG	A207058	002	Jun 06, 2016	May NEWA
AB		0.5MG	A207058	003	Jun 06, 2016	May NEWA
	TIKOSYN					
AB	PFIZER	0.125MG	N020931	001	Oct 01, 1999	May CFTG
AB		0.25MG	N020931	002	Oct 01, 1999	May CFTG
AB	+	0.5MG	N020931	003	Oct 01, 1999	May CFTG

DOLASETRON MESYLATEINJECTABLE; INJECTION
ANZEMET

+	US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Jan CAHN
+		12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Jan CAHN
+		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997	Jan CAHN
@		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001	Jun DISC
+		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001	Jan CAHN

TABLET; ORAL
ANZEMET

US PHARM HOLDINGS	50MG	N020623	001	Sep 11, 1997	Jan CAHN
+	100MG	N020623	002	Sep 11, 1997	Jan CAHN

DOLUTEGRAVIR SODIUMTABLET; ORAL
TIVICAY

VIIV HLTHCARE	EQ 10MG BASE	N204790	002	Jun 09, 2016	Jun NEWA
	EQ 25MG BASE	N204790	003	Jun 09, 2016	Jun NEWA

DONEPEZIL HYDROCHLORIDETABLET; ORAL
DONEPEZIL HYDROCHLORIDE

AB	DEXCEL PHARMA	23MG	A203713	001	Feb 19, 2016	Feb NEWA
AB	INDICUS PHARMA	23MG	A203419	001	Apr 12, 2016	Mar NEWA
AB	OSMOTICA PHARM CORP	23MG	A203114	001	Jan 26, 2016	Jan NEWA
AB	OSMOTICA PHARM US	23MG	A203114	001	Jan 26, 2016	Jun CAHN
AB	UNICHEM LABS LTD	5MG	A203656	001	Jun 23, 2016	Jun NEWA
AB		10MG	A203656	002	Jun 23, 2016	Jun NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

DONEPEZIL HYDROCHLORIDE

@ SUN PHARM INDS

5MG

A077975 002 Dec 11, 2009 Mar CAHN

@

10MG

A077975 001 Dec 11, 2009 Mar CAHN

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

NAMZARIC

FOREST LABS LLC

10MG;7MG

N206439 003 Jul 18, 2016 Aug NEWA

10MG;21MG

N206439 004 Jul 18, 2016 Aug NEWA

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

@ LANNETT HOLDINGS INC EQ 2% BASE;EQ 0.5% BASE

A201998 001 Dec 17, 2014 Aug DISC

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOXAPRAM HYDROCHLORIDE

AP AMPHASTAR PHARMS INC

20MG/ML

A076266 001 Jan 10, 2003 Jun CAHN

AP EUROHLTH INTL SARL

20MG/ML

A076266 001 Jan 10, 2003 Apr CAHN

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

@ IDT AUSTRALIA LTD

EQ 1MG BASE

A075432 001 Oct 18, 2000 Mar CAHN

@

EQ 2MG BASE

A075432 002 Oct 18, 2000 Mar CAHN

@

EQ 4MG BASE

A075432 003 Oct 18, 2000 Mar CAHN

@

EQ 8MG BASE

A075432 004 Oct 18, 2000 Mar CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

@ SUN PHARM INDS

EQ 25MG BASE

A071502 001 Feb 18, 1988 Mar CAHN

@

EQ 50MG BASE

A071653 001 Feb 18, 1988 Mar CAHN

@

EQ 75MG BASE

A071654 001 Feb 18, 1988 Mar CAHN

@

EQ 100MG BASE

A071521 001 Feb 18, 1988 Mar CAHN

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB MYLAN PHARMS INC

EQ 3MG BASE

A202337 001 Jan 20, 2016 Jan NEWA

AB

EQ 6MG BASE

A202337 002 Jan 20, 2016 Jan NEWA

DOXERCALCIFEROL

CAPSULE;ORAL

DOXERCALCIFEROL

AB RISING PHARMS INC

0.5MCG

A201518 001 Sep 09, 2016 Aug NEWA

AB

1MCG

A201518 002 Sep 09, 2016 Aug NEWA

AB

2.5MCG

A201518 003 Sep 09, 2016 Aug NEWA

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP AKORN INC

2MCG/ML (2MCG/ML)

A203929 002 Mar 28, 2016 Mar NEWA

HECTOROL

AP GENZYME CORP

2MCG/ML (2MCG/ML)

N021027 002 Apr 06, 2000 Mar CFTG

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP ACTAVIS INC

2MG/ML

A203622 001 Jun 27, 2014 May CRLD

AP 200MG/100ML

A203622 002 Jun 27, 2014 May CRLD

>D> AP EUROHLTH INTL SARL

2MG/ML

A062975 001 Mar 17, 1989 Sep CAHN

>D> AP + 10MG/VIAL

A062921 001 Mar 17, 1989 Sep CAHN

>D> AP + 20MG/VIAL

A062921 002 Mar 17, 1989 Sep CAHN

>D> AP + 50MG/VIAL

A062921 003 Mar 17, 1989 Sep CAHN

>D> AP 200MG/100ML

A064097 001 Sep 13, 1994 Sep CAHN

AP + PHARMACIA AND UPJOHN

2MG/ML

N050629 001 Dec 23, 1987 May CRLD

AP + 200MG/100ML

N050629 002 May 03, 1988 May CRLD

>A> AP WEST-WARD PHARMS INT

2MG/ML

A062975 001 Mar 17, 1989 Sep CAHN

>A> AP + 10MG/VIAL

A062921 001 Mar 17, 1989 Sep CAHN

>A> AP + 20MG/VIAL

A062921 002 Mar 17, 1989 Sep CAHN

>A> AP + 50MG/VIAL

A062921 003 Mar 17, 1989 Sep CAHN

>A> AP 200MG/100ML

A064097 001 Sep 13, 1994 Sep CAHN

DOXYCYCLINECAPSULE;ORAL
DOXYCYCLINE

AB	G AND W LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	Mar CAHN
AB		EQ 75MG BASE	A204446	002	May 28, 2015	Mar CAHN
AB		EQ 100MG BASE	A204446	003	May 28, 2015	Mar CAHN
AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A205115	001	Feb 18, 2016	Feb NEWA
AB		EQ 75MG BASE	A205115	002	Feb 18, 2016	Feb NEWA
AB		EQ 100MG BASE	A205115	003	Feb 18, 2016	Feb NEWA

TABLET;ORAL
DOXYCYCLINE

@	SUN PHARM INDS	EQ 50MG BASE	A065471	001	Apr 17, 2009	Jun CAHN
@		EQ 75MG BASE	A065471	002	Apr 17, 2009	Jun CAHN
@		EQ 100MG BASE	A065471	003	Apr 17, 2009	Jun CAHN

DOXYCYCLINE HYCLATECAPSULE;ORAL
ACTICLATE CAP

+	AQUA PHARMS	EQ 75MG BASE	N208253	001	Apr 26, 2016	Apr NEWA
	DOXYCYCLINE HYCLATE					
AB	AMNEAL PHARMS	EQ 100MG BASE	A207289	001	Jun 27, 2016	Jun NEWA
AB	SUN PHARM INDS	EQ 100MG BASE	A062676	001	Jul 10, 1986	Mar CAHN

INJECTABLE;INJECTION
DOXYCYCLINE

>D>	AP	+	EUROHLTH INTL SARL	EQ 100MG BASE/VIAL	A062569	001	Mar 09, 1988	Sep CAHN
>D>		@		EQ 200MG BASE/VIAL	A062569	002	Mar 09, 1988	Sep CAHN
>A>	AP	+	WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062569	001	Mar 09, 1988	Sep CAHN
>A>		@		EQ 200MG BASE/VIAL	A062569	002	Mar 09, 1988	Sep CAHN

TABLET;ORAL

DOXYCYCLINE HYCLATE

@	COREPHARMA	EQ 20MG BASE	A065182	001	May 13, 2005	Mar DISC
AB	SUN PHARM INDS	EQ 20MG BASE	A065134	001	May 13, 2005	Mar CAHN
AB		EQ 100MG BASE	A062677	001	Jul 10, 1986	Mar CAHN
@	VINTAGE PHARMS	EQ 100MG BASE	A062538	001	Apr 07, 1986	Mar DISC

TABLET, DELAYED RELEASE;ORAL

DORYX

AB	MAYNE PHARMA	EQ 50MG BASE	N050795	006	Dec 19, 2014	Jul CTNA
AB		EQ 50MG BASE	N050795	006	Dec 19, 2014	May CFTG
AB		EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr CFTG
AB	+	EQ 200MG BASE	N050795	005	Apr 11, 2013	May CFTG

DORYX MPC

MAYNE PHARMA

EQ 60MG BASE	N050795	007	May 20, 2016	Jul CTNA
EQ 60MG BASE	N050795	007	May 20, 2016	May NEWA
EQ 120MG BASE	N050795	008	May 20, 2016	Jul CTNA
EQ 120MG BASE	N050795	008	May 20, 2016	May NEWA

DOXYCYCLINE HYCLATE

@	IMPAX LABS INC	EQ 75MG BASE	A090505	001	Dec 28, 2010	Mar DISC
@		EQ 100MG BASE	A090505	002	Dec 28, 2010	Mar DISC
AB	MYLAN	EQ 50MG BASE	A090431	003	May 23, 2016	May NEWA
AB		EQ 80MG BASE	A090431	004	Apr 29, 2016	Apr NEWA
AB		EQ 200MG BASE	A090431	005	May 19, 2016	May NEWA

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL

DICLEGIS

AB	+	DUCHESNAY	10MG;10MG	N021876	001	Apr 08, 2013	Aug CFTG
		DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE					
AB		ACTAVIS LABS FL INC	10MG;10MG	A205811	001	Aug 19, 2016	Aug NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

MELAMISA

AB	NOVAST LABS LTD	3MG;0.02MG	A202016	001	Jan 26, 2016	Jan NEWA
----	-----------------	------------	---------	-----	--------------	----------

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

>A>	AB	APOTEX INC	3MG;0.03MG	A205876	001	Sep 21, 2016	Sep NEWA
	AB	GLENMARK PHARMS LTD	3MG;0.03MG	A204848	001	Mar 25, 2016	Mar NEWA
	AB	MAYNE PHARMA	3MG;0.03MG	A090081	001	Sep 07, 2010	Aug CAHN

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET; ORAL

BEYAZ

>D>	BAYER HLTHCARE	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	N022532	001	Sep 24, 2010	Sep CFTG
>A> AB		3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	N022532	001	Sep 24, 2010	Sep CFTG
>A>	DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM					
>A> AB	WATSON LABS INC	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	A203593	001	Oct 11, 2016	Sep NEWA
>A> AB		3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	A203594	001	Oct 11, 2016	Sep NEWA
	SAFYRAL					
>D>	+ BAYER HLTHCARE	3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	N022574	001	Dec 16, 2010	Sep CFTG
>A> AB	+	3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	N022574	001	Dec 16, 2010	Sep CFTG

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

DULOXETINE HYDROCHLORIDE

AB	HETERO LABS LTD III	EQ 20MG BASE	A204343	001	Aug 03, 2016	Jul NEWA
AB		EQ 30MG BASE	A204343	002	Aug 03, 2016	Jul NEWA
AB		EQ 60MG BASE	A204343	003	Aug 03, 2016	Jul NEWA

DUTASTERIDE

CAPSULE; ORAL

DUTASTERIDE

AB	AUROLIFE PHARMA LLC	0.5MG	A202660	001	Nov 20, 2015	Apr CAHN
AB	BIONPHARMA INC	0.5MG	A200899	001	Nov 20, 2015	Jan CAHN
AB	INTERGEL PHARMS INC	0.5MG	A206373	001	Mar 17, 2016	Feb NEWA
AB	MYLAN PHARMS INC	0.5MG	A203241	001	Jun 14, 2016	May NEWA
AB	STRIDES PHARMA	0.5MG	A204262	001	Nov 20, 2015	Mar CAHN

DYPHYLLINE

TABLET; ORAL

LUFYLLIN

@	MEDA PHARMS	200MG	A084566	001		Jun DISC
@		400MG	A084566	002		Jun DISC

ECONAZOLE NITRATE

AEROSOL, FOAM; TOPICAL

ECOZA

+	EXELTIS SUISSE	1%	N205175	001	Oct 24, 2013	Jul CAHN
---	----------------	----	---------	-----	--------------	----------

CREAM; TOPICAL

ECONAZOLE NITRATE

AB	TELIGENT PHARMA INC	1%	A076574	001	Dec 17, 2004	May CAHN
	SPECTAZOLE					
@	ALVOGEN MALTA	1%	N018751	001	Dec 23, 1982	Jul CAHN

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

TENSILON PRESERVATIVE FREE

@	TELIGENT PHARMA INC	10MG/ML	N007959	002		Jan CAHN
---	---------------------	---------	---------	-----	--	----------

EFAVIRENZ

TABLET; ORAL

EFAVIRENZ

AB	MYLAN LABS LTD	600MG	A091471	001	Feb 17, 2016	Feb NEWA
AB	MYLAN PHARMS INC	600MG	A091471	001	Feb 17, 2016	Jun CAHN
	SUSTIVA					
AB	+ BRISTOL MYERS SQUIBB	600MG	N021360	002	Feb 01, 2002	Feb CFTG

ELBASVIR; GRAZOPREVR

TABLET; ORAL

ZEPATIER

+	MERCK SHARP DOHME	50MG;100MG	N208261	001	Jan 28, 2016	Jan NEWA
---	-------------------	------------	---------	-----	--------------	----------

ELUXADOLINE

TABLET; ORAL

VIBERZI

	ALLERGAN HOLDINGS	75MG	N206940	001	May 27, 2015	May CAHN
+		100MG	N206940	002	May 27, 2015	May CAHN

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATETABLET; ORAL
ODEFSEY

+ GILEAD SCIENCES INC 200MG;EQ 25MG BASE;EQ 25MG BASE N208351 001 Mar 01, 2016 Apr CAIN

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
ODEFSEY

+ GILEAD SCIENCES INC 200MG;EQ 25MG BASE;EQ 25MG BASE N208351 001 Mar 01, 2016 Mar NEWA

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATETABLET; ORAL
DESCOVY

+ GILEAD SCIENCES INC 200MG;EQ 25MG BASE N208215 001 Apr 04, 2016 Apr NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
TRUVADA

GILEAD

100MG;150MG

N021752 002 Mar 10, 2016 Mar NEWA

133MG;200MG

N021752 003 Mar 10, 2016 Mar NEWA

167MG;250MG

N021752 004 Mar 10, 2016 Mar NEWA

ENALAPRIL MALEATESOLUTION; ORAL
EPANED

>A>

>A>

SILVERGATE PHARMS

1MG/ML

N208686 001 Sep 20, 2016 Sep NEWA

ENALAPRILATINJECTABLE; INJECTION
ENALAPRILAT

AP + AMPHASTAR PHARMS INC 1.25MG/ML

A075634 001 Aug 22, 2000 Jun CAHN

AP + EUROHLTH INTL SARL 1.25MG/ML

A075634 001 Aug 22, 2000 Apr CAHN

ENFLURANELIQUID; INHALATION
ENFLURANE

@ PIRAMAL CRITICAL

99.9%

A074396 001 Jul 29, 1994 Aug DISC

ETHRANE

@ BAXTER HLTHCARE

99.9%

N017087 001 Aug DISC

EPHEDRINE SULFATESOLUTION; INTRAVENOUS
AKOVAZ

+ FLAMEL IRELAND LTD 50MG/ML

N208289 001 Apr 29, 2016 Apr NEWA

EPINASTINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
EPINASTINE HYDROCHLORIDE

AT SOMERSET THERAPS LLC 0.05%

A090951 001 Oct 31, 2011 Mar CAHN

EPINEPHRINEINJECTABLE; INJECTION
SUS-PHRINE SULFITE FREE

@ FOREST LABS

1.5MG/AMP

N007942 003 Feb 05, 1999 Mar CMS1

@

5MG/ML

N007942 001 Mar CMS1

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
AUVI-Q

BX + KALEO INC EQ 0.15MG/DELIVERY

N201739 002 Aug 10, 2012 Mar CAHN

BX EQ 0.3MG/DELIVERY

N201739 001 Aug 10, 2012 Mar CAHN

TWINJECT 0.15

@ AMEDRA PHARMS

EQ 0.15MG/DELIVERY

N020800 002 May 28, 2004 May DISC

TWINJECT 0.3

@ AMEDRA PHARMS

EQ 0.3MG/DELIVERY

N020800 001 May 30, 2003 May DISC

SOLUTION; IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

BELCHER PHARMS LLC

EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N205029 001 Jul 29, 2014 Jul CAIN

EPINEPHRINE HYDROCHLORIDE

SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE

BELCHER PHARMS LLC EQ 1MG BASE/ML (EQ 1MG BASE/ML) N205029 001 Jul 29, 2014 Feb CDFR

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION
EPIRUBICIN HYDROCHLORIDE

>D>	AP	EUROHLTH INTL SARL	50MG/25ML (2MG/ML)	A065289	001	Jun 27, 2007	Sep CAHN
>D>	AP		200MG/100ML (2MG/ML)	A065289	002	Jun 27, 2007	Sep CAHN
	AP	IMPAX LABS INC	50MG/25ML (2MG/ML)	A065331	001	Aug 09, 2007	Aug CAHN
	AP		200MG/100ML (2MG/ML)	A065331	002	Aug 09, 2007	Aug CAHN
>A>	AP	WEST-WARD PHARMS INT	50MG/25ML (2MG/ML)	A065289	001	Jun 27, 2007	Sep CAHN
>A>	AP		200MG/100ML (2MG/ML)	A065289	002	Jun 27, 2007	Sep CAHN

EPTIFIBATIDE

INJECTABLE;INJECTION
EPTIFIBATIDE

@ TEVA PHARMS USA 75MG/100ML A091555 001 Jun 05, 2015 Aug DISC

ERGOCALCIFEROL

CAPSULE;ORAL
DRISDOL

AA	+	US PHARM HOLDINGS	50,000 IU	N003444	001		Jan CAHN
		VITAMIN D					
AA		BIONPHARMA INC	50,000 IU	A080704	001		Jan CAHN

ERGOLOID MESYLATES

TABLET;ORAL
ERGOLOID MESYLATES

AB		SUN PHARM INDS	1MG	A081113	001	Oct 31, 1991	Mar CAHN
		TABLET;SUBLINGUAL					
		ERGOLOID MESYLATES					
		@ SUN PHARM INDS	0.5MG	A087407	001		Jun CAHN
		@	1MG	A087552	001		Jun CAHN

ERGOTAMINE TARTRATE

TABLET;SUBLINGUAL
ERGOMAR

+ TERSERA THERAP 2MG A087693 001 Feb 24, 1983 Aug CAHN

ERYTHROMYCIN

SOLUTION;TOPICAL
C-SOLVE-2

		@ FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985	Feb DISC
		ERYTHRO-STATIN					
		@ HI TECH PHARMA	2%	A064101	001	Oct 22, 1996	Feb DISC
		ERYTHROMYCIN					
AT	+	FOUGERA PHARMS	2%	A064187	001	Sep 30, 1997	Jan CRLD
AT		PERRIGO NEW YORK	2%	A063038	001	Jan 11, 1991	Jan CRLD

ESCITALOPRAM OXALATE

SOLUTION;ORAL
ESCITALOPRAM OXALATE

AA MACLEODS PHARMS LTD EQ 5MG BASE/5ML A202754 001 Mar 31, 2016 Mar NEWA

ESMOLOL HYDROCHLORIDE

SOLUTION;INTRAVENOUS
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

	+	HQ SPCLT PHARMA	2GM/100ML (20MG/ML)	N205703	002	Apr 07, 2016	Apr NEWA
		ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER					
	+	HQ SPCLT PHARMA	2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016	Jun CRLD
			2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016	Apr NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL
ESOMEPRAZOLE MAGNESIUM

AB		AUROBINDO PHARMA LTD	EQ 20MG BASE	A205606	001	Apr 21, 2016	Apr NEWA
AB			EQ 40MG BASE	A205606	002	Apr 21, 2016	Apr NEWA
BX		HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Apr CTEC

CAPSULE, DELAYED REL PELLETS;ORAL
ESOMEPRAZOLE MAGNESIUM

BX		EQ 40MG BASE	A202784	002	Sep 21, 2015	Apr CTEC
----	--	--------------	---------	-----	--------------	----------

ESOMEPRAZOLE SODIUMINJECTABLE;INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP	AUROBINDO PHARMA LTD	EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	Jul NEWA
AP		EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Jul NEWA

ESTAZOLAMTABLET;ORAL
ESTAZOLAM

AB	MAYNE PHARMA	1MG	A074921	001	Jul 10, 1997	Aug CAHN
AB	+	2MG	A074921	002	Jul 10, 1997	Aug CAHN

ESTRADIOLCREAM;VAGINAL
ESTRACE+ ALLERGAN SALES LLC 0.01%
FILM, EXTENDED RELEASE;TRANSDERMAL
ALORA

A086069	001	Jan 31, 1984	Apr CAHN
---------	-----	--------------	----------

BX	ALLERGAN SALES LLC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar CAHN
BX		0.05MG/24HR	N020655	001	Dec 20, 1996	Mar CAHN
BX		0.075MG/24HR	N020655	002	Dec 20, 1996	Mar CAHN
BX		0.1MG/24HR	N020655	003	Dec 20, 1996	Mar CAHN

TABLET;ORAL
ESTRADIOL

AB	MAYNE PHARMA	0.5MG	A040114	003	Mar 14, 1996	Aug CAHN
AB		1MG	A040114	001	Mar 14, 1996	Aug CAHN
AB		2MG	A040114	002	Mar 14, 1996	Aug CAHN
>D> AB	USL PHARMA	0.5MG	A040297	001	Apr 17, 2002	Sep DISC
>A>	@	0.5MG	A040297	001	Apr 17, 2002	Sep DISC
>D> AB		1MG	A040297	002	Apr 17, 2002	Sep DISC
>A>	@	1MG	A040297	002	Apr 17, 2002	Sep DISC
>D> AB		2MG	A040297	003	Apr 17, 2002	Sep DISC
>A>	@	2MG	A040297	003	Apr 17, 2002	Sep DISC

TABLET;VAGINAL
ESTRADIOL

AB	AMNEAL PHARMS	10MCG	A205256	001	May 29, 2015	Aug CMFD
AB	+	NOVO NORDISK INC 10MCG	N020908	002	Nov 25, 2009	Aug CTEC

ESTRADIOL ACETATEINSERT, EXTENDED RELEASE;VAGINAL
FEMRINGAPIL EQ 0.05MG BASE/24HR
+ EQ 0.1MG BASE/24HR

N021367	001	Mar 20, 2003	Jan CAHN
N021367	002	Mar 20, 2003	Jan CAHN

TABLET;ORAL
FEMTRACEAPIL 0.45MG
0.9MG
+ 1.8MG

N021633	001	Aug 20, 2004	Jan CAHN
N021633	002	Aug 20, 2004	Jan CAHN
N021633	003	Aug 20, 2004	Jan CAHN

ESTRADIOL HEMIHYDRATEEMULSION;TOPICAL
ESTRASORB

+ EXELTIS USA INC 0.25%

N021371	001	Oct 09, 2003	Jun CAHN
---------	-----	--------------	----------

ESTRADIOL; NORETHINDRONE ACETATETABLET;ORAL
AMABELZ

AB	LUPIN LTD	0.5MG;0.1MG	A203339	001	Jun 20, 2016	Jun NEWA
AB		1MG;0.5MG	A203339	002	Jun 20, 2016	Jun NEWA

ESTROGENS, CONJUGATED SYNTHETIC ATABLET;ORAL
CENESTIN@ TEVA BRANDED PHARM 0.3MG
@ 0.45MG
@ 0.625MG
@ 0.9MG

N020992	001	Jun 21, 2002	Jun DISC
N020992	005	Feb 05, 2004	Jun DISC
N020992	002	Mar 24, 1999	Jun DISC
N020992	003	Mar 24, 1999	Jun DISC

TABLET;ORAL
CENESTIN
@

1.25MG

N020992 004 Mar 13, 2000 Jun DISC

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET;ORAL
ENJUVIA

@ TEVA WOMENS

0.625MG

N021443 003 May 10, 2004 Jun DISC

>D> + 1.25MG

N021443 004 May 10, 2004 Sep DISC

>A> @ 1.25MG

N021443 004 May 10, 2004 Sep DISC

ESZOPICLONE

TABLET;ORAL
ESZOPICLONE

>A> AB AUROBINDO PHARMA LTD 1MG

A208451 001 Sep 15, 2016 Sep NEWA

>A> AB 2MG

A208451 002 Sep 15, 2016 Sep NEWA

>A> AB 3MG

A208451 003 Sep 15, 2016 Sep NEWA

>A> ETEPLIRSEN

>A> SOLUTION;IV (INFUSION)

>A> EXONDYS 51

>A> + SAREPTA THERAPS INC 100MG/2ML (50MG/ML)

N206488 001 Sep 19, 2016 Sep NEWA

>A> + 500MG/10ML (50MG/ML)

N206488 002 Sep 19, 2016 Sep NEWA

ETHACRYNATE SODIUM

INJECTABLE;INJECTION
ETHACRYNATE SODIUM

AP MYLAN INSTITUTIONAL EQ 50MG BASE/VIAL

A204634 001 Aug 23, 2016 Aug NEWA

ETHACRYNIC ACID

TABLET;ORAL
EDECIN

AB + ATON 25MG

N016092 001 Jun CFTG

ETHACRYNIC ACID

AB EDENBRIDGE PHARMS 25MG

A205609 001 Jun 30, 2016 Jun NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB JAI PHARMA LTD 0.05MG;1MG

A204704 001 Feb 09, 2016 Jan NEWA

ZOVIA 1/35E-28

AB MAYNE PHARMA 0.035MG;1MG

A072721 001 Dec 30, 1991 Aug CAHN

ZOVIA 1/50E-28

AB + WATSON LABS 0.05MG;1MG

A072723 001 Dec 30, 1991 Jan CTEC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL
FAYOSIM

AB LUPIN LTD 0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A

A205943 001 Mar 29, 2016 Mar NEWA

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB AMNEAL PHARMS 0.03MG;0.15MG

A203871 001 Nov 13, 2015 Jul CAHN

AB HAUPT PHARMA 0.03MG,0.01MG;0.15MG,N/A

A203872 001 Dec 22, 2015 Jul CMS1

AB MAYNE PHARMA 0.02MG,0.01MG;0.1MG,N/A

A200407 001 Oct 25, 2011 Aug CAHN

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

AB MAYNE PHARMA 0.03MG,0.01MG;0.15MG,N/A

A078834 001 May 31, 2011 Aug CAHN

QUARTETTE

AB + TEVA BRANDED PHARM 0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A

N204061 001 Mar 28, 2013 Mar CFTG

TABLET;ORAL-21

TRIVORA-21

@ MAYNE PHARMA 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG

A074538 001 Dec 18, 1997 Aug CAHN

TABLET;ORAL-28

AYUNA

>A> AB AUROBINDO PHARMA LTD 0.03MG;0.15MG

A206866 001 Sep 23, 2016 Sep NEWA

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1 AMNEAL PHARMS 0.02MG;0.1MG

A201108 001 Feb 05, 2014 May CAHN

AB 0.03MG;0.15MG

A201095 001 Dec 08, 2014 Jul CAHN

AB1 + MAYNE PHARMA 0.02MG;0.1MG

A076625 001 Nov 18, 2004 Aug CAHN

AB2 + 0.02MG;0.1MG

A077681 001 May 31, 2006 Aug CAHN

TABLET;ORAL-28							
LEVORA 0.15/30-28							
AB	+	MAYNE PHARMA	0.03MG;0.15MG	A073594	001	Dec 13, 1993	Aug CAHN
TRIVORA-28							
AB	+	MAYNE PHARMA	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A074538	002	Dec 18, 1997	Aug CAHN
<u>ETHINYL ESTRADIOL; NORETHINDRONE</u>							
TABLET;ORAL-21							
BREVICON 21-DAY							
		@ ALLERGAN SALES LLC	0.035MG;0.5MG	N017566	001		Apr CAHN
NORINYL 1+35 21-DAY							
AB		ALLERGAN SALES LLC	0.035MG;1MG	N017565	001		Mar CAHN
TRI-NORINYL 21-DAY							
		@ MAYNE PHARMA	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	001	Apr 13, 1984	Aug CAHN
TABLET;ORAL-28							
BREVICON 28-DAY							
AB		ALLERGAN SALES LLC	0.035MG;0.5MG	N017743	001		Mar CAHN
NORETHINDRONE AND ETHINYL ESTRADIOL							
AB		MAYNE PHARMA	0.035MG;0.5MG	A070686	001	Jan 29, 1987	Aug CAHN
NORINYL 1+35 28-DAY							
AB		ALLERGAN SALES LLC	0.035MG;1MG	N017565	002		Mar CAHN
TRI-NORINYL 28-DAY							
AB	+	MAYNE PHARMA	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	002	Apr 13, 1984	Aug CAHN
TABLET, CHEWABLE;ORAL							
FEMCON FE							
AB	+	APIL	0.035MG;0.4MG	N021490	001	Nov 14, 2003	Jan CAHN
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB	+	APIL	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jan CAHN
AB		LUPIN LTD	0.035MG;0.4MG	A091332	001	Mar 23, 2016	Mar NEWA
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE</u>							
CAPSULE;ORAL							
TAYTULLA							
	+	APIL	0.02MG;1MG	N204426	001	Apr 19, 2013	Aug CTNA
	@		0.02MG;1MG	N204426	001	Apr 19, 2013	Apr CAHN
TABLET;ORAL							
FEMHRT							
AB		APIL	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Jan CAHN
	@		0.005MG;1MG	N021065	002	Oct 15, 1999	Jan CAHN
LERIBANE							
AB		NOVAST LABS LTD	0.0025MG;0.5MG	A203435	002	Jun 03, 2016	May NEWA
AB			0.005MG;1MG	A203435	001	Jun 03, 2016	May NEWA
LO LOESTRIN FE							
AB	+	APIL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	May CFTG
	+		0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	Jan CAHN
LOESTRIN 24 FE							
AB		APIL	0.02MG;1MG	N021871	001	Feb 17, 2006	Aug CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB		JAI PHARMA LTD	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016	May NEWA
TABLET;ORAL-21							
ESTROSTEP 21							
	@	APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	001	Oct 09, 1996	Jan CAHN
LOESTRIN 21 1.5/30							
AB		APIL	0.03MG;1.5MG	N017875	001		Apr CAHN
LOESTRIN 21 1/20							
AB		APIL	0.02MG;1MG	N017876	001		Apr CAHN
MICROGESTIN 1.5/30							
AB		MAYNE PHARMA	0.03MG;1.5MG	A075548	002	Jul 30, 2003	Aug CAHN
MICROGESTIN 1/20							
AB		MAYNE PHARMA	0.02MG;1MG	A075647	002	Jul 30, 2003	Aug CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB		GLENMARK PHARMS LTD	0.02MG;1MG	A206969	001	Jan 20, 2016	Jan NEWA
TABLET;ORAL-28							
ESTROSTEP FE							
AB	+	APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	002	Oct 09, 1996	Jan CAHN
LOESTRIN FE 1.5/30							
AB	+	APIL	0.03MG;1.5MG	N017355	001		Apr CAHN

TABLET;ORAL-28

LOESTRIN FE 1/20							
AB	APIL	0.02MG;1MG	N017354	001		Apr	CAHN
MICROGESTIN FE 1.5/30							
AB	MAYNE PHARMA	0.03MG;1.5MG	A075548	001	Feb 05, 2001	Aug	CAHN
MICROGESTIN FE 1/20							
AB	MAYNE PHARMA	0.02MG;1MG	A075647	001	Feb 05, 2001	Aug	CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB	MAYNE PHARMA	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076629	001	Mar 18, 2010	Aug	CAHN
TABLET, CHEWABLE;ORAL							
MIBELAS 24 FE							
AB	LUPIN ATLANTIS	0.02MG;1MG	A206287	001	May 24, 2016	May	NEWA
MINASTRIN 24 FE							
AB	+ APIL	0.02MG;1MG	N203667	001	May 08, 2013	May	CFTG
	+	0.02MG;1MG	N203667	001	May 08, 2013	Jan	CAHN
TABLET, CHEWABLE, TABLET;ORAL							
LO MINASTRIN FE							
	+ APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jan	CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

MILI

AB	AUROBINDO PHARMA LTD	0.035MG;0.25MG	A205449	001	Jul 07, 2016	Jun	NEWA
NORGESTIMATE AND ETHINYL ESTRADIOL							
>A> AB	AMNEAL PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A203870	001	Nov 12, 2015	Sep	CAHN
		15MG,0.25MG					
AB		0.035MG;0.25MG	A203865	001	Oct 27, 2015	May	CAHN
AB	GLENMARK PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A204057	001	Feb 23, 2016	Jun	CAHN
		15MG,0.25MG					
AB	GLENMARK PHARMS LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A204057	001	Feb 23, 2016	Feb	NEWA
		15MG,0.25MG					
>D> AB	HAUPT PHARMA	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A203870	001	Nov 12, 2015	Sep	CAHN
		15MG,0.25MG					
AB		0.025MG,0.025MG,0.025MG;0.18MG,0.2	A203873	001	May 12, 2016	May	NEWA
		15MG,0.25MG					
AB	JAI PHARMA LTD	0.035MG, 0.035MG, 0.035MG;0.18MG,	A201897	001	Jan 27, 2016	Jan	NEWA
		0.215MG, 0.25MG					
AB		0.035MG;0.25MG	A201896	001	Jan 27, 2016	Jan	NEWA
AB	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A205588	001	Apr 26, 2016	Apr	NEWA
		15MG,0.25MG					
TRI-MILI							
AB	AUROBINDO PHARMA LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A205441	001	Jul 06, 2016	Jun	NEWA
		15MG,0.25MG					

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21

LO/OVRAL

@ PELAGIUS		0.03MG;0.3MG	N017612	001		Jun	CAHN
LOW-OGESTREL-21							
@ MAYNE PHARMA		0.03MG;0.3MG	A075288	001	Jul 28, 1999	Aug	CAHN
TABLET;ORAL-28							
LO/OVRAL-28							
@ WYETH PHARMS		0.03MG;0.3MG	N017802	001		Jun	DISC
LOW-OGESTREL-28							
AB	MAYNE PHARMA	0.03MG;0.3MG	A075288	002	Jul 28, 1999	Aug	CAHN
NORGESTREL AND ETHINYL ESTRADIOL							
AB	JAI PHARMA LTD	0.03MG;0.3MG	A201828	001	Jun 21, 2016	Jun	NEWA

ETHIODIZED OIL

OIL;INTRALYMPHATIC, INTRAUTERINE

LIPIODOL

	+ GUERBET	EQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML)	N009190	001		Aug	CPOT
--	-----------	---	---------	-----	--	-----	------

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

AB	BIONPHARMA INC	250MG	A040430	001	Oct 28, 2002	Jan	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

ETIDRONATE DISODIUMTABLET; ORAL
DIDRONE

AB	APIL	200MG	N017831	001		Apr	CAHN
AB	+	400MG	N017831	002		Apr	CAHN

ETODOLACCAPSULE; ORAL
ETODOLAC

@	IDT AUSTRALIA LTD	200MG	A074840	001	Aug 29, 1997	May	CAHN
@		300MG	A074840	002	Aug 29, 1997	May	CAHN
@	LEHIGH VALLEY	300MG	A074929	001	Jan 30, 1998	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL
ETODOLAC

@	IDT AUSTRALIA LTD	400MG	A075943	001	Jul 26, 2002	Aug	CAHN
@		500MG	A075943	002	Jul 26, 2002	Aug	CAHN
@		600MG	A075943	003	Jul 26, 2002	Aug	CAHN

ETOMIDATEINJECTABLE; INJECTION
ETOMIDATE

AP	EUROHLTH INTL SARL	2MG/ML	A074593	001	Nov 04, 1996	Apr	CAHN
AP	HIKMA FARMACEUTICA	2MG/ML	A202354	001	Feb 25, 2016	Feb	NEWA

ETOPOSIDEINJECTABLE; INJECTION
ETOPOSIDE

>D>	AP	EUROHLTH INTL SARL	20MG/ML	A074290	001	Jul 17, 1995	Sep	CAHN
>A>	AP	WEST-WARD PHARMS INT	20MG/ML	A074290	001	Jul 17, 1995	Sep	CAHN

EXEMESTANETABLET; ORAL
EXEMESTANE

AB	ALVOGEN MALTA	25MG	A200898	001	Jul 28, 2014	Jan	CAHN
----	---------------	------	---------	-----	--------------	-----	------

EXENATIDE SYNTHETICFOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS
BYDUREON PEN

+	ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014	Feb	NEWA
---	----------------	-----	---------	-----	--------------	-----	------

FAMOTIDINEINJECTABLE; INJECTION
FAMOTIDINE

AP	AMPHASTAR PHARMS INC	10MG/ML	A075651	001	Apr 16, 2001	Jun	CAHN
AP		10MG/ML	A075684	001	Apr 16, 2001	Jun	CAHN
AP	EUROHLTH INTL SARL	10MG/ML	A075651	001	Apr 16, 2001	Apr	CAHN
AP		10MG/ML	A075684	001	Apr 16, 2001	Apr	CAHN

FAMOTIDINE PRESERVATIVE FREE

AP	AMPHASTAR PHARMS INC	10MG/ML	A075622	001	Apr 16, 2001	Jun	CAHN
AP		10MG/ML	A075825	001	Apr 17, 2001	Jun	CAHN
AP	EUROHLTH INTL SARL	10MG/ML	A075622	001	Apr 16, 2001	Apr	CAHN
AP		10MG/ML	A075825	001	Apr 17, 2001	Apr	CAHN

TABLET; ORAL
FAMOTIDINE

@	SUN PHARM INDS	20MG	A075639	002	Dec 12, 2001	Mar	CAHN
@		40MG	A075639	001	Dec 12, 2001	Mar	CAHN

FELBAMATETABLET; ORAL
FELBAMATE

AB	ALVOGEN MALTA	400MG	A204595	001	Jan 11, 2016	Aug	CAHN
AB		600MG	A204595	002	Jan 11, 2016	Aug	CAHN

FELODIPINETABLET, EXTENDED RELEASE; ORAL
FELODIPINE

AB	JUBILANT GENERICS	2.5MG	A203983	001	Aug 19, 2016	Aug	NEWA
AB		5MG	A203983	002	Aug 19, 2016	Aug	NEWA
AB		10MG	A203983	003	Aug 19, 2016	Aug	NEWA
AB	SUN PHARM INDS	2.5MG	A075896	001	Nov 02, 2004	Mar	CAHN
AB		5MG	A075896	002	Nov 02, 2004	Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL							
FELODIPINE							
AB		10MG		A075896	003	Nov 02, 2004	Mar CAHN
<u>FENOFIBRATE</u>							
TABLET;ORAL							
FENOFIBRATE							
AB	AUROBINDO PHARMA LTD	48MG		A205118	001	May 05, 2016	Apr NEWA
AB		145MG		A205118	002	May 05, 2016	Apr NEWA
AB	HETERO LABS LTD III	48MG		A204598	001	Jul 12, 2016	Jun NEWA
AB		145MG		A204598	002	Jul 12, 2016	Jun NEWA
AB	MYLAN	40MG		A204475	001	Jun 23, 2016	Jun NEWA
AB		120MG		A204475	002	Jun 23, 2016	Jun NEWA
FENOGLIDE							
AB	SANTARUS INC	40MG		N022118	001	Aug 10, 2007	Jun CFTG
AB	+	120MG		N022118	002	Aug 10, 2007	Jun CFTG
<u>FENOFIBRIC ACID</u>							
TABLET;ORAL							
FIBRICOR							
	ARALENZ PHARMS	35MG		N022418	001	Aug 14, 2009	Apr CAHN
+		105MG		N022418	002	Aug 14, 2009	Apr CAHN
	ARALEZ PHARMS INC	35MG		N022418	001	Aug 14, 2009	Jun CAHN
+		105MG		N022418	002	Aug 14, 2009	Jun CAHN
<u>FENOPROFEN CALCIUM</u>							
CAPSULE;ORAL							
FENOPROFEN CALCIUM							
	@ AUROLIFE PHARMA LLC	EQ 200MG BASE		A072394	001	Oct 17, 1988	Mar CAHN
	@	EQ 300MG BASE		A072395	001	Oct 17, 1988	Feb CAHN
TABLET;ORAL							
FENOPROFEN CALCIUM							
	@ AUROLIFE PHARMA LLC	EQ 600MG BASE		A072396	001	Oct 17, 1988	Feb CAHN
	@ SUN PHARM INDS	EQ 600MG BASE		A072902	001	Dec 21, 1990	Mar CAHN
<u>FENTANYL</u>							
FILM, EXTENDED RELEASE;TRANSDERMAL							
FENTANYL-12							
AB	AVEVA	12.5MCG/HR		A077449	005	Sep 11, 2015	Jan NEWA
<u>FERRIC PYROPHOSPHATE CITRATE</u>							
FOR SOLUTION;INTRAVENOUS							
TRIFERIC							
+	ROCKWELL MEDICAL INC	272MG IRON/PACKET		N208551	001	Apr 25, 2016	Apr NEWA
<u>FESOTERODINE FUMARATE</u>							
TABLET, EXTENDED RELEASE;ORAL							
FESOTERODINE FUMARATE							
	@ ALKEM LABS LTD	4MG		A204827	001	Dec 10, 2015	Jan DISC
	@	8MG		A204827	002	Dec 10, 2015	Jan DISC
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>							
TABLET, EXTENDED RELEASE;ORAL							
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE							
	@ BARR	60MG;120MG		A076236	001	Apr 14, 2005	Mar DISC
	@ IMPAX PHARMS	60MG;120MG		A076298	001	Nov 12, 2010	Mar DISC
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL</u>							
EMULSION;INTRAVENOUS							
SMOFLIPID 20%							
+	FRESENIUS KABI USA	3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (100ML)		N207648	001	Jul 13, 2016	Jul NEWA
+		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (250ML)		N207648	002	Jul 13, 2016	Jul NEWA
+		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (500ML)		N207648	003	Jul 13, 2016	Jul NEWA

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

@ IMPAX PHARMS	100MG	A076234	001	Aug 28, 2003	Mar DISC
----------------	-------	---------	-----	--------------	----------

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

@ IDT AUSTRALIA LTD	50MG	A076030	001	Oct 28, 2002	May CAHN
@	100MG	A076030	002	Oct 28, 2002	May CAHN
@	150MG	A076030	003	Oct 28, 2002	May CAHN

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

>D>	+	AVID RADIOPHARMS INC	10ML (13.5-51mCi/ML)	N202008	001	Apr 06, 2012	Sep DISC
>A>	@		10ML (13.5-51mCi/ML)	N202008	001	Apr 06, 2012	Sep DISC

FLUCICLOVINE F-18

SOLUTION; INTRAVENOUS

AXUMIN

+	BLUE EARTH	9-221mCi/ML	N208054	001	May 27, 2016	May NEWA
---	------------	-------------	---------	-----	--------------	----------

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

@ SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Feb DISC
@	200MG/5ML	A076332	002	Jul 29, 2004	Feb DISC

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

		EUROHLTH INTL SARL	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Apr CAHN
AP			200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004	Apr CAHN
AP			400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004	Apr CAHN
	@	TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	Jan DISC
	@		400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	Jan DISC
		FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP		ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar CMS1
AP			400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar CMS1
AP		EUROHLTH INTL SARL	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Jun CAHN
AP			400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jun CAHN

TABLET; ORAL

FLUCONAZOLE

@ IDT AUSTRALIA LTD	50MG	A076086	001	Jul 29, 2004	May CAHN
@	100MG	A076086	002	Jul 29, 2004	May CAHN
@	150MG	A076086	003	Jul 29, 2004	May CAHN
@	200MG	A076086	004	Jul 29, 2004	May CAHN

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

AP		SAGENT PHARMS	50MG/VIAL	A076349	001	Aug 28, 2003	Aug CAHN
AP			50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Aug CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP		KREITCHMAN PET CTR	10-100mCi/ML	A203942	001	Apr 11, 2016	Mar NEWA
AP	+	QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015	Mar CTEC
AP		ZEVACOR PHARMA INC	20-300mCi/ML	A203591	001	Aug 31, 2015	Feb CAHN

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP		EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Apr CAHN
AP			1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Apr CAHN

FLUOCINOLONE ACETONIDE

OIL;TOPICAL

FLUOCINOLONE ACETONIDE

AT	LYNE	0.01%	A090982	001	Apr 25, 2016	Apr NEWA
AT		0.01%	A203377	001	Apr 25, 2016	Apr NEWA
AT	TARO	0.01%	A202368	001	May 19, 2016	May NEWA
AT		0.01%	A209336	001	May 19, 2016	May NEWA

OIL/DROPS;OTIC

FLUOCINOLONE ACETONIDE

AT	LYNE	0.01%	A203378	001	Apr 25, 2016	Apr NEWA
AT	VERSAPHARM INC	0.01%	A202705	001	Sep 09, 2016	Aug NEWA

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

>A> AT	G AND W LABS INC	0.01%	A207441	001	Sep 28, 2016	Sep NEWA
--------	------------------	-------	---------	-----	--------------	----------

FLUOCINONIDE

OINTMENT;TOPICAL

LIDEX

>D>	@ CNTY LINE PHARMS	0.05%	N016909	002		Sep CMFD
>A> AB		0.05%	N016909	002		Sep CMFD

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

AP	SAGENT PHARMS	2.5GM/50ML (50MG/ML)	A203609	001	Feb 17, 2016	Feb NEWA
AP		5GM/100ML (50MG/ML)	A203609	002	Feb 17, 2016	Feb NEWA
	@ SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N012209	001		Jan CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE

@ SUN PHARM INDS	EQ 10MG BASE	A075787	001	Jan 29, 2002	Mar CAHN
------------------	--------------	---------	-----	--------------	----------

@	EQ 20MG BASE	A075787	002	Jan 29, 2002	Mar CAHN
---	--------------	---------	-----	--------------	----------

FLUOXETINE HYDROCHLORIDE

>D> AB2	MYLAN	EQ 10MG BASE	A078045	001	Nov 17, 2008	Sep CTEC
>A>		EQ 10MG BASE	A078045	001	Nov 17, 2008	Sep CTEC

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

@ LANNETT	EQ 20MG BASE/5ML	A076458	001	May 14, 2004	Aug DISC
-----------	------------------	---------	-----	--------------	----------

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

+	EDGEMONT PHARMS LLC	EQ 60MG BASE	N202133	001	Oct 06, 2011	Mar CRLD
AB +	MYLAN	EQ 20MG BASE	A075755	002	Aug 02, 2001	Aug CTEC
AB	PAR FORM	EQ 10MG BASE	A203836	001	Aug 19, 2016	Aug NEWA
AB		EQ 20MG BASE	A203836	002	Aug 19, 2016	Aug NEWA

SARAFEM

AB1	APIL	EQ 10MG BASE	N021860	001	May 19, 2006	Jan CAHN
AB1		EQ 15MG BASE	N021860	002	May 19, 2006	Jan CAHN
AB1 +		EQ 20MG BASE	N021860	003	May 19, 2006	Jan CAHN

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION

FLUPHENAZINE DECANOATE

>D> AO	EUROHLTH INTL SARL	25MG/ML	A074531	001	Aug 30, 1996	Sep CAHN
>A> AO	WEST-WARD PHARMS INT	25MG/ML	A074531	001	Aug 30, 1996	Sep CAHN

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

>A> AB	LANNETT	1MG	A089743	002	Aug 25, 1988	Sep NEWA
>A> AB		2.5MG	A089743	003	Aug 25, 1988	Sep NEWA
>A> AB		5MG	A089743	004	Aug 25, 1988	Sep NEWA

FLURANDRENOLIDE

CREAM;TOPICAL

CORDRAN SP

AT +	AQUA PHARMS	0.05%	N012806	002		Mar CFTG
------	-------------	-------	---------	-----	--	----------

FLURANDRENOLIDE

AT	TELIGENT PHARMA INC	0.05%	A205342	001	Apr 13, 2016	Mar NEWA
----	---------------------	-------	---------	-----	--------------	----------

	LOTION; TOPICAL						
	CORDRAN						
AT	+ AQUA PHARMS	0.05%	N013790	001			Aug CTEC
	FLURANDRENOLIDE						
AT	PERRIGO UK FINCO	0.05%	A207133	001	Aug 30, 2016		Aug NEWA
	TAPE; TOPICAL						
	CORDRAN						
	+ ALLERGAN SALES LLC	0.004MG/SQ CM	N016455	001			Apr CAHN

FLURANDRENOLIDE; NEOMYCIN SULFATE

	CREAM; TOPICAL						
	CORDRAN N						
	@ LILLY	0.05%; EQ 3.5MG BASE/GM	N050346	001			Mar CMS1
	OINTMENT; TOPICAL						
	CORDRAN N						
	@ LILLY	0.05%; EQ 3.5MG BASE/GM	N050345	001			Mar CMS1

FLURAZEPAM HYDROCHLORIDE

	CAPSULE; ORAL						
	FLURAZEPAM HYDROCHLORIDE						
	@ AUROLIFE PHARMA LLC	15MG	A071716	001	Jul 31, 1991		Feb CAHN
	@	30MG	A071717	001	Jul 31, 1991		Feb CAHN
	@ HIKMA INTL PHARMS	15MG	A071107	001	Dec 08, 1986		May CAHN
	@ SUN PHARM INDS	15MG	A070454	001	Aug 04, 1986		Mar CAHN
	@	30MG	A070455	001	Aug 04, 1986		Mar CAHN

FLURBIPROFEN

	TABLET; ORAL						
	FLURBIPROFEN						
	@ AUROLIFE PHARMA LLC	50MG	A074448	001	Jul 28, 1995		Feb CAHN
	@	100MG	A074448	002	Jul 28, 1995		Feb CAHN

FLUTAMIDE

	CAPSULE; ORAL						
	FLUTAMIDE						
>A> AB	+ CIPLA LTD	125MG	A075780	001	Sep 19, 2001		Sep CAHN
>D> AB	+ IVAX SUB TEVA PHARMS	125MG	A075780	001	Sep 19, 2001		Sep CAHN

FLUTICASONE FUROATE

	POWDER; INHALATION						
	ARNUITY ELLIPTA						
	+ GLAXOSMITHKLINE	0.1MG/INH	N205625	001	Aug 20, 2014		Mar CRLD

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

	POWDER; INHALATION						
	BREO ELLIPTA						
	+ GLAXO GRP LTD	0.2MG/INH; EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015		Mar CRLD

FLUTICASONE PROPIONATE

	SPRAY, METERED; NASAL						
	FLONASE						
	@ GLAXOSMITHKLINE	0.05MG/SPRAY	N020121	001	Oct 19, 1994		Jun DISC

FLUVASTATIN SODIUM

	TABLET, EXTENDED RELEASE; ORAL						
	FLUVASTATIN SODIUM						
AB	MYLAN PHARMS INC	EQ 80MG BASE	A202458	001	Sep 11, 2015		May CPOT
AB	TEVA PHARMS USA	EQ 80MG BASE	A079011	001	Jan 27, 2016		May CPOT
AB		80MG	A079011	001	Jan 27, 2016		Jan NEWA
	LESCOL XL						
AB	+ NOVARTIS	EQ 80MG BASE	N021192	001	Oct 06, 2000		May CPOT

FLUVOXAMINE MALEATE

	TABLET; ORAL						
	FLUVOXAMINE MALEATE						
	@ NOSTRUM LABS INC	25MG	A075900	001	Feb 23, 2006		Feb CAHN
	@	50MG	A075900	002	Feb 23, 2006		Feb CAHN
	@	100MG	A075900	003	Feb 23, 2006		Feb CAHN
	@ SUN PHARM INDS	25MG	A076125	001	Apr 29, 2002		Mar CAHN
	@	50MG	A076125	002	Apr 29, 2002		Mar CAHN
	@	100MG	A076125	003	Apr 29, 2002		Mar CAHN

FOLIC ACIDINJECTABLE; INJECTION
FOLVITE

@ WYETH PHARMS INC 5MG/ML N005897 008 May CAHN

TABLET; ORAL

FOLIC ACID

@ SUN PHARM INDS 1MG A040582 001 Jul 18, 2005 Mar CAHN

FOLVITE

@ WYETH PHARMS INC 1MG N005897 004 May CAHN

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

@ ORGANON USA INC 75 IU/0.5ML N021273 001 Aug 26, 2005 Jun DISC

@ 150 IU/0.5ML N021273 002 Aug 26, 2005 Jun DISC

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION

BEVESPI AEROSPHERE

+ PEARL THERAPS INC 0.0048MG/INH; 0.0090MG/INH N208294 001 Apr 25, 2016 Apr NEWA

FOSAMPRENAVIR CALCIUM

TABLET; ORAL

FOSAMPRENAVIR CALCIUM

AB MYLAN PHARMS INC EQ 700MG BASE A204060 001 Apr 15, 2016 Apr NEWA

LEXIVA

AB + VIIV HLTHCARE EQ 700MG BASE N021548 001 Oct 20, 2003 Apr CFTG

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

AP + MERCK AND CO INC EQ 150MG BASE/VIAL N022023 002 Nov 12, 2010 May CFTG

FOSAPREPITANT DIMEGLUMINE

AP FRESENIUS KABI USA EQ 150MG BASE/VIAL A206197 001 Jun 09, 2016 May NEWA

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@ ACTAVIS LABS FL INC 10MG A076620 001 Oct 15, 2004 Jan DISC

@ 20MG A076620 002 Oct 15, 2004 Jan DISC

@ 40MG A076620 003 Oct 15, 2004 Jan DISC

AB PRINSTON INC 10MG A205670 001 Aug 29, 2016 Aug NEWA

AB 20MG A205670 002 Aug 29, 2016 Aug NEWA

AB 40MG A205670 003 Aug 29, 2016 Aug NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@ ACTAVIS LABS FL INC 10MG; 12.5MG A076608 001 Dec 03, 2004 Jan DISC

@ 20MG; 12.5MG A076608 002 Dec 03, 2004 Jan DISC

@ SUN PHARM INDS LTD 10MG; 12.5MG A076739 001 Dec 17, 2004 Feb DISC

@ 20MG; 12.5MG A076739 002 Dec 17, 2004 Feb DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

AP + PARKE DAVIS EQ 50MG PHENYTOIN NA/ML N020450 001 Aug 05, 1996 Aug CRLD

FOSPHENYTOIN SODIUM

AP EUROHLTH INTL SARL EQ 50MG PHENYTOIN NA/ML A077481 001 Aug 06, 2007 Jun CAHN

@ FRESENIUS KABI USA EQ 50MG PHENYTOIN NA/ML A078052 001 Aug 06, 2007 Aug DISC

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVATRIPTAN SUCCINATE

AB GLENMARK PHARMS LTD EQ 2.5MG BASE A204730 001 Mar 11, 2016 Feb NEWA

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

AP	AMNEAL PHARMS CO	10MG/ML	A207552	001	Jul 20, 2016	Jul NEWA
AP	CLARIS	10MG/ML	A202747	001	Jan 27, 2014	May CAHN
	@ EUROHLTH INTL SARL	10MG/ML	A071439	001	Sep 14, 1990	Jan CAHN

TABLET; ORAL
FUROSEMID

	@	SUN PHARM INDS	20MG	A070043	001	Sep 26, 1985	Mar	CAHN
	@		80MG	A070100	001	Jan 26, 1988	Mar	CAHN
		LASIX						
AB		US PHARM HOLDINGS	20MG	N016273	002		Jan	CAHN
AB			40MG	N016273	001		Jan	CAHN
AB	+		80MG	N016273	003		Jan	CAHN

GABAPENTIN

CAPSULE; ORAL
GABAPENTIN

AB	SCIEGEN PHARMS INC	100MG	A204989	001	Feb 18, 2016	Feb	NEWA
AB		300MG	A204989	002	Feb 18, 2016	Feb	NEWA
AB		400MG	A204989	003	Feb 18, 2016	Feb	NEWA
	@ SUN PHARM INDS	100MG	A076537	001	Jun 30, 2005	Mar	CAHN
	@	300MG	A076537	002	Jun 30, 2005	Mar	CAHN
	@	400MG	A076537	003	Jun 30, 2005	Mar	CAHN
>D> AB	SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005	Sep	DISC
>A>	@	100MG	A076606	001	Oct 07, 2005	Sep	DISC
>D> AB		300MG	A076606	002	Oct 07, 2005	Sep	DISC
>A>	@	300MG	A076606	002	Oct 07, 2005	Sep	DISC
>D> AB		400MG	A076606	003	Oct 07, 2005	Sep	DISC
>A>	@	400MG	A076606	003	Oct 07, 2005	Sep	DISC

SOLUTION; ORAL
GABAPENTIN

AA	TRIS PHARMA INC	250MG/5ML	A091286	001	Mar 14, 2016	Feb NEWA
----	-----------------	-----------	---------	-----	--------------	----------

TABLET; ORAL
GABAPENTIN

AB	SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan NEWA
AB		800MG	A205101	002	Feb 04, 2016	Jan NEWA

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL
HORIZANT

	ARBOR PHARMS LLC	300MG	N022399	002	Dec 13, 2011	Jul CAHN
+		600MG	N022399	001	Apr 06, 2011	Jul CAHN

GADOFOSVESET TRISODIUM

SOLUTION; INTRAVENOUS
ABLAVAR

>D>	LANTHEUS MEDCL	2440MG/10ML (244MG/ML)	N021711	001	Dec 22, 2008	Sep DISC
>A>	@	2440MG/10ML (244MG/ML)	N021711	001	Dec 22, 2008	Sep DISC
>D>	+	3660MG/15ML (244MG/ML)	N021711	002	Dec 22, 2008	Sep DISC
>A>	@	3660MG/15ML (244MG/ML)	N021711	002	Dec 22, 2008	Sep DISC

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL
GALANTAMINE HYDROBROMIDE

AB	AUROBINDO PHARMA LTD	EQ 8MG BASE	A204895	001	Aug 05, 2016	Jul	NEWA
AB		EQ 16MG BASE	A204895	002	Aug 05, 2016	Jul	NEWA
AB		EQ 24MG BASE	A204895	003	Aug 05, 2016	Jul	NEWA
@	IMPAX LABS	EQ 8MG BASE	A078484	001	May 27, 2009	Feb	DISC
@		EQ 16MG BASE	A078484	002	May 27, 2009	Feb	DISC
@		EQ 24MG BASE	A078484	003	May 27, 2009	Feb	DISC

SOLUTION; ORAL

GALANTAMINE HYDROBROMIDE

+	ROXANE	4MG/ML	A078185	001	Jan 30, 2009	May CRLD
	RAZADYNE					
@	JANSSEN PHARMS	4MG/ML	N021224	001	Jun 22, 2001	May DISC

GALLIUM DOTATATE GA-68POWDER; INTRAVENOUS
NETSPOT

+	AAA USA INC	2.1-5.5mCi/ML	N208547	001	Jun 01, 2016	Aug NEWA
---	-------------	---------------	---------	-----	--------------	----------

GATIFLOXACINSOLUTION/DROPS; OPHTHALMIC
GATIFLOXACIN

AT	ALCON RES LTD	0.5%	A204227	001	Jul 11, 2016	Jun NEWA
----	---------------	------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

AP	ACTAVIS INC	200MG/5.26ML (38MG/ML)	A204549	001	Apr 11, 2016	Mar NEWA	
AP		1GM/26.3ML (38MG/ML)	A204549	002	Apr 11, 2016	Mar NEWA	
AP		2GM/52.6ML (38MG/ML)	A204549	003	Apr 11, 2016	Mar NEWA	
AP	+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Mar CFTG
AP	+		1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Mar CFTG
AP	+		2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Mar CFTG

GEMFIBROZILTABLET; ORAL
GEMFIBROZIL

AB	CADILA PHARMS LTD	600MG	A203266	001	Jun 17, 2016	Jun NEWA
----	-------------------	-------	---------	-----	--------------	----------

GLIMEPIRIDETABLET; ORAL
GLIMEPIRIDE

@	ACTAVIS LABS FL INC	1MG	A076995	001	Apr 27, 2010	Jan DISC
@		2MG	A076995	002	Apr 27, 2010	Jan DISC
@		4MG	A076995	003	Apr 27, 2010	Jan DISC

GLIMEPIRIDE; ROSIGLITAZONE MALEATETABLET; ORAL
ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

+	TEVA PHARMS USA	1MG; 4MG	A078709	001	Apr 01, 2016	Mar NEWA
		2MG; 4MG	A078709	002	Apr 01, 2016	Mar NEWA
		2MG; 8MG	A078709	004	Apr 01, 2016	Mar NEWA
		4MG; 4MG	A078709	003	Apr 01, 2016	Mar NEWA
		4MG; 8MG	A078709	005	Apr 01, 2016	Mar NEWA

GLYBURIDETABLET; ORAL
GLYBURIDE

AB1	PHARMADAX INC	1.25MG	A203581	001	Apr 14, 2016	Apr NEWA
AB1		2.5MG	A203581	002	Apr 14, 2016	Apr NEWA
AB1		5MG	A203581	003	Apr 14, 2016	Apr NEWA
AB1	ZYDUS PHARMS USA INC	1.25mg	A206749	001	May 10, 2016	Apr NEWA
AB1		2.5mg	A206749	002	May 10, 2016	Apr NEWA
AB1		5MG	A206749	003	May 10, 2016	Apr NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDETABLET; ORAL
GLYBURIDE AND METFORMIN HYDROCHLORIDE

@	COREPHARMA	1.25MG; 250MG	A076731	001	Nov 19, 2004	Jan DISC
@		2.5MG; 500MG	A076731	002	Nov 19, 2004	Jan DISC
@		5MG; 500MG	A076731	003	Nov 19, 2004	Jan DISC
AB	IMPAX LABS INC	1.25MG; 250MG	A076345	001	Feb 18, 2004	Aug CAHN
AB		2.5MG; 500MG	A076345	002	Feb 18, 2004	Aug CAHN
AB		5MG; 500MG	A076345	003	Feb 18, 2004	Aug CAHN
AB	ZYDUS PHARMS USA INC	1.25MG; 250MG	A206748	001	Feb 29, 2016	Feb NEWA
AB		2.5MG; 500MG	A206748	002	Feb 29, 2016	Feb NEWA
AB		5MG; 500MG	A206748	003	Feb 29, 2016	Feb NEWA

GLYCOPYRROLATEINJECTABLE; INJECTION
GLYCOPYRROLATE

AP	+	HIKMA FARMACEUTICA	0.2MG/ML	A090963	001	Sep 21, 2011	Feb CRLD
----	---	--------------------	----------	---------	-----	--------------	----------

TABLET; ORAL

		GLYCOPYRROLATE				
@	HIKMA INTL PHARMS	1MG	A040836	001	Mar 05, 2009	May CAHN

TABLET;ORAL

GLYCOPYRROLATE

	@	2MG	A040836	002	Mar 05, 2009	May CAHN
AA	NATCO PHARMA LTD	1MG	A091413	001	Jun 20, 2016	Jun NEWA
AA		2MG	A091413	002	Jun 20, 2016	Jun NEWA
AA	RISING PHARMS INC	1MG	A040821	001	Dec 29, 2008	Jan CAHN
AA		2MG	A040821	002	Dec 29, 2008	Jan CAHN
	ROBINUL					
AA	+ CASPER PHARMA LLC	1MG	N012827	001		Jan CAHN
	ROBINUL FORTE					
AA	+ CASPER PHARMA LLC	2MG	N012827	002		Jan CAHN

GRANISETRON

FILM, EXTENDED RELEASE;TRANSDERMAL

SANCUSO

	+ KYOWA KIRIN	3.1MG/24HR	N022198	001	Sep 12, 2008	Aug CAHN
	INJECTION, EXTENDED RELEASE;SUBCUTANEOUS					
	SUSTOL					
	+ HERON THERAPS INC	10MG/0.4ML (10MG/0.4ML)	N022445	001	Aug 09, 2016	Aug NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204238	001	Jul 06, 2016	Jun NEWA
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204238	002	Jul 06, 2016	Jun NEWA
AP	BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN
	@ CLARIS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007	May CAHN
AP	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A077913	001	Jun 26, 2008	Jun CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077186	001	Jun 30, 2008	Jun CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077187	001	Jun 30, 2008	Jun CAHN
AP	HIKMA FARMACEUTICA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078629	001	Dec 23, 2009	Jan CMS1
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078629	002	Dec 23, 2009	Jan CMS1
	GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN
	TABLET;ORAL					
	GRANISETRON HYDROCHLORIDE					
	@ COREPHARMA	EQ 1MG BASE	A078260	001	Dec 31, 2007	Mar DISC

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

GRISEOFULVIN

>A>	AB	CIPLA LTD	125MG/5ML	A065354	001	Sep 10, 2007	Sep CAHN
>D>	AB	IVAX SUB TEVA PHARMS	125MG/5ML	A065354	001	Sep 10, 2007	Sep CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYCOFENIX

	+ MISSION PHARMACAL CO	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015	Apr CAHN
--	------------------------	------------------------------	---------	-----	--------------	----------

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

	@ IMPAX LABS INC	EQ 1MG BASE	A202238	001	Oct 20, 2015	Mar DISC
	@	EQ 2MG BASE	A202238	002	Oct 20, 2015	Mar DISC
	@	EQ 3MG BASE	A202238	003	Oct 20, 2015	Mar DISC
	@	EQ 4MG BASE	A202238	004	Oct 20, 2015	Mar DISC

HALOBETASOL PROPIONATE

LOTION;TOPICAL

ULTRAVATE

	+ SUN PHARM INDS	0.05%	N208183	001	Nov 06, 2015	Jun CAHN
--	------------------	-------	---------	-----	--------------	----------

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

	@ CYCLE PHARMS LTD	2MG	A071130	001	Feb 17, 1987	Jan CAHN
	@ FRONTIDA BIOPHARM	0.5MG	A071156	001	Jan 02, 1987	Jul CAHN
	@	1MG	A071157	001	Jan 02, 1987	Jul CAHN

TABLET;ORAL
HALOPERIDOL

@	2MG	A071172	001	Jan 02, 1987	Jul CAHN
@	5MG	A071212	001	Jan 07, 1988	Jul CAHN
@	10MG	A071173	001	Jan 07, 1988	Jul CAHN
@ SUN PHARM INDS	0.5MG	A071156	001	Jan 02, 1987	Jun CAHN
@	1MG	A071157	001	Jan 02, 1987	Jun CAHN
@	2MG	A071172	001	Jan 02, 1987	Mar CAHN
@	5MG	A071212	001	Jan 07, 1988	Mar CAHN
@	10MG	A071173	001	Jan 07, 1988	Mar CAHN
@	20MG	A071177	001	Jan 07, 1988	Mar CAHN
@ VINTAGE	0.5MG	A071235	002	Nov 03, 1986	Jan CMS1
@	1MG	A071235	003	Nov 03, 1986	Jan CMS1
@	5MG	A071235	004	Nov 03, 1986	Jan CMS1
@	10MG	A071235	005	Jul 20, 1987	Jan CMS1

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION
HALOPERIDOL DECANOATE

>D> AO	EUROHLTH INTL SARL	EQ 50MG BASE/ML	A074811	001	Jan 30, 1998	Sep CAHN
>A> AO	WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A074811	001	Jan 30, 1998	Sep CAHN

HEPARIN SODIUM

INJECTABLE;INJECTION
HEPARIN SODIUM

AP	FRESENIUS KABI USA	5,000 UNITS/ML	A206552	001	Jun 10, 2016	May NEWA
----	--------------------	----------------	---------	-----	--------------	----------

HEXACHLOROPHENE

EMULSION;TOPICAL
PHISOHEX

@ SANOFI AVENTIS US	3%	N006882	001		May DISC
---------------------	----	---------	-----	--	----------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET;ORAL
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

@ ACTAVIS ELIZABETH	1.5MG;5MG	A040295	001	Dec 01, 2000	Jan CMS1
---------------------	-----------	---------	-----	--------------	----------

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
HYDRALAZINE HYDROCHLORIDE

AP	MYLAN INSTITUTIONAL	20MG/ML	A204680	001	Apr 28, 2016	Apr NEWA
----	---------------------	---------	---------	-----	--------------	----------

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

@ ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013	Apr DISC
@	25MG	A091679	002	Mar 04, 2013	Apr DISC
@	50MG	A091679	003	Mar 04, 2013	Apr DISC
@	100MG	A091679	004	Mar 04, 2013	Apr DISC
@ FRONTIDA BIOPHARM	10MG	A089359	001	Jul 25, 1986	Jul CAHN
@	25MG	A089258	001	May 05, 1986	Jul CAHN
@	50MG	A089259	001	May 05, 1986	Jul CAHN
@	100MG	A088729	001	Apr 11, 1985	Jul CAHN
@ SUN PHARM INDS	10MG	A089359	001	Jul 25, 1986	Mar CAHN
@	25MG	A089258	001	May 05, 1986	Mar CAHN
@	50MG	A089259	001	May 05, 1986	Mar CAHN
@	100MG	A088729	001	Apr 11, 1985	Jun CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
HYDRALAZINE AND HYDROCHLOROTHIAZIDE

@ WATSON LABS	25MG;15MG	A085827	001		Feb CMS1
---------------	-----------	---------	-----	--	----------

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL
RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ SUN PHARM INDS	25MG;15MG;0.1MG	A088570	001	Apr 10, 1984	Mar CAHN
------------------	-----------------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL
HYDROCHLOROTHIAZIDE

@ LANNETT HOLDINGS INC	12.5MG	A091662	001	Jan 27, 2012	Aug DISC
AB + ALLERGAN SALES LLC	12.5MG	N020504	001	Dec 27, 1996	Apr CAHN

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB	@ AUROLIFE PHARMA LLC	25MG	A083899	001		Feb	CAHN
	@	50MG	A085219	001		Feb	CAHN
	@ HIKMA INTL PHARMS	25MG	A084878	002	Jul 12, 2006	May	CAHN
		50MG	A084878	001		May	CAHN
	@ LANNETT	25MG	A084325	001		Aug	DISC
	@	50MG	A084324	001		Aug	DISC
	@ SUN PHARM INDS	25MG	A083972	001		Mar	CAHN
	@	50MG	A083972	002		Mar	CAHN
	@	100MG	A083972	003		Mar	CAHN
	ORETIC						
	@ ABBVIE	50MG	N011971	002		Jan	DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

>D>	AB	ALEMBIC LTD	12.5MG;150MG	A091370	001	Oct 15, 2012	Sep	CAHN
>D>	AB		12.5MG;300MG	A091370	002	Oct 15, 2012	Sep	CAHN
>A>	AB	ALEMBIC PHARMS LTD	12.5MG;150MG	A091370	001	Oct 15, 2012	Sep	CAHN
>A>	AB		12.5MG;300MG	A091370	002	Oct 15, 2012	Sep	CAHN
>A>	AB		25MG;300MG	A091370	003	Oct 12, 2016	Sep	NEWA
>A>	AB		25MG;300MG	A091370	003	Oct 12, 2016	Sep	CAHN
	AB	AUROBINDO PHARMA LTD	25MG;300MG	A203630	003	Mar 31, 2016	Mar	NEWA
	AB	INTL SPECLT CHEMS	12.5MG;150MG	A203036	001	Jan 15, 2016	Jan	NEWA
	AB		12.5MG;300MG	A203036	002	Jan 15, 2016	Jan	NEWA
	AB		25MG;300MG	A203036	003	Jan 15, 2016	Mar	CTEC
			25MG;300MG	A203036	003	Jan 15, 2016	Jan	NEWA
	AB	MYLAN PHARMS INC	25MG;300MG	A077969	003	Jul 20, 2016	Jul	NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

ZESTORETIC

AB		ALVOGEN MALTA	12.5MG;10MG	N019888	003	Nov 18, 1993	Jan	CAHN
AB	+		12.5MG;20MG	N019888	001	Sep 20, 1990	Jan	CAHN
AB	+		25MG;20MG	N019888	002	Jul 20, 1989	Jan	CAHN

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	+	TEVA	25MG;15MG	A076980	002	Mar 07, 2007	Aug	CRLD
		UNIRETIC						
	@	UCB INC	12.5MG;7.5MG	N020729	001	Jun 27, 1997	Aug	DISC
	@		12.5MG;15MG	N020729	003	Feb 14, 2002	Aug	DISC
	@		25MG;15MG	N020729	002	Jun 27, 1997	Aug	DISC

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB		SUN PHARM INDS	25MG;25MG	A089534	001	Jul 02, 1987	Mar	CAHN
----	--	----------------	-----------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		PRINSTON INC	12.5MG;80MG	A206083	001	Feb 08, 2016	Jan	NEWA
AB			12.5MG;160MG	A206083	002	Feb 08, 2016	Jan	NEWA
AB			12.5MG;320MG	A206083	003	Feb 08, 2016	Jan	NEWA
AB			25MG;160MG	A206083	004	Feb 08, 2016	Jan	NEWA
AB			25MG;320MG	A206083	005	Feb 08, 2016	Jan	NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

	@	ACTAVIS LABS FL INC	5MG;200MG	A077454	001	Jun 23, 2010	Jan	DISC
AB		AUROLIFE PHARMA LLC	7.5MG;200MG	A204575	001	Jun 02, 2016	May	NEWA

HYDROCORTISONE

TABLET; ORAL

HYDROCORTISONE

AB		PHARMACEUTICS INTL	5MG	A207029	001	Apr 26, 2016	Apr	NEWA
AB			10MG	A207029	002	Apr 26, 2016	Apr	NEWA
AB			20MG	A207029	003	Apr 26, 2016	Apr	NEWA

HYDROCORTISONE VALERATECREAM; TOPICAL
WESTCORT@ RANBAXY LABS LTD 0.2%
@ SUN PHARM INDS LTD 0.2%N017950 001
N017950 001Jul CAHN
Jun CAHNHYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATESUSPENSION/DROPS; OTIC
PEDIOTIC@ MONARCH PHARMS 1%; EQ 3.5MG BASE/ML; 10,000
UNITS/ML

A062822 001 Sep 29, 1987 Jan DISC

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

AB AUROLIFE PHARMA LLC 2MG
AB 4MG
AB 8MG
AB MALLINCKRODT 2MG
AB 4MGA205814 001 May 13, 2016 May NEWA
A205814 002 May 13, 2016 May NEWA
A205814 003 May 13, 2016 May NEWA
A076855 002 Sep 19, 2007 Aug NEWA
A076855 003 Sep 19, 2007 Aug NEWATABLET, EXTENDED RELEASE; ORAL
EXALGOAB + MALLINCKRODT INC 32MG
HYDROMORPHONE HYDROCHLORIDE
AB ACTAVIS LABS FL INC 32MG
AB OSMOTICA 8MG
AB 12MG
AB 16MG
AB 32MGN021217 004 Aug 24, 2012 Jun CFTG
A202144 004 Jun 30, 2016 Jun NEWA
A205629 001 Jul 07, 2016 Jun NEWA
A205629 002 Jul 07, 2016 Jun NEWA
A205629 003 Jul 07, 2016 Jun NEWA
A205629 004 Jul 07, 2016 Jun NEWAHYDROXOCOBALAMININJECTABLE; INJECTION
CYANOKIT@ SERB SA 2.5GM/VIAL (5GM/KIT)
+ 5GM/VIAL (5GM/KIT)N022041 002 Dec 15, 2006 Jan CAHN
N022041 001 Apr 08, 2011 Jan CAHNHYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB WATSON LABS 200MG

A040133 001 Nov 30, 1995 Feb CMFD

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

@ ALLERGAN SALES LLC 125MG/ML
@ 250MG/ML
+ ASPEN GLOBAL INC 250MG/MLN017439 001 Jul CAHN
N017439 002 Jul CAHN
A200271 001 Aug 24, 2015 Jan CAHNSOLUTION; INTRAMUSCULAR
MAKENA+ AMAG PHARMA USA 250MG/ML (250MG/ML)
+ 1250MG/5ML (250MG/ML)
+ LUMARA HEALTH INC 250MG/ML (250MG/ML)
MAKENA PRESERVATIVE FREE
+ AMAG PHARMA USA 250MG/ML (250MG/ML)N021945 002 Feb 19, 2016 Jun CAHN
N021945 001 Feb 03, 2011 Jun CAHN
N021945 002 Feb 19, 2016 Feb NEWA
N021945 003 Jul 15, 2016 Jul NEWAHYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB @ AUROLIFE PHARMA LLC 10MG
AB @ 25MG
AB @ 50MG
AB ECI PHARMS LLC 10MG
AB 25MG
AB 50MG
AB ELITE LABS INC 10MG
AB 25MG
@ SUN PHARM INDS 10MG
@ 25MG
@ 50MG
@ 100MGA087869 001 Dec 20, 1982 Feb CAHN
A087870 001 Dec 20, 1982 Feb CAHN
A087871 001 Dec 20, 1982 Feb CAHN
A040804 001 Jun 30, 2008 May CAHN
A040804 002 Jun 30, 2008 May CAHN
A040804 003 Jun 30, 2008 May CAHN
A040604 002 Dec 28, 2004 Jun NEWA
A040604 003 Dec 28, 2004 Jun NEWA
A089381 001 May 19, 1986 Mar CAHN
A089382 001 May 19, 1986 Mar CAHN
A089383 001 May 19, 1986 Mar CAHN
A087862 001 Apr 18, 1983 Mar CAHN

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

AB	IMPAX LABS INC	EQ 25MG HCL	A040156	001	Jul 15, 1996	Aug CAHN
AB		EQ 50MG HCL	A040156	002	Jul 15, 1996	Aug CAHN

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

IBANDRONATE SODIUM

AP	ACCORD HLTHCARE	EQ 3MG BASE/3ML	A206058	001	Feb 05, 2016	Jan NEWA
----	-----------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

IBANDRONATE SODIUM

AB	AUROBINDO PHARMA LTD	EQ 150MG BASE	A204502	001	Mar 11, 2016	Feb NEWA
AB	SUN PHARM INDS	EQ 150MG BASE	A078996	001	Aug 15, 2012	Mar CAHN

IBUPROFEN

TABLET;ORAL

IBUPROFEN

	@ AUROLIFE PHARMA LLC	300MG	A070734	001	Jun 12, 1986	Feb CAHN
	@	400MG	A070735	001	Jun 12, 1986	Feb CAHN
	@	600MG	A070736	001	Jun 12, 1986	Feb CAHN
	@	800MG	A071938	001	Jan 14, 1988	Mar CAHN
>A> AB	CONTRACT PHARMACAL	400MG	A071268	002	Oct 15, 1986	Sep NEWA
>A> AB		800MG	A071268	003	Jul 01, 1988	Sep NEWA
	@ J AND J CONSUMER INC	400MG	A070081	001	Jun 16, 1986	Jul CAHN
AB	STRIDES PHARMA	400MG	A078329	001	Feb 05, 2009	May CAHN
AB		600MG	A078329	002	Feb 05, 2009	May CAHN
AB		800MG	A078329	003	Feb 05, 2009	May CAHN
	@ SUN PHARM INDS	400MG	A070079	001	Jul 24, 1985	Mar CAHN
	@	600MG	A070080	001	Jul 24, 1985	Mar CAHN
	@	800MG	A071448	001	Feb 18, 1987	Mar CAHN

IBUPROFEN LYSINE

INJECTABLE;INTRAVENOUS

IBUPROFEN LYSINE

AP	EXELA PHARMA SCIENCE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Mar NEWA
AP	+ RECORDATI RARE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006	Mar CFTG

IDARUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

IDARUBICIN HYDROCHLORIDE

>D> AP	EUROHLTH INTL SARL	1MG/ML	A065275	001	Dec 14, 2006	Sep CAHN
>D> AP		1MG/ML	A065288	001	May 15, 2007	Sep CAHN
>A> AP	WEST-WARD PHARMS INT	1MG/ML	A065275	001	Dec 14, 2006	Sep CAHN
>A> AP		1MG/ML	A065288	001	May 15, 2007	Sep CAHN

IDOXURIDINE

SOLUTION/DROPS;OPHTHALMIC

DENDRID

+	ALCON	0.1%	N014169	001		Aug CTEC
	HERPLEX					
@	ALLERGAN	0.1%	N013935	002		Aug DISC

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

AB	APOTEX INC	EQ 100MG BASE	A079179	001	Aug 05, 2016	Jul NEWA
AB		EQ 400MG BASE	A079179	002	Aug 05, 2016	Jul NEWA
AB	TEVA PHARMS USA	EQ 100MG BASE	A204285	001	Aug 04, 2016	Jul NEWA
AB		EQ 400MG BASE	A204285	002	Aug 04, 2016	Jul NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL

IMIPRAMINE HYDROCHLORIDE

AB	SUN PHARM INDS	10MG	A081048	001	Jun 05, 1990	Mar CAHN
AB		25MG	A081049	001	Jun 05, 1990	Mar CAHN
AB		50MG	A081050	001	Jun 05, 1990	Mar CAHN

IMIPRAMINE PAMOATE

CAPSULE;ORAL

IMIPRAMINE PAMOATE

AB	+	ROXANE	EQ 75MG HCL	A091099	001	Apr 16, 2010	Feb CRLD
----	---	--------	-------------	---------	-----	--------------	----------

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

>D>		@ AMERIGEN PHARMS LTD	1.25MG	A075201	001	Dec 04, 1998	Sep CMFD
>A>	AB		1.25MG	A075201	001	Dec 04, 1998	Sep CMFD
>D>		@	2.5MG	A075201	002	Dec 04, 1998	Sep CMFD
>A>	AB		2.5MG	A075201	002	Dec 04, 1998	Sep CMFD

INDIUM IN-111 CHLORIDE

INJECTABLE;INJECTION

INDIUM IN 111 CHLORIDE

+	MALLINKRODT NUCLEAR	5mCi/0.5ML	N019841	001	Sep 27, 1994	Jan CAHN
---	---------------------	------------	---------	-----	--------------	----------

INDIUM IN-111 OXYQUINOLINE

INJECTABLE;INJECTION

INDIUM IN 111 OXYQUINOLINE

+	GE HEALTHCARE	1mCi/ML	N019044	001	Dec 24, 1985	Mar CMS1
---	---------------	---------	---------	-----	--------------	----------

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE;INJECTION

OCTREOSCAN

+	MALLINKRODT NUCLEAR	3mCi/ML	N020314	001	Jun 02, 1994	Jan CAHN
---	---------------------	---------	---------	-----	--------------	----------

INDOCYANINE GREEN

INJECTABLE;INJECTION

INDOCYANINE GREEN

AP		DIAGNOSTIC GREEN	25MG/VIAL	A040811	001	Nov 21, 2007	Jan CAHN
----	--	------------------	-----------	---------	-----	--------------	----------

INDOMETHACIN

CAPSULE;ORAL

INDOMETHACIN

>D>		@ MUTUAL PHARM	50MG	A070900	001	Feb 09, 1987	Sep CAHN
>A>		@ SUN PHARM INDS	25MG	A070900	002	Feb 09, 1987	Sep CMS1
>A>		@	50MG	A070900	001	Feb 09, 1987	Sep CAHN

INDOMETHACIN SODIUM

INJECTABLE;INJECTION

INDOMETHACIN SODIUM

AP		HOSPIRA INC	EQ 1MG BASE/VIAL	A204118	001	Apr 19, 2016	Apr NEWA
----	--	-------------	------------------	---------	-----	--------------	----------

INSULIN DETEMIR RECOMBINANT

INJECTABLE;SUBCUTANEOUS

LEVEMIR FLEXPEN

@	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	002	Jun 16, 2005	Feb DISC
---	------------------	------------------------------	---------	-----	--------------	----------

INSULIN HUMAN

SOLUTION;SUBCUTANEOUS

HUMULIN R

+	LILLY	10000 UNITS/20ML (500 UNITS/ML)	N018780	004	Mar 31, 1994	Jan CAIN
---	-------	---------------------------------	---------	-----	--------------	----------

HUMULIN R KWIKPEN

+	LILLY	1500 UNITS/3ML (500 UNITS/ML)	N018780	002	Dec 29, 2015	Jan NEWA
---	-------	-------------------------------	---------	-----	--------------	----------

INSULIN RECOMBINANT HUMAN

POWDER;INHALATION

AFREZZA

+	MANNKIND	4 UNITS/INH	N022472	001	Jun 27, 2014	Mar CAHN
		8 UNITS/INH	N022472	002	Jun 27, 2014	Mar CAHN
		12 UNITS/INH	N022472	003	Apr 17, 2015	Mar CAHN

IOXILAN

INJECTABLE;INJECTION

OXILAN-300

@ GUERBET

OXILAN-350

@ GUERBET

62%	N020316	001	Dec 21, 1995	Jun DISC
-----	---------	-----	--------------	----------

73%	N020316	002	Dec 21, 1995	Jun DISC
-----	---------	-----	--------------	----------

IPRATROPIUM BROMIDESOLUTION; INHALATION
IPRATROPIUM BROMIDE

	@ MYLAN SPEC LT	0.02%	A074755	001	Jan 10, 1997	Jul DISC
AN	+ RITEDOSE CORP	0.02%	A075693	001	Jan 26, 2001	Jul CRLD

IRBESARTANTABLET; ORAL
IRBESARTAN

AB	HISUN PHARM HANGZHOU	75MG	A206194	001	Jun 14, 2016	May NEWA
AB		150MG	A206194	002	Jun 14, 2016	May NEWA
AB		300MG	A206194	003	Jun 14, 2016	May NEWA

IRINOTECAN HYDROCHLORIDEINJECTABLE; INJECTION
CAMPOTOSAR

AP	+ PFIZER INC	300MG/15ML (20MG/ML)	N020571	003	Aug 05, 2010	Apr CTEC
	IRINOTECAN HYDROCHLORIDE					
AP	EUROHLTH INTL SARL	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008	Jun CAHN
AP		100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008	Jun CAHN
AP	QILU PHARM CO LTD	40MG/2ML (20MG/ML)	A203380	001	May 03, 2016	Apr NEWA
AP		100MG/5ML (20MG/ML)	A203380	002	May 03, 2016	Apr NEWA
AP		300MG/15ML (20MG/ML)	A203380	003	May 03, 2016	Apr NEWA
AP	SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009	Jan CAHN
AP		100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009	Jan CAHN

IRON DEXTRANINJECTABLE; INJECTION
INFED

BP	+ ALLERGAN SALES LLC	EQ 50MG IRON/ML	N017441	001		Apr CAHN
----	----------------------	-----------------	---------	-----	--	----------

ISONIAZIDTABLET; ORAL
ISONIAZID

AA	MIKART	100MG	A040090	001	Jun 26, 1997	Jun CMFD
AA		300MG	A040090	002	Jun 26, 1997	Jun CMFD
	@ SUN PHARM INDS	100MG	A080136	001		Mar CAHN
	@	300MG	A083633	001		Mar CAHN

ISOSORBIDE DINITRATECAPSULE, EXTENDED RELEASE; ORAL
DILATRATE-SR

+	AUXILIUM PHARMS INC	40MG	N019790	001	Sep 02, 1988	Mar CAHN
+	AUXILIUM PHARMS LLC	40MG	N019790	001	Sep 02, 1988	Jul CAHN

TABLET; ORAL

ISOSORBIDE DINITRATE

@	SUN PHARM INDS	5MG	A086166	002	Sep 19, 1986	Mar CAHN
@		10MG	A086169	001	Sep 19, 1986	Jun CAHN
@		20MG	A086167	001	Sep 19, 1986	Jun CAHN
@		30MG	A087564	001	Sep 18, 1986	Jun CAHN

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

@	SUN PHARM INDS	2.5MG	A084204	001	Sep 18, 1986	Jun CAHN
@		5MG	A086168	001	Sep 18, 1986	Jun CAHN
@		10MG	A087545	001	Sep 18, 1986	Jun CAHN

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE DINITRATE

@	COREPHARMA	40MG	A040723	001	Mar 17, 2008	Mar DISC
+	SUN PHARM INDS INC	40MG	A040009	001	Dec 30, 1998	Mar CTEC

ISOSORBIDE MONONITRATETABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

>A> AB	DEXCEL LTD	30MG	A075522	002	Sep 20, 2016	Sep NEWA
--------	------------	------	---------	-----	--------------	----------

ISOSULFAN BLUE

INJECTABLE; INJECTION
ISOSULFAN BLUE

AP	AUROBINDO PHARMA LTD	1%	A206831	001	Feb 02, 2016	Jan NEWA
AP	+ MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	Jan CTEC

ISOTRETINOIN

CAPSULE; ORAL
ABSORICA

BX	RANBAXY	10MG	N021951	001	May 25, 2012	Aug CAHN	
BX		20MG	N021951	002	May 25, 2012	Aug CAHN	
		25MG	N021951	005	Aug 15, 2014	Aug CAHN	
BX		30MG	N021951	003	May 25, 2012	Aug CAHN	
		35MG	N021951	006	Aug 15, 2014	Aug CAHN	
BX	+	40MG	N021951	004	May 25, 2012	Aug CAHN	
BX	RANBAXY LABS LTD	10MG	N021951	001	May 25, 2012	Jul CAHN	
BX		20MG	N021951	002	May 25, 2012	Jul CAHN	
		25MG	N021951	005	Aug 15, 2014	Aug CAHN	
		25MG	N021951	005	Aug 15, 2014	Jul CAHN	
BX		30MG	N021951	003	May 25, 2012	Jul CAHN	
		35MG	N021951	006	Aug 15, 2014	Aug CAHN	
		35MG	N021951	006	Aug 15, 2014	Jul CAHN	
BX	+	40MG	N021951	004	May 25, 2012	Jul CAHN	
>D>	SOTRET						
>D>	AB	SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002	Sep DISC
>A>	@	10MG	A076041	001	Dec 24, 2002	Sep DISC	
>D>	AB		20MG	A076041	002	Dec 24, 2002	Sep DISC
>A>	@	20MG	A076041	002	Dec 24, 2002	Sep DISC	
>D>	AB		30MG	A076503	001	Jun 20, 2003	Sep DISC
>A>	@	30MG	A076503	001	Jun 20, 2003	Sep DISC	
>D>	AB		40MG	A076041	003	Dec 24, 2002	Sep DISC
>A>	@	40MG	A076041	003	Dec 24, 2002	Sep DISC	

ITRACONAZOLE

CAPSULE; ORAL
ITRACONAZOLE

AB	ACCORD HLTHCARE	100MG	A205991	001	May 26, 2016	May NEWA	
>A>	AB	AMNEAL PHARMS	100MG	A205080	001	Sep 26, 2016	Sep NEWA

SOLUTION; ORAL

ITRACONAZOLE

@ AMNEAL PHARMS 10MG/ML
SPORANOX

A205573 001 Oct 30, 2015 Apr DISC

+ JANSSEN PHARMS 10MG/ML

N020657 001 Feb 21, 1997 Apr CTEC

IVACAFTOR; LUMACFTOR

TABLET; ORAL

ORKAMBI

>A>	VERTEX PHARMS INC	125MG; 100MG	N206038	002	Sep 28, 2016	Sep NEWA
-----	-------------------	--------------	---------	-----	--------------	----------

IVERMECTIN

LOTION; TOPICAL

SKLICE

+ ARBOR PHARMS LLC 0.5%

N202736 001 Feb 07, 2012 May CAHN

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETAMINE HYDROCHLORIDE

>D>	AP	EUROHLTH INTL SARL	EQ 50MG BASE/ML	A074524	001	Mar 22, 1996	Sep CAHN
>D>	AP		EQ 100MG BASE/ML	A074524	002	Mar 22, 1996	Sep CAHN
>A>	AP	WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A074524	001	Mar 22, 1996	Sep CAHN
>A>	AP		EQ 100MG BASE/ML	A074524	002	Mar 22, 1996	Sep CAHN

KETOCONAZOLE

TABLET; ORAL

KETOCONAZOLE

@ SUN PHARM INDS 200MG

A075314 001 Jun 15, 1999 Jan CAHN

KETOPROFENCAPSULE;ORAL
KETOPROFEN

@ AUROLIFE PHARMA LLC	50MG	A074024	001	Dec 29, 1995	Feb CAHN
@	75MG	A074024	002	Dec 29, 1995	Feb CAHN

KETOROLAC TROMETHAMINEINJECTABLE;INJECTION
KETOROLAC TROMETHAMINE

@ EUROHLTH INTL SARL	15MG/ML	A075222	001	Apr 26, 1999	Apr CAHN
@	30MG/ML	A075222	002	Apr 26, 1999	Apr CAHN
@	30MG/ML	A075228	001	Apr 26, 1999	May CAHN

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDESOLUTION;IRRIGATION
OMIDRIA

+ OMEROS	EQ 0.3% BASE;EQ 1% BASE	N205388	001	May 30, 2014	Aug CPOT
----------	-------------------------	---------	-----	--------------	----------

LABETALOL HYDROCHLORIDEINJECTABLE;INJECTION
LABETALOL HYDROCHLORIDE

AP	SAGENT STRIDES	5MG/ML	A079134	001	Feb 03, 2010	Jan CTNA
	TRANDATE					
	@ SEBELA IRELAND LTD	5MG/ML	N019425	001	Dec 31, 1985	Jan CAHN

TABLET;ORAL

	LABETALOL HYDROCHLORIDE					
AB	NOSTRUM LABS INC	100MG	A075215	001	Jul 29, 1999	Jan CAHN
AB		200MG	A075215	002	Jul 29, 1999	Jan CAHN
AB		300MG	A075215	003	Jul 29, 1999	Jan CAHN

LACOSAMIDESOLUTION;ORAL
LACOSAMIDE

AA	AMNEAL PHARMS	10MG/ML	A204839	001	Apr 28, 2016	Apr NEWA
	VIMPAT					
AA	+ UCB INC	10MG/ML	N022255	001	Apr 20, 2010	Apr CFTG

TABLET;ORAL

	LACOSAMIDE					
AB	ACTAVIS LABS FL INC	50MG	A204855	001	Apr 28, 2016	Apr NEWA
AB		100MG	A204855	002	Apr 28, 2016	Apr NEWA
AB		150MG	A204855	003	Apr 28, 2016	Apr NEWA
AB		200MG	A204855	004	Apr 28, 2016	Apr NEWA
AB	ALEMBIC PHARMS LTD	50MG	A204974	001	Apr 28, 2016	Apr NEWA
AB		100MG	A204974	002	Apr 28, 2016	Apr NEWA
AB		150MG	A204974	003	Apr 28, 2016	Apr NEWA
AB		200MG	A204974	004	Apr 28, 2016	Apr NEWA
AB	AMNEAL PHARMS	50MG	A204857	001	Sep 09, 2016	Aug NEWA
AB		100MG	A204857	002	Sep 09, 2016	Aug NEWA
AB		150MG	A204857	003	Sep 09, 2016	Aug NEWA
AB		200MG	A204857	004	Sep 09, 2016	Aug NEWA
AB	AUROBINDO PHARMA LTD	50MG	A204994	001	Apr 28, 2016	Apr NEWA
AB		100MG	A204994	002	Apr 28, 2016	Apr NEWA
AB		150MG	A204994	003	Apr 28, 2016	Apr NEWA
AB		200MG	A204994	004	Apr 28, 2016	Apr NEWA
AB	MSN LABS PVT LTD	50MG	A204921	001	Apr 28, 2016	Apr NEWA
AB		100MG	A204921	002	Apr 28, 2016	Apr NEWA
AB		150MG	A204921	003	Apr 28, 2016	Apr NEWA
AB		200MG	A204921	004	Apr 28, 2016	Apr NEWA
AB	MYLAN PHARMS INC	50MG	A205026	001	Apr 28, 2016	Apr NEWA
AB		100MG	A205026	002	Apr 28, 2016	Apr NEWA
AB		150MG	A205026	003	Apr 28, 2016	Apr NEWA
AB		200MG	A205026	004	Apr 28, 2016	Apr NEWA
AB	SUN PHARMA GLOBAL	50MG	A205031	001	Apr 28, 2016	Apr NEWA
AB		100MG	A205031	002	Apr 28, 2016	Apr NEWA
AB		150MG	A205031	003	Apr 28, 2016	Apr NEWA
AB		200MG	A205031	004	Apr 28, 2016	Apr NEWA
	VIMPAT					
AB	UCB INC	50MG	N022253	001	Oct 28, 2008	Apr CFTG
AB		100MG	N022253	002	Oct 28, 2008	Apr CFTG
AB		150MG	N022253	003	Oct 28, 2008	Apr CFTG
AB	+	200MG	N022253	004	Oct 28, 2008	Apr CFTG

LACTULOSE

	SOLUTION;ORAL						
	CONSTULOSE						
	@ ACTAVIS MID ATLANTIC	10GM/15ML	A070288	001	Aug 15, 1988	Aug	DISC
	LACTULOSE						
AA	+ HI TECH PHARMA	10GM/15ML	A074076	001	Jul 03, 1995	Aug	CRLD

LAMIVUDINE

	TABLET;ORAL						
	LAMIVUDINE						
AB	MYLAN PHARMS INC	150MG	A204528	001	Mar 04, 2016	Feb	NEWA
AB		300MG	A204528	002	Mar 04, 2016	Feb	NEWA

LAMOTRIGINE

	TABLET;ORAL						
	LAMOTRIGINE						
AB	JUBILANT CADISTA	25MG	A079132	001	Jan 27, 2009	Jun	CAHN
AB		100MG	A079132	002	Jan 27, 2009	Jun	CAHN
AB		150MG	A079132	003	Jan 27, 2009	Jun	CAHN
AB		200MG	A079132	004	Jan 27, 2009	Jun	CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	LAMICTAL XR						
AB	+ GLAXOSMITHKLINE LLC	200MG	N022115	004	May 29, 2009	Jan	CRLD
	TABLET, ORALLY DISINTEGRATING;ORAL						
	LAMOTRIGINE						
AB	SCIEGEN PHARMS INC	25MG	A206382	001	Jun 17, 2016	Jun	NEWA
AB		50MG	A206382	002	Jun 17, 2016	Jun	NEWA
AB		100MG	A206382	003	Jun 17, 2016	Jun	NEWA
AB		200MG	A206382	004	Jun 17, 2016	Jun	NEWA

LANSOPRAZOLE

	CAPSULE, DELAYED REL PELLETS;ORAL						
	LANSOPRAZOLE						
AB	ANCHEN PHARMS	15MG	A203203	001	Jul 25, 2016	Jul	NEWA
AB		30MG	A203203	002	Jul 25, 2016	Jul	NEWA

LATANOPROST

	SOLUTION/DROPS;OPHTHALMIC						
	LATANOPROST						
AT	FDC LTD	0.005%	A202442	001	Apr 22, 2016	Apr	NEWA

LESINURAD

	TABLET;ORAL						
	ZURAMPIC						
	+ IRONWOOD PHARMS INC	200MG	N207988	001	Dec 22, 2015	Aug	CAHN

LETROZOLE

	TABLET;ORAL						
	LETROZOLE						
AB	HIKMA PHARMS	2.5MG	A203796	001	Jun 03, 2016	May	NEWA
AB	KREMERS URBAN PHARMS	2.5MG	A091098	001	Jun 03, 2011	Jan	CAHN

LEUCOVORIN CALCIUM

	INJECTABLE;INJECTION						
	LEUCOVORIN CALCIUM PRESERVATIVE FREE						
>D>	+ EUROHLTH INTL SARL	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Sep	CAHN
>D> AP	+	EQ 200MG BASE/VIAL	A040056	001	May 23, 1995	Sep	CAHN
>D> AP	+	EQ 350MG BASE/VIAL	A040335	001	Apr 20, 2000	Sep	CAHN
>A>	+ WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Sep	CAHN
>A> AP	+	EQ 200MG BASE/VIAL	A040056	001	May 23, 1995	Sep	CAHN
>A> AP	+	EQ 350MG BASE/VIAL	A040335	001	Apr 20, 2000	Sep	CAHN
	TABLET;ORAL						
	LEUCOVORIN CALCIUM						
	@ IDT AUSTRALIA LTD	EQ 15MG BASE	A075327	001	Mar 24, 1999	May	CAHN
	ROXANE	EQ 15MG BASE	A072735	001	Feb 22, 1993	Jun	CTEC

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN	IMPAX LABS INC	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	Aug CAHN
AN		EQ 0.021% BASE	A077756	001	Apr 09, 2008	Aug CAHN
AN		EQ 0.042% BASE	A077756	002	Apr 09, 2008	Aug CAHN
AN	RITEDOSE CORP	EQ 0.0103% BASE	A203653	001	Mar 22, 2016	Mar NEWA
AN		EQ 0.021% BASE	A203653	002	Mar 22, 2016	Mar NEWA
AN		EQ 0.042% BASE	A203653	003	Mar 22, 2016	Mar NEWA

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP	AUROBINDO PHARMA LTD	500MG/5ML (100MG/ML)	A204312	001	Feb 01, 2016	Jan NEWA
AP	JUBILANT LIFE	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	May NEWA
>A> AP	MYLAN LABS LTD	500MG/5ML (100MG/ML)	A203308	001	Sep 16, 2016	Sep NEWA

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

AB	INTELLIPHARMACEUTICS	500MG	A204511	001	Feb 23, 2016	Feb NEWA
AB		750MG	A204511	002	Feb 23, 2016	Feb NEWA
AB	LOTUS PHARM CO LTD	500MG	A202095	002	Jun 06, 2016	May NEWA
AB		750MG	A202095	001	Jun 06, 2016	May NEWA
AB	NOSTRUM LABS INC	500MG	A204754	001	Aug 26, 2016	Aug NEWA
AB		750MG	A204754	002	Aug 26, 2016	Aug NEWA
AB	SUN PHARM INDS	500MG	A091285	001	Sep 12, 2011	Mar CAHN
AB		750MG	A091285	002	Sep 12, 2011	Mar CAHN

TABLET, FOR SUSPENSION; ORAL

SPRITAM

	APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015	Feb CDFR
		500MG	N207958	002	Jul 31, 2015	Feb CDFR
		750MG	N207958	003	Jul 31, 2015	Feb CDFR
+		1GM	N207958	004	Jul 31, 2015	Mar CRLD
		1GM	N207958	004	Jul 31, 2015	Feb CDFR

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

AT	ALCON LABS INC	0.25%	A074851	001	Oct 28, 1996	Jul CAHN
----	----------------	-------	---------	-----	--------------	----------

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

@	JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jun DISC
@		EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jun DISC
@		EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jun DISC

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	AUROBINDO PHARMA LTD	EQ 250MG/50ML (EQ 5MG/ML)	A206919	001	Feb 10, 2016	Jan NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A206919	002	Feb 10, 2016	Jan NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A206919	003	Feb 10, 2016	Jan NEWA

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

AT	+ RISING PHARMS INC	0.5%	A077700	001	Dec 20, 2010	Jan CAHN
----	---------------------	------	---------	-----	--------------	----------

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)

FUSILEV

AP	+ SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Jun CFTG
	LEVOLEUCOVORIN CALCIUM					
>A>	ACTAVIS LLC	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016	Sep NEWA
AP	EUROHLTH INTL SARL	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016	Jun NEWA

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

KYLEENA

>A>	+ BAYER HLTHCARE	19.5MG	N208224	001	Sep 16, 2016	Sep NEWA
-----	------------------	--------	---------	-----	--------------	----------

TABLET; ORAL

LEVONORGESTREL

AB	JAI PHARMA LTD	0.75MG	A202740	001	Sep 02, 2016	Aug NEWA
AB	LOTUS PHARM CO LTD	0.75MG	A202684	001	Sep 02, 2016	Aug NEWA
AB	+ PERRIGO R AND D	0.75MG	A090740	001	Dec 30, 2010	Aug CTEC
+		0.75MG	A090740	001	Dec 30, 2010	Apr CRLD

LEVOTHYROXINE SODIUM

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

AP	FERA PHARMS LLC	100MCG/VIAL	A206163	001	Jun 29, 2016	Jun NEWA
AP		500MCG/VIAL	A206163	002	Jun 29, 2016	Jun NEWA
AP	+ FRESSENIUS KABI USA	100MCG/VIAL	N202231	001	Jun 24, 2011	Jun CFTG
AP	+	500MCG/VIAL	N202231	003	Jun 24, 2011	Jun CFTG

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOLET

@ LEHIGH VALLEY	0.025MG	N021137	001	Jun 06, 2003	Jul CAHN
@	0.05MG	N021137	002	Jun 06, 2003	Jul CAHN
@	0.075MG	N021137	003	Jun 06, 2003	Jul CAHN
@	0.088MG	N021137	004	Jun 06, 2003	Jul CAHN
@	0.1MG	N021137	005	Jun 06, 2003	Jul CAHN
@	0.112MG	N021137	006	Jun 06, 2003	Jul CAHN
@	0.125MG	N021137	007	Jun 06, 2003	Jul CAHN
@	0.137MG	N021137	008	Jun 06, 2003	Jul CAHN
@	0.15MG	N021137	009	Jun 06, 2003	Jul CAHN
@	0.175MG	N021137	010	Jun 06, 2003	Jul CAHN
@	0.2MG	N021137	011	Jun 06, 2003	Jul CAHN
@	0.3MG	N021137	012	Jun 06, 2003	Jul CAHN

LEVOTHROID

@ LLOYD	0.025MG	N021116	001	Oct 24, 2002	May DISC
@	0.05MG	N021116	002	Oct 24, 2002	May DISC
@	0.075MG	N021116	003	Oct 24, 2002	May DISC
@	0.088MG	N021116	010	Oct 24, 2002	May DISC
@	0.1MG	N021116	004	Oct 24, 2002	May DISC
@	0.112MG	N021116	011	Oct 24, 2002	May DISC
@	0.125MG	N021116	005	Oct 24, 2002	May DISC
@	0.137MG	N021116	012	Dec 07, 2004	May DISC
@	0.15MG	N021116	006	Oct 24, 2002	May DISC
@	0.175MG	N021116	007	Oct 24, 2002	May DISC
@	0.2MG	N021116	008	Oct 24, 2002	May DISC
@	0.3MG	N021116	009	Oct 24, 2002	May DISC

LEVOTHYROXINE SODIUM

AB1, MYLA1	.3MG	A076187	011	Jun 05, 2002	May CRLD
AB2,					
AB3,					
AB4 +					

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

AT	GLENMARK PHARMS LTD	5%	A206498	001	Sep 09, 2016	Aug NEWA
AT	SEPTODONT INC	5%	A040911	001	May 23, 2011	Jun CAHN
AT	TELIGENT PHARMA INC	5%	A205318	001	Feb 01, 2016	Jan NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA	400MG/100ML	N018388	002		Feb DISC
-----------	-------------	---------	-----	--	----------

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA	800MG/100ML	N018388	003	Nov 05, 1982	Feb DISC
-----------	-------------	---------	-----	--------------	----------

JELLY; TOPICAL

ANESTACON

@ BIONPHARMA INC	2%	A080429	001		Jan CAHN
------------------	----	---------	-----	--	----------

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

AT + VINTAGE	2%	A040708	001	Feb 27, 2007	Aug CRLD
--------------	----	---------	-----	--------------	----------

XYLOCAINE VISCOUS

@ FRESSENIUS KABI USA	2%	N009470	001		Aug DISC
-----------------------	----	---------	-----	--	----------

SOLUTION; TOPICAL

LIDOCAINE HYDROCHLORIDE

AT	TELIGENT PHARMA INC	4%	A204494	001	Mar 12, 2014	May CAHN
----	---------------------	----	---------	-----	--------------	----------

LIFITEGRASTSOLUTION/DROPS;OPHTHALMIC
XIIDRA

+	SHIRE DEV LLC	5%	N208073	001	Jul 11, 2016	Jul NEWA
---	---------------	----	---------	-----	--------------	----------

LINAGLIPTIN; METFORMIN HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
JENTADUETO XR

	BOEHRINGER INGELHEIM	2.5MG;1GM	N208026	001	May 27, 2016	May NEWA
+		5MG;1GM	N208026	002	May 27, 2016	May NEWA

LINEZOLID

SOLUTION;IV (INFUSION)

LINEZOLID

AP	AUROBINDO PHARMA LTD	600MG/300ML (2MG/ML)	A206917	001	Aug 04, 2016	Jul NEWA
AP	FRESENIUS KABI USA	600MG/300ML (2MG/ML)	A204764	001	Mar 15, 2016	Feb NEWA

TABLET;ORAL

LINEZOLID

AB	GATE PHARMS	600MG	A091210	001	Feb 05, 2016	Jan NEWA
AB	GLENMARK PHARMS	600MG	A078987	001	Dec 21, 2015	Mar CAHN
AB	NOVEL LABS INC	600MG	A207526	001	Aug 22, 2016	Aug NEWA

LIOTHYRONINE SODIUM

TABLET;ORAL

LIOTHYRONINE SODIUM

AB	MAYNE PHARMA INC	EQ 0.005MG BASE	A090097	001	Mar 20, 2009	Mar CAHN
AB		EQ 0.025MG BASE	A090097	002	Mar 20, 2009	Mar CAHN
AB		EQ 0.05MG BASE	A090097	003	Mar 20, 2009	Mar CAHN
AB	SUN PHARM INDS LTD	EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Apr NEWA
AB		EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Apr NEWA
AB		EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Apr NEWA

LISINOPRIL

SOLUTION;ORAL

QBRELIS

+	SILVERGATE PHARMS	1MG/ML	N208401	001	Jul 29, 2016	Jul NEWA
---	-------------------	--------	---------	-----	--------------	----------

TABLET;ORAL

ZESTRIL

AB	ALVOGEN MALTA	2.5MG	N019777	005	Apr 29, 1993	Jan CAHN
AB		5MG	N019777	001	May 19, 1988	Jan CAHN
AB		10MG	N019777	002	May 19, 1988	Jan CAHN
AB		20MG	N019777	003	May 19, 1988	Jan CAHN
AB		30MG	N019777	006	Jan 20, 1999	Jan CAHN
AB	+	40MG	N019777	004	May 19, 1988	Jan CAHN

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB	DELCOR ASSET CORP	150MG	A076243	002	Feb 24, 2003	Feb CAHN
AB		300MG	A076243	001	Jun 27, 2002	Feb CAHN
AB		600MG	A078763	001	Apr 15, 2008	Feb CAHN
AB	HIKMA PHARMS	600MG	A078763	001	Apr 15, 2008	Jan CMFD

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

>A>	AB	HERITAGE PHARMA	300MG	A205532	001	Sep 29, 2016	Sep NEWA
-----	----	-----------------	-------	---------	-----	--------------	----------

LIXISENATIDE

SOLUTION;SUBCUTANEOUS

ADLYXIN

+	SANOFI-AVENTIS US	0.15MG/3ML (0.05MG/ML)	N208471	001	Jul 27, 2016	Aug CPOT
+		0.05MG/ML	N208471	001	Jul 27, 2016	Jul NEWA
+		0.1MG/ML	N208471	002	Jul 27, 2016	Jul NEWA
+		0.3MG/3ML (0.1MG/ML)	N208471	002	Jul 27, 2016	Aug CPOT

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

	AEGERION	EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan CRLD
+		EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan CRLD

LOPERAMIDE HYDROCHLORIDE

	CAPSULE; ORAL					
	IMODIUM					
	@ J AND J CONSUMER INC	2MG	N017694	001		Feb DISC
	LOPERAMIDE HYDROCHLORIDE					
AB	+ MYLAN	2MG	A072741	001	Sep 18, 1991	Feb CRLD

LORAZEPAM

	TABLET; ORAL					
	LORAZEPAM					
>A>	@ FRONTIDA BIOPHARM	0.5MG	A072553	001	Mar 29, 1991	Sep CAHN
>A>	@	1MG	A072554	001	Mar 29, 1991	Sep CAHN
	@	2MG	A072555	001	Mar 29, 1991	Jul CAHN
>D>	@ MUTUAL PHARM	0.5MG	A072553	001	Mar 29, 1991	Sep CAHN
>D>	@	1MG	A072554	001	Mar 29, 1991	Sep CAHN

LORCASERIN HYDROCHLORIDE

	TABLET, EXTENDED RELEASE; ORAL					
	BELVIQ XR					
	+ EISAI INC	20MG	N208524	001	Jul 15, 2016	Jul NEWA

LOSARTAN POTASSIUM

	TABLET; ORAL					
	LOSARTAN POTASSIUM					
BX	HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015	Apr CTEC
BX		50MG	A203835	002	Aug 12, 2015	Apr CTEC
BX		100MG	A203835	003	Aug 12, 2015	Apr CTEC
BX	LUPIN LTD	25MG	A078232	001	Oct 06, 2010	Apr CTEC
BX		50MG	A078232	002	Oct 06, 2010	Apr CTEC
BX		100MG	A078232	003	Oct 06, 2010	Apr CTEC

LOVASTATIN

	TABLET; ORAL					
	LOVASTATIN					
AB	SUN PHARM INDS	10MG	A077520	001	Apr 14, 2006	Mar CAHN
AB		20MG	A077520	002	Apr 14, 2006	Mar CAHN
AB		40MG	A077520	003	Apr 14, 2006	Mar CAHN

LOXAPINE

	POWDER; INHALATION					
	ADASUVE					
	+ ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012	Feb CAHN

LUCINACTANT

	SUSPENSION; INTRATRACHEAL					
	SURFAXIN					
	@ WINDTREE THERAP	8.5ML	N021746	001	Mar 06, 2012	Aug CAHN

MAGNESIUM SULFATE

	INJECTABLE; INJECTION					
	MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	FRESENIUS KABI USA	1GM/100ML	A206486	001	Mar 07, 2016	Feb NEWA
AP	+ HOSPIRA	1GM/100ML	N020488	001	Jul 11, 1995	Feb CFTG
AP	HQ SPCLT PHARMA	1GM/100ML	A207349	001	Mar 02, 2016	Feb NEWA
	MAGNESIUM SULFATE IN PLASTIC CONTAINER					
AP	FRESENIUS KABI USA	4GM/100ML (40MG/ML)	A206485	001	Mar 15, 2016	Feb NEWA
AP		4GM/50ML (80MG/ML)	A206485	002	Mar 15, 2016	Feb NEWA
AP		2GM/50ML (40MG/ML)	A206485	003	Mar 15, 2016	Mar NEWA
AP		20GM/500ML (40MG/ML)	A206485	004	Mar 15, 2016	Mar NEWA
AP		40GM/1000ML (40MG/ML)	A206485	005	Mar 15, 2016	Mar NEWA
AP	HOSPIRA	2GM/50ML (40MG/ML)	N020309	003	Jan 26, 2007	Mar CFTG
AP	+	4GM/100ML (40MG/ML)	N020309	001	Jun 24, 1994	Feb CFTG
AP	+	4GM/50ML (80MG/ML)	N020309	002	Jun 24, 1994	Feb CFTG
AP		20GM/500ML (40MG/ML)	N020309	004	Jan 18, 1995	Mar CFTG
AP		40GM/1000ML (40MG/ML)	N020309	005	Jan 18, 1995	Mar CFTG
	SOLUTION; INTRAMUSCULAR, INTRAVENOUS					
	MAGNESIUM SULFATE					
	+ FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan NEWA
	+	25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016	Jan NEWA

MEBENDAZOLETABLET, CHEWABLE;ORAL
EMVERM

+ AMEDRA PHARMS LLC 100MG A073580 001 Jan 04, 1995 Aug CTNA

MECLIZINE HYDROCHLORIDETABLET;ORAL
MECLIZINE HYDROCHLORIDE

@ RISING PHARMS INC 12.5MG A040179 001 Jan 30, 1997 Jan CAHN

@ 25MG A040179 002 Jan 30, 1997 Jan CAHN

TABLET, CHEWABLE;ORAL
ANTIVERT

@ CASPER PHARMA LLC 25MG N010721 005 Jun DISC

MEFLOQUINE HYDROCHLORIDETABLET;ORAL
MEFLOQUINE HYDROCHLORIDE

@ HIKMA INTL PHARMS 250MG A077699 001 Apr 21, 2010 May CAHN

MEGESTROL ACETATESUSPENSION;ORAL
MEGACE ES

AB + ENDO PHARMS INC 125MG/ML N021778 001 Jul 05, 2005 Feb CAHN

MELOXICAMTABLET;ORAL
MELOXICAM

@ FRONTIDA BIOPHARM 7.5MG A077935 001 Jul 19, 2006 Jul CAHN

@ 15MG A077935 002 Jul 19, 2006 Jul CAHN

@ SUN PHARM INDS 7.5MG A077935 001 Jul 19, 2006 Jan CAHN

@ 15MG A077935 002 Jul 19, 2006 Jan CAHN

MELPHALANTABLET;ORAL
ALKERAN

+ APOTEX INC 2MG N014691 002 Jan CAHN

MELPHALAN HYDROCHLORIDEINJECTABLE;INJECTION
ALKERAN

AP + APOTEX INC EQ 50MG BASE/VIAL N020207 001 Nov 18, 1992 Jan CAHN

MELPHALAN HYDROCHLORIDE

AP PAR STERILE PRODUCTS EQ 50MG BASE/VIAL A204773 001 Aug 22, 2016 Aug NEWA

POWDER;IV (INFUSION)
EVOMELA

SPECTRUM PHARMS EQ 50MG BASE/VIAL N207155 001 Mar 10, 2016 Mar NEWA

MEMANTINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
MEMANTINE HYDROCHLORIDE

>A> LUPIN LTD 7MG A206028 001 Sep 28, 2016 Sep NEWA

>A> AB 14MG A206028 002 Sep 28, 2016 Sep NEWA

>A> AB 21MG A206028 003 Sep 28, 2016 Sep NEWA

>A> AB 28MG A206028 004 Sep 28, 2016 Sep NEWA

>A> AB MYLAN PHARMS INC 7MG A206032 001 Sep 28, 2016 Sep NEWA

>A> AB 14MG A206032 002 Sep 28, 2016 Sep NEWA

>A> AB 21MG A206032 003 Sep 28, 2016 Sep NEWA

>A> AB 28MG A206032 004 Sep 28, 2016 Sep NEWA

>A> AB SUN PHARMA GLOBAL 7MG A205905 001 Sep 28, 2016 Sep NEWA

>A> AB 14MG A205905 002 Sep 28, 2016 Sep NEWA

>A> AB 21MG A205905 003 Sep 28, 2016 Sep NEWA

>A> AB 28MG A205905 004 Sep 28, 2016 Sep NEWA

NAMENDA XR

>D> FOREST LABS LLC 7MG N022525 001 Jun 21, 2010 Sep CFTG

>A> AB 7MG N022525 001 Jun 21, 2010 Sep CFTG

>D> 14MG N022525 002 Jun 21, 2010 Sep CFTG

>A> AB 14MG N022525 002 Jun 21, 2010 Sep CFTG

>D> 21MG N022525 003 Jun 21, 2010 Sep CFTG

>A> AB 21MG N022525 003 Jun 21, 2010 Sep CFTG

>D> + 28MG N022525 004 Jun 21, 2010 Sep CFTG

>A> AB + 28MG N022525 004 Jun 21, 2010 Sep CFTG

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION					
DEMEROL					
	@ US PHARM HOLDINGS	25MG/ML	N005010	007	Jan CAHN
	@	50MG/ML	N005010	002	Jan CAHN
	@	75MG/ML	N005010	009	Jan CAHN
	@	100MG/ML	N005010	003	Jan CAHN
SYRUP; ORAL					
DEMEROL					
	@ US PHARM HOLDINGS	50MG/5ML	N005010	005	Jan CAHN
TABLET; ORAL					
DEMEROL					
AA	+ US PHARM HOLDINGS	50MG	N005010	001	Jan CAHN
AA	+	100MG	N005010	004	Jan CAHN
MEPERIDINE HYDROCHLORIDE					
	@ SUN PHARM INDS	50MG	A080448	001	Mar CAHN
	@	100MG	A080448	002	Mar CAHN

MEPROBAMATE

TABLET; ORAL					
MEPROBAMATE					
	@ AUROLIFE PHARMA LLC	400MG	A080655	001	Feb CAHN
	@ SUN PHARM INDS	200MG	A080699	001	Mar CAHN
	@	400MG	A080699	002	Mar CAHN

MERCAPTOPURINE

TABLET; ORAL					
MERCAPTOPURINE					
AB	DR REDDYS LABS INTL	50MG	A040461	001	Feb 11, 2004 Apr CAHN
PURINETHOL					
AB	STASON PHARMS	50MG	N009053	002	Aug CMFD
	@	50MG	N009053	002	Jan CAHN

MEROPENEM

INJECTABLE; INJECTION					
MEROPENEM					
AP	AMNEAL PHARMS	500MG/VIAL	A205883	001	Apr 12, 2016 Mar NEWA
AP		1GM/VIAL	A205883	002	Apr 12, 2016 Mar NEWA
AP	GLAND PHARMA LTD	500MG/VIAL	A206141	001	Jun 08, 2016 May NEWA
AP		1GM/VIAL	A206141	002	Jun 08, 2016 May NEWA
AP	PAR STERILE PRODUCTS	500MG/VIAL	A204139	001	Jun 09, 2016 May NEWA
AP		1GM/VIAL	A204139	002	Jun 09, 2016 May NEWA
AP	SAVIOR LIFETEC CORP	500MG/VIAL	A206086	001	Apr 19, 2016 Apr NEWA
AP		1GM/VIAL	A206086	002	Apr 19, 2016 Apr NEWA

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL					
DELZICOL					
	+ APIL	400MG	N204412	001	Feb 01, 2013 Jan CAHN
TABLET, DELAYED RELEASE; ORAL					
ASACOL					
	@ APIL	400MG	N019651	001	Jan 31, 1992 Jan CAHN
ASACOL HD					
	+ APIL	800MG	N021830	001	May 29, 2008 Jan CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL					
METFORMIN HYDROCHLORIDE					
AB	CSPC OUYI PHARM CO	500MG	A205096	001	Jul 11, 2016 Jun NEWA
AB		850MG	A205096	002	Jul 11, 2016 Jun NEWA
AB		1GM	A205096	003	Jul 11, 2016 Jun NEWA
AB	SUN PHARM INDS	500MG	A076038	001	Feb 21, 2002 Mar CAHN
AB		850MG	A076038	002	Feb 21, 2002 Mar CAHN
AB		1GM	A076038	003	Feb 21, 2002 Mar CAHN
TABLET, EXTENDED RELEASE; ORAL					
GLUMETZA					
AB3	SANTARUS INC	500MG	N021748	001	Jun 03, 2005 Jan CTEC
AB3	+	1GM	N021748	002	Jun 03, 2005 Jan CTEC
METFORMIN HYDROCHLORIDE					
AB3	ACTAVIS LABS FL INC	500MG	A203755	001	Aug 01, 2016 Jul NEWA
AB3		1GM	A203755	002	Aug 01, 2016 Jul NEWA

TABLET, EXTENDED RELEASE;ORAL
METFORMIN HYDROCHLORIDE

	@ IMPAX LABS	500MG	A076249	001	Jul 30, 2004	Mar	DISC
	@	750MG	A076985	001	Sep 13, 2005	Mar	DISC
AB1	MARKSANS PHARMA	500MG	A090295	001	Apr 29, 2016	Apr	NEWA
AB		750MG	A090295	002	Apr 29, 2016	Apr	NEWA
	@ SUN PHARM INDS	500MG	A077124	001	Dec 21, 2005	Mar	CAHN
AB3	SUN PHARMA GLOBAL	500MG	A202917	001	Aug 01, 2016	Jul	NEWA
AB3		1GM	A202917	002	Aug 01, 2016	Jul	NEWA

METHADONE HYDROCHLORIDE

TABLET, FOR SUSPENSION;ORAL
METHADOSE

AA	MALLINCKRODT INC	40MG	A074184	001	Apr 29, 1993	Aug	CAHN
----	------------------	------	---------	-----	--------------	-----	------

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL
METHAMPHETAMINE HYDROCHLORIDE

AA	MAYNE PHARMA INC	5MG	A091189	001	Apr 21, 2010	Aug	CAHN
----	------------------	-----	---------	-----	--------------	-----	------

METHENAMINE HIPPURATE

TABLET;ORAL
HIPREX

AB	+ US PHARM HOLDINGS	1GM	N017681	001		Jan	CAHN
AB	METHENAMINE HIPPURATE						
AB	AUROBINDO PHARMA LTD	1GM	A205661	001	Jul 05, 2016	Jun	NEWA

METHIMAZOLE

TABLET;ORAL
METHIMAZOLE

AB	ECI PHARMS LLC	5MG	A040547	001	Feb 18, 2005	Jul	CAHN
AB		10MG	A040547	002	Feb 18, 2005	Jul	CAHN
	@	20MG	A040547	004	Feb 18, 2005	Jul	CAHN
AB	RISING PHARMS INC	5MG	A202068	001	Mar 07, 2012	Jan	CAHN
AB		10MG	A202068	002	Mar 07, 2012	Jan	CAHN

METHOCARBAMOL

SOLUTION;IM-IV
METHOCARBAMOL

AP	AUROBINDO PHARMA LTD	1GM/10ML (100MG/ML)	A206128	001	May 27, 2016	May	NEWA
----	----------------------	---------------------	---------	-----	--------------	-----	------

TABLET;ORAL
METHOCARBAMOL

	@ LANNETT HOLDINGS INC	500MG	A084756	002	Mar 31, 2003	Aug	DISC
	@	750MG	A084756	001		Aug	DISC
	@ SANDOZ	500MG	A084616	001		Feb	DISC
	@	750MG	A084615	001		Feb	DISC
	@ SUN PHARM INDS	500MG	A084488	001		Mar	CAHN
	@	750MG	A084486	001		Mar	CAHN
	ROBAXIN						
AA	+ AUXILIUM PHARMS INC	500MG	N011011	004		Mar	CAHN
AA	+ AUXILIUM PHARMS LLC	500MG	N011011	004		Jul	CAHN
	ROBAXIN-750						
AA	+ AUXILIUM PHARMS INC	750MG	N011011	006		Mar	CAHN
AA	+ AUXILIUM PHARMS LLC	750MG	N011011	006		Jul	CAHN

METHOHEXITAL SODIUM

INJECTABLE;INJECTION
BREVITAL SODIUM

	@ PAR STERILE PRODUCTS	200MG/VIAL	N011559	004	Dec 21, 2012	Jun	DISC
--	------------------------	------------	---------	-----	--------------	-----	------

METHOTREXATE

SOLUTION;SUBCUTANEOUS
OTREXUP

>D>	ANTARES PHARMA INC	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014	Sep	DISC
>A>	@	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014	Sep	DISC
		12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	May	NEWA
		17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	May	NEWA
		22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	May	NEWA

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

>D>	+	EUROHLTH INTL SARL	EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005	Sep CAHN
AP		SANDOZ INC	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A090039	001	Mar 31, 2009	Jan CAHN
AP			EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A090039	002	Mar 31, 2009	Jan CAHN
AP			EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A090029	001	Mar 31, 2009	Jan CAHN
>A>	+	WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005	Sep CAHN

METHOXSALEN

CAPSULE;ORAL

METHOXSALEN

@ IDT AUSTRALIA LTD

10MG

A087781 001 Jun 08, 1982 Aug CAHN

INJECTABLE;INJECTION

UVADEX

+ MALLINCKRODT HOSP

0.02MG/ML

N020969 001 Feb 25, 1999 Apr CAHN

METHYLDOPA

TABLET;ORAL

METHYLDOPA

@ SUN PHARM INDS

125MG

A070073 001 Oct 09, 1986 Mar CAHN

@

250MG

A070060 001 Oct 09, 1986 Mar CAHN

@

500MG

A070074 001 Oct 09, 1986 Mar CAHN

METHYLENE BLUE

SOLUTION;INTRAVENOUS

PROVAYBLUE

+ PROVEPHARM SAS

50MG/10ML (5MG/ML)

N204630 001 Apr 08, 2016 Apr NEWA

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHERGINE

@ EDISON THERAPS LLC

0.2MG

N006035 003 Jan DISC

METHYLERGONOVINE MALEATE

+ NOVEL LABS INC

0.2MG

A091577 001 May 02, 2011 Jan CRLD

METHYLNALTREXONE BROMIDE

SOLUTION;SUBCUTANEOUS

RELISTOR

+ SALIX PHARMS

8MG/0.4ML (8MG/0.4ML)

N021964 002 Sep 27, 2010 Jul CRLD

TABLET;ORAL

RELISTOR

+ SALIX PHARMS INC

150MG

N208271 001 Jul 19, 2016 Jul NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB2 COREPHARMA

10MG

A205105 001 Jul 28, 2016 Jul NEWA

AB2

20MG

A205105 002 Jul 28, 2016 Jul NEWA

AB2

30MG

A205105 003 Jul 28, 2016 Jul NEWA

AB2

40MG

A205105 004 Jul 28, 2016 Jul NEWA

AB2

50MG

A205105 005 Jul 28, 2016 Jul NEWA

AB2

60MG

A205105 006 Jul 28, 2016 Jul NEWA

AB1 MAYNE PHARMA

20MG

A078458 001 Dec 01, 2011 Aug CAHN

AB1

30MG

A078458 002 Dec 01, 2011 Aug CAHN

AB1

40MG

A078458 003 Dec 01, 2011 Aug CAHN

AB1

60MG

A078458 004 Jun 23, 2016 Aug CAHN

AB1 WATSON LABS INC

60MG

A078458 004 Jun 23, 2016 Jun NEWA

RITALIN LA

AB1 + NOVARTIS

60MG

N021284 005 Oct 27, 2014 Jun CFTG

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA NOSTRUM LABS INC

5MG/5ML

A201466 001 Nov 12, 2013 Feb CAHN

AA

10MG/5ML

A201466 002 Nov 12, 2013 Feb CAHN

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A> AB CNTY LINE PHARMS

5MG

A206840 001 Sep 15, 2016 Sep NEWA

>A> AB

10MG

A206840 002 Sep 15, 2016 Sep NEWA

>A> AB

20MG

A206840 003 Sep 15, 2016 Sep NEWA

TABLET, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB	CNTY LINE PHARMS	10MG	A204772	001	Feb 29, 2016	Aug CAHN
AB		20MG	A204772	002	Feb 29, 2016	Aug CAHN
AB	TEDOR PHARMA INC	10MG	A204772	001	Feb 29, 2016	Feb NEWA
AB		20MG	A204772	002	Feb 29, 2016	Feb NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

AP	HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	A202691	001	Feb 16, 2016	Feb NEWA
AP		EQ 1GM BASE/VIAL	A202691	002	Feb 16, 2016	Feb NEWA
AP	SAGENT PHARMS	EQ 40MG BASE/VIAL	A040888	001	Jul 18, 2011	Jan CAHN
AP		EQ 125MG BASE/VIAL	A040888	002	Jul 18, 2011	Jan CAHN
AP		EQ 500MG BASE/VIAL	A040888	003	Jul 18, 2011	Jan CAHN
AP		EQ 1GM BASE/VIAL	A040888	004	Jul 18, 2011	Jan CAHN
AP		EQ 2GM BASE/VIAL	A040888	005	Jul 18, 2011	Jan CAHN

METHYLTESTOSTERONE

TABLET;ORAL
ANDROID 10

	@ VALEANT PHARM INTL	10MG	A086450	001		Apr DISC
	METHYLTESTOSTERONE					
	@ IMPAX LABS	25MG	A084310	001		Mar DISC

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION;ORAL
METOCLOPRAMIDE HYDROCHLORIDE

	@ SILARX	EQ 5MG BASE/5ML	A073680	001	Oct 27, 1992	Aug DISC
--	----------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB	IMPAX LABS INC	EQ 5MG BASE	A072750	001	Dec 28, 1995	Aug CAHN
AB		EQ 10MG BASE	A071250	001	Feb 03, 1988	Aug CAHN
AB	SUN PHARM INDS	EQ 5MG BASE	A071536	002	Jan 16, 1997	Mar CAHN
	@	EQ 10MG BASE	A071536	001	Apr 28, 1993	Mar CAHN

METOPROLOL TARTRATE

INJECTABLE;INJECTION
METOPROLOL TARTRATE

AP	EUROHLTH INTL SARL	1MG/ML	A076495	001	Jul 07, 2003	Apr CAHN
----	--------------------	--------	---------	-----	--------------	----------

TABLET;ORAL

METOPROLOL TARTRATE

	@ SANDOZ	50MG	A073288	001	Mar 25, 1994	May DISC
	@	100MG	A073289	001	Mar 25, 1994	May DISC
AB	SUN PHARM INDS	25MG	A073654	002	Jul 15, 2009	Mar CAHN
AB		100MG	A073654	001	Dec 21, 1993	Mar CAHN

METRONIDAZOLE

GEL;VAGINAL
NUVESSA

	+ ALLERGAN SALES LLC	1.3%	N205223	001	Mar 24, 2014	Apr CAHN
--	----------------------	------	---------	-----	--------------	----------

TABLET;ORAL

METRONIDAZOLE

AB	FLAMINGO PHARMS	250MG	A207309	001	May 16, 2016	May NEWA
AB		500MG	A207309	002	May 16, 2016	May NEWA
AB	NOSTRUM LABS INC	250MG	A070772	001	Jul 16, 1986	Jan CAHN
AB		500MG	A070773	001	Jul 16, 1986	Jan CAHN
AB	STRIDES PHARMA	250MG	A208162	001	May 25, 2016	May NEWA
AB		500MG	A208162	002	May 25, 2016	May NEWA
AB	VIVIMED LABS	250MG	A070040	001	Jan 29, 1985	May CMFD
AB		500MG	A070039	001	Jan 29, 1985	May CMFD

MICAFUNGIN SODIUM

INJECTABLE;IV (INFUSION)
MYCAMINE

>D>	+ ASTELLAS	50MG/VIAL	N021506	002	Mar 16, 2005	Sep CPOT
>A>	+	EQ 50MG BASE/VIAL	N021506	002	Mar 16, 2005	Sep CPOT
>D>	+	100MG/VIAL	N021506	003	Jun 27, 2006	Sep CPOT
>A>	+	EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006	Sep CPOT

MICONAZOLETABLET;BUCCAL
ORAVIG

+	MIDATECH PHARMA US	50MG	N022404	001	Apr 16, 2010	Jan CAHN
---	--------------------	------	---------	-----	--------------	----------

MIDAZOLAM HYDROCHLORIDEINJECTABLE;INJECTION
MIDAZOLAM HYDROCHLORIDE

AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075247	002	Jun 23, 2000	May CAHN
AP		EQ 1MG BASE/ML	A075421	002	Jun 20, 2000	Apr CAHN
AP		EQ 5MG BASE/ML	A075247	001	Jun 23, 2000	May CAHN
AP		EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Apr CAHN

MIGLITOLTABLET;ORAL
GLYSET

AB	+	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Feb CRLD
AB			100MG	N020682	003	Dec 18, 1996	Feb CRLD

MILNACIPRAN HYDROCHLORIDETABLET;ORAL
MILNACIPRAN HYDROCHLORIDE

AB	AMNEAL PHARMS	12.5MG	A205081	001	Apr 22, 2016	Apr NEWA
AB		25MG	A205081	002	Apr 22, 2016	Apr NEWA
AB		50MG	A205081	003	Apr 22, 2016	Apr NEWA
AB		100MG	A205081	004	Apr 22, 2016	Apr NEWA
	@ LIBERTY PHARMA INC	12.5MG	A205071	001	Jan 27, 2016	Jan DISC
		12.5MG	A205071	001	Jan 27, 2016	Jan NEWA
	@	25MG	A205071	002	Jan 27, 2016	Jan DISC
		25MG	A205071	002	Jan 27, 2016	Jan NEWA
	@	50MG	A205071	003	Jan 27, 2016	Jan DISC
		50MG	A205071	003	Jan 27, 2016	Jan NEWA
	@	100MG	A205071	004	Jan 27, 2016	Jan DISC
		100MG	A205071	004	Jan 27, 2016	Jan NEWA
	SAVELLA					
AB	CYPRESS BIOSCIENCE	12.5MG	N022256	001	Jan 14, 2009	Apr CFTG
AB		25MG	N022256	002	Jan 14, 2009	Apr CFTG
AB	+	50MG	N022256	003	Jan 14, 2009	Apr CFTG
AB		100MG	N022256	004	Jan 14, 2009	Apr CFTG

MILRINONE LACTATEINJECTABLE;INJECTION
MILRINONE LACTATE

AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075660	001	May 28, 2002	Apr CAHN
	MILRINONE LACTATE IN DEXTROSE 5%					
AP	CLARIS	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Mar CAHN
	MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
>D> AP	B BRAUN	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076414	001	Aug 18, 2004	Sep DISC
>A>	@	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076414	001	Aug 18, 2004	Sep DISC
	@ CLARIS	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Mar CAHN
AP	EUROHLTH INTL SARL	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jun CAHN
AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jun CAHN

MINOCYCLINE HYDROCHLORIDECAPSULE;ORAL
MINOCYCLINE HYDROCHLORIDE

AB	ZYDUS WORLDWIDE	EQ 50MG BASE	A063011	001	Mar 02, 1992	Aug CAHN
AB		EQ 75MG BASE	A063009	002	Aug 12, 2003	Aug CAHN
AB	+	EQ 100MG BASE	A063009	001	Mar 02, 1992	Aug CAHN

TABLET;ORAL
MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS	EQ 50MG BASE	A090217	001	Jan 29, 2016	Jan NEWA
AB		EQ 75MG BASE	A090217	002	Jan 29, 2016	Jan NEWA
AB		EQ 100MG BASE	A090217	003	Jan 29, 2016	Jan NEWA

TABLET, EXTENDED RELEASE;ORAL
MINOCYCLINE HYDROCHLORIDE

>A>	AB	ALKEM LABS LTD	EQ 45MG BASE	A204453	001	Sep 28, 2016	Sep NEWA
>A>	AB		EQ 80MG BASE	A204453	002	Sep 28, 2016	Sep NEWA
>A>	AB		EQ 90MG BASE	A204453	003	Sep 28, 2016	Sep NEWA
>A>	AB		EQ 105MG BASE	A204453	004	Sep 28, 2016	Sep NEWA
>A>	AB		EQ 135MG BASE	A204453	005	Sep 28, 2016	Sep NEWA
	AB	AUROBINDO PHARMA LTD	EQ 80MG BASE	A202261	006	Jun 13, 2016	May NEWA
	AB		EQ 105MG BASE	A202261	007	Jun 13, 2016	May NEWA
		@ IMPAX LABS INC	EQ 45MG BASE	A090024	001	Feb 03, 2009	Mar DISC
		@	EQ 90MG BASE	A090024	002	Feb 03, 2009	Mar DISC
		@	EQ 135MG BASE	A090024	003	Feb 03, 2009	Mar DISC

MINOXIDIL

TABLET;ORAL
MINOXIDIL

AB		SUN PHARM INDS	10MG	A072709	001	Dec 14, 1995	Mar CAHN
----	--	----------------	------	---------	-----	--------------	----------

MIPOMERSEN SODIUM

SOLUTION;SUBCUTANEOUS
KYNAMRO

+		KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jun CAHN
---	--	--------------------	---------------------	---------	-----	--------------	----------

MIRTAZAPINE

TABLET;ORAL
MIRTAZAPINE

@	ACTAVIS LABS FL INC	15MG	A076336	001	Jun 20, 2003	Jan DISC
@		30MG	A076336	002	Jun 20, 2003	Jan DISC
@		45MG	A076336	003	Jun 20, 2003	Jan DISC

TABLET, ORALLY DISINTEGRATING;ORAL
MIRTAZAPINE

AB		IMPAX LABS INC	15MG	A076901	001	Jun 28, 2005	Aug CAHN
AB			30MG	A076901	002	Jun 28, 2005	Aug CAHN
AB			45MG	A076901	003	Jun 28, 2005	Aug CAHN

MITOMYCIN

INJECTABLE;INJECTION
MITOMYCIN

AP		EUROHLTH INTL SARL	5MG/VIAL	A064117	001	Apr 19, 1995	Apr CAHN
AP			5MG/VIAL	A064180	001	Dec 23, 1999	Jan CAHN
AP			20MG/VIAL	A064117	002	Apr 19, 1995	Apr CAHN
AP			20MG/VIAL	A064180	002	Dec 23, 1999	Jan CAHN

MODAFINIL

TABLET;ORAL
MODAFINIL

AB		WATSON LABS INC	100MG	A076715	001	Nov 01, 2012	Jan CAHN
AB			200MG	A076715	002	Nov 01, 2012	Jan CAHN

MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL
MOEXIPRIL HYDROCHLORIDE

AB	+	TEVA	15MG	A076204	002	May 08, 2003	Aug CRLD
		UNIVASC					
	@	UCB INC	7.5MG	N020312	001	Apr 19, 1995	Aug DISC
	@		15MG	N020312	002	Apr 19, 1995	Aug DISC

MOMETASONE FUROATE

CREAM;TOPICAL
ELOCON

AB	+	@ MERCK SHARP DOHME	0.1%	N019625	001	May 06, 1987	Aug DISC
			0.1%	N019625	002	Apr 19, 2013	Aug CRLD

SPRAY, METERED;NASAL
MOMETASONE FUROATE

AB		APOTEX INC	EQ 0.05MG BASE/SPRAY	A091161	001	Mar 22, 2016	Mar NEWA
		NASONEX					
AB	+	MERCK SHARP DOHME	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997	Mar CFTG

MORPHINE SULFATECAPSULE, EXTENDED RELEASE;ORAL
KADIAN

AB	+	ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Feb CTEC
AB			20MG	N020616	001	Jul 03, 1996	Feb CTEC
AB			30MG	N020616	004	Mar 09, 2001	Feb CTEC
AB			40MG	N020616	009	Jul 09, 2012	Feb CTEC
AB			50MG	N020616	002	Jul 03, 1996	Feb CTEC
AB			60MG	N020616	005	Mar 09, 2001	Feb CTEC
AB			70MG	N020616	010	Jul 09, 2012	Feb CTEC
AB			80MG	N020616	006	Oct 27, 2006	Feb CTEC
AB	+		100MG	N020616	003	Jul 03, 1996	Feb CTEC
	+		200MG	N020616	007	Feb 27, 2007	Feb CTEC
AB	+	ALLERGAN SALES LLC	10MG	N020616	008	Apr 20, 2007	Apr CAHN
AB			20MG	N020616	001	Jul 03, 1996	Apr CAHN
AB			30MG	N020616	004	Mar 09, 2001	Apr CAHN
AB			40MG	N020616	009	Jul 09, 2012	Apr CAHN
AB			50MG	N020616	002	Jul 03, 1996	Apr CAHN
AB			60MG	N020616	005	Mar 09, 2001	Apr CAHN
AB			70MG	N020616	010	Jul 09, 2012	Apr CAHN
AB			80MG	N020616	006	Oct 27, 2006	Apr CAHN
AB	+		100MG	N020616	003	Jul 03, 1996	Apr CAHN
			130MG	N020616	011	Jul 09, 2012	Apr CAHN
			150MG	N020616	012	Jul 09, 2012	Apr CAHN
	+		200MG	N020616	007	Feb 27, 2007	Apr CAHN

MORPHINE SULFATE

AB		IMPAX LABS INC	20MG	A200411	001	Apr 12, 2016	Mar NEWA
AB			30MG	A200411	002	Apr 12, 2016	Mar NEWA
AB			50MG	A200411	003	Apr 12, 2016	Mar NEWA
AB			60MG	A200411	004	Apr 12, 2016	Mar NEWA
AB			80MG	A200411	005	Apr 12, 2016	Mar NEWA
AB			100MG	A200411	006	Apr 12, 2016	Mar NEWA
AB		PAR PHARM INC	20MG	A200812	001	Nov 10, 2011	Feb CTEC
AB			30MG	A200812	002	Nov 10, 2011	Feb CTEC
AB			50MG	A200812	003	Nov 10, 2011	Feb CTEC
AB			60MG	A200812	004	Nov 10, 2011	Feb CTEC
AB			80MG	A200812	005	Nov 10, 2011	Feb CTEC
AB			100MG	A200812	006	Nov 10, 2011	Feb CTEC
AB		TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014	Feb CTEC
AB			30MG	A202718	002	Dec 29, 2014	Feb CTEC
AB			40MG	A202718	007	Jun 03, 2015	Feb CTEC
AB			50MG	A202718	003	Dec 29, 2014	Feb CTEC
AB			60MG	A202718	004	Dec 29, 2014	Feb CTEC
AB			70MG	A202718	008	Jun 03, 2015	Feb CTEC
AB			80MG	A202718	005	Dec 29, 2014	Feb CTEC
AB			100MG	A202718	006	Dec 29, 2014	Feb CTEC
AB		UPSHER SMITH	10MG	A202104	001	Jun 03, 2013	Feb CTEC
AB			20MG	A202104	002	Jun 03, 2013	Feb CTEC
AB			30MG	A202104	003	Jun 03, 2013	Feb CTEC
AB			50MG	A202104	004	Jun 03, 2013	Feb CTEC
AB			60MG	A202104	005	Jun 03, 2013	Feb CTEC
AB			80MG	A202104	006	Jun 03, 2013	Feb CTEC
AB			100MG	A202104	007	Jun 03, 2013	Feb CTEC

SOLUTION;ORAL

MORPHINE SULFATE

AA		NOSTRUM LABS INC	10MG/5ML	A201011	001	Feb 05, 2014	Mar CAHN
AA			20MG/5ML	A201011	002	Feb 05, 2014	Mar CAHN
>A> AA			100MG/5ML	A204053	001	Oct 06, 2016	Sep NEWA
AA		RHODES PHARMS	20MG/5ML	A206420	001	Jul 12, 2016	Jun NEWA
AA		TRIS PHARMA INC	20MG/5ML	A203519	001	May 18, 2016	May NEWA

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

AB		COREPHARMA	15MG	A091357	001	Jun 23, 2016	Jun NEWA
AB			30MG	A091357	002	Jun 23, 2016	Jun NEWA
AB			60MG	A091357	003	Jun 23, 2016	Jun NEWA
AB			100MG	A091357	004	Jun 23, 2016	Jun NEWA
AB			200MG	A091357	005	Jun 23, 2016	Jun NEWA
AB		SUN PHARM INDS LTD	15MG	A205634	001	Aug 25, 2016	Aug NEWA
AB			30MG	A205634	002	Aug 25, 2016	Aug NEWA
AB			60MG	A205634	003	Aug 25, 2016	Aug NEWA
AB			100MG	A205634	004	Aug 25, 2016	Aug NEWA
AB			200MG	A205634	005	Aug 25, 2016	Aug NEWA

MOXIFLOXACIN HYDROCHLORIDE

TABLET; ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB	CROSSMEDIKA SA	EQ 400MG BASE	A205348	001	Jan 14, 2016	Jan NEWA
----	----------------	---------------	---------	-----	--------------	----------

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

AB	JUBILANT CADISTA	250MG	A090762	001	Dec 15, 2014	Jun CAHN
----	------------------	-------	---------	-----	--------------	----------

TABLET; ORAL

MYCOPHENOLATE MOFETIL

AB	JUBILANT CADISTA	500MG	A090661	001	Dec 15, 2014	Jun CAHN
----	------------------	-------	---------	-----	--------------	----------

NABUMETONE

TABLET; ORAL

NABUMETONE

AB	IMPAX LABS INC	500MG	A075189	001	May 26, 2000	Aug CAHN
----	----------------	-------	---------	-----	--------------	----------

AB	+	750MG	A075189	002	Sep 24, 2001	Aug CAHN
----	---	-------	---------	-----	--------------	----------

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIFINE HYDROCHLORIDE

AB	TARO	1%	A205975	001	Sep 08, 2016	Aug NEWA
----	------	----	---------	-----	--------------	----------

NAFTIN

AB	+	MERZ PHARMS	1%	N019599	001	Feb 29, 1988	Aug CFTG
----	---	-------------	----	---------	-----	--------------	----------

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NUBAIN

@ PAR PHARM INC 10MG/ML

N018024	001		Aug CAHN
---------	-----	--	----------

@ 20MG/ML

N018024	002	May 27, 1982	Aug CAHN
---------	-----	--------------	----------

NALIDIXIC ACID

TABLET; ORAL

NALIDIXIC ACID

@ SUN PHARM INDS 250MG

A070270	001	Jun 29, 1988	Mar CAHN
---------	-----	--------------	----------

@ 500MG

A070271	001	Jun 29, 1988	Jun CAHN
---------	-----	--------------	----------

@ 1GM

A070272	001	Jun 29, 1988	Mar CAHN
---------	-----	--------------	----------

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HYDROCHLORIDE

AP	MYLAN INSTITUTIONAL	0.4MG/ML	A205014	001	Jun 29, 2016	Jun NEWA
----	---------------------	----------	---------	-----	--------------	----------

NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TROXYCA ER

PFIZER INC

1.2MG; 10MG

N207621	001	Aug 19, 2016	Aug NEWA
---------	-----	--------------	----------

2.4MG; 20MG

N207621	002	Aug 19, 2016	Aug NEWA
---------	-----	--------------	----------

3.6MG; 30MG

N207621	003	Aug 19, 2016	Aug NEWA
---------	-----	--------------	----------

4.8MG; 40MG

N207621	004	Aug 19, 2016	Aug NEWA
---------	-----	--------------	----------

7.2MG; 60MG

N207621	005	Aug 19, 2016	Aug NEWA
---------	-----	--------------	----------

9.6MG; 80MG

N207621	006	Aug 19, 2016	Aug NEWA
---------	-----	--------------	----------

NAPROXEN

SUSPENSION; ORAL

NAPROSYN

AB	+	ATNAHS PHARMA US	25MG/ML	N018965	001	Mar 23, 1987	Jun CAHN
----	---	------------------	---------	---------	-----	--------------	----------

TABLET; ORAL

NAPROSYN

AB	ATNAHS PHARMA US	250MG	N017581	002		Feb CAHN
----	------------------	-------	---------	-----	--	----------

AB		375MG	N017581	003		Feb CAHN
----	--	-------	---------	-----	--	----------

AB	+	500MG	N017581	004	Apr 15, 1982	Feb CAHN
----	---	-------	---------	-----	--------------	----------

NAPROXEN

@ SANDOZ 250MG

A074140	001	Dec 21, 1993	Feb DISC
---------	-----	--------------	----------

@ 375MG

A074140	002	Dec 21, 1993	Feb DISC
---------	-----	--------------	----------

@ 500MG

A074140	003	Dec 21, 1993	Feb DISC
---------	-----	--------------	----------

TABLET, DELAYED RELEASE; ORAL

EC-NAPROSYN

AB	+	ATNAHS PHARMA US	375MG	N020067	002	Oct 14, 1994	Feb CAHN
----	---	------------------	-------	---------	-----	--------------	----------

TABLET, DELAYED RELEASE;ORAL									
EC-NAPROSYN									
AB	+		500MG		N020067	003	Oct 14, 1994	Feb	CAHN
NAPROXEN									
	@	SANDOZ	375MG		A075061	001	Feb 18, 1998	Feb	DISC
	@		500MG		A075061	002	Feb 18, 1998	Feb	DISC
<u>NAPROXEN SODIUM</u>									
TABLET;ORAL									
ANAPROX									
AB		ATNAHS PHARMA US	EQ 250MG BASE		N018164	001		Feb	CAHN
ANAPROX DS									
AB	+	ATNAHS PHARMA US	EQ 500MG BASE		N018164	003	Sep 30, 1987	Feb	CAHN
TABLET, EXTENDED RELEASE;ORAL									
NAPRELAN									
AB	+	ALVOGEN MALTA	EQ 750MG BASE		N020353	003	Jan 05, 1996	Aug	CFTG
NAPROXEN SODIUM									
AB		ACTAVIS LABS FL INC	EQ 750MG BASE		A075416	003	Aug 11, 2016	Aug	NEWA
<u>NATEGLINIDE</u>									
TABLET;ORAL									
NATEGLINIDE									
AB		ZYDUS PHARMS USA INC	60MG		A205248	001	Jul 06, 2016	Jun	NEWA
AB			120MG		A205248	002	Jul 06, 2016	Jun	NEWA
<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN</u>									
TABLET;ORAL									
BYVALSON									
		FOREST LABS LLC	EQ 5MG BASE;80MG		N206302	001	Jun 03, 2016	Jun	NEWA
<u>NEFAZODONE HYDROCHLORIDE</u>									
TABLET;ORAL									
NEFAZODONE HYDROCHLORIDE									
	@	SUN PHARM INDS LTD	50MG		A076409	001	Sep 16, 2003	Feb	DISC
	@		100MG		A076409	002	Sep 16, 2003	Feb	DISC
	@		150MG		A076409	003	Sep 16, 2003	Feb	DISC
	@		200MG		A076409	004	Sep 16, 2003	Feb	DISC
	@		250MG		A076409	005	Sep 16, 2003	Feb	DISC
<u>NEOMYCIN SULFATE</u>									
TABLET;ORAL									
NEOMYCIN SULFATE									
AA		LANNETT HOLDINGS INC	500MG		A204435	001	Jun 10, 2016	May	NEWA
<u>NICARDIPINE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
CARDENE									
	@	CHIESI USA INC	20MG		N019488	001	Dec 21, 1988	May	DISC
	@		30MG		N019488	002	Dec 21, 1988	May	DISC
NICARDIPINE HYDROCHLORIDE									
AB	+	MYLAN	30MG		A074642	002	Jul 18, 1996	May	CRLD
INJECTABLE;INJECTION									
NICARDIPINE HYDROCHLORIDE									
AP		EUROHLTH INTL SARL	25MG/10ML (2.5MG/ML)		A078714	001	Dec 28, 2009	Jun	CAHN
<u>NIFEDIPINE</u>									
CAPSULE;ORAL									
NIFEDIPINE									
AB		VALIDUS PHARMS	10MG		A073250	001	Oct 08, 1991	Jul	CMFD
	@		10MG		A073250	001	Oct 08, 1991	Mar	CAHN
AB			20MG		A074045	001	Apr 30, 1992	Jul	CMFD
	@		20MG		A074045	001	Apr 30, 1992	Mar	CAHN
TABLET, EXTENDED RELEASE;ORAL									
ADALAT CC									
AB1		ALVOGEN	30MG		N020198	001	Apr 21, 1993	Feb	CAHN
AB1	+		60MG		N020198	002	Apr 21, 1993	Feb	CAHN
AB1	+		90MG		N020198	003	Apr 21, 1993	Feb	CAHN
NIFEDIPINE									
AB1		NOVAST LABS LTD	30MG		A202987	001	Aug 25, 2016	Aug	NEWA
AB1			60MG		A202987	002	Aug 25, 2016	Aug	NEWA
AB1			90MG		A202987	003	Aug 25, 2016	Aug	NEWA

TABLET, EXTENDED RELEASE;ORAL							
NIFEDIPINE							
AB2	OSMOTICA PHARM US	30MG	A077127	001	Nov 21, 2005	Jun	CAHN
AB2		60MG	A077127	002	Nov 21, 2005	Jun	CAHN
AB1	VALEANT PHARMS NORTH	30MG	A075269	001	Dec 04, 2000	Jan	CAHN
AB1		60MG	A075269	002	Dec 04, 2000	Jan	CAHN
AB1		90MG	A076070	001	Aug 16, 2002	Jan	CAHN
<u>NILUTAMIDE</u>							
TABLET;ORAL							
NILANDRON							
AB	+ CONCORDIA PHARMS INC	150MG	N020169	002	Apr 30, 1999	Jul	CFTG
NILUTAMIDE							
AB	ANI PHARMS INC	150MG	A207631	001	Jul 15, 2016	Jul	NEWA
<u>NIMODIPINE</u>							
CAPSULE;ORAL							
NIMODIPINE							
AB	+ BIONPHARMA INC	30MG	A076740	001	Jan 17, 2008	Jan	CAHN
AB	HERITAGE PHARMS INC	30MG	A077811	001	May 02, 2007	Aug	CAHN
<u>NITISINONE</u>							
CAPSULE;ORAL							
ORFADIN							
+	SWEDISH ORPHAN	20MG	N021232	004	Jun 13, 2016	Jun	NEWA
SUSPENSION;ORAL							
ORFADIN							
+	SWEDISH ORPHAN	4MG/ML	N206356	001	Apr 22, 2016	Apr	NEWA
<u>NITRIC OXIDE</u>							
GAS; INHALATION							
INOMAX							
+	MALLINCKRODT HOSP	800PPM	N020845	003	Dec 23, 1999	Jan	CAHN
<u>NITROFURANTOIN</u>							
SUSPENSION;ORAL							
FURADANTIN							
AB	+ CASPER PHARMA LLC	25MG/5ML	N009175	001		Jun	CAHN
NITROFURANTOIN							
AB	ACTAVIS MID ATLANTIC	25MG/5ML	A205180	001	May 03, 2016	Apr	NEWA
AB	NOSTRUM LABS INC	25MG/5ML	A201355	001	Aug 14, 2013	Feb	CAHN
<u>NITROFURANTOIN, MACROCRYSTALLINE</u>							
CAPSULE;ORAL							
NITROFURANTOIN							
AB	IMPAX LABS INC	50MG	A073671	001	Jan 28, 1993	Aug	CAHN
AB		100MG	A073652	001	Jan 28, 1993	Aug	CAHN
AB	SUN PHARM INDS	25MG	A201722	001	Feb 16, 2016	Feb	NEWA
AB		50MG	A201722	002	Feb 16, 2016	Feb	NEWA
AB		100MG	A201722	003	Feb 16, 2016	Feb	NEWA
<u>NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE</u>							
CAPSULE;ORAL							
MACROBID							
AB	+ ALVOGEN MALTA	75MG;25MG	N020064	001	Dec 24, 1991	Jan	CAHN
<u>NITROGLYCERIN</u>							
FILM, EXTENDED RELEASE;TRANSDERMAL							
MINITRAN							
AB1	VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996	May	CAHN
POWDER;SUBLINGUAL							
GONITRO							
+	POHL BOSKAMP	0.4MG/PACKET	N208424	001	Jun 08, 2016	Jun	NEWA
TABLET;SUBLINGUAL							
NITROGLYCERIN							
AB	DR REDDYS LABS INC	0.3MG	A208191	001	Aug 26, 2016	Aug	NEWA
AB		0.4MG	A208191	002	Aug 26, 2016	Aug	NEWA
AB		0.6MG	A208191	003	Aug 26, 2016	Aug	NEWA
NITROSTAT							
AB	PFIZER PHARMS	0.3MG	N021134	001	May 01, 2000	Aug	CFTG
AB		0.4MG	N021134	002	May 01, 2000	Aug	CFTG

TABLET;SUBLINGUAL
NITROSTAT

AB + 0.6MG N021134 003 May 01, 2000 Aug CFTG

NIZATIDINE

SOLUTION;ORAL
NIZATIDINE

+ AMNEAL PHARMS 15MG/ML A090576 001 Nov 18, 2009 Feb CRLD

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION
NOREPINEPHRINE BITARTRATE

AP CLARIS EQ 1MG BASE/ML A040859 001 Mar 27, 2012 Jan CAHN

AP EUROHLTH INTL SARL EQ 1MG BASE/ML A040462 001 Oct 31, 2003 Apr CAHN

NORETHINDRONE

TABLET;ORAL-28
CAMILA

AB1 MAYNE PHARMA 0.35MG A076177 001 Oct 21, 2002 Aug CAHN

ERRIN

AB2 MAYNE PHARMA 0.35MG A076225 001 Oct 21, 2002 Aug CAHN

>A> INCASSIA

>A> AB1 AUROBINDO PHARMA LTD 0.35MG A207304 001 Sep 23, 2016 Sep NEWA

NOR-QD

AB1 + APIL 0.35MG N017060 001 Jan CAHN

NORETHINDRONE

AB1 AMNEAL PHARMS 0.35MG A202260 001 Aug 01, 2013 Aug CAHN

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC EQ 10MG BASE A074835 001 Jun 30, 1997 Feb CAHN

@ EQ 25MG BASE A074835 002 Jun 30, 1997 Feb CAHN

@ EQ 50MG BASE A074835 003 Jun 30, 1997 Feb CAHN

@ EQ 75MG BASE A074835 004 Jun 30, 1997 Feb CAHN

@ IDT AUSTRALIA LTD EQ 10MG BASE A074054 001 Dec 31, 1992 May CAHN

@ EQ 25MG BASE A074054 002 Dec 31, 1992 May CAHN

@ EQ 50MG BASE A074054 003 Dec 31, 1992 May CAHN

@ EQ 75MG BASE A074054 004 Dec 31, 1992 May CAHN

AB MAYNE PHARMA EQ 10MG BASE A073553 001 Mar 30, 1992 Aug CAHN

AB EQ 25MG BASE A073554 001 Mar 30, 1992 Aug CAHN

AB EQ 50MG BASE A073555 001 Mar 30, 1992 Aug CAHN

AB EQ 75MG BASE A073556 001 Mar 30, 1992 Aug CAHN

NYSTATIN

POWDER;TOPICAL
NYSTATIN

AT + MAYNE PHARMA INC 100,000 UNITS/GM A065203 001 Jul 15, 2004 Aug CAHN

TABLET;ORAL
NYSTATIN

AA SUN PHARM INDS 500,000 UNITS A062838 001 Dec 22, 1988 Mar CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

NYSTATIN TRIAMCINOLONE ACETONIDE

@ PHARMADERM 100,000 UNITS/GM;0.1% A062596 001 Oct 08, 1985 Mar CMS1

OINTMENT;TOPICAL
MYKACET

AT G AND W LABS INC 100,000 UNITS/GM;0.1% A062733 001 Mar 06, 1987 May CMS1

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT GLENMARK PHARMS LTD 100,000 UNITS/GM;0.1% A208300 001 Jun 23, 2016 Jun NEWA

OBETICHOLIC ACID

TABLET;ORAL
OCALIVA

INTERCEPT PHARMS INC 5MG N207999 001 May 27, 2016 May NEWA

+ 10MG N207999 002 May 27, 2016 May NEWA

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

@ WOCKHARDT USA EQ 0.2MG BASE/ML

A090986 001 May 11, 2011 Jan DISC

@ EQ 1MG BASE/ML

A090986 002 May 11, 2011 Jan DISC

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

@ WOCKHARDT USA EQ 0.05MG BASE/ML

A090985 001 May 11, 2011 Jan DISC

@ EQ 0.1MG BASE/ML

A090985 002 May 11, 2011 Jan DISC

@ EQ 0.5MG BASE/ML

A090985 003 May 11, 2011 Jan DISC

OCTREOTIDE ACETATE PRESERVATIVE FREE

@ WOCKHARDT USA EQ 0.05MG BASE/ML

A090985 001 May 11, 2011 Feb CMS1

@ EQ 0.1MG BASE/ML

A090985 002 May 11, 2011 Feb CMS1

@ EQ 0.5MG BASE/ML

A090985 003 May 11, 2011 Feb CMS1

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

AT ALVOGEN 0.3%

A076830 001 Aug 31, 2004 Mar CAHN

SOLUTION/DROPS; OTIC

OFLOXACIN

AT ALVOGEN 0.3%

A090395 001 Aug 11, 2009 Mar CAHN

AT + BAUSCH AND LOMB 0.3%

A076128 001 Mar 17, 2008 Feb CRLD

OLANZAPINE

TABLET; ORAL

OLANZAPINE

AB AJANTA PHARMA LTD 2.5MG

A206711 001 Aug 30, 2016 Aug NEWA

AB 5MG

A206711 002 Aug 30, 2016 Aug NEWA

AB 7.5MG

A206711 003 Aug 30, 2016 Aug NEWA

AB 10MG

A206711 004 Aug 30, 2016 Aug NEWA

AB 15MG

A206711 005 Aug 30, 2016 Aug NEWA

AB 20MG

A206711 006 Aug 30, 2016 Aug NEWA

AB INVAGEN PHARMS 2.5MG

A203333 001 Mar 15, 2016 Feb NEWA

AB 5MG

A203333 002 Mar 15, 2016 Feb NEWA

AB 7.5MG

A203333 003 Mar 15, 2016 Feb NEWA

AB 10MG

A203333 004 Mar 15, 2016 Feb NEWA

AB 15MG

A203333 005 Mar 15, 2016 Feb NEWA

AB 20MG

A203333 006 Mar 15, 2016 Feb NEWA

AB QILU PHARM CO LTD 2.5MG

A204319 001 Jan 27, 2016 Jan NEWA

AB 5MG

A204319 002 Jan 27, 2016 Jan NEWA

AB 7.5MG

A204319 003 Jan 27, 2016 Jan NEWA

AB 10MG

A204319 004 Jan 27, 2016 Jan NEWA

AB 15MG

A204319 005 Jan 27, 2016 Jan NEWA

AB 20MG

A204319 006 Jan 27, 2016 Jan NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB INVAGEN PHARMS 5MG

A203456 001 Mar 16, 2016 Feb NEWA

AB 10MG

A203456 002 Mar 16, 2016 Feb NEWA

AB 15MG

A203456 003 Mar 16, 2016 Feb NEWA

AB 20MG

A203456 004 Mar 16, 2016 Feb NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AT SOMERSET THERAPS LLC EQ 0.1% BASE

A206306 001 Dec 07, 2015 Mar CAHN

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

OMEGA-3-ACID ETHYL ESTERS

AB AMNEAL PHARMS 1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY
ACIDS

A204940 001 Nov 27, 2015 Jan CMS1

OMEGA-3-ACID ETHYL ESTERS TYPE A

CAPSULE; ORAL

OMTRYG

+ TRYGG 1.2GM CONTAINS AT LEAST 900MG OF
THE ETHYL ESTERS OF OMEGA-3 FATTY
ACIDS

N204977 001 Apr 23, 2014 Mar CAIN

OMEPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

AB	+	SANDOZ	20MG	A075757	002	Jan 28, 2003	Mar CRLD
AB	+		40MG	A076515	001	Jan 21, 2009	Mar CRLD

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB		AJANTA PHARMA LTD	20MG;1.1GM	A204228	001	Jul 15, 2016	Jul NEWA
AB			40MG;1.1GM	A204228	002	Jul 15, 2016	Jul NEWA
AB		AUROLIFE PHARMA LLC	20MG;1.1GM	A204922	001	Aug 19, 2016	Aug NEWA
AB			40MG;1.1GM	A204922	002	Aug 19, 2016	Aug NEWA
AB		DR REDDYS LABS LTD	20MG;1.1GM	A204068	001	Jul 15, 2016	Jul NEWA
AB			40MG;1.1GM	A204068	002	Jul 15, 2016	Jul NEWA

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AA		AJANTA PHARMA LTD	20MG/PACKET;1.68GM/PACKET	A205545	001	Jul 27, 2016	Jul NEWA
AA			40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Jul NEWA
		ZEGERID					
AA		SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jul CTEC
AA	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jul CTEC

ONDANSETRON

FILM;ORAL

ZUPLENZ

		MIDATECH PHARMA US	4MG	N022524	001	Jul 02, 2010	Jun CAHN
	+		8MG	N022524	002	Jul 02, 2010	Jun CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

AP	+	CLARIS	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Aug CRLD
AP		EUROHLTH INTL SARL	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Apr CAHN
		@ LANNETT	EQ 2MG BASE/ML	A090883	001	Aug 05, 2010	Aug DISC
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP		ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016	Feb NEWA
AP	+	CLARIS	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Aug CRLD
AP		EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Apr CAHN
		ZOFRAN					
		@ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Aug DISC
		ZOFRAN PRESERVATIVE FREE					
		@ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Aug DISC
		TABLET;ORAL					
		ONDANSETRON HYDROCHLORIDE					
		@ HIKMA INTL PHARMS	EQ 4MG BASE	A077545	001	Sep 06, 2007	May CAHN
		@	EQ 8MG BASE	A077545	002	Sep 06, 2007	May CAHN
		@	EQ 24MG BASE	A077545	003	Sep 06, 2007	May CAHN

ORPHENADRINE CITRATE

INJECTABLE;INJECTION

ORPHENADRINE CITRATE

>D>	AP	EUROHLTH INTL SARL	30MG/ML	A040463	001	Mar 04, 2003	Sep CAHN
>A>	AP	WEST-WARD PHARMS INT	30MG/ML	A040463	001	Mar 04, 2003	Sep CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB		NATCO PHARMA LTD	EQ 30MG BASE	A202595	001	Aug 03, 2016	Jul NEWA
AB			EQ 45MG BASE	A202595	002	Aug 03, 2016	Jul NEWA
AB			EQ 75MG BASE	A202595	003	Aug 03, 2016	Jul NEWA
		TAMIFLU					
AB		ROCHE	EQ 30MG BASE	N021087	003	Jul 02, 2007	Jul CFTG
AB			EQ 45MG BASE	N021087	002	Jul 02, 2007	Jul CFTG
AB	+		EQ 75MG BASE	N021087	001	Oct 27, 1999	Jul CFTG

OXALIPLATIN

	INJECTABLE;IV (INFUSION)						
	ELOXATIN						
AP	+	@ SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Jun DISC
			200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	May CFTG
	OXALIPLATIN						
AP		QILU PHARM CO LTD	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	May NEWA
AP			50MG/VIAL	A204616	001	May 11, 2016	Apr NEWA
AP			100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	May NEWA
AP			100MG/VIAL	A204616	002	May 11, 2016	Apr NEWA
AP	+		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jun CRLD
			200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	May NEWA
		@ SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Aug DISC
		@	100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Aug DISC

OXAZEPAM

CAPSULE;ORAL							
OXAZEPAM							
		@ SUN PHARM INDS	10MG	A071026	002	Aug 10, 1987	Mar CAHN
		@	15MG	A071026	003	Aug 10, 1987	Mar CAHN
		@	30MG	A071026	001	Aug 10, 1987	Mar CAHN
TABLET;ORAL							
OXAZEPAM							
		@ FRONTIDA BIOPHARM	15MG	A070683	001	Jan 16, 1987	Jul CAHN
		@ SUN PHARM INDS	15MG	A070683	001	Jan 16, 1987	Jun CAHN

OXCARBAZEPINE

TABLET;ORAL							
OXCARBAZEPINE							
AB		ANI PHARMS INC	150MG	A078005	001	Dec 11, 2007	Jun CMFD
AB			300MG	A078005	002	Dec 11, 2007	Jun CMFD
AB			600MG	A078005	003	Dec 11, 2007	Jun CMFD

OXICONAZOLE NITRATE

CREAM;TOPICAL							
OXICONAZOLE NITRATE							
AB		TARO	EQ 1% BASE	A205076	001	Mar 07, 2016	Feb NEWA
OXISTAT							
AB	+	FOUGERA PHARMS	EQ 1% BASE	N019828	001	Dec 30, 1988	Feb CFTG

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL							
OXYTROL							
AB	+	ALLERGAN SALES LLC	3.9MG/24HR	N021351	002	Feb 26, 2003	Apr CAHN
GEL, METERED;TRANSDERMAL							
GELNIQUE 3%							
	+	ALLERGAN SALES LLC	3%	N202513	001	Dec 07, 2011	Apr CAHN

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL							
GELNIQUE							
	+	ALLERGAN SALES LLC	10%(100MG/PACKET)	N022204	001	Jan 27, 2009	Apr CAHN
TABLET, EXTENDED RELEASE;ORAL							
OXYBUTYNIN CHLORIDE							
AB		ACCORD HLTHCARE	5MG	A207138	001	Feb 29, 2016	Feb NEWA
AB			10MG	A207138	002	Feb 29, 2016	Feb NEWA
AB			15MG	A207138	003	Feb 29, 2016	Feb NEWA
AB		OSMOTICA PHARM US	5MG	A078503	001	Feb 04, 2009	Jun CAHN
AB			10MG	A078503	002	Feb 04, 2009	Jun CAHN
AB			15MG	A078503	003	Feb 04, 2009	Jun CAHN
AB		UNIQUE PHARM LABS	5MG	A206121	001	May 27, 2016	May NEWA
AB			10MG	A206121	002	May 27, 2016	May NEWA
AB			15MG	A206121	003	May 27, 2016	May NEWA

OXYCODONE

CAPSULE, EXTENDED RELEASE;ORAL							
XTAMPZA ER							
		COLLEGIUM PHARM INC	9MG	N208090	001	Apr 26, 2016	May CAIN
			13.5MG	N208090	002	Apr 26, 2016	May CAIN
			18MG	N208090	003	Apr 26, 2016	May CAIN
			27MG	N208090	004	Apr 26, 2016	May CAIN

CAPSULE, EXTENDED RELEASE;ORAL								
XTAMPZA ER								
	+	36MG	N208090	005	Apr 26, 2016	May	CAIN	
<u>OXYCODONE HYDROCHLORIDE</u>								
CAPSULE;ORAL								
OXYCODONE HYDROCHLORIDE								
AB	ANI PHARMS INC	5MG	A205177	001	Mar 31, 2016	Mar	NEWA	
AB	MAYNE PHARMA INC	5MG	A203107	001	Jul 26, 2012	Aug	CAHN	
CAPSULE, EXTENDED RELEASE;ORAL								
XTAMPZA ER								
	COLLEGIUM PHARM INC	EQ 9MG BASE	N208090	001	Apr 26, 2016	Apr	NEWA	
		EQ 13.5MG BASE	N208090	002	Apr 26, 2016	Apr	NEWA	
		EQ 18MG BASE	N208090	003	Apr 26, 2016	Apr	NEWA	
		EQ 27MG BASE	N208090	004	Apr 26, 2016	Apr	NEWA	
	+	EQ 36MG BASE	N208090	005	Apr 26, 2016	May	CRLD	
		EQ 36MG BASE	N208090	005	Apr 26, 2016	Apr	NEWA	
SOLUTION;ORAL								
OXYCODONE HYDROCHLORIDE								
AA	MAYNE PHARMA INC	100MG/5ML	A204092	001	Jun 05, 2014	Aug	CAHN	
TABLET;ORAL								
OXYCODONE HYDROCHLORIDE								
AB	ALVOGEN MALTA	5MG	A202116	001	Dec 30, 2011	Jan	CAHN	
AB		15MG	A202116	002	Dec 30, 2011	Jan	CAHN	
AB		30MG	A202116	003	Dec 30, 2011	Jan	CAHN	
AB	COASTAL PHARMS	10MG	A091313	004	Apr 29, 2016	Apr	NEWA	
AB		20MG	A091313	005	Apr 29, 2016	Apr	NEWA	
AB	KEN LIFESCIENCE	5MG	A207119	001	Apr 12, 2016	Mar	NEWA	
AB		10MG	A207119	002	Apr 12, 2016	Mar	NEWA	
AB		15MG	A207119	003	Apr 12, 2016	Mar	NEWA	
AB		20MG	A207119	004	Apr 12, 2016	Mar	NEWA	
AB		30MG	A207119	005	Apr 12, 2016	Mar	NEWA	
AB	MAYNE PHARMA INC	5MG	A091313	001	Feb 18, 2011	Aug	CAHN	
AB		10MG	A091313	004	Apr 29, 2016	Aug	CAHN	
AB		15MG	A091313	002	Feb 18, 2011	Aug	CAHN	
AB		20MG	A091313	005	Apr 29, 2016	Aug	CAHN	
AB		30MG	A091313	003	Feb 18, 2011	Aug	CAHN	
<u>OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE</u>								
SPRAY, METERED;NASAL								
KOVANAZE								
	+	ST RENATUS	0.1MG/SPRAY; 6MG/SPRAY	N208032	001	Jun 29, 2016	Jun	NEWA
<u>OXYMORPHONE HYDROCHLORIDE</u>								
TABLET;ORAL								
OXYMORPHONE HYDROCHLORIDE								
AB	AUROLIFE PHARMA LLC	5MG	A204459	001	Apr 26, 2016	Apr	NEWA	
AB		10MG	A204459	002	Apr 26, 2016	Apr	NEWA	
<u>PACLITAXEL</u>								
INJECTABLE;INJECTION								
PACLITAXEL								
AP	GLAND PHARMA LTD	6MG/ML	A207326	001	Aug 23, 2016	Aug	NEWA	
AP	SANDOZ INC	6MG/ML	A078167	001	Dec 26, 2007	Jan	CAHN	
<u>PALIPERIDONE PALMITATE</u>								
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR								
INVEGA SUSTENNA								
	JANSSEN PHARMS	117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Mar	CRLD	
	+	156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Mar	CRLD	
<u>PALONOSETRON HYDROCHLORIDE</u>								
INJECTABLE;INTRAVENOUS								
PALONOSETRON HYDROCHLORIDE								
AP	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016	Apr	NEWA	
AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A201533	002	Apr 21, 2016	Apr	NEWA	
SOLUTION;INTRAVENOUS								
PALONOSETRON HYDROCHLORIDE								
	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG	N203050	001	Mar 01, 2016	Mar	NEWA	

SOLUTION; INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

		BASE/ML)							
		EQ 0.25MG BASE/5ML (EQ 0.05MG	N203050	002	Mar 01, 2016	Mar	NEWA		
		BASE/ML)							
	EXELA PHARMA SCIENCE	EQ 0.25MG BASE/2ML (EQ 0.125MG	N207963	001	Aug 22, 2016	Aug	NEWA		
		BASE/ML)							

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
PAMIDRONATE DISODIUM

>D>	AP	+	EUROHLTH INTL SARL	30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	Sep	CAHN
>D>	AP	+		90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	Sep	CAHN
	AP		SAGENT PHARMS	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	Jan	CAHN
	AP			90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	Jan	CAHN
>A>	AP	+	WEST-WARD PHARMS INT	30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	Sep	CAHN
>A>	AP	+		90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	Sep	CAHN

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)
PANTOPRAZOLE SODIUM

AP		AUROBINDO PHARMA LTD	EQ 40MG BASE/VIAL	A205675	001	Mar 30, 2016	Mar	NEWA	
		TABLET, DELAYED RELEASE; ORAL							
		PANTOPRAZOLE SODIUM							
AB		AMNEAL PHARMS	EQ 20MG BASE	A205119	001	Jan 26, 2016	Jan	NEWA	
AB			EQ 40MG BASE	A205119	002	Jan 26, 2016	Jan	NEWA	

PARICALCITOL

CAPSULE; ORAL
PARICALCITOL

AB		BIONPHARMA INC	1MCG	A202539	001	Mar 27, 2014	Jan	CAHN	
AB			2MCG	A202539	002	Mar 27, 2014	Jan	CAHN	
AB			4MCG	A202539	003	Mar 27, 2014	Jan	CAHN	
AB		LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016	Feb	NEWA	
AB			2MCG	A206710	002	Feb 24, 2016	Feb	NEWA	
AB			4MCG	A206710	003	Feb 24, 2016	Feb	NEWA	
>A>	AB	MARKSANS PHARMA	1MCG	A204948	001	Oct 07, 2016	Sep	NEWA	
>A>	AB		2MCG	A204948	002	Oct 07, 2016	Sep	NEWA	
>A>	AB		4MCG	A204948	003	Oct 07, 2016	Sep	NEWA	
AB	+	TEVA PHARMS USA	4MCG	A090829	003	Sep 27, 2013	Aug	CRLD	
		ZEMPLAR							
		@ ABBVIE	4MCG	N021606	003	May 26, 2005	Aug	DISC	

SOLUTION; INTRAVENOUS
PARICALCITOL

AP		ACCORD HLTHCARE	0.002MG/ML (0.002MG/ML)	N207174	001	Feb 04, 2016	Feb	NEWA	
AP			0.005MG/ML (0.005MG/ML)	N207174	002	Feb 04, 2016	Feb	NEWA	
AP			0.01MG/2ML (0.005MG/ML)	N207174	003	Feb 04, 2016	Feb	NEWA	
AP		DR REDDYS LABS LTD	0.002MG/ML (0.002MG/ML)	A204910	001	Aug 17, 2016	Aug	NEWA	
AP			0.005MG/ML (0.005MG/ML)	A204910	002	Aug 17, 2016	Aug	NEWA	
AP			0.01MG/2ML (0.005MG/ML)	A204910	003	Aug 17, 2016	Aug	NEWA	

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PAROXETINE HYDROCHLORIDE

AB		KREMERS URBAN PHARMS	EQ 12.5MG BASE	A204744	001	Jun 10, 2016	May	NEWA	
AB			EQ 25MG BASE	A204744	002	Jun 10, 2016	May	NEWA	
AB			EQ 37.5MG BASE	A204744	003	Jun 10, 2016	May	NEWA	

PAROXETINE MESYLATE

CAPSULE; ORAL
BRISDELLE

+		SEBELA IRELAND LTD	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Aug	CAHN	
		TABLET; ORAL							
		PEXEVA							
		SEBELA IRELAND LTD	EQ 10MG BASE	N021299	001	Jul 03, 2003	Aug	CAHN	
			EQ 20MG BASE	N021299	002	Jul 03, 2003	Aug	CAHN	
			EQ 30MG BASE	N021299	003	Jul 03, 2003	Aug	CAHN	
	+		EQ 40MG BASE	N021299	004	Jul 03, 2003	Aug	CAHN	

PENBUTOLOL SULFATE

TABLET; ORAL

LEVATOL

@	AUXILIUM PHARMS INC	10MG	N018976	001	Dec 30, 1987	Mar CAHN
@		20MG	N018976	004	Jan 05, 1989	Mar CAHN
@	AUXILIUM PHARMS LLC	10MG	N018976	001	Dec 30, 1987	Aug CAHN
@		20MG	N018976	004	Jan 05, 1989	Aug CAHN

PENCICLOVIR

CREAM; TOPICAL

DENA VIR

+	DENCO ASSET	1%	N020629	001	Sep 24, 1996	Apr CAIN
---	-------------	----	---------	-----	--------------	----------

PENTETATE CALCIUM TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE CALCIUM TRISODIUM

+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Apr CMFD
@		EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Feb CAHN

PENTETATE ZINC TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE ZINC TRISODIUM

+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Apr CMFD
@		EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Feb CAHN

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

AP	+	OAK PHARMS	50MG/ML	A083246	001		May CTEC
----	---	------------	---------	---------	-----	--	----------

PENTOBARBITAL SODIUM

AP		MYLAN INSTITUTIONAL	50MG/ML	A206404	001	May 23, 2016	May NEWA
----	--	---------------------	---------	---------	-----	--------------	----------

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

AB	+	APOTEX	400MG	A075191	001	Jun 09, 1999	Mar CRLD
	@	IMPAX LABS	400MG	A075093	001	Aug 10, 1999	Mar DISC
	@	PLIVA	400MG	A074874	001	May 25, 1999	Mar DISC
		TRENTAL					
	@	US PHARM HOLDINGS	400MG	N018631	001	Aug 30, 1984	Jan CAHN

PERAMPANEL

SUSPENSION; ORAL

FYCOMPA

+	EISAI INC	0.5MG/ML	N208277	001	Apr 29, 2016	Apr NEWA
---	-----------	----------	---------	-----	--------------	----------

PERINDOPRIL ERBUMINE

TABLET; ORAL

PERINDOPRIL ERBUMINE

>D>	AB	LUPIN LTD	2MG	A078263	001	Jan 27, 2010	Sep DISC
>A>		@	2MG	A078263	001	Jan 27, 2010	Sep DISC
>D>	AB		4MG	A078263	002	Jan 27, 2010	Sep DISC
>A>		@	4MG	A078263	002	Jan 27, 2010	Sep DISC
>D>	AB		8MG	A078263	003	Jan 27, 2010	Sep DISC
>A>		@	8MG	A078263	003	Jan 27, 2010	Sep DISC

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

>A>	AB	SANDOZ	2MG	A089685	002	Dec 08, 1988	Sep NEWA
>A>	AB		4MG	A089685	003	Dec 08, 1988	Sep NEWA
>A>	AB	+	16MG	A089685	004	Dec 08, 1988	Sep NEWA
	AB	WILSHIRE PHARMS INC	2MG	A205973	001	Dec 17, 2015	Jan CAHN
	AB		4MG	A205973	002	Dec 17, 2015	Jan CAHN
	AB		8MG	A205973	003	Dec 17, 2015	Jan CAHN
	AB		16MG	A205973	004	Dec 17, 2015	Jan CAHN

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE

@ ABLE	200MG, N/A, N/A, N/A, 800MG, 160MG	N021105	001	Jun 26, 2001	Jan CMS1
--------	------------------------------------	---------	-----	--------------	----------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA	SUN PHARM INDS	30MG	A040525	001	Oct 23, 2003	Mar CAHN
	@	37.5MG	A040527	001	Oct 23, 2003	Mar CAHN

TABLET; ORAL

LOMAIRA

+	AVANTHI INC	8MG	A203495	001	Sep 12, 2016	Aug NEWA
---	-------------	-----	---------	-----	--------------	----------

PHENTERMINE HYDROCHLORIDE

AA	INGENUS PHARMS NJ	37.5MG	A091451	001	Sep 21, 2012	Jan CAHN
AA	SUN PHARM INDS	37.5MG	A040526	001	Oct 23, 2003	Mar CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

@	CITIUS PHARMS	15MG	N202088	001	Jun 13, 2011	Jun DISC
@		30MG	N202088	002	Jun 13, 2011	Jun DISC
@		37.5MG	N202088	003	Mar 27, 2012	Jun DISC

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

@	LANNETT HOLDINGS INC	EQ 15MG BASE	A040872	001	Jul 28, 2011	Aug DISC
@		EQ 30MG BASE	A040872	002	Jul 28, 2011	Aug DISC

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

PHENTOLAMINE MESYLATE

>D>	AP	EUROHLTH INTL SARL	5MG/VIAL	A040235	001	Mar 11, 1998	Sep CAHN
>A>	AP	WEST-WARD PHARMS INT	5MG/VIAL	A040235	001	Mar 11, 1998	Sep CAHN

PHENYLBUTAZONE

CAPSULE; ORAL

PHENYLBUTAZONE

@	SUN PHARM INDS	100MG	A088994	001	Dec 04, 1985	Mar CAHN
---	----------------	-------	---------	-----	--------------	----------

TABLET; ORAL

PHENYLBUTAZONE

@	SUN PHARM INDS	100MG	A088863	001	Dec 04, 1985	Mar CAHN
---	----------------	-------	---------	-----	--------------	----------

PIMAVANSERIN TARTRATE

TABLET; ORAL

NUPLAZID

+	ACADIA PHARMS INC	EQ 17MG BASE	N207318	001	Apr 29, 2016	Apr NEWA
---	-------------------	--------------	---------	-----	--------------	----------

PINDOLOL

TABLET; ORAL

PINDOLOL

@	IDT AUSTRALIA LTD	5MG	A073608	001	Mar 29, 1993	May CAHN
@		10MG	A073609	001	Mar 29, 1993	May CAHN
AB	SUN PHARM INDS	5MG	A074063	001	Jan 27, 1994	Mar CAHN
AB		10MG	A074063	002	Jan 27, 1994	Mar CAHN

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB	FLAMINGO PHARMS	10MG	A207938	001	Sep 09, 2016	Aug NEWA
AB		20MG	A207938	002	Sep 09, 2016	Aug NEWA
AB	MYLAN IRELAND LTD	10MG	A074116	001	Jun 15, 1993	Aug CAHN
AB		20MG	A074118	001	Jun 15, 1993	Aug CAHN
AB	MYLAN PHARMS INC	20MG	A074118	001	Jun 15, 1993	Jan CAHN
@	SUN PHARM INDS	20MG	A073536	001	Mar 12, 1993	Mar CAHN

PODOFILOX

	GEL;TOPICAL								
	CONDYLOX								
	+ ALLERGAN SALES LLC	0.5%		N020529	001	Mar 13, 1997	Mar	CAHN	
	SOLUTION;TOPICAL								
	CONDYLOX								
AT	+ ALLERGAN SALES LLC	0.5%		N019795	001	Dec 13, 1990	Mar	CAHN	

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

	FOR SOLUTION;ORAL								
	COLYTE								
	@ MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT		N018983	010	Jan 31, 1989	May	DISC	
	COLYTE WITH FLAVOR PACKS								
AA	MEDA PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT		N018983	012	Oct 08, 1998	Jul	CTEC	

POLYMYXIN B SULFATE

	INJECTABLE;INJECTION								
	POLYMYXIN B SULFATE								
AP	AUROBINDO PHARMA LTD	EQ 500,000 UNITS BASE/VIAL		A206589	001	Apr 04, 2016	Mar	NEWA	
>D> AP	+ EUROHLTH INTL SARL	EQ 500,000 UNITS BASE/VIAL		A060716	001		Sep	CAHN	
AP	GLAND PHARMA LTD	EQ 500,000 UNITS BASE/VIAL		A207322	001	Apr 14, 2016	Apr	NEWA	
>A> AP	+ WEST-WARD PHARMS INT	EQ 500,000 UNITS BASE/VIAL		A060716	001		Sep	CAHN	

POTASSIUM CHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL								
	POTASSIUM CHLORIDE								
AB	GLENMARK PHARMS LTD	10MEQ		A202868	001	Jan 19, 2016	Jan	NEWA	
AB	KREMERS URBAN PHARMS	8MEQ		A204210	001	Mar 28, 2016	Mar	NEWA	
AB		10MEQ		A204210	002	Mar 28, 2016	Mar	NEWA	
AB	NOVEL LABS INC	8MEQ		A204828	001	Aug 16, 2016	Aug	NEWA	
AB		10MEQ		A204828	002	Aug 16, 2016	Aug	NEWA	
AB	TRIS PHARMA INC	8MEQ		A201944	001	Mar 04, 2016	Feb	NEWA	
AB		10MEQ		A201944	002	Mar 04, 2016	Feb	NEWA	
	FOR SOLUTION;ORAL								
	POTASSIUM CHLORIDE								
	+ PHARMA RES SOFTWARE	20MEQ		N208019	001	Aug 19, 2015	Jul	CRLD	
	TABLET, EXTENDED RELEASE;ORAL								
	POTASSIUM CHLORIDE								
AB1	GLENMARK PHARMS LTD	10MEQ		A203562	001	Jul 26, 2016	Jul	NEWA	
AB1		20MEQ		A203562	002	Jul 26, 2016	Jul	NEWA	
AB2	NOVEL LABS INC	8MEQ		A206759	001	Aug 09, 2016	Jul	NEWA	
AB1		10MEQ		A206347	001	Jan 21, 2016	Jan	NEWA	
AB2		10MEQ		A206759	002	Aug 09, 2016	Jul	NEWA	
AB1		20MEQ		A206347	002	Jan 21, 2016	Jan	NEWA	
AB2	SIGMAPHARM LABS LLC	8MEQ		A207528	001	Aug 19, 2016	Aug	NEWA	
AB2		10MEQ		A207528	002	Aug 19, 2016	Aug	NEWA	

PRAMIPEXOLE DIHYDROCHLORIDE

	TABLET, EXTENDED RELEASE;ORAL								
	PRAMIPEXOLE DIHYDROCHLORIDE								
AB	ACTAVIS ELIZABETH	0.375MG		A201963	001	Apr 21, 2016	Apr	NEWA	
AB		0.75MG		A201963	002	Apr 21, 2016	Apr	NEWA	
AB		1.5MG		A201963	003	Apr 21, 2016	Apr	NEWA	
AB		3MG		A201963	004	Apr 21, 2016	Apr	NEWA	
AB		4.5MG		A201963	005	Apr 21, 2016	Apr	NEWA	
AB	MACLEODS PHARMS LTD	0.375MG		A206156	001	Jun 24, 2016	Jun	NEWA	
AB		0.75MG		A206156	002	Jun 24, 2016	Jun	NEWA	
AB		1.5MG		A206156	003	Jun 24, 2016	Jun	NEWA	
AB		2.25MG		A206156	004	Jun 24, 2016	Jun	NEWA	
AB		3MG		A206156	005	Jun 24, 2016	Jun	NEWA	
AB		4.5MG		A206156	007	Jun 24, 2016	Jun	NEWA	
AB	SANDOZ INC	0.375MG		A202353	001	Dec 04, 2014	Jul	CDFR	
AB		0.75MG		A202353	002	Dec 04, 2014	Jul	CDFR	
AB		1.5MG		A202353	003	Dec 04, 2014	Jul	CDFR	
AB		3MG		A202353	004	Dec 04, 2014	Jul	CDFR	
AB		4.5MG		A202353	005	Dec 04, 2014	Jul	CDFR	

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB	CIPLA LTD	80MG	A077904	004	Mar 22, 2016	Mar NEWA
	@ MYLAN	10MG	A077013	001	Oct 23, 2006	Mar DISC
	@	20MG	A077013	002	Oct 23, 2006	Mar DISC
	@	40MG	A077013	003	Oct 23, 2006	Mar DISC
	@	80MG	A077013	004	Dec 28, 2007	Mar DISC

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

	@ IDT AUSTRALIA LTD	EQ 1MG BASE	A072576	001	May 16, 1989	May CAHN
	@	EQ 2MG BASE	A072577	001	May 16, 1989	May CAHN
	@	EQ 5MG BASE	A072578	001	May 16, 1989	May CAHN
>A> AB	TEVA PHARMS	EQ 1MG BASE	A071745	002	Sep 12, 1988	Sep NEWA
>A> AB		EQ 2MG BASE	A071745	003	Sep 12, 1988	Sep NEWA

PREDNISOLONE

TABLET;ORAL

PREDNISOLONE

	@ AUROLIFE PHARMA LLC	5MG	A084773	001		Feb CAHN
--	-----------------------	-----	---------	-----	--	----------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA	+ WOCKHARDT	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Mar CRLD
----	-------------	------------------	---------	-----	--------------	----------

PREDNISONE

TABLET;ORAL

PREDNISONE

	@ AUROLIFE PHARMA LLC	5MG	A084774	001		Mar CAHN
	@	10MG	A089983	001	Jan 12, 1989	Mar CAHN
	@	20MG	A085813	001		Mar CAHN
	@	50MG	A089984	001	Jan 12, 1989	Mar CAHN
AB	DELCOR ASSET CORP	5MG	A080292	001		Mar CAHN
AB		10MG	A088832	001	Dec 04, 1985	Mar CAHN
AB		20MG	A083677	001		Mar CAHN
AB	SUN PHARM INDS	20MG	A089247	001	Dec 04, 1985	Mar CAHN
	@	50MG	A086596	001		Jun CAHN

PRIMAQUINE PHOSPHATE

TABLET;ORAL

PRIMAQUINE PHOSPHATE

AB	INGENUS PHARMS NJ	EQ 15MG BASE	A206043	001	Jun 23, 2016	Jun NEWA
----	-------------------	--------------	---------	-----	--------------	----------

PRIMIDONE

TABLET;ORAL

PRIMIDONE

AB	FRONTIDA BIOPHARM	50MG	A040626	001	Sep 29, 2005	Jul CAHN
AB		250MG	A040626	002	Sep 29, 2005	Jul CAHN
	@ HIKMA INTL PHARMS	50MG	A040667	001	Jul 27, 2006	Jul CAHN
AB		250MG	A040667	002	Jul 27, 2006	Jul CAHN
	@ IMPAX LABS	50MG	A040717	001	Feb 12, 2008	Mar DISC
	@	250MG	A040717	002	Feb 12, 2008	Mar DISC
AB	SUN PHARM INDS	50MG	A040626	001	Sep 29, 2005	Mar CAHN
AB		250MG	A040626	002	Sep 29, 2005	Mar CAHN

PROCAINAMIDE HYDROCHLORIDE

CAPSULE;ORAL

PROCAINAMIDE HYDROCHLORIDE

	@ IDT AUSTRALIA LTD	375MG	A089220	001	Jul 01, 1986	May CAHN
--	---------------------	-------	---------	-----	--------------	----------

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE

	@ AMPHASTAR PHARMS INC	EQ 5MG BASE/ML	A040540	001	May 28, 2004	Aug DISC
AP		EQ 5MG BASE/ML	A040540	001	May 28, 2004	Jun CAHN
>D> AP	+ EMCURE PHARMS LTD	EQ 5MG BASE/ML	A204147	001	Oct 15, 2013	Sep CTEC
>A>	+	EQ 5MG BASE/ML	A204147	001	Oct 15, 2013	Sep CTEC
AP	+	EQ 5MG BASE/ML	A204147	001	Oct 15, 2013	Aug CRLD

INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE

AP	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A040540	001	May 28, 2004	Apr CAHN
@		EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Aug DISC

PROGESTERONE

CAPSULE;ORAL

PROGESTERONE

AB	BIONPHARMA INC	100MG	A200900	001	Aug 16, 2013	Jan CAHN
AB		200MG	A200900	002	Aug 16, 2013	Jan CAHN

PROMETRIUM

AB	VIRTUS PHARMS	100MG	N019781	001	May 14, 1998	Jun CAHN
AB	+	200MG	N019781	002	Oct 15, 1999	Jun CAHN
@		300MG	N019781	003	Oct 15, 1999	Jun CAHN

GEL;VAGINAL

CRINONE

+	ALLERGAN SALES LLC	4%	N020701	001	Jul 31, 1997	Apr CAHN
+		8%	N020701	002	Jul 31, 1997	Apr CAHN

INJECTABLE;INJECTION

PROGESTERONE

AO	+	ALLERGAN SALES LLC	50MG/ML	N017362	002	Apr CAHN
----	---	--------------------	---------	---------	-----	----------

PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE

AA	NOSTRUM LABS INC	6.25MG/5ML	A040891	001	Mar 13, 2009	Feb CAHN
----	------------------	------------	---------	-----	--------------	----------

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

@	IMPAX LABS	12.5MG	A040724	001	Feb 12, 2008	Mar DISC
@		25MG	A040724	002	Feb 12, 2008	Mar DISC
@		50MG	A040791	001	May 20, 2008	Mar DISC
@	SUN PHARM INDS	12.5MG	A084555	001		Mar CAHN
@		25MG	A084554	001		Mar CAHN
@		50MG	A084557	001		Jan CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPAFENONE HYDROCHLORIDE

AB	MYLAN PHARMS INC	225MG	A203803	001	Apr 29, 2016	Apr NEWA
AB		325MG	A203803	002	Apr 29, 2016	Apr NEWA
AB		425MG	A203803	003	Apr 29, 2016	Apr NEWA

TABLET;ORAL

PROPAFENONE HYDROCHLORIDE

AB	ORION CORP ORION	150MG	A202445	001	May 11, 2016	Apr NEWA
AB		225MG	A202445	002	May 11, 2016	Apr NEWA
AB		300MG	A202445	003	May 11, 2016	Apr NEWA
AB	SUN PHARM INDS	150MG	A075998	001	Nov 29, 2001	Mar CAHN
AB		225MG	A075998	002	Nov 29, 2001	Mar CAHN
AB		300MG	A075998	003	Nov 29, 2001	Mar CAHN

PROPOFOL

INJECTABLE;INJECTION

PROPOFOL

>D>	@	EUROHLTH INTL SARL	10MG/ML	A074848	001	Apr 19, 2005	Sep CAHN
AB		SAGENT PHARMS	10MG/ML	A075102	001	Jan 04, 1999	Aug CAHN
>A>	@	WEST-WARD PHARMS INT	10MG/ML	A074848	001	Apr 19, 2005	Sep CAHN

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

INDERAL LA

AB	ANI PHARMS INC	60MG	N018553	004	Mar 18, 1987	Apr CAHN
AB		80MG	N018553	002	Apr 19, 1983	Apr CAHN
AB		120MG	N018553	003	Apr 19, 1983	Apr CAHN
AB	+	160MG	N018553	001	Apr 19, 1983	Apr CAHN

PROPRANOLOL HYDROCHLORIDE

BX	UPSHER SMITH	60MG	A078311	001	Mar 06, 2009	Jun CMFD
@		60MG	A078311	001	Mar 06, 2009	May DISC
BX		60MG	A078311	001	Mar 06, 2009	Mar CTEC
BX		80MG	A078311	002	Mar 06, 2009	Jun CMFD
@		80MG	A078311	002	Mar 06, 2009	May DISC
BX		80MG	A078311	002	Mar 06, 2009	Mar CTEC
BX		120MG	A078311	003	Mar 06, 2009	Jun CMFD

CAPSULE, EXTENDED RELEASE;ORAL
PROPRANOLOL HYDROCHLORIDE

	@	120MG	A078311	003	Mar 06, 2009	May	DISC
BX		120MG	A078311	003	Mar 06, 2009	Mar	CTEC
BX		160MG	A078311	004	Mar 06, 2009	Jun	CMFD
	@	160MG	A078311	004	Mar 06, 2009	May	DISC
BX		160MG	A078311	004	Mar 06, 2009	Mar	CTEC

INJECTABLE;INJECTION
PROPRANOLOL HYDROCHLORIDE

AP		AMPHASTAR PHARMS INC	1MG/ML	A075792	001	Aug 29, 2000	Jun	CAHN
AP		EUROHLTH INTL SARL	1MG/ML	A075792	001	Aug 29, 2000	Apr	CAHN
	@	SANDOZ	1MG/ML	A076400	001	Feb 26, 2003	Mar	DISC

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

	@	FRONTIDA BIOPHARM	10MG	A070319	001	Oct 22, 1985	Jul	CAHN
	@		20MG	A070320	001	Oct 22, 1985	Jul	CAHN
	@		40MG	A070103	001	Oct 22, 1985	Jul	CAHN
	@		60MG	A070321	001	Sep 24, 1986	Jul	CAHN
	@		80MG	A070322	001	Aug 04, 1986	Jul	CAHN
AB		IMPAX LABS INC	10MG	A071972	001	Apr 06, 1988	Aug	CAHN
AB			20MG	A071973	001	Apr 06, 1988	Aug	CAHN
AB			40MG	A071974	001	Apr 06, 1988	Aug	CAHN
AB			60MG	A071975	001	Apr 06, 1988	Aug	CAHN
AB	+		80MG	A071976	001	Apr 06, 1988	Aug	CAHN
	@	SUN PHARM INDS	10MG	A070319	001	Oct 22, 1985	Mar	CAHN
	@		20MG	A070320	001	Oct 22, 1985	Mar	CAHN
	@		40MG	A070103	001	Oct 22, 1985	Mar	CAHN
	@		60MG	A070321	001	Sep 24, 1986	Jun	CAHN
	@		80MG	A070322	001	Aug 04, 1986	Mar	CAHN

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

	@	HIKMA INTL PHARMS	50MG	A080154	001		Jul	CAHN
	@	SUN PHARM INDS	50MG	A083982	001		Mar	CAHN

PYRAZINAMIDE

TABLET;ORAL

PYRAZINAMIDE

>D>	AB	MIKART	500MG	A081319	001	Jun 30, 1992	Sep	CAHN
>A>	AB	VERSAPHARM INC	500MG	A081319	001	Jun 30, 1992	Sep	CAHN

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE;ORAL

PYRIDOSTIGMINE BROMIDE

AB		ALVOGEN MALTA	180MG	A204737	001	Jun 26, 2015	Jan	CAHN
----	--	---------------	-------	---------	-----	--------------	-----	------

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION

PYRIDOXINE HYDROCHLORIDE

AP	+	FRESENIUS KABI USA	100MG/ML	A080618	001		Jul	CTEC
AP		MYLAN INSTITUTIONAL	100MG/ML	A204879	001	Jul 14, 2016	Jul	NEWA

QUAZEPAM

TABLET;ORAL

DORAL

	@	CUTIS HEALTH LLC	7.5MG	N018708	003	Feb 26, 1987	Mar	CAHN
	+		15MG	N018708	001	Dec 27, 1985	Apr	CMFD
	@		15MG	N018708	001	Dec 27, 1985	Mar	CAHN

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

	@	ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013	Apr	DISC
	@		EQ 50MG BASE	A201762	002	Feb 27, 2013	Apr	DISC
	@		EQ 100MG BASE	A201762	003	Feb 27, 2013	Apr	DISC
	@		EQ 150MG BASE	A201762	004	Feb 27, 2013	Apr	DISC
	@		EQ 200MG BASE	A201762	005	Feb 27, 2013	Apr	DISC
	@		EQ 300MG BASE	A201762	006	Feb 27, 2013	Apr	DISC
	@		EQ 400MG BASE	A201762	007	Feb 27, 2013	Apr	DISC
AB		MACLEODS PHARMS LTD	EQ 25MG BASE	A203359	001	May 17, 2016	May	NEWA
AB			EQ 50MG BASE	A203359	002	May 17, 2016	May	NEWA

TABLET;ORAL

QUETIAPINE FUMARATE

AB		EQ 100MG BASE	A203359	003	May 17, 2016	May NEWA
AB		EQ 200MG BASE	A203359	004	May 17, 2016	May NEWA
AB		EQ 300MG BASE	A203359	005	May 17, 2016	May NEWA
AB		EQ 400MG BASE	A203359	006	May 17, 2016	May NEWA
AB	UNICHEM LABS LTD	EQ 25MG BASE	A202674	001	Mar 08, 2016	Feb NEWA
AB		EQ 50MG BASE	A202674	002	Mar 08, 2016	Feb NEWA
AB		EQ 100MG BASE	A202674	003	Mar 08, 2016	Feb NEWA
AB		EQ 200MG BASE	A202674	004	Mar 08, 2016	Feb NEWA
AB		EQ 300MG BASE	A202674	005	Mar 08, 2016	Feb NEWA
AB		EQ 400MG BASE	A202674	006	Mar 08, 2016	Feb NEWA

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

	@ ACTAVIS LABS FL INC	EQ 5MG BASE	A076049	001	Jan 14, 2005	Jan DISC
	@	EQ 10MG BASE	A076049	002	Jan 14, 2005	Jan DISC
	@	EQ 20MG BASE	A076049	003	Jan 14, 2005	Jan DISC
	@	EQ 40MG BASE	A076049	004	Jan 14, 2005	Jan DISC
>A> AB	PRINSTON INC	EQ 5MG BASE	A205823	001	Sep 15, 2016	Sep NEWA
>A> AB		EQ 10MG BASE	A205823	002	Sep 15, 2016	Sep NEWA
>A> AB		EQ 20MG BASE	A205823	003	Sep 15, 2016	Sep NEWA
>A> AB		EQ 40MG BASE	A205823	004	Sep 15, 2016	Sep NEWA

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

	@ AUROLIFE PHARMA LLC	324MG	A089894	001	Dec 15, 1988	Mar CAHN
BX	+ SUN PHARM INDS	324MG	A089338	001	Feb 11, 1987	Mar CAHN

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

	@ SUN PHARM INDS	100MG	A081029	001	Apr 14, 1989	Jun CAHN
AB		200MG	A081030	001	Apr 14, 1989	Mar CAHN
AB		300MG	A081031	001	Apr 14, 1989	Mar CAHN

QUININE SULFATE

CAPSULE;ORAL

QUALAQUIN

AB	+ SUN PHARM INDS	324MG	N021799	001	Aug 12, 2005	Jun CAHN
----	------------------	-------	---------	-----	--------------	----------

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE;ORAL

ACIPHEX SPRINKLE

	FSC THERAP	5MG	N204736	001	Mar 26, 2013	Jun CAHN
	+	10MG	N204736	002	Mar 26, 2013	Jun CAHN

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

RALOXIFENE HYDROCHLORIDE

AB	AMNEAL PHARMS	60MG	A208206	001	Apr 08, 2016	Mar NEWA
AB	GLENMARK PHARMS LTD	60MG	A204491	001	Mar 22, 2016	Mar NEWA

RAMELTEON

TABLET;ORAL

RAMELTEON

AB	DR REDDYS LABS INTL	8MG	A091693	001	Jul 26, 2013	Aug CAHN
----	---------------------	-----	---------	-----	--------------	----------

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

@ SANDOZ	1.25MG
@	2.5MG
@	5MG
@	10MG

A077514	001	Jun 18, 2008	Aug DISC
A077514	002	Jun 18, 2008	Aug DISC
A077514	003	Jun 18, 2008	Aug DISC
A077514	004	Jun 18, 2008	Aug DISC

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

>D>	AP	EUROHLTH INTL SARL	EQ 25MG BASE/ML	A074777	001	Mar 02, 2005	Sep CAHN
	AP	MYLAN LABS LTD	EQ 25MG BASE/ML	A079076	001	Jun 09, 2016	May NEWA
>A>	AP	WEST-WARD PHARMS INT	EQ 25MG BASE/ML	A074777	001	Mar 02, 2005	Sep CAHN
	AP	ZYDUS PHARMS USA INC	EQ 25MG BASE/ML	A091534	001	Feb 22, 2013	May CPOT
		ZANTAC					
	AP	+ IGI LABS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan CAHN
		ZANTAC IN PLASTIC CONTAINER					
		@ IGI LABS INC	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Jan CAHN
		@	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Jan CAHN

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

AA		NOSTRUM LABS INC	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Mar CAHN
		@ WOCKHARDT	EQ 15MG BASE/ML	A079211	001	May 26, 2009	Apr DISC
		@	EQ 15MG BASE/ML	A079212	001	Feb 23, 2009	Apr DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

AB		STRIDES PHARMA	EQ 150MG BASE	A205512	001	Aug 22, 2016	Aug NEWA
AB			EQ 300MG BASE	A205512	002	Aug 22, 2016	Aug NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

AB		ORCHID HLTHCARE	EQ 0.5MG BASE	A201970	001	Mar 15, 2016	Feb NEWA
AB			EQ 1MG BASE	A201970	002	Mar 15, 2016	Feb NEWA

RESERPINE

TABLET;ORAL

RESERPINE

		@ HIKMA INTL PHARMS	0.1MG	A080975	001		Feb CAHN
		@	0.25MG	A080975	002		Feb CAHN
		@	1MG	A080975	003		Feb CAHN

RETAPAMULIN

OINTMENT;TOPICAL

ALTABAX

		+ AQUA PHARMS LLC	1%	N022055	001	Apr 12, 2007	Jan CAHN
--	--	-------------------	----	---------	-----	--------------	----------

RIBAVIRIN

FOR SOLUTION;INHALATION

RIBAVIRIN

>A>							
>A>	AN	NAVINTA LLC	6GM/VIAL	A207366	001	Oct 06, 2016	Sep NEWA
		VIRAZOLE					
>D>		+ VALEANT PHARM INTL	6GM/VIAL	N018859	001	Dec 31, 1985	Sep CFTG
>A>	AN	+	6GM/VIAL	N018859	001	Dec 31, 1985	Sep CFTG

RIBOFLAVIN 5'-PHOSPHATE SODIUM

SOLUTION/DROPS;OPHTHALMIC

PHOTREXA

		+ AVEDRO INC	0.146%	N203324	001	Apr 15, 2016	Apr NEWA
		PHOTREXA VISCOUS IN DEXTRAN 20%					
		+ AVEDRO INC	0.146%	N203324	002	Apr 15, 2016	Jun CMS1
		PHOTREXA VISCOUS IN DEXTROSE 20%					
		+ AVEDRO INC	0.146%	N203324	002	Apr 15, 2016	Apr NEWA

RIFAMPIN

INJECTABLE;INJECTION

RIFAMPIN

AP		EUROHLTH INTL SARL	600MG/VIAL	A064217	001	Oct 29, 1999	Apr CAHN
AP		HIKMA PHARMS	600MG/VIAL	A205039	001	Mar 03, 2016	Feb NEWA
AP		WATSON PHARMS INC	600MG/VIAL	A206736	001	Jan 19, 2016	Jan NEWA

RILUZOLE

TABLET;ORAL

RILUZOLE

AB		ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016	Mar NEWA
----	--	----------------	------	---------	-----	--------------	----------

RIMEXOLONESUSPENSION/DROPS;OPHTHALMIC
VEXOL

@ ALCON	1%	N020474	001	Dec 30, 1994	Jun DISC
---------	----	---------	-----	--------------	----------

RISEDRONATE SODIUMTABLET;ORAL
ACTONEL

AB	APIL	5MG	N020835	002	Apr 14, 2000	Jan CAHN
AB		30MG	N020835	001	Mar 27, 1998	Jan CAHN
AB	+	35MG	N020835	003	May 25, 2002	Jan CAHN
	@	75MG	N020835	004	Apr 16, 2007	Jan CAHN
AB	+	150MG	N020835	005	Apr 22, 2008	Jan CAHN

TABLET, DELAYED RELEASE;ORAL
ATELVIA

AB	+	APIL	35MG	N022560	001	Oct 08, 2010	Jan CAHN
----	---	------	------	---------	-----	--------------	----------

RISPERIDONESOLUTION;ORAL
RISPERIDONE

@ SILARX PHARMS INC	1MG/ML	A202386	001	Jan 12, 2015	Aug DISC
@ WOCKHARDT	1MG/ML	A078744	001	Oct 08, 2009	Apr DISC

RIVASTIGMINEFILM, EXTENDED RELEASE;TRANSDERMAL
RIVASTIGMINE

AB	ALVOGEN MALTA	4.6MG/24HR	A204403	001	Sep 03, 2015	Jan CAHN
AB		9.5MG/24HR	A204403	002	Sep 03, 2015	Jan CAHN
AB		13.3MG/24HR	A204403	003	Aug 31, 2015	Jan CAHN

RIVASTIGMINE TARTRATECAPSULE;ORAL
EXELON

AB	+	NOVARTIS	EQ 6MG BASE	N020823	006	Apr 21, 2000	Jan CRLD
		RIVASTIGMINE TARTRATE					
AB		AUROBINDO PHARMA LTD	EQ 1.5MG BASE	A204572	001	Mar 25, 2016	Mar NEWA
AB			EQ 3MG BASE	A204572	002	Mar 25, 2016	Mar NEWA
AB			EQ 4.5MG BASE	A204572	003	Mar 25, 2016	Mar NEWA
AB			EQ 6MG BASE	A204572	004	Mar 25, 2016	Mar NEWA

RIZATRIPTAN BENZOATETABLET;ORAL
RIZATRIPTAN BENZOATE

AB	ALKEM LABS LTD	EQ 5MG BASE	A203269	001	Feb 18, 2016	Feb NEWA
AB		EQ 10MG BASE	A203269	002	Feb 18, 2016	Feb NEWA
AB	NOSTRUM LABS INC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Jan CAHN
AB		EQ 10MG BASE	A202047	002	Dec 31, 2012	Jan CAHN

ROPIVACAINE HYDROCHLORIDEINJECTABLE;INJECTION
ROPIVACAINE HYDROCHLORIDE

AP	AKORN INC	5MG/ML	A203955	001	Apr 11, 2016	Mar NEWA
----	-----------	--------	---------	-----	--------------	----------

SOLUTION;INJECTION
NAROPIN

	@ FRESSENIUS KABI USA	50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May DISC
		50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May NEWA
AP		20MG/10ML (2MG/ML)	N020533	001	May 01, 1998	May CMS1
AP		20MG/10ML (2MG/ML)	N020533	001	Sep 24, 1996	Mar CDFR
AP		40MG/20ML (2MG/ML)	N020533	002	Sep 24, 1996	Mar NEWA
	@	75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr DISC
		75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr NEWA
AP		100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	Jun CFTG
		100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	May CMS1
		100MG/20ML (5MG/ML)	N020533	003	Sep 24, 1996	Mar CDFR
AP		100MG/10ML (10MG/ML)	N020533	005	Sep 24, 1996	Mar NEWA
AP		150MG/20ML (7.5MG/ML)	N020533	004	Sep 24, 1996	Mar CDFR
AP		150MG/30ML (5MG/ML)	N020533	008	Sep 24, 1996	Mar NEWA
AP		200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Jun CFTG
		200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Mar NEWA
AP	+	200MG/20ML (10MG/ML)	N020533	011	Sep 24, 1996	Mar NEWA
		400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996	Mar NEWA

SOLUTION; INJECTION
NAROPIN

500MG/100ML (5MG/ML)	N020533	009	Jan 04, 2011	Apr CMS1
500MG/100ML (5MG/ML)	N020533	009	Sep 24, 1996	Mar NEWA
1GM/200ML (5MG/ML)	N020533	010	Jan 04, 2011	Apr CMS1
1GM/200ML (5MG/ML)	N020533	010	Sep 24, 1996	Mar NEWA

ROPIVACAINE HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	40MG/20ML (2MG/ML)	A205612	001	Jul 13, 2016	Jun NEWA
AP		100MG/20ML (5MG/ML)	A205612	003	Jul 13, 2016	Jun NEWA
AP		100MG/10ML (10MG/ML)	A205612	006	Jul 13, 2016	Jun NEWA
AP		150MG/30ML (5MG/ML)	A205612	004	Jul 13, 2016	Jun NEWA
AP		150MG/20ML (7.5MG/ML)	A205612	005	Jul 13, 2016	Jun NEWA
AP		200MG/100ML (2MG/ML)	A205612	002	Jul 13, 2016	Jun NEWA
AP		200MG/20ML (10MG/ML)	A205612	007	Jul 13, 2016	Jun NEWA
AP	HOSPIRA	20MG/10ML (2MG/ML)	A090194	001	Sep 23, 2014	Mar CDFR
AP		40MG/20ML (2MG/ML)	A090194	005	Sep 23, 2014	Mar NEWA
AP		100MG/10ML (10MG/ML)	A090194	004	Sep 23, 2014	Mar CDFR
AP		150MG/30ML (5MG/ML)	A090194	002	Sep 23, 2014	Mar CDFR
AP		150MG/20ML (7.5MG/ML)	A090194	003	Sep 23, 2014	Mar CDFR
AP		200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014	Mar NEWA
AP	NAVINTA LLC	150MG/30ML (5MG/ML)	A078601	002	Jul 17, 2014	Mar CDFR
AP		200MG/20ML (10MG/ML)	A078601	003	Jul 17, 2014	Mar CDFR
AP	SAGENT STRIDES	40MG/20ML (2MG/ML)	A090318	001	Sep 23, 2014	Mar CDFR
AP		150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014	Mar CDFR
AP		150MG/20ML (7.5MG/ML)	A090318	003	Sep 23, 2014	Mar CDFR
AP		200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014	Mar CDFR

ROSUVASTATIN CALCIUMTABLET; ORAL
CRESTOR

AB	IPR	5MG	N021366	002	Aug 12, 2003	Apr CFTG
AB		10MG	N021366	003	Aug 12, 2003	Apr CFTG
AB		20MG	N021366	004	Aug 12, 2003	Apr CFTG
AB	+	40MG	N021366	005	Aug 12, 2003	Apr CFTG
	ROSUVASTATIN CALCIUM					
AB	APOTEX INC	5MG	A079145	001	Jul 19, 2016	Jul NEWA
AB		10MG	A079145	002	Jul 19, 2016	Jul NEWA
AB		20MG	A079145	003	Jul 19, 2016	Jul NEWA
AB		40MG	A079145	004	Jul 19, 2016	Jul NEWA
AB	AUROBINDO PHARMA LTD	5MG	A079170	001	Jul 19, 2016	Jul NEWA
AB		10MG	A079170	002	Jul 19, 2016	Jul NEWA
AB		20MG	A079170	003	Jul 19, 2016	Jul NEWA
AB		40MG	A079170	004	Jul 19, 2016	Jul NEWA
>A>	AB	GLENMARK PHARMS	A079172	001	Jul 19, 2016	Sep CAHN
>A>	AB		A079172	002	Jul 19, 2016	Sep CAHN
>A>	AB		A079172	003	Jul 19, 2016	Sep CAHN
>A>	AB		A079172	004	Jul 19, 2016	Sep CAHN
>D>	AB	GLENMARK PHARMS LTD	A079172	001	Jul 19, 2016	Sep CAHN
	AB		A079172	001	Jul 19, 2016	Jul NEWA
>D>	AB		A079172	002	Jul 19, 2016	Sep CAHN
	AB		A079172	002	Jul 19, 2016	Jul NEWA
>D>	AB		A079172	003	Jul 19, 2016	Sep CAHN
	AB		A079172	003	Jul 19, 2016	Jul NEWA
>D>	AB		A079172	004	Jul 19, 2016	Sep CAHN
	AB		A079172	004	Jul 19, 2016	Jul NEWA
AB	MYLAN PHARMS INC	5MG	A079161	001	Jul 19, 2016	Jul NEWA
AB		10MG	A079161	002	Jul 19, 2016	Jul NEWA
AB		20MG	A079161	003	Jul 19, 2016	Jul NEWA
AB		40MG	A079161	004	Jul 19, 2016	Jul NEWA
AB	PAR PHARM INC	5MG	A079168	001	Jul 19, 2016	Jul NEWA
AB		10MG	A079168	002	Jul 19, 2016	Jul NEWA
AB		20MG	A079168	003	Jul 19, 2016	Jul NEWA
AB		40MG	A079168	004	Jul 19, 2016	Jul NEWA
AB	SANDOZ INC	5MG	A079171	001	Jul 19, 2016	Jul NEWA
AB		10MG	A079171	002	Jul 19, 2016	Jul NEWA
AB		20MG	A079171	003	Jul 19, 2016	Jul NEWA
AB		40MG	A079171	004	Jul 19, 2016	Jul NEWA
AB	SUN PHARMA GLOBAL	5MG	A079169	001	Jul 19, 2016	Jul NEWA
AB		10MG	A079169	002	Jul 19, 2016	Jul NEWA
AB		20MG	A079169	003	Jul 19, 2016	Jul NEWA
AB		40MG	A079169	004	Jul 19, 2016	Jul NEWA
AB	TEVA PHARMS USA	5MG	A079166	001	Jul 19, 2016	Jul NEWA
AB		10MG	A079166	002	Jul 19, 2016	Jul NEWA

TABLET;ORAL

ROSUVASTATIN CALCIUM

AB		20MG	A079166	003	Jul 19, 2016	Jul NEWA
AB		40MG	A079166	004	Jul 19, 2016	Jul NEWA
AB	WATSON LABS INC	5MG	A079167	001	Apr 29, 2016	Apr NEWA
AB		10MG	A079167	002	Apr 29, 2016	Apr NEWA
AB		20MG	A079167	003	Apr 29, 2016	Apr NEWA
AB		40MG	A079167	004	Apr 29, 2016	Apr NEWA

RUBIDIUM CHLORIDE RB-82

SOLUTION;INTRAVENOUS

>A> RUBY-FILL

>A> JUBILANT DRAXIMAGE N/A N202153 001 Sep 30, 2016 Sep NEWA

RUFINAMIDE

TABLET;ORAL

BANZEL

AB	EISAI INC	200MG	N021911	002	Nov 14, 2008	May CFTG
AB	+	400MG	N021911	003	Nov 14, 2008	May CFTG

RUFINAMIDE

AB	GLENMARK PHARMS LTD	200MG	A205075	001	May 16, 2016	May NEWA
AB		400MG	A205075	002	May 16, 2016	May NEWA
AB	MYLAN PHARMS INC	200MG	A205095	001	May 16, 2016	May NEWA
AB		400MG	A205095	002	May 16, 2016	May NEWA
AB	ROXANE	200MG	A204988	001	May 16, 2016	May NEWA
AB		400MG	A204988	002	May 16, 2016	May NEWA

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

TRANSDERM SCOP

AB	+	GLAXOSMITHKLINE CON	1MG/72HR	N017874	001	May CAHN
----	---	---------------------	----------	---------	-----	----------

SECOBARBITAL SODIUM

CAPSULE;ORAL

SECONAL SODIUM

+	VALEANT PHARMS NORTH	50MG	A086101	001	Oct 03, 1983	Aug CAHN
+		100MG	A086101	002	Oct 03, 1983	Aug CAHN

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@	FRONTIDA BIOPHARM	EQ 25MG BASE	A077818	001	Feb 06, 2007	Jul CAHN
@		EQ 50MG BASE	A077818	002	Feb 06, 2007	Jul CAHN
@		EQ 100MG BASE	A077818	003	Feb 06, 2007	Jul CAHN
@	SUN PHARM INDS	EQ 25MG BASE	A077818	001	Feb 06, 2007	Mar CAHN
@		EQ 50MG BASE	A077818	002	Feb 06, 2007	Mar CAHN
@		EQ 100MG BASE	A077818	003	Feb 06, 2007	Mar CAHN

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

AB	@	ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013	Apr DISC
		RUBICON RES PVT LTD	EQ 20MG BASE	A204883	001	Jun 20, 2016	Jun NEWA
	@	TEVA	EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb DISC
			EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb NEWA
	@		EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb DISC
			EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb NEWA
	@		EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb DISC
			EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb NEWA

SILODOSIN

CAPSULE;ORAL

RAPAFLO

+	ALLERGAN SALES LLC	4MG	N022206	001	Oct 08, 2008	Apr CAHN
		8MG	N022206	002	Oct 08, 2008	Apr CAHN

SIMVASTATIN

SUSPENSION;ORAL

SIMVASTATIN

	ROSEMONT PHARMS LTD	20MG/5ML	N206679	001	Apr 21, 2016	Apr NEWA
+		40MG/5ML	N206679	002	Apr 21, 2016	Apr NEWA

TABLET;ORAL									
SIMVASTATIN									
	@ SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Feb	DISC		
	@	10MG	A076285	002	Dec 20, 2006	Feb	DISC		
	@	20MG	A076285	003	Dec 20, 2006	Feb	DISC		
	@	40MG	A076285	004	Dec 20, 2006	Feb	DISC		
	@	80MG	A076285	005	Jun 23, 2006	Feb	DISC		
<u>SODIUM BENZOATE; SODIUM PHENYLACETATE</u>									
SOLUTION;IV (INFUSION)									
AMMONUL									
AP	+ MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Feb	CFTG		
SODIUM PHENYLACETATE AND SODIUM BENZOATE									
AP	AILEX PHARMS PVT LTD	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Feb	NEWA		
AP	NAVINTA LLC	10%;10% (5GM/50ML;5GM/50ML)	A205880	001	Aug 04, 2016	Jul	NEWA		
<u>SODIUM BICARBONATE</u>									
INJECTABLE;INJECTION									
SODIUM BICARBONATE									
	HOSPIRA INC	0.5MEQ/ML	A202981	001	Mar 04, 2016	Feb	NEWA		
<u>SODIUM CHLORIDE</u>									
INJECTABLE;INJECTION									
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER									
AP	+ HOSPIRA	450MG/100ML	N018090	001		Aug	CRLD		
SODIUM CHLORIDE 0.9%									
	B BRAUN	900MG/10ML	N019635	005	Aug 11, 2016	Aug	NEWA		
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER									
AP	JUBILANT HOLLISTRSTR	9MG/ML	A203352	001	May 18, 2016	May	NEWA		
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER									
	+ BAXTER HLTHCARE	3GM/100ML	N019022	001	Nov 01, 1983	Aug	CRLD		
<u>SODIUM FLUORIDE F-18</u>									
INJECTABLE;INTRAVENOUS									
SODIUM FLUORIDE F-18									
AP	KREITCHMAN PET CTR	10-200mCi/ML	A203936	001	May 19, 2016	May	NEWA		
AP	ZEVACOR PHARMA INC	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb	CAHN		
<u>SODIUM IODIDE I-131</u>									
CAPSULE;ORAL									
SODIUM IODIDE I 131									
	JUBILANT DRAXIMAGE	0.009-0.1mCi	N021305	006	May 19, 2005	Mar	CMS1		
	@	2-200mCi	N021305	004	Nov 18, 2004	Mar	CMS1		
<u>SODIUM PHENYLBUTYRATE</u>									
POWDER;ORAL									
BUPHENYL									
AB	+ HORIZON PHARMA INC	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Mar	CAHN		
SODIUM PHENYLBUTYRATE									
AB	PAR PHARM	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Jun	NEWA		
TABLET;ORAL									
BUPHENYL									
AB	+ HORIZON PHARMA INC	500MG	N020572	001	May 13, 1996	Mar	CAHN		
SODIUM PHENYLBUTYRATE									
AB	PAR PHARM	500MG	A204395	001	Apr 15, 2016	Apr	NEWA		
<u>SODIUM POLYSTYRENE SULFONATE</u>									
POWDER;ORAL, RECTAL									
SODIUM POLYSTYRENE SULFONATE									
AA	BELCHER PHARMS LLC	454GM/BOT	A205727	001	Feb 23, 2016	Feb	NEWA		
AA	INVATECH PHARMA	454GM/BOT	A206815	001	Feb 18, 2016	Feb	NEWA		
<u>SOFOSBUVIR; VELPATASVIR</u>									
TABLET;ORAL									
EPCLUSA									
	+ GILEAD SCIENCES INC	400MG;100MG	N208341	001	Jun 28, 2016	Jun	NEWA		

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

@ IMPAX PHARMS	80MG	A075663	001	Nov 07, 2000	Mar DISC
@	120MG	A075663	002	Nov 07, 2000	Mar DISC
@	160MG	A075663	003	Nov 07, 2000	Mar DISC
@	240MG	A075663	004	Nov 07, 2000	Mar DISC
@ SUN PHARM INDS	80MG	A075515	001	Oct 15, 2001	Mar CAHN
@	80MG	A076576	001	Apr 08, 2004	Mar CAHN
@	120MG	A075515	004	Oct 15, 2001	Mar CAHN
@	120MG	A076576	002	Apr 08, 2004	Mar CAHN
@	160MG	A075515	002	Oct 15, 2001	Mar CAHN
@	160MG	A076576	003	Apr 08, 2004	Mar CAHN
@	240MG	A075515	003	Oct 15, 2001	Mar CAHN

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

>A> AB	ACCORD HLTHCARE INC	25MG	A203512	001	Sep 19, 2016	Sep NEWA
>A> AB		50MG	A203512	002	Sep 19, 2016	Sep NEWA
>A> AB		100MG	A203512	003	Sep 19, 2016	Sep NEWA
AB	SUN PHARM INDS	25MG	A089424	001	Jul 23, 1986	Mar CAHN
AB		50MG	A089424	002	Aug 11, 1999	Mar CAHN
AB		100MG	A089424	003	Aug 11, 1999	Mar CAHN

SUCRALFATE

TABLET; ORAL

SUCRALFATE

AB	MYLAN IRELAND LTD	1GM	A074415	001	Jun 08, 1998	Jan CAHN
----	-------------------	-----	---------	-----	--------------	----------

SUGAMMADEX SODIUM

SOLUTION; INTRAVENOUS

BRIDION

ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jan CPOT
+	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jan CPOT

SULFAMETHOXAZOLE

TABLET; ORAL

SULFAMETHOXAZOLE

@ AUROLIFE PHARMA LLC	500MG	A085844	001		Feb CAHN
-----------------------	-------	---------	-----	--	----------

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

BACTRIM

@ SUN PHARM INDS	200MG/5ML; 40MG/5ML	N017560	001		Jun CAHN
BACTRIM PEDIATRIC					
@ SUN PHARM INDS	200MG/5ML; 40MG/5ML	N017560	002		Jun CAHN

TABLET; ORAL

BACTRIM

AB	SUN PHARM INDS	400MG; 80MG	N017377	001		Mar CAHN
	BACTRIM DS					
AB	+ SUN PHARM INDS	800MG; 160MG	N017377	002		Mar CAHN
	SULFAMETHOXAZOLE AND TRIMETHOPRIM					
AB	SUN PHARM INDS	800MG; 160MG	A071017	001	Aug 25, 1986	Mar CAHN

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE

@ SUN PHARM INDS	500MG	A089590	001	Oct 19, 1987	Mar CAHN
------------------	-------	---------	-----	--------------	----------

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

@ AUROLIFE PHARMA LLC	500MG	A085628	001		Feb CAHN
-----------------------	-------	---------	-----	--	----------

SULINDACTABLET; ORAL
SULINDAC

AB	SUN PHARM INDS	150MG	A072050	001	Apr 17, 1991	Mar CAHN
AB		200MG	A072051	001	Apr 17, 1991	Mar CAHN

SUMATRIPTANSPRAY; NASAL
IMITREX

AB	+	GLAXOSMITHKLINE	5MG/SPRAY	N020626	001	Aug 26, 1997	Feb CFTG
AB	+		20MG/SPRAY	N020626	003	Aug 26, 1997	Feb CFTG
SUMATRIPTAN							
AB		LANNETT	5MG/SPRAY	A204841	001	Feb 19, 2016	Feb NEWA
AB			20MG/SPRAY	A204841	002	Feb 19, 2016	Feb NEWA

SUMATRIPTAN SUCCINATEINJECTABLE; SUBCUTANEOUS
ALSUMA

>D>							
>D>	BX	MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377	001	Jun 29, 2010	Sep DISC
>A>	@		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377	001	Jun 29, 2010	Sep DISC
SUMATRIPTAN SUCCINATE							
AP		EUROHLTH INTL SARL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079123	001	Feb 06, 2009	Jun CAHN
POWDER; INHALATION							
ONZETRA XSAIL							
	+	AVANIR PHARMS	EQ 11MG BASE	N206099	001	Jan 27, 2016	Jan NEWA
SOLUTION; SUBCUTANEOUS							
ZEMBRACE SYMTOUCH							
		DR REDDYS LABS LTD	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016	Jan NEWA

TACROLIMUSOINTMENT; TOPICAL
PROTOPIC

AB	+	LEO PHARMA AS	0.03%	N050777	001	Dec 08, 2000	Jun CAHN
AB	+		0.1%	N050777	002	Dec 08, 2000	Jun CAHN

TAMOXIFEN CITRATESOLUTION; ORAL
SOLTAMOX

		MIDATECH PHARMA US	EQ 10MG BASE/5ML	N021807	001	Oct 29, 2005	Jan CAHN
TABLET; ORAL							
TAMOXIFEN CITRATE							
	@	ACTAVIS LABS FL INC	EQ 10MG BASE	A076179	001	Feb 20, 2003	Jan DISC
	@		EQ 20MG BASE	A076179	002	Feb 20, 2003	Jan DISC
AB		MAYNE PHARMA	EQ 10MG BASE	A075797	001	Feb 20, 2003	Aug CAHN
AB	+		EQ 20MG BASE	A074858	001	Feb 20, 2003	Aug CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATORSOLUTION; INTRAVENOUS
ULTRA-TECHNEKOW FM

	+	MALLINKRODT NUCLEAR	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	Jan CAHN
	@		0.25-3 CI/GENERATOR	N017243	002		Jan CAHN

TECHNETIUM TC-99M SUCCIMER KITINJECTABLE; INJECTION
MPI DMSA KIDNEY REAGENT

@	GE HEALTHCARE	N/A	N017944	001	May 18, 1982	Aug DISC
---	---------------	-----	---------	-----	--------------	----------

TEGASEROD MALEATETABLET; ORAL
ZELNORM

@	US WORLDMEDS LLC	EQ 2MG BASE	N021200	001	Jul 24, 2002	Jan CAHN
@		EQ 6MG BASE	N021200	002	Jul 24, 2002	Jan CAHN

TELITHROMYCIN

TABLET; ORAL

KETEK

@	SANOFI AVENTIS US	300MG	N021144	002	Feb 09, 2005	Mar	DISC
@		400MG	N021144	001	Apr 01, 2004	Mar	DISC

TELMISARTAN

TABLET; ORAL

TELMISARTAN

AB	HETERO LABS LTD V	20MG	A205901	001	Apr 22, 2016	Apr	NEWA
AB		40MG	A205901	002	Apr 22, 2016	Apr	NEWA
AB		80MG	A205901	003	Apr 22, 2016	Apr	NEWA
AB	JUBILANT GENERICS	20MG	A204164	001	Aug 22, 2016	Aug	NEWA
AB		40MG	A204164	002	Aug 22, 2016	Aug	NEWA
AB		80MG	A204164	003	Aug 22, 2016	Aug	NEWA

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB	AMNEAL PHARMS	7.5MG	A203482	001	May 23, 2016	May	NEWA
AB		15MG	A203482	002	May 23, 2016	May	NEWA
AB		22.5MG	A203482	003	May 23, 2016	May	NEWA
AB		30MG	A203482	004	May 23, 2016	May	NEWA
AB	SUN PHARM INDS	7.5MG	A078581	001	Sep 08, 2009	Mar	CAHN
	@	15MG	A071174	001	Jul 10, 1986	Mar	CAHN
AB		22.5MG	A071175	002	Sep 14, 2009	Mar	CAHN
	@	30MG	A071175	001	Jul 10, 1986	Mar	CAHN

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

AB	AMERIGEN PHARMS LTD	5MG	A203490	001	Jul 13, 2016	Jul	NEWA
AB		20MG	A203490	002	Jul 13, 2016	Jul	NEWA
AB		100MG	A203490	003	Jul 13, 2016	Jul	NEWA
AB		140MG	A203490	004	Jul 13, 2016	Jul	NEWA
AB		180MG	A203490	005	Jul 13, 2016	Jul	NEWA
AB		250MG	A203490	006	Jul 13, 2016	Jul	NEWA
AB	IDT AUSTRALIA LTD	5MG	A206413	001	Apr 12, 2016	Mar	NEWA
AB		20MG	A206413	002	Apr 12, 2016	Mar	NEWA
AB		100MG	A206413	003	Apr 12, 2016	Mar	NEWA
AB		140MG	A206413	004	Apr 12, 2016	Mar	NEWA
AB		180MG	A206413	005	Apr 12, 2016	Mar	NEWA
AB		250MG	A206413	006	Apr 12, 2016	Mar	NEWA
AB	KREMERS URBAN PHARMS	5MG	A203898	001	Feb 10, 2016	Jan	NEWA
AB		20MG	A203898	002	Feb 10, 2016	Jan	NEWA
AB		100MG	A203898	003	Feb 10, 2016	Jan	NEWA
AB		140MG	A203898	004	Feb 10, 2016	Jan	NEWA
AB		180MG	A203898	005	Feb 10, 2016	Jan	NEWA
AB		250MG	A203898	006	Feb 10, 2016	Jan	NEWA
AB	LOTUS PHARM CO LTD	5MG	A206309	001	Apr 27, 2016	Apr	NEWA
AB		20MG	A206309	002	Apr 27, 2016	Apr	NEWA
AB		100MG	A206309	003	Apr 27, 2016	Apr	NEWA
AB		140MG	A206309	004	Apr 27, 2016	Apr	NEWA
AB		180MG	A206309	005	Apr 27, 2016	Apr	NEWA
AB		250MG	A206309	006	Apr 27, 2016	Apr	NEWA
AB	MYLAN PHARMS INC	5MG	A205227	001	Jun 29, 2016	Jun	NEWA
AB		20MG	A205227	002	Jun 29, 2016	Jun	NEWA
AB		100MG	A205227	003	Jun 29, 2016	Jun	NEWA
AB		140MG	A205227	004	Jun 29, 2016	Jun	NEWA
AB		180MG	A205227	005	Jun 29, 2016	Jun	NEWA
AB		250MG	A205227	006	Jun 29, 2016	Jun	NEWA

TERBUTALINE SULFATE

INJECTABLE; INJECTION

BRETHINE

>D>	@	AAIPHARMA LLC	1MG/ML	N018571	001		Sep	CAHN
>A>	@	PHARMACARE	1MG/ML	N018571	001		Sep	CAHN
		TERBUTALINE SULFATE						
AP	+	AMPHASTAR PHARMS INC	1MG/ML	A076770	001	Apr 23, 2004	Jun	CAHN
AP	+	EUROHLTH INTL SARL	1MG/ML	A076770	001	Apr 23, 2004	Apr	CAHN

TABLET;ORAL									
TERBUTALINE SULFATE									
	@ IMPAX LABS	2.5MG	A075877	001	Jun 26, 2001	Mar	DISC		
	@	5MG	A075877	002	Jun 26, 2001	Mar	DISC		
	LANNETT	2.5MG	A077152	001	Mar 25, 2005	Mar	CTEC		
		5MG	A077152	002	Mar 25, 2005	Mar	CTEC		
<u>TESTOSTERONE</u>									
FILM, EXTENDED RELEASE;TRANSDERMAL									
ANDRODERM									
+	ALLERGAN SALES LLC	2MG/24HR	N020489	003	Oct 20, 2011	Mar	CAHN		
	@	2.5MG/24HR	N020489	001	Sep 29, 1995	Mar	CAHN		
+		4MG/24HR	N020489	004	Oct 20, 2011	Mar	CAHN		
	@	5MG/24HR	N020489	002	May 02, 1997	Mar	CAHN		
GEL, METERED;NASAL									
NATESTO									
	AYTU BIOSCIENCE INC	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jun	CAHN		
PELLET;IMPLANTATION									
TESTOPEL									
+	AUXILIUM PHARMS INC	75MG	A080911	001		Mar	CAHN		
TABLET, EXTENDED RELEASE;BUCCAL									
STRIANT									
+	AUXILIUM PHARMS INC	30MG	N021543	001	Jun 19, 2003	Mar	CAHN		
<u>TESTOSTERONE CYPIONATE</u>									
INJECTABLE;INJECTION									
TESTOSTERONE CYPIONATE									
AO	EUROHLTH INTL SARL	100MG/ML	A090387	001	Jul 15, 2010	Jun	CAHN		
AO		200MG/ML	A090387	002	Jul 15, 2010	Jun	CAHN		
<u>TETRABENAZINE</u>									
TABLET;ORAL									
TETRABENAZINE									
AB	HETERO LABS LTD V	12.5MG	A204574	001	Feb 03, 2016	Jan	NEWA		
AB		25MG	A204574	002	Feb 03, 2016	Jan	NEWA		
<u>TETRACAINE HYDROCHLORIDE</u>									
SOLUTION;OPHTHALMIC									
TETRACAINE HYDROCHLORIDE									
+	ALCON RES LTD	0.5%	N208135	001	Feb 29, 2016	Feb	NEWA		
<u>TETRACYCLINE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
TETRACYCLINE HYDROCHLORIDE									
AB	CHARTWELL CIENCA	250MG	A062752	001	Aug 12, 1988	Apr	CMFD		
AB		500MG	A062752	002	Aug 12, 1988	Apr	CMFD		
	@ IDT AUSTRALIA LTD	250MG	A061471	001		Aug	CAHN		
	@ SUN PHARM INDS	250MG	A060736	001		Mar	CAHN		
	@	500MG	A060736	002		Mar	CAHN		
<u>THEOPHYLLINE</u>									
CAPSULE, EXTENDED RELEASE;ORAL									
THEO-24									
	AUXILIUM PHARMS INC	200MG	A087943	001	Aug 22, 1983	Mar	CAHN		
		300MG	A087944	001	Aug 22, 1983	Mar	CAHN		
+		400MG	A081034	001	Feb 28, 1992	Mar	CAHN		
	AUXILIUM PHARMS LLC	200MG	A087943	001	Aug 22, 1983	Jul	CAHN		
		300MG	A087944	001	Aug 22, 1983	Jul	CAHN		
SOLUTION, ELIXIR;ORAL									
ELIXOPHYLLIN									
+	NOSTRUM LABS INC	80MG/15ML	A085186	001		Jan	CAHN		
TABLET, EXTENDED RELEASE;ORAL									
THEOCHRON									
AB	NOSTRUM LABS INC	100MG	A088320	001	Feb 21, 1985	Jan	CAHN		
AB		200MG	A088321	001	Feb 21, 1985	Jan	CAHN		
	@	300MG	A087400	002	Jan 11, 1983	Jan	CAHN		
THEOPHYLLINE									
AB	MYLAN IRELAND LTD	400MG	A040560	003	Apr 21, 2006	Jan	CAHN		
AB	+	600MG	A040560	002	Apr 21, 2006	Jan	CAHN		
AB	RHODES PHARMS	400MG	A087571	001	Sep 01, 1982	Aug	CTNA		

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

AB	SUN PHARM INDS	10MG	A089953	004	Aug 01, 1986	Mar CAHN
	@	15MG	A088461	001	Nov 18, 1983	Mar CAHN
AB		25MG	A089953	003	Aug 01, 1986	Mar CAHN
AB		50MG	A089953	002	Aug 01, 1986	Mar CAHN
AB		100MG	A089953	001	Oct 07, 1988	Mar CAHN
	@	150MG	A088737	001	Sep 26, 1984	Mar CAHN
	@	200MG	A088738	001	Oct 16, 1984	Mar CAHN

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

>D>	+	EUROHLTH INTL SARL	15MG/VIAL	A075547	001	Apr 02, 2001	Sep CAHN
>A>	+	WEST-WARD PHARMS INT	15MG/VIAL	A075547	001	Apr 02, 2001	Sep CAHN

THIOTHIXENE

CAPSULE; ORAL

NAVANE

@	PFIZER	1MG	N016584	001		Aug DISC
@		2MG	N016584	002		Aug DISC
@		5MG	N016584	003		Aug DISC
@		10MG	N016584	004		Aug DISC

THIOTHIXENE

	MYLAN	1MG	A071093	002	Jun 23, 1987	Aug CTEC
		2MG	A071093	003	Jun 23, 1987	Aug CTEC
+		5MG	A071093	004	Jun 23, 1987	Aug CRLD
		10MG	A071093	001	Jun 23, 1987	Aug CTEC
>A>	@ SANDOZ	1MG	A071529	002	Jun 24, 1987	Sep CMS1
>A>	@	2MG	A071529	003	Jun 24, 1987	Sep CMS1
	@	5MG	A071529	001	Jun 24, 1987	Mar DISC
>A>	@	10MG	A071529	004	Jun 24, 1987	Sep CMS1

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

>D>	+	OAK PHARMS INC	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Sep CFTG
>A>	AT	+	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Sep CFTG
>D>	+		EQ 0.5% BASE	N020439	002	Mar 31, 1995	Sep CFTG
>A>	AT	+	EQ 0.5% BASE	N020439	002	Mar 31, 1995	Sep CFTG
>A>		TIMOLOL					
>A>	AT	AKORN	EQ 0.25% BASE	A205309	001	Sep 30, 2016	Sep NEWA
>A>	AT		EQ 0.5% BASE	A205309	002	Sep 30, 2016	Sep NEWA

TINIDAZOLE

TABLET; ORAL

TINIDAZOLE

BX	UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Apr CTEC
BX		500MG	A202489	002	Oct 09, 2013	Apr CTEC

TIROFIBAN HYDROCHLORIDE

SOLUTION; INJECTION

AGGRASTAT

+	MEDICURE	EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML)	N020912	002	Aug 31, 2016	Aug NEWA
---	----------	---	---------	-----	--------------	----------

TOBRAMYCIN

SOLUTION; INHALATION

BETHKIS

>D>		CHIESI USA INC	300MG/4ML	N201820	001	Oct 12, 2012	Sep CRLD
>A>	+		300MG/4ML	N201820	001	Oct 12, 2012	Sep CRLD

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

AP	CLARIS	EQ 40MG BASE/ML	A206965	001	Jul 01, 2016	Jun NEWA
----	--------	-----------------	---------	-----	--------------	----------

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE;ORAL
XELJANZ XR

+ PFIZER INC EQ 11MG BASE N208246 001 Feb 23, 2016 Feb NEWA

TOLAZAMIDE

TABLET;ORAL
TOLAZAMIDE

@ SUN PHARM INDS 100MG A071357 001 Jul 16, 1987 Mar CAHN
@ 250MG A071358 001 Jul 16, 1987 Mar CAHN
@ 500MG A071359 001 Jul 16, 1987 Mar CAHN

TOLMETIN SODIUM

CAPSULE;ORAL
TOLMETIN SODIUM

@ SUN PHARM INDS EQ 400MG BASE A073311 001 Nov 27, 1991 Mar CAHN

TABLET;ORAL

TOLMETIN SODIUM

AB SUN PHARM INDS EQ 200MG BASE A073310 001 Nov 27, 1991 Mar CAHN

TOPIRAMATE

TABLET;ORAL
TOPIRAMATE

@ ACTAVIS TOTOWA 25MG A078637 001 Feb 27, 2013 Apr DISC
AB 25MG A078637 001 Feb 27, 2013 Jan CAHN
@ 50MG A078637 002 Feb 27, 2013 Apr DISC
AB 50MG A078637 002 Feb 27, 2013 Jan CAHN
@ 100MG A078637 003 Feb 27, 2013 Apr DISC
AB 100MG A078637 003 Feb 27, 2013 Jan CAHN
@ 200MG A078637 004 Feb 27, 2013 Apr DISC
AB 200MG A078637 004 Feb 27, 2013 Jan CAHN

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

AB ACI HEALTHCARE LTD 50MG A202075 001 Nov 28, 2011 Mar CAHN
AB SUN PHARM INDS 50MG A076100 001 Jun 20, 2002 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

ULTRAM ER

AB1 + VALEANT PHARMS 100MG N021692 001 Sep 08, 2005 Mar CAHN
AB1 200MG N021692 002 Sep 08, 2005 Mar CAHN
AB1 300MG N021692 003 Sep 08, 2005 Mar CAHN
AB1 300MG N021692 003 Sep 08, 2005 Mar CAHN

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

AP AKORN 100MG/ML A206634 001 Jun 09, 2016 May NEWA
AP AUROBINDO PHARMA LTD 100MG/ML A205035 001 Jan 14, 2016 Jan NEWA
AP NORTH CREEK PHARMS 100MG/ML A202755 001 Feb 25, 2016 Feb NEWA

TABLET;ORAL

TRANEXAMIC ACID

@ AMERIGEN PHARMS LTD 650MG A203256 001 Jul 25, 2016 Jul DISC
AB 650MG A203256 001 Jul 25, 2016 Jul NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 50MG A072484 001 Apr 30, 1990 Feb CAHN
AB SUN PHARM INDS 50MG A073137 002 Mar 24, 1993 Mar CAHN
AB 100MG A073137 001 Mar 24, 1993 Mar CAHN
AB 150MG A073137 003 Dec 22, 1995 Mar CAHN

TRETINOIN

CREAM;TOPICAL

TRETINOIN

+ ALLERGAN SALES LLC 0.0375% A090098 001 Mar 22, 2010 Jul CAHN
0.075% A202209 001 Oct 11, 2012 Jul CAHN
AB ELAN PHARMA INTL LTD 0.025% A075264 001 Dec 24, 1998 Feb CAHN
AB1 0.05% A075265 001 Dec 24, 1998 Feb CAHN
AB 0.1% A075213 001 Dec 24, 1998 Feb CAHN

CREAM; TOPICAL							
TRETINOIN							
AB	PERRIGO PHARMA INTL	0.025%	A075264	001	Dec 24, 1998	Jul	CAHN
AB1		0.05%	A075265	001	Dec 24, 1998	Jul	CAHN
AB		0.1%	A075213	001	Dec 24, 1998	Jul	CAHN
GEL; TOPICAL							
TRETINOIN							
AB	ELAN PHARMA INTL LTD	0.01%	A075589	001	Jun 11, 2002	Feb	CAHN
AB		0.025%	A075529	001	Feb 22, 2000	Feb	CAHN
AB	PERRIGO PHARMA INTL	0.01%	A075589	001	Jun 11, 2002	Jul	CAHN
AB		0.025%	A075529	001	Feb 22, 2000	Jul	CAHN
<u>TRIAMCINOLONE ACETONIDE</u>							
CREAM; TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT	GLENMARK PHARMS LTD	0.1%	A207117	001	Aug 05, 2016	Jul	NEWA
LOTION; TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT	TELIGENT PHARMA INC	0.025%	A204608	001	Jul 07, 2016	Jun	NEWA
AT		0.1%	A204606	001	Jul 07, 2016	Jun	NEWA
OINTMENT; TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT	GLENMARK PHARMS LTD	0.5%	A206379	001	Jul 22, 2016	Jul	NEWA
AT	TELIGENT PHARMA INC	0.1%	A205373	001	May 13, 2016	May	NEWA
PASTE; DENTAL							
TRIAMCINOLONE ACETONIDE							
AT	VERSAPHARM INC	0.1%	A206312	001	Aug 11, 2016	Jul	NEWA
SPRAY; TOPICAL							
KENALOG							
AT	+ RANBAXY LABS LTD	0.147MG/GM	N012104	001		Jul	CAHN
<u>TRIMETHOBENZAMIDE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
TRIMETHOBENZAMIDE HYDROCHLORIDE							
AB	SUN PHARM INDS	300MG	A076570	001	Aug 28, 2003	Mar	CAHN
<u>TRIMETHOPRIM</u>							
TABLET; ORAL							
TRIMETHOPRIM							
AB	+ MAYNE PHARMA	100MG	N018679	001	Jul 30, 1982	Aug	CAHN
	@ SUN PHARM INDS	100MG	A070494	001	Jan 22, 1986	Jun	CAHN
	@	200MG	A070495	001	Sep 24, 1986	Mar	CAHN
<u>TRIMETHOPRIM HYDROCHLORIDE</u>							
SOLUTION; ORAL							
PRIMSOL							
	+ AYTU BIOSCIENCE INC	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jun	CAHN
	@ AYTU PHARMS	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Jun	CMS2
	@	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Jan	CAHN
	+	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jan	CAHN
<u>TRIMIPRAMINE MALEATE</u>							
CAPSULE; ORAL							
TRIMIPRAMINE MALEATE							
AB	CROSSMEDIKA SA	EQ 25MG BASE	A208127	001	Apr 15, 2016	Apr	NEWA
AB		EQ 50MG BASE	A208127	002	Apr 15, 2016	Apr	NEWA
AB		EQ 100MG BASE	A208127	003	Apr 15, 2016	Apr	NEWA
<u>TRIPTORELIN PAMOATE</u>							
INJECTABLE; INTRAMUSCULAR							
TRELSTAR							
	+ ALLERGAN SALES LLC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Apr	CAHN
	+	EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Apr	CAHN
	+	EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Apr	CAHN
<u>TROSPIMUM CHLORIDE</u>							
CAPSULE, EXTENDED RELEASE; ORAL							
TROSPIMUM CHLORIDE							
AB	+ ACTAVIS LABS FL INC	60MG	A091289	001	Oct 12, 2012	Aug	CRLD
	@ SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Apr	DISC

TABLET;ORAL

TROSPIMUM CHLORIDE

AB	+	GLENMARK GENERICS	20MG	A091575	001	Aug 13, 2010	Aug CRLD
AB		HERITAGE PHARMS INC	20MG	A204945	001	Aug 30, 2016	Aug NEWA
AB		INVAGEN PHARMS	20MG	A091688	001	Aug 23, 2016	Aug NEWA

URSODIOL

CAPSULE;ORAL

ACTIGALL

		@ ALLERGAN SALES LLC	150MG	N019594	001	Dec 31, 1987	Mar CAHN
AB	+		300MG	N019594	002	Dec 31, 1987	Mar CAHN

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALCYTE

AB	+	HOFFMANN LA ROCHE	50MG/ML	N022257	001	Aug 28, 2009	Jul CFTG
		VALGANCICLOVIR HYDROCHLORIDE					
AB		ACTAVIS LABS FL INC	50MG/ML	A205220	001	Jul 18, 2016	Jul NEWA

TABLET;ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	EQ 450MG BASE	A204750	001	Mar 31, 2016	Mar NEWA
AB		HETERO LABS LTD V	EQ 450MG BASE	A205166	001	Mar 18, 2016	Mar NEWA

VALPROATE SODIUM

INJECTABLE;INJECTION

VALPROATE SODIUM

AP		AMPHASTAR PHARMS INC	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Jun CAHN
AP		EUROHLTH INTL SARL	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Apr CAHN

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

AB		BIONPHARMA INC	250MG	A073484	001	Jun 29, 1993	Jan CAHN
----	--	----------------	-------	---------	-----	--------------	----------

SYRUP;ORAL

VALPROIC ACID

AA		NOSTRUM LABS INC	250MG/5ML	A090517	001	May 28, 2010	Mar CAHN
----	--	------------------	-----------	---------	-----	--------------	----------

VALSARTAN

TABLET;ORAL

VALSARTAN

>A>	AB	MACLEODS PHARMS LTD	40MG	A202696	001	Sep 16, 2016	Sep NEWA
>A>	AB		80MG	A202696	002	Sep 16, 2016	Sep NEWA
>A>	AB		160MG	A202696	003	Sep 16, 2016	Sep NEWA
>A>	AB		320MG	A202696	004	Sep 16, 2016	Sep NEWA

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

AP		AMNEAL PHARMS CO	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	May CAHN
AP			EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	May CAHN
AP		AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A205780	001	Mar 31, 2016	Mar NEWA
AP			EQ 1GM BASE/VIAL	A205780	002	Mar 31, 2016	Mar NEWA
AP			EQ 5GM BASE/VIAL	A205779	001	Mar 29, 2016	Mar NEWA
AP			EQ 10GM BASE/VIAL	A205779	002	Mar 29, 2016	Mar NEWA
AP		CFT PHARMS LLC	EQ 5GM BASE/VIAL	A204125	001	Dec 28, 2015	Jul CAHN
AP			EQ 10GM BASE/VIAL	A204125	002	Dec 28, 2015	Jul CAHN
AP			EQ 500MG BASE/VIAL	A204107	001	Dec 28, 2015	Jul CAHN
AP			EQ 1GM BASE/VIAL	A204107	002	Dec 28, 2015	Jul CAHN
AP		FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A062663	005	Aug 17, 2016	Aug NEWA
AP		GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A205694	001	Jan 21, 2016	Jan NEWA
AP			EQ 1GM BASE/VIAL	A205694	002	Jan 21, 2016	Jan NEWA

VANDETANIB

TABLET;ORAL

CAPRELSA

		GENZYME CORP	100MG	N022405	001	Apr 06, 2011	Jun CAHN
	+		300MG	N022405	002	Apr 06, 2011	Jun CAHN

VECURONIUM BROMIDE

INJECTABLE;INJECTION
VECURONIUM BROMIDE

AP	EUROHLTH INTL SARL	10MG/VIAL	A075549	001	Jun 13, 2000	Apr CAHN
AP		20MG/VIAL	A075549	002	Jun 13, 2000	Apr CAHN
AP	GLAND PHARMA LTD	10MG/VIAL	A205390	001	May 26, 2016	May NEWA
AP		20MG/VIAL	A205390	002	May 26, 2016	May NEWA
AP	SAGENT PHARMS	10MG/VIAL	A078274	001	Dec 29, 2008	Jan CAHN
AP		20MG/VIAL	A078274	002	Dec 29, 2008	Jan CAHN

VENETOCLAX

TABLET;ORAL
VENCLEXTA

	ABBVIE INC	10MG	N208573	001	Apr 11, 2016	Apr NEWA
		50MG	N208573	002	Apr 11, 2016	Apr NEWA
+		100MG	N208573	003	Apr 11, 2016	Apr NEWA

VERAPAMIL HYDROCHLORIDE

SOLUTION;INTRAVENOUS
VERAPAMIL HYDROCHLORIDE

AP	EXELA PHARMA SCS LLC	5MG/2ML (2.5MG/ML)	N018925	001	Mar 30, 1984	Apr CMFD
----	----------------------	--------------------	---------	-----	--------------	----------

TABLET;ORAL
CALAN

>D>	AB	GD SEARLE LLC	40MG	N018817	003	Feb 23, 1988	Sep DISC
>A>		@	40MG	N018817	003	Feb 23, 1988	Sep DISC
		VERAPAMIL HYDROCHLORIDE					
		@ SUN PHARM INDS	80MG	A071489	002	Jan 13, 1988	Jun CAHN
		@	120MG	A071489	001	Jan 13, 1988	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL
CALAN SR

	@ PFIZER	180MG	N019152	002	Dec 15, 1989	Feb DISC
	VERAPAMIL HYDROCHLORIDE					
AB	+ GLENMARK GENERICS	180MG	A090700	002	Aug 03, 2011	Aug CRLD

VINORELBINE TARTRATE

INJECTABLE;INJECTION
VINORELBINE TARTRATE

AP	EUROHLTH INTL SARL	EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Apr CAHN
----	--------------------	-----------------	---------	-----	--------------	----------

VORAPAXAR SULFATE

TABLET;ORAL
ZONTIVITY

>A>	+	ARALEZ PHARMS	EQ 2.08MG BASE	N204886	001	May 08, 2014	Sep CAHN
>D>	+	MERCK SHARP DOHME	EQ 2.08MG BASE	N204886	001	May 08, 2014	Sep CAHN

VORICONAZOLE

FOR SUSPENSION;ORAL
VORICONAZOLE

AB	AMNEAL PHARMS	200MG/5ML	A205034	001	Apr 13, 2016	Mar NEWA
AB	NOVEL LABS INC	200MG/5ML	A206799	001	May 31, 2016	May NEWA

INJECTABLE;IV (INFUSION)
VORICONAZOLE

AP	ALVOGEN INC	200MG/VIAL	A206398	001	Mar 23, 2016	Mar NEWA
----	-------------	------------	---------	-----	--------------	----------

TABLET;ORAL
VORICONAZOLE

AB	AJANTA PHARMA LTD	50MG	A206181	001	May 24, 2016	May NEWA
AB		200MG	A206181	002	May 24, 2016	May NEWA
AB	APPCO PHARMA LLC	50MG	A206762	001	May 24, 2016	May NEWA
AB		200MG	A206762	002	May 24, 2016	May NEWA
AB	AUROBINDO PHARMA LTD	50MG	A206837	001	Jan 22, 2016	Jan NEWA
AB		200MG	A206837	002	Jan 22, 2016	Jan NEWA
AB	NOVEL LABS INC	50MG	A207371	001	May 24, 2016	May NEWA
AB		200MG	A207371	002	May 24, 2016	May NEWA
AB	PRINSTON INC	50MG	A206654	001	Aug 08, 2016	Jul NEWA
AB		200MG	A206654	002	Aug 08, 2016	Jul NEWA
AB	VERSAPHARM INC	50MG	A207049	001	Sep 07, 2016	Aug NEWA
AB		200MG	A207049	002	Sep 07, 2016	Aug NEWA
AB	ZYDUS PHARMS USA INC	50MG	A206747	001	May 24, 2016	May NEWA
AB		200MG	A206747	002	May 24, 2016	May NEWA

VORTIOXETINE HYDROBROMIDETABLET; ORAL
TRINTELLIX

TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013	Jun CTNA
	EQ 10MG BASE	N204447	002	Sep 30, 2013	Jun CTNA
	EQ 15MG BASE	N204447	003	Sep 30, 2013	Jun CTNA
+	EQ 20MG BASE	N204447	004	Sep 30, 2013	Jun CTNA

XENON XE-133GAS; INHALATION
XENON XE 133

LANTHEUS MEDCL	20mCi/VIAL	N017284	002		Feb CTEC
MALLINKRODT NUCLEAR	10mCi/VIAL	N018327	001	Mar 09, 1982	Feb CMFD
	20mCi/VIAL	N018327	002	Mar 09, 1982	Feb CMFD

ZIDOVUDINETABLET; ORAL
ZIDOVUDINE

@ SUNSHINE LAKE	300MG	A202058	001	Oct 07, 2011	Aug DISC
-----------------	-------	---------	-----	--------------	----------

ZOLEDRONIC ACIDINJECTABLE; IV (INFUSION)
ZOLEDRONIC ACID

>A> AP	AUROBINDO PHARMA LTD	EQ 4MG BASE/5ML	A207751	001	Sep 26, 2016	Sep NEWA
AP	GLAND PHARMA LTD	EQ 5MG BASE/100ML	A204217	001	Aug 18, 2016	Aug NEWA

ZOLMITRIPTANTABLET; ORAL
ZOLMITRIPTAN

AB	AJANTA PHARMA LTD	2.5MG	A204041	001	May 20, 2016	May NEWA
AB		5MG	A204041	002	May 20, 2016	May NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A207021	001	May 11, 2016	Apr NEWA
AB		5MG	A207021	002	May 11, 2016	Apr NEWA

ZOLPIDEM TARTRATETABLET; ORAL
ZOLPIDEM TARTRATE

AB	SANDOZ INC	5MG	A077322	001	Apr 23, 2007	Aug CAHN
AB		10MG	A077322	002	Apr 23, 2007	Aug CAHN
	@ SUN PHARM INDS	5MG	A077288	001	Apr 23, 2007	Mar CAHN
	@	10MG	A077288	002	Apr 23, 2007	Mar CAHN

TABLET; SUBLINGUAL
EDLUAR

AB	MEDA PHARMS	5MG	N021997	001	Mar 13, 2009	Jul CFTG
AB	+	10MG	N021997	002	Mar 13, 2009	Jul CFTG
	ZOLPIDEM TARTRATE					
AB	MYLAN PHARMS INC	5MG	A202657	001	Aug 08, 2016	Jul NEWA
AB		10MG	A202657	002	Aug 08, 2016	Jul NEWA
AB	PAR FORM	5MG	A201509	001	Aug 01, 2016	Jul NEWA
AB		10MG	A201509	002	Aug 01, 2016	Jul NEWA

ZONISAMIDECAPSULE; ORAL
ZONEGRAN

AB	SUNOVION PHARMS INC	25MG	N020789	003	Aug 22, 2003	Feb CAHN
AB		50MG	N020789	002	Aug 22, 2003	Feb CAHN
AB	+	100MG	N020789	001	Mar 27, 2000	Feb CAHN

ZONISAMIDE

AB	BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Jan CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan CAHN
	@ SUN PHARM INDS	25MG	A077635	001	Dec 22, 2005	Mar CAHN
	@	50MG	A077635	002	Dec 22, 2005	Mar CAHN
	@	100MG	A077635	003	Dec 22, 2005	Mar CAHN

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

EXCEDRIN (MIGRAINE)

+	GLAXOSMITHKLINE CONS	250MG; 250MG; 65MG	N020802	001	Jan 14, 1998	Feb CAHN
---	----------------------	--------------------	---------	-----	--------------	----------

ADAPALENE

GEL; TOPICAL

DIFFERIN

+	GALDERMA LABS LP	0.1%	N020380	002	Jul 08, 2016	Aug NEWA
---	------------------	------	---------	-----	--------------	----------

BUDESONIDE

SPRAY, METERED; NASAL

BUDESONIDE

	APOTEX INC	0.032MG/SPRAY	A078949	002	Nov 20, 2015	Apr NEWA
--	------------	---------------	---------	-----	--------------	----------

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE

	PERRIGO R AND D	800MG; 10MG; 165MG	A077355	001	Feb 06, 2008	Aug CTNA
		800MG; 10MG; 165MG	A204782	001	Aug 29, 2016	Aug NEWA

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	APOTEX INC	10MG	A207235	001	Aug 12, 2016	Aug NEWA
--	------------	------	---------	-----	--------------	----------

	BIONPHARMA INC	5MG	N022429	001	Jul 23, 2009	Jan CAHN
--	----------------	-----	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	BIONPHARMA INC	5MG	N022429	003	Jul 23, 2009	Jan CAHN
--	----------------	-----	---------	-----	--------------	----------

+		10MG	N022429	002	Jul 23, 2009	Jan CAHN
---	--	------	---------	-----	--------------	----------

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@	CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008	Apr DISC
---	---------------	---------	---------	-----	--------------	----------

	NOSTRUM LABS INC	5MG/5ML	A091327	001	Oct 17, 2011	Mar CAHN
--	------------------	---------	---------	-----	--------------	----------

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008	Apr DISC
---	---------------	---------	---------	-----	--------------	----------

	NOSTRUM LABS INC	5MG/5ML	A091327	002	Oct 17, 2011	Mar CAHN
--	------------------	---------	---------	-----	--------------	----------

TABLET, CHEWABLE; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	NOVEL LABS INC	5MG	A206793	001	Mar 08, 2016	Feb NEWA
--	----------------	-----	---------	-----	--------------	----------

		10MG	A206793	002	Mar 08, 2016	Feb NEWA
--	--	------	---------	-----	--------------	----------

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL

CHLORHEXIDINE GLUCONATE

+	BECTON DICKINSON	4%	A072525	001	Oct 24, 1989	Jun CRLD
---	------------------	----	---------	-----	--------------	----------

PHARMASEAL SCRUB CARE

@	CAREFUSION	4%	N019793	001	Dec 02, 1988	Jun DISC
---	------------	----	---------	-----	--------------	----------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP ONE-STEP

+	BECTON DICKINSON CO	2%; 70% (3ML)	N020832	001	Jul 14, 2000	May CAHN
---	---------------------	---------------	---------	-----	--------------	----------

+		2%; 70% (10.5ML)	N020832	004	Aug 20, 2003	May CAHN
---	--	------------------	---------	-----	--------------	----------

+		2%; 70% (26ML)	N020832	006	Nov 21, 2006	May CAHN
---	--	----------------	---------	-----	--------------	----------

CHLORAPREP ONE-STEP FREPP

+	BECTON DICKINSON CO	2%; 70% (1.5ML)	N020832	003	Apr 26, 2002	May CAHN
---	---------------------	-----------------	---------	-----	--------------	----------

CHLORAPREP WITH TINT

+	BECTON DICKINSON CO	2%; 70% (26ML)	N020832	002	May 03, 2005	May CAHN
---	---------------------	----------------	---------	-----	--------------	----------

+		2%; 70% (10.5ML)	N020832	005	Apr 03, 2006	May CAHN
---	--	------------------	---------	-----	--------------	----------

+		2%; 70% (3ML)	N020832	007	Oct 10, 2006	May CAHN
---	--	---------------	---------	-----	--------------	----------

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+	BECTON DICKINSON CO	2%; 70% (0.67ML)	N021555	001	Oct 07, 2002	May CAHN
---	---------------------	------------------	---------	-----	--------------	----------

CHLORAPREP SINGLE SWABSTICK

+	BECTON DICKINSON CO	2%; 70% (1.75ML)	N021555	002	May 10, 2005	May CAHN
---	---------------------	------------------	---------	-----	--------------	----------

CHLORAPREP TRIPLE SWABSTICK

+	BECTON DICKINSON CO	2%; 70% (5.25ML)	N021555	003	Jun 10, 2009	May CAHN
---	---------------------	------------------	---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL
 CHLORPHENIRAMINE MALEATE
 @ AUROLIFE PHARMA LLC 12MG

A070797 001 Aug 12, 1988 Feb CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE
 BIONPHARMA INC 25MG;EQ 200MG FREE ACID AND
 POTASSIUM SALT

A090397 001 Nov 22, 2010 Jan CAHN

FAMOTIDINE

TABLET;ORAL
 FAMOTIDINE
 AUROBINDO PHARMA LTD 10MG
 20MG

A206531 001 Apr 26, 2016 Apr NEWA
 A206531 002 Apr 26, 2016 Apr NEWA

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY
 HETERO LABS LTD V 30MG
 FEXOFENADINE HYDROCHLORIDE ALLERGY
 HETERO LABS LTD V 60MG
 180MG

A204097 001 Aug 19, 2016 Aug NEWA
 A204097 002 Aug 19, 2016 Aug NEWA
 A204097 003 Aug 19, 2016 Aug NEWA

FLUTICASONE FUROATE

SPRAY, METERED;NASAL
 FLONASE SENSIMIST ALLERGY RELIEF
 + GLAXOSMITHKLINE 0.0275MG/SPRAY

N022051 002 Aug 02, 2016 Aug NEWA

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL
 FLUTICASONE PROPIONATE
 APOTEX INC 0.05MG/SPRAY
 APOTEX TECHNOLOGIES 0.05MG/SPRAY
 ROXANE 0.05MG/SPRAY

A208150 001 Feb 29, 2016 Jul CAHN
 A208150 001 Feb 29, 2016 Feb NEWA
 A207957 001 May 26, 2016 May NEWA

IBUPROFEN

CAPSULE;ORAL
 IBUPROFEN
 BIONPHARMA INC EQ 200MG FREE ACID AND POTASSIUM
 SALT
 >A> HUMANWELL PURACAP EQ 200MG FREE ACID AND POTASSIUM
 SALT
 >D> PURACAP PHARM LLC EQ 200MG FREE ACID AND POTASSIUM
 SALT
 EQ 200MG FREE ACID AND POTASSIUM
 SALT
 SOFGEN PHARMS EQ 200MG FREE ACID AND POTASSIUM
 SALT
 MIDOL LIQUID GELS
 + BIONPHARMA INC 200MG
 TABLET;ORAL
 IBUPROFEN
 >A> GRANULES INDIA LTD 200MG
 STRIDES PHARMA 200MG
 200MG
 @ SUN PHARM INDS 200MG
 @ 200MG
 @ 200MG

A078682 001 Mar 24, 2009 Jan CAHN
 A206568 001 Jun 21, 2016 Sep CAHN
 A206568 001 Jun 21, 2016 Sep CAHN
 A206568 001 Jun 21, 2016 Jun NEWA
 A203599 001 Sep 07, 2016 Aug NEWA
 N021472 001 Oct 18, 2002 Jan CAHN
 A202312 001 Oct 07, 2016 Sep NEWA
 A079129 001 Mar 28, 2011 May CAHN
 A091355 001 Apr 04, 2011 May CAHN
 A070493 001 Dec 24, 1985 Mar CAHN
 A070908 001 Sep 26, 1986 Mar CAHN
 A071462 001 Oct 02, 1986 Mar CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC
 KETOTIFEN FUMARATE
 + ALCON PHARMS LTD EQ 0.025% BASE
 ZADITOR
 @ ALCON PHARMA EQ 0.025% BASE

A077200 001 Sep 02, 2008 Aug CRLD
 N021066 002 Oct 19, 2006 Aug DISC

LANSOPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLEMYLAN PHARMS INC 15MG A203187 001 Jun 01, 2016 May NEWA
PREVACID 24 HR

+ GLAXOSMITHKLINE CONS 15MG N022327 001 May 18, 2009 Aug CAHN

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

DEXCEL PHARMA 15MG N208025 001 Jun 07, 2016 Jun NEWA

LEVONORGESTREL

TABLET;ORAL

HER STYLE

NOVAST LABS LTD 1.5MG A207976 001 Mar 11, 2016 Feb NEWA

LEVONORGESTREL

GLENMARK PHARMS LTD 1.5MG A207044 001 Mar 25, 2016 Mar NEWA

JAI PHARMA LTD 0.75MG A202740 001 Sep 02, 2016 Aug NEWA

LOTUS PHARM CO LTD 0.75MG A202684 001 Sep 02, 2016 Aug NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

BIONPHARMA INC 1MG N021855 001 Aug 04, 2005 Jan CAHN

+ 2MG N021855 002 Aug 04, 2005 Jan CAHN

LORATADINE

CAPSULE;ORAL

LORATADINE

MARKSANS PHARMA 10MG A206214 001 Sep 23, 2016 Sep NEWA

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MONISTAT 3 COMBINATION PACK

+ MEDTECH PRODUCTS 2%,200MG N020670 002 Apr 16, 1996 Mar CMS1

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+ BIONPHARMA INC EQ 200MG BASE N021920 001 Feb 17, 2006 Mar CAHN

TABLET;ORAL

NAPROXEN SODIUM

AUROBINDO PHARMA LTD EQ 200MG BASE A205497 001 Mar 18, 2016 Mar NEWA

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

HABITROL

DR REDDYS LABS INC 7MG/24HR N020076 004 Nov 12, 1999 Aug CRLD

14MG/24HR N020076 005 Nov 12, 1999 Aug CRLD

NICODERM CQ

SANOFI AVENTIS US 7MG/24HR N020165 006 Aug 02, 1996 Aug CRLD

14MG/24HR N020165 005 Aug 02, 1996 Aug CRLD

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

ACTAVIS LABS NY INC EQ 2MG BASE A204794 001 May 10, 2016 Apr NEWA

EQ 4MG BASE A204833 001 Feb 26, 2016 Feb NEWA

OMEPRazole; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRazole AND SODIUM BICARBONATE

ACTAVIS ELIZABETH 20MG;1.1GM A204137 001 Jul 15, 2016 Jul NEWA

PAR PHARM 20MG;1.1GM A201946 001 Jul 15, 2016 Jul NEWA

PERRIGO R AND D 20MG;1.1GM A201361 001 Jul 15, 2016 Jul NEWA

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL FOR WOMEN

+	ALLERGAN SALES LLC	3.9MG/24HR	N202211	001	Jan 25, 2013	Jan CAHN
---	--------------------	------------	---------	-----	--------------	----------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL
POLYETHYLENE GLYCOL 3350

STRIDES PHARMA	17GM/SCOOPFUL	A203928	001	Aug 24, 2016	Aug NEWA
	17GM/PACKET	A203928	002	Aug 24, 2016	Aug NEWA

POTASSIUM IODIDE

SOLUTION;ORAL
POTASSIUM IODIDE

MISSION PHARMACAL CO	65MG/ML	A206211	001	Mar 24, 2016	Mar NEWA
----------------------	---------	---------	-----	--------------	----------

TABLET;ORAL

THYRO-BLOCK					
@ MEDA PHARMS	130MG	N018307	001		May CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL
RANITIDINE HYDROCHLORIDE

STRIDES PHARMA	EQ 75MG BASE	A201745	001	Feb 29, 2012	May CAHN
----------------	--------------	---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 09 SEPTEMBER 2016

NO SEPTEMBER 2016 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO SEPTEMBER 2016 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	9242986	Dec 08, 2029	DS DP			
<u>ABACAVIR SULFATE; LAMIVUDINE - ABACAVIR SULFATE AND LAMIVUDINE</u>						
A 079246 001					>A> PC	Mar 29, 2017
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	6028222	Aug 05, 2017	DP		PED	Jan 11, 2017
	6028222*PED	Feb 05, 2018				
	6992218	Jun 06, 2021	DP			
	6992218*PED	Dec 06, 2021				
	9399012	Sep 11, 2031	U-1882			
	9399012*PED	Mar 11, 2032				
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	9327028	Jul 21, 2031	U-1839			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	8747894	May 08, 2032	DP U-1373			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	8747894	May 08, 2032	DP U-1373			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	9333195	Jul 07, 2020	DP U-1263			
<u>ADAPALENE - DIFFERIN</u>						
N 020380 002					>A> RTO	Jul 08, 2019
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8809305	Dec 23, 2022	U-1078			
	9381179	Mar 12, 2023	U-1078			
	9387187	Mar 12, 2023	U-1078			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	8426586	Oct 10, 2029	DS		I-730	Apr 15, 2019
	RE43431	Jan 22, 2022	DS		ODE	Apr 15, 2023
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	8978966	Jan 13, 2032	DP		NPP	Apr 28, 2019
	9216260	Jun 28, 2031	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001	9365514	Mar 04, 2032	DP		ODE	Dec 11, 2022
	>A> 9440922	Jun 09, 2030	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001					M-177	Apr 05, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006					M-177	Apr 05, 2019
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001					NP	May 10, 2019
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	8709491	Jun 28, 2032	DP			
	>A> 8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	8709491	Jun 28, 2032	DP			
	>A> 8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	8709491	Jun 28, 2032	DP			
	>A> 8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	8709491	Jun 28, 2032	DP			
	>A> 8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	8709491	Jun 28, 2032	DP			
	>A> 8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	8709491	Jun 28, 2032	DP			
	>A> 8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	8709491	Jun 28, 2032	DP			
	>A> 8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	9326945	Feb 24, 2031	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	9326945	Feb 24, 2031	DP			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021713 001	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 002	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 003	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 004	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001 >A>	9452131	Mar 19, 2035		U-543		
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002 >A>	9452131	Mar 19, 2035		U-543		
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003 >A>	9452131	Mar 19, 2035		U-543		
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 001					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 002					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 003					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200156 004					PC	Nov 28, 2016
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 003	5763476	Jun 09, 2020	DP	U-1893		
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP	U-1893		
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	9216150	Sep 29, 2032	DP			
	9226892	Sep 29, 2032		U-1731		
	9226892	Sep 29, 2032		U-1732		
	9226892	Sep 29, 2032		U-1733		
	9351984	Dec 19, 2021	DP			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001					>A> NC	Sep 14, 2019
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002					>A> NC	Sep 14, 2019
<u>AVANAFIL - STENDRA</u>						
N 202276 001	6656935	Apr 27, 2025	DS DP	U-155		
<u>AVANAFIL - STENDRA</u>						
N 202276 002	6656935	Apr 27, 2025	DS DP	U-155		
<u>AVANAFIL - STENDRA</u>						
N 202276 003	6656935	Apr 27, 2025	DS DP	U-155		
<u>AXITINIB - INLYTA</u>						
N 202324 001	6534524	Apr 29, 2025	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AXITINIB - INLYTA</u>						
N 202324 002	6534524	Apr 29, 2025	DS DP			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	9265725	Dec 08, 2027	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	9259428	Jun 13, 2023	U-644			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9169238	Feb 04, 2030	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9169238	Feb 04, 2030	DP			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	9192616	Aug 02, 2026	U-1229			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9265831	Jan 28, 2031	DP			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9364485	Aug 31, 2030	DP U-1858		NDF	Feb 05, 2019
	9433630	Aug 31, 2030	DP U-1858			
	>A> 9439911	Aug 31, 2030	DP U-1858			
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	9241918	Mar 16, 2025	DP U-1814			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9216183	Jan 15, 2023	U-1487			
	9226931	Jan 15, 2023	U-1799			
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258 001	RE43298	Dec 22, 2024	DS DP U-1128			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001					>A> M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002					>A> M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003					>A> M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004					>A> M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005					>A> M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006					>A> M-186	Sep 23, 2019
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BROMFENAC SODIUM - BROMSITE</u>						
N 206911 001	8778999	Sep 03, 2029	DP U-1834		NP	Apr 08, 2019
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9192576	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - ENTOCORT EC</u>						
N 021324 001					M-178 NPP	Apr 29, 2019 Apr 29, 2019
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9320716	Jun 09, 2020	DP U-1325			
<u>BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE</u>						
N 204442 001	7736665	Apr 25, 2024	U-1878		NP	May 26, 2019
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	8603514	Apr 03, 2024	DP U-1464			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	9259421	Sep 18, 2032	DP			
	>A> 9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	9259421	Sep 18, 2032	DP			
	>A> 9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	9259421	Sep 18, 2032	DP			
	>A> 9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	9259421	Sep 18, 2032	DP			
	>A> 9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	9259421	Sep 18, 2032	DP			
	>A> 9439900	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	9248123	Jan 13, 2032	U-1808			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	6582727	Aug 22, 2020	DP		NP	Jun 17, 2019
	8207149	Apr 25, 2028	U-1871			
	8361488	Jul 19, 2028	DP			
	8426391	Aug 27, 2028	DP U-1872			
	8778373	Apr 25, 2028	U-1873			
	8906410	Feb 02, 2027	DP			
	9408858	Apr 25, 2028	U-1888			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					I-733	May 20, 2019
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					I-733	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					I-735	May 20, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	002				I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	003				I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	004				I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	001				>A> I-735 >A> NC >A> NCE	May 20, 2019 Aug 08, 2017 Mar 29, 2018
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	002				>A> I-735 >A> NC >A> NCE	May 20, 2019 Aug 08, 2017 Mar 29, 2018
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	003				>A> I-735 >A> NC >A> NCE	May 20, 2019 Aug 08, 2017 Mar 29, 2018
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	004				>A> I-735 >A> NC >A> NCE	May 20, 2019 Aug 08, 2017 Mar 29, 2018
<u>CANGRELOR - KENGREAL</u>						
N 204958	001	9295687	Jul 10, 2035	DP		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	001	>A> 9463246	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	002	>A> 9463246	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	003	>A> 9463246	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	004	>A> 9463246	Dec 26, 2028	DP U-219		
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	001	7417042 8129346	Jul 20, 2026 Apr 14, 2025	DS DP U-1260	I-722 I-723	Jan 21, 2019 Jan 21, 2019
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	002	7232818 7417042 7491704 7737112 8129346 8207125 8207126 8207127 8207297	Apr 14, 2025 Jul 20, 2026 Apr 14, 2025 Dec 07, 2027 Apr 14, 2025 Apr 14, 2025 Apr 14, 2025 Apr 14, 2025 Apr 14, 2025	DS DP DS DP U-1260 DP U-1260 DS DP DP U-1260 DS DP		
<u>CEFIXIME - SUPRAX</u>						
N 202091	001	9233112	Dec 14, 2028	DP U-1676		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001					NPP	May 27, 2019
					NPP	May 27, 2019
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002					NPP	May 27, 2019
					NPP	May 27, 2019
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	9320740	Mar 14, 2034	DP			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	9309229	Jan 18, 2032	DS DP			
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 001					NCE	Mar 17, 2020
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 002					NCE	Mar 17, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001	9375405	Sep 22, 2026	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002	9375405	Sep 22, 2026	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003	9375405	Sep 22, 2026	DP			
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	9233068	Dec 11, 2029	DP		NP	Dec 10, 2018
<u>CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL</u>						
N 208251 001	8932610	Mar 24, 2030	DP U-1578		NC	Apr 29, 2019
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	9345714	Sep 13, 2022	DP U-1578			
	9402805	Sep 13, 2022	DP U-1578			
	9402805	Sep 13, 2022	DP U-1679			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7803788	Feb 02, 2022	U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001					ODE	Nov 10, 2022
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	9399036	Aug 22, 2033	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					ODE	Mar 11, 2023
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					ODE	Mar 11, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001 >A>	9415007	Jul 28, 2024	U-1896			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 001	9375410	Nov 14, 2023	U-1088			
	9399025	Nov 14, 2023	DP U-979			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 002	9375410	Nov 14, 2023	U-1088			
	9399025	Nov 14, 2023	DP U-979			
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	9248191	Aug 27, 2024	U-1479			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9233077	Jun 17, 2034	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9233077	Jun 17, 2034	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001 >A>	9421192	Aug 08, 2027	DS U-1724		D-161	Feb 05, 2019
	>A> 9421192	Aug 08, 2027	DS U-1725		D-162	Feb 05, 2019
					I-726	Feb 05, 2019
					I-727	Feb 05, 2019
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002 >A>	9421192	Aug 08, 2027	DS U-1724		D-161	Feb 05, 2019
	>A> 9421192	Aug 08, 2027	DS U-1725		D-162	Feb 05, 2019
					I-726	Feb 05, 2019
					I-727	Feb 05, 2019
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 003 >A>	9421192	Aug 08, 2027	DS U-1724			
	>A> 9421192	Aug 08, 2027	DS U-1725			
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001					D-154	Jan 20, 2019
<u>DAPSONE - ACZONE</u>						
N 207154 001	5863560	Sep 11, 2016	DP		NS	Feb 24, 2019
	6060085	Sep 11, 2016	U-124			
	6620435	Sep 11, 2016	DP			
	9161926	Nov 18, 2033	DP			
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	8492386	Sep 04, 2032	U-1840		D-163	Apr 22, 2019
	8685984	Sep 04, 2032	U-1840			
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	7148359	Jul 19, 2019	DP		NCE	Dec 19, 2019
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1840			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1840			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
	9333204	Jan 02, 2035	DP U-1889			
<u>DEFERASIROX - JADENU</u>						
N 206910 001	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 002	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 003	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001					NCE ODE	Mar 30, 2021 Mar 30, 2023
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001 >A>	9415085	Apr 27, 2032	U-1895			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002 >A>	9415085	Apr 27, 2032	U-1895			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	9283178	Oct 20, 2020	U-1205			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818 001	8450287	Dec 19, 2027	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9233103	Mar 05, 2032	U-1805		NPP	Jul 08, 2019
	9238029	Jan 17, 2026	DP		NPP	Jul 08, 2019
					NPP	Jul 08, 2019
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	9233103	Mar 05, 2032	U-1805		NPP	Jul 08, 2019
	9238029	Jan 17, 2026	DP		NPP	Jul 08, 2019
					NPP	Jul 08, 2019
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	6328994	May 17, 2019	DP			
	6328994*PED	Nov 17, 2019				
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6462058*PED	Dec 15, 2020				
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	7399485	May 26, 2018	DP			
	7399485*PED	Nov 26, 2018				
	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				
	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023	DP			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9238029	Jan 17, 2026	DP			
	9241910	Mar 10, 2029	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002 >A>	9320712	Jan 04, 2032	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003 >A>	9320712	Jan 04, 2032	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004 >A>	9320712	Jan 04, 2032	DP			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9220784	Oct 17, 2027	U-1488			
	9339551	Oct 17, 2027	U-1488			
	9339552	Oct 17, 2027	DP U-1488			
	9370501	Jul 10, 2029	U-1614			
	9375412	Jul 10, 2029	U-1614			
	9415029	Jul 10, 2029	U-1614			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	9308195	Sep 30, 2033	DP			
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 001					PC	Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 002					PC	Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 003					PC	Dec 04, 2016
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 002	8129385	Oct 05, 2027	DS DP		>A> NCE	Aug 12, 2018
	9242986	Dec 08, 2029	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 003	8129385	Oct 05, 2027	DS DP		>A> NCE	Aug 12, 2018
	9242986	Dec 08, 2029	DS DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	8039009	Mar 24, 2029		U-1641		
	8039009*PED	Sep 24, 2029				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025		U-1641		
	8362085	Nov 22, 2025		U-1641		
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025		U-1641		
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 003	8039009	Mar 24, 2029		U-1641		
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029		U-1641		
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025		U-1641		
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025		U-1641		
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025		U-1641		
	8362085	Nov 22, 2025		U-1641		
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025		U-1641		
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
	<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>					
N 206439 004	8039009	Mar 24, 2029		U-1641		
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029		U-1641		
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025		U-1641		
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025		U-1641		
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025		U-1641		
	8362085	Nov 22, 2025		U-1641		
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025		U-1641		
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
	<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>					
N 022036 001	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	9241946	Apr 05, 2022	U-1063			
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431 003					PC	Nov 19, 2016
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431 005					PC	Nov 15, 2016
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795 007	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
	9295652	Oct 23, 2034	DP U-918			
>A>	9446057	Dec 23, 2034	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795 008	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
	9295652	Oct 23, 2034	DP U-918			
>A>	9446057	Dec 23, 2034	DP U-918			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9302009	Oct 24, 2030	DP			
<u>ELBASVIR; GRAZOPREVR - ZEPATIER</u>						
N 208261 001	7973040	Jul 24, 2029	DS DP U-1813		NCE	Jan 28, 2021
	8871759	May 04, 2031	DS DP U-1813			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	9364489	Jul 07, 2028	U-1709			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	9364489	Jul 07, 2028	U-1709			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	8551957	Oct 14, 2029	DP U-1651		M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	8551957	Oct 14, 2029	DP U-1651		M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	7407955	May 02, 2025	DS DP			
	8551957	Oct 14, 2029	DP U-1651			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	7407955	May 02, 2025	DS DP			
	8551957	Oct 14, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001					M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002					M-174	Mar 18, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003					M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004					M-174	Mar 18, 2019
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	5814639	Sep 29, 2015	DS DP		NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020		U-257		
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 21, 2025	DS DP U-257			
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022		U-257		
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	7125879	Apr 21, 2025	DS DP U-257			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	5814639	Sep 29, 2015	DS DP	Y	NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020		U-257		
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022		U-257		
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6043230	Jul 25, 2017		U-248		
	6043230	Jul 25, 2017		U-541		
	6043230	Jul 25, 2017		U-1170		
	6043230	Jul 25, 2017		U-1259		
	6043230*PED	Jan 25, 2018				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS	U-248		
	5922695	Jul 25, 2017	DS	U-541		
	5922695	Jul 25, 2017	DS	U-1170		
	5922695	Jul 25, 2017	DS	U-1259		
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	8778366	Nov 06, 2032	U-3			
	8778366	Nov 06, 2032	U-71			
	8778366	Nov 06, 2032	U-185			
	8778366	Nov 06, 2032	U-1723			
	8778366	Nov 06, 2032	U-1892			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035	U-1829			
	9295657	Mar 13, 2035	U-1830			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	9295657	Mar 13, 2035	U-1829			
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 205029 001	9283197	Aug 15, 2034	DP U-1828			
	9283197	Aug 15, 2034	DP U-1829			
	9283197	Aug 15, 2034	DP U-1830			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6469182	Jun 16, 2019	U-1096		I-721	Jan 28, 2019
	6469182	Jun 16, 2019	U-1812		ODE	Jan 28, 2023
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001					D-164	May 20, 2019
					M-181	Jun 01, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002					D-164	May 20, 2019
					M-181	Jun 01, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003					D-164	May 20, 2019
					M-181	Jun 01, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER</u>						
N 205703 001	6310094	Jan 12, 2021	DP			
	6528540	Jan 12, 2021	DP			
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 205703 002	6310094	Jan 12, 2021	DP			
	6528540	Jan 12, 2021	DP			
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	6369085	May 25, 2018	DS DP U-1509			
	6369085	May 25, 2018	DS DP U-1875			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810	Nov 03, 2019	DP U-1874			
	6428810*PED	May 03, 2020				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	9220698	Mar 10, 2031			U-1781	
	9345695	May 31, 2022	DP			
	9393208	Sep 03, 2029			U-1781	
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	9345695	May 31, 2022	DP			
	9393208	Sep 03, 2029			U-1781	
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001					>A> NCE	Sep 19, 2021
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002					>A> NCE	Sep 19, 2021
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	9238076	Apr 15, 2024	DP U-412			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	5424286	Dec 01, 2016	U-1108			
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	8216180	Jan 12, 2028	DP			
	8329648	Aug 18, 2026	U-1313			
	8431685	Apr 13, 2025	DP U-412			
	8439864	Mar 25, 2028	DP			
	8461105	Apr 13, 2025	DP U-412			
	8906851	Aug 18, 2026	U-1313			
	9238076	Apr 15, 2024	DP U-412			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005	9314447	May 31, 2033	DP U-1447			
	9314447	May 31, 2033	DP U-1448			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	9241935	Jan 25, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788 005	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	9241935	Jan 25, 2027	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	9364656	Sep 30, 2031	U-736			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	9387191	Jul 21, 2030	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	8586551	Jul 15, 2023	DS DP			
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	5808146	Nov 09, 2016	DS		NCE	May 27, 2021
	9387266	Nov 28, 2026	U-1879			
<u>FLUTICASONE FUROATE - FLONASE SENSIMIST ALLERGY RELIEF</u>						
N 022051 002	6858596	Aug 03, 2021	DP U-1890			
	7101866	Aug 03, 2021	DS DP U-1890			
	7541350	Aug 03, 2021	DP U-1890			
	8062264	Apr 05, 2026	DP			
	8147461	Oct 15, 2028	DP			
	8347879	Jul 15, 2028	DP			
	8752543	Apr 05, 2026	DP			
	9320862	Nov 06, 2024	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	9333310	Oct 02, 2027	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	8324266	May 28, 2030	U-1841		NP	Apr 25, 2019
	8703806	May 28, 2030	U-1841			
	8808713	May 28, 2030	DP U-1841			
	8815258	Mar 17, 2031	U-1841			
	9415009	May 28, 2030	U-1841			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002					D-155	Feb 01, 2019
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-596		I-725	Feb 19, 2019
	6774122	Jan 09, 2021	U-1826			
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-596			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	7456160	Jan 09, 2021	U-1826			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-596			
	8329680	Jan 09, 2021	U-1826			
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021	U-596			
	8466139	Jan 09, 2021	U-1826			
	8466139*PED	Jul 09, 2021				
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-731	Apr 27, 2019
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006	5980864	Nov 09, 2021	DS DP U-1119			
<u>GALLIUM DOTATATE GA-68 - NETSPOT</u>						
N 208547 001					NCE ODE	Jun 01, 2021 Jun 01, 2023
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	9402874	Aug 19, 2030	U-441			
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 001					PC	Jul 27, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 002					PC	Apr 25, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 003					PC	Apr 25, 2016
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Jul 28, 2018	DS DP U-1378			
	9254278	Mar 09, 2032	U-1816			
	9326966	Mar 09, 2032	U-1816			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	6582678	Apr 24, 2018	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	6582678	Apr 24, 2018	DP		>A> NCE	Jul 01, 2016
	6878721	Feb 25, 2025	DS DP U-1773			
<u>GRANISETRON - SANCUSO</u>						
N 022198 001	7608282	Jan 22, 2025	DP U-1011			
<u>GRANISETRON - SUSTOL</u>						
N 022445 001	6613355	Jun 28, 2021	DP		NDF	Aug 09, 2019
	6790458	May 11, 2021	DP			
	8252304	Sep 28, 2024	DP			
	8252305	Sep 28, 2024	U-1891			
	8715710	Sep 28, 2024	DP			
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183 001					NP	Nov 06, 2018
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	>A> 9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	>A> 9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	>A> 9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	>A> 9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	>A> 9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	>A> 9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9289391	Oct 30, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9289391	Oct 30, 2021	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	9296753	Oct 30, 2033	DS DP		D-165 I-729 I-736 I-737 ODE ODE	May 06, 2019 Mar 04, 2019 May 06, 2019 May 06, 2019 Mar 04, 2023 May 06, 2023
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9295639	Sep 30, 2029	U-1756			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001					NCE	Jul 26, 2017
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007					M-180	May 26, 2019
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 001					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 002					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	RE43932 RE43932*PED	Jul 16, 2018 Jan 16, 2019	DS DP			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	RE43932 RE43932*PED	Jul 16, 2018 Jan 16, 2019	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	6958335	Dec 19, 2021	U-791			
	6958335	Dec 19, 2021	U-1883			
	6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP		Y	
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	6958335	Dec 19, 2021	U-791			
	6958335	Dec 19, 2021	U-1883			
	6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP		Y	
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	6878721	Feb 25, 2025	DS DP U-1168			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	7410656	Oct 10, 2020	U-1222			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	7410656	Oct 10, 2020	U-1222			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	9265893	Sep 23, 2032	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	9265893	Sep 23, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536 002	9265893	Sep 23, 2032	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	>A> 9408979	Mar 02, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	9345750	May 18, 2031	DP U-1855			
	>A> 9408979	Mar 02, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	>A> 9408979	Mar 02, 2024	DP			
<u>INSULIN HUMAN - HUMULIN R</u>						
N 018780 004	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	9339497	Jun 12, 2033	U-1848		ODE	Oct 22, 2022
	9364473	Jun 12, 2033	U-1856			
>A>	9452162	Jun 12, 2033	U-1899			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001				>A>	NCE	Jan 31, 2017
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002				>A>	NCE	Jan 31, 2017
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	9216969	Nov 08, 2026	DS DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002				>A>	NPP	Sep 28, 2019
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	9233117	Mar 13, 2034	U-1631			
	9233118	Mar 13, 2034	U-1631			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	9216167	May 28, 2024	U-1800			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA</u>						
N 205388 001	9278101	Jul 30, 2023	U-1518			
	9399040	Jul 30, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003	9339504	Jul 02, 2028	DP U-1596			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004	9339504	Jul 02, 2028	DP U-1596			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	9284342	Sep 13, 2030	DS DP U-1470		D-158	Feb 12, 2019
	9393256	Sep 14, 2032	U-1470		D-159	Feb 12, 2019
					D-160	Feb 12, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001					I-734	May 13, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002					I-734	May 13, 2019
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029		U-1801		
	8283369	Nov 26, 2028		U-1802		
	8283369	Nov 26, 2028		U-1804		
	8357713	Nov 26, 2028	DP	U-1801		
	8357713	Nov 26, 2028	DP	U-1802		
	8357713	Nov 26, 2028	DP	U-1803		
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029		U-1803		
	9216179	Aug 02, 2030		U-1806		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	9283282	Oct 28, 2018	DS DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	9339489	Mar 14, 2034	DP	U-1850		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	9339489	Mar 14, 2034	DP	U-1850		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	9339489	Mar 14, 2034	DP	U-1850		
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 206263 001					PC	Feb 11, 2017
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	>A> 7252839	Nov 13, 2023	DP		>A> NP	Sep 16, 2019
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	>A> 7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	>A> 7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	>A> 7691411	Mar 14, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	>A> 7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	>A> 7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	>A> 7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	>A> 7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	>A> 7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	>A> 7691411	Mar 14, 2024	DP			
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114 001	9358338	Apr 27, 2035	U-1870			
	9370622	Sep 28, 2035	U-1870			
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	7314938	Mar 10, 2025	DS DP		NCE	Jul 11, 2021
	7745460	Nov 05, 2024	DS DP	U-1880		
	7790743	Nov 05, 2024		U-1880		
	7928122	Nov 05, 2024	DS DP			
	8084047	May 17, 2026	DS DP			
	8168655	May 09, 2029		U-1880		
	8367701	Apr 15, 2029	DP	U-1880		
	8592450	May 17, 2026		U-1880		
	8927574	Nov 12, 2030	DP			
	9085553	Jul 25, 2033	DP			
	9216174	Nov 05, 2024	DP			
	9353088	Oct 21, 2030	DP			
	>A> 9447077	Apr 15, 2029		U-1900		
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8748573	Oct 30, 2031		U-1515		
	8748573	Oct 30, 2031		U-1516		
	8802628	Dec 08, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8748573	Oct 30, 2031		U-1515		
	8748573	Oct 30, 2031		U-1516		
	8802628	Dec 08, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	7407955	May 02, 2025	DS DP			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	7407955	May 02, 2025	DS DP			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	7407955	May 02, 2025	DS DP			
	9415016	Apr 02, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	6303661	Apr 24, 2017	U-802			
	6340475	Sep 19, 2016	DP U-1852			
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019	U-803			
	7078381	Feb 02, 2019	U-803			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-803			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	6303661	Apr 24, 2017	U-802			
	6340475	Sep 19, 2016	DP U-1852			
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019	U-803			
	7078381	Feb 02, 2019	U-803			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-803			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	9265893	Sep 23, 2032	DP		M-176	Apr 22, 2019
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	8475414	Dec 28, 2030	DP U-1881		NCE	Jul 27, 2021
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
	RE45313	Jul 12, 2020	DS DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	8475414	Dec 28, 2030	DP U-1881		NCE	Jul 27, 2021
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
	RE45313	Jul 12, 2020	DS DP			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	6953787	Apr 10, 2023	DS DP U-1252		NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP U-1253			
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7514422	Apr 10, 2023	U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1255			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
	8207158	Apr 10, 2023	U-1255			
	8273734	Apr 10, 2023	U-1254			
	8273734	Apr 10, 2023	U-1255			
	8367657	Apr 10, 2023	DS DP U-1252			
	8367657	Apr 10, 2023	DS DP U-1253			
	8367657	Apr 10, 2023	DS DP U-1254			
	8367657	Apr 10, 2023	DS DP U-1255			
	8546379	Apr 10, 2023	DS DP U-1252			
	8546379	Apr 10, 2023	DS DP U-1253			
	8546379	Apr 10, 2023	DS DP U-1254			
	8546379	Apr 10, 2023	DS DP U-1255			
	8575149	Apr 10, 2023	U-1452			
	8697686	Dec 20, 2025	DS DP			
	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			
	8980881	Dec 20, 2025	U-1255			
	8999970	Feb 07, 2033	U-1688			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	8999970	Feb 07, 2033	U-1689			
	8999970	Feb 07, 2033	U-1692			
	9169213	Dec 06, 2032	U-1884			
	9169213	Dec 06, 2032	U-1885			
	9169213	Dec 06, 2032	U-1886			
	9169213	Dec 06, 2032	U-1887			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	9370629	May 20, 2024	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jul 05, 2017	DS DP U-540			
	9199977	Sep 06, 2033	DS DP			
	>A> 9453006	Sep 06, 2033	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9259423	May 23, 2031	U-1822			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	9265762	May 29, 2027	DP U-1820			
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317 001	9382191	Mar 07, 2026	DP			
<u>MEGESTROL ACETATE - MEGESTROL ACETATE</u>						
A 203139 001					PC	Jan 24, 2016
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	8410077	Mar 13, 2029	DP		ODE	Mar 10, 2023
	9200088	Mar 13, 2029	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 001	9233184	Aug 01, 2027	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 002	9233184	Aug 01, 2027	DP			
<u>MESALAMINE - CANASA</u>						
N 021252 001					>A> M-187	Sep 02, 2019
<u>MESALAMINE - CANASA</u>						
N 021252 002					>A> M-187	Sep 02, 2019
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 001					PC	Jul 30, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 002					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 001	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 002	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	9339472	Jul 13, 2025	DP		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1097			
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	7326708	Nov 24, 2026	DS DP U-1227			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	>A> 9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	>A> 9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	>A> 9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	>A> 9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	>A> 9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	>A> 9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
>A>	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
>A>	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					ODE	Apr 08, 2023
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	6559158	Nov 03, 2017	U-1185		NP	Jul 19, 2019
	8420663	Sep 30, 2029	U-1185			
	8524276	Mar 10, 2031	DP			
	8956651	Mar 10, 2031	DP			
	9180125	Sep 30, 2029	DP U-1185			
	9314461	Mar 10, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9278105	May 12, 2031	U-282			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	6346532	Mar 27, 2022	DS DP			
	RE44872	Nov 04, 2023	U-1527			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	6346532	Mar 27, 2022	DS DP			
	RE44872	Nov 04, 2023	U-1527			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 001	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 002	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 003	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 004	7955619	Aug 12, 2028	DP			
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX</u>						
N 021085 001					>A> M-185	Sep 27, 2019
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>						
N 021277 001					>A> M-185	Sep 27, 2019
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	>A> 7786133	Dec 19, 2027	DS DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	>A> 7786133	Dec 19, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	9238108	Jan 22, 2027	DP			
	9278182	Feb 01, 2026	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9205082	Dec 22, 2018	DP U-1556		NC	Jul 23, 2017
	9283216	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9205082	Dec 22, 2018	DP U-1556		NC	Jul 23, 2017
	9283216	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	9205082	Dec 22, 2018	DP U-1556		NC	Jul 23, 2017
	9283216	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 001	>A> 7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	>A> 8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 002	>A> 7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	>A> 8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 003	>A> 7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	>A> 8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 004	>A> 7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	>A> 8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 005	>A> 7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	>A> 8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 006	>A> 7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	>A> 8685443	Jul 03, 2025	U-1508			
<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON</u>						
N 206302 001	7803838	Aug 29, 2026	DP		NC	Jun 03, 2019
	7838552	Oct 04, 2027	U-185			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	9271975	Sep 09, 2031	U-528			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	9364564	Dec 26, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	9364564	Dec 26, 2027	DP			
<u>NITISINONE - ORFADIN</u>						
N 206356 001	9301932	Feb 28, 2033	DP U-1836			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2034	DP U-1823			
	9279794*PED	Aug 19, 2034				
	9295802	Jan 06, 2031	DP U-1226			
	9295802*PED	Jul 06, 2031				
	9408993	Jan 06, 2031	DP U-1824			
	9408993*PED	Jul 06, 2031				
<u>NITROGLYCERIN - GONITRO</u>						
N 208424 001	9101592	Mar 11, 2032	DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022	U-1854		ODE	May 27, 2023
	8377916	Feb 21, 2022	U-1854			
	9238673	Jun 17, 2033	DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022	U-1854		ODE	May 27, 2023
	8377916	Feb 21, 2022	U-1854			
	9238673	Jun 17, 2033	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001					M-173	Mar 18, 2019
<u>OMEGA-3-ACID ETHYL ESTERS TYPE A - OMTRYG</u>						
N 204977 001					NCE	Apr 23, 2019
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2017	DP		NCE	May 05, 2019
	5948818	May 13, 2017	DP			
<u>OMEPRazole MAGNESIUM - PRILOSEC</u>						
N 022056 001	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
	6428810	Nov 03, 2019	DP U-1817			
<u>OMEPRazole MAGNESIUM - PRILOSEC</u>						
N 022056 002	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	5840737	Jul 15, 2016	U-588			
	6489346	Jul 15, 2016	DP U-588		Y	
	6645988	Jul 15, 2016	DP		Y	
	6699885	Jul 15, 2016	U-588		Y	
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-588			
	RE45198	Jul 15, 2016	U-588			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	5840737	Jul 15, 2016	U-623			
	5840737	Jul 15, 2016	U-624			
	6489346	Jul 15, 2016	DP U-623	Y		
	6489346	Jul 15, 2016	DP U-624	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	U-623	Y		
	6699885	Jul 15, 2016	U-624	Y		
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
	RE45198	Jul 15, 2016	U-623			
	RE45198	Jul 15, 2016	U-624			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 001	7399772	Jul 15, 2016	U-588			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 002	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001					ODE	Nov 13, 2022
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002					ODE	Nov 13, 2022
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	9259388	Nov 06, 2029	U-1644			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE</u>						
N 208032 001	6413499	Mar 20, 2020	U-1876		NC	Jun 29, 2019
	8580282	Apr 02, 2030	DP U-1876			
	9308191	Apr 02, 2030	DP U-1876			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	9393318	Aug 03, 2032	U-1290			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001	>A> 9439906	Jan 26, 2031	U-543			
	>A> 9439906	Jan 26, 2031	U-1901			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002	>A> 9439906	Jan 26, 2031	U-543			
	>A> 9439906	Jan 26, 2031	U-1901			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003	>A> 9439906	Jan 26, 2031	U-543			
	>A> 9439906	Jan 26, 2031	U-1901			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	>A> 9439906	Jan 26, 2031	U-543			
	>A> 9439906	Jan 26, 2031	U-1901			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005	>A> 9439906	Jan 26, 2031	U-543			
	>A> 9439906	Jan 26, 2031	U-1901			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 001	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 002	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 003	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 004	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	7598271	May 04, 2025	DS			
	>A> 9393237	Aug 04, 2026	U-904			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
	8772497	May 16, 2026	DS			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	8658205	Jun 18, 2019	DP			
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001					NPP	Mar 18, 2019
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	6756393	Mar 06, 2021	DS DP		NCE	Apr 29, 2021
	6815458	Mar 06, 2021	DS DP U-1843			
	7115634	Oct 06, 2021	DS DP			
	7601740	Jun 17, 2027	DS DP			
	7659285	Aug 24, 2026	U-1844			
	7732615	Jun 03, 2028	DS DP			
	7858789	Dec 13, 2020	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8110574	Dec 13, 2020	DS DP			
	8618130	Jan 15, 2024	U-1845			
	8921393	Jan 15, 2024	U-1846			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	9296694	Mar 06, 2021	DS DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9358297	Jun 24, 2031	DP U-1454			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206 004					PC	May 18, 2016
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206 006					PC	Jan 01, 2017
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	5288726	Apr 14, 2017	DS DP U-991		M-182	Jul 12, 2019
	5288726*PED	Oct 14, 2017			PED	Jan 12, 2020
	8404703	Jan 02, 2023	U-1381			
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	5288726	Apr 14, 2017	DS DP U-991		M-182	Jul 12, 2019
	5288726*PED	Oct 14, 2017			PED	Jan 12, 2020
	8404703	Jan 02, 2023	U-1381			
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				
<u>PROPOFOL - PROPOFOL</u>						
A 205307 001					PC	Feb 24, 2016
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	9289446	Jun 22, 2019	DP U-116			
<u>RETAPAMULIN - ALTABAX</u>						
N 022055 001	>A> 8207191	Aug 30, 2024	U-805			
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA</u>						
N 203324 001					NP	Apr 15, 2019
					ODE	Apr 15, 2023
					ODE	Jul 15, 2023
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20%</u>						
N 203324 002					NP	Apr 15, 2019
					ODE	Apr 15, 2023
					ODE	Jul 15, 2023
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	9271968	Feb 27, 2026	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	9271968	Feb 27, 2026	DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	>A> 7585860	Dec 11, 2020	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
>A>	7585860	Dec 11, 2020	DS			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
>A>	7585860	Dec 11, 2020	DS			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 006	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 001					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 002					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 003					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 004					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6858618	Dec 17, 2021	U-618		I-732	May 27, 2019
	6858618	Dec 17, 2021	U-1032		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005					ODE	May 27, 2023
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001 >A>	9388134	Nov 08, 2026	U-1723			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002 >A>	9388134	Nov 08, 2026	U-1723			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003 >A>	9388134	Nov 08, 2026	U-1723			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001 >A>	9433624	Nov 17, 2024	U-1589			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	9216178	Nov 01, 2032	DP			
	>A> 9433624	Nov 17, 2024	U-1589			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 002	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	>A> 9433624	Nov 17, 2024	U-1589			
	RE43797	Nov 17, 2024	U-1590			
	RE43797*PED	May 17, 2025				
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 001	9095509	Dec 06, 2030	DP			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 002	9095509	Dec 06, 2030	DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9353103	Jul 28, 2026	U-1467		M-171 M-179	Feb 26, 2019 May 20, 2019
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	7326708	Nov 24, 2026	DS DP U-802			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9284342	Sep 13, 2030	DS DP U-1470			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	7964580	Mar 26, 2029	DS DP U-1470		NCE	Jun 28, 2021
	8334270	Mar 21, 2028	DS DP U-1470			
	8575135	Nov 16, 2032	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8735372	Mar 21, 2028	U-1470			
	8889159	Mar 26, 2029	DP U-1470			
	8921341	Nov 16, 2032	DS DP U-1470			
	8940718	Nov 16, 2032	DS DP U-1470			
	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	7964580	Mar 26, 2029	DS DP U-1470		NCE	Jun 28, 2021
	8334270	Mar 21, 2028	DS DP U-1470			
	8575135	Nov 16, 2032	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8735372	Mar 21, 2028	U-1470			
	8889159	Mar 26, 2029	DP U-1470			
	8921341	Nov 16, 2032	DS DP U-1470			
	8940718	Nov 16, 2032	DS DP U-1470			
	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001 >A>	5686060	Nov 11, 2017	DS DP		I-728	Mar 31, 2019
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	9272137	Sep 07, 2027	DP			
	9327114	Oct 08, 2032	DP U-1328			
>A>	9427578	Apr 12, 2027	DP U-1328			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	6715485	Mar 03, 2020	DP			
	7975690	Aug 18, 2025	DP U-1809			
	8047202	Jul 02, 2023	DP			
	8327844	Oct 03, 2023	U-1809			
	8550073	Oct 22, 2029	DP			
	8555877	Mar 03, 2020	DP			
	8590530	Sep 15, 2025	DP U-1809			
	8875704	Apr 07, 2028	DP U-1809			
	8899229	Aug 18, 2030	DP			
	8978647	Dec 06, 2030	DP			
	9108015	Sep 15, 2025	DP			
	9119932	Apr 23, 2024	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	5886035	Dec 18, 2022	DS DP U-778			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	9289586	Feb 26, 2027	U-1390			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	9295675	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	9295675	Feb 11, 2034	DP U-1531			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171			
	6525060	Dec 02, 2019	DS DP U-1860			
	6525060	Dec 02, 2019	DS DP U-1862			
	6525060	Dec 02, 2019	DS DP U-1863			
	7250419	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1860			
	7250419	Dec 02, 2019	DS DP U-1864			
	7250419	Dec 02, 2019	DS DP U-1865			
	7250419	Dec 02, 2019	DS DP U-1866			
	7250419	Dec 02, 2019	DS DP U-1867			
	7265124	Jul 09, 2021	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1860			
	7265124	Jul 09, 2021	DS DP U-1868			
	7265124	Jul 09, 2021	DS DP U-1869			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6525060	Dec 02, 2019	DS DP U-1171			
	6525060	Dec 02, 2019	DS DP U-1860			
	6525060	Dec 02, 2019	DS DP U-1862			
	6525060	Dec 02, 2019	DS DP U-1863			
	7250419	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1860			
	7250419	Dec 02, 2019	DS DP U-1864			
	7250419	Dec 02, 2019	DS DP U-1865			
	7250419	Dec 02, 2019	DS DP U-1866			
	7250419	Dec 02, 2019	DS DP U-1867			
	7265124	Jul 09, 2021	DS DP U-1171			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	7265124	Jul 09, 2021	DS DP U-1860			
	7265124	Jul 09, 2021	DS DP U-1868			
	7265124	Jul 09, 2021	DS DP U-1869			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	9254328	Mar 13, 2026	DP			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 002	>A> 5733919	Oct 23, 2016	DS			
	>A> 5965581	Oct 23, 2016	DP			
	>A> 5972967	Oct 23, 2016	DP			
	>A> 5978698	Oct 08, 2017	U-1897			
	>A> 6136794	Jan 29, 2019	U-1898			
	>A> 6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001	6770660	Jun 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002	6770660	Jun 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003	6770660	Jun 01, 2023	U-1444			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	6956027	Mar 25, 2023	DS		NCE	Nov 06, 2017
	6956041	Dec 08, 2020	DP			
	7091208	Dec 08, 2020	U-247			
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	RE41783	Dec 08, 2020	DS			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9339507	Mar 10, 2028	DP			
	9358240	May 05, 2028	U-1849			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
	9422223	May 24, 2024	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
	9422223	May 24, 2024	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
	9422223	May 24, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
	9422223	May 24, 2024	DP			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	9283233	Apr 13, 2030	U-1821			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	9333310	Oct 02, 2027	DP		M-172	Feb 24, 2019
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	9333310	Oct 02, 2027	DP			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001					ODE	Dec 11, 2022
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	RE42353	Jun 27, 2022	DS DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	RE42353	Jun 27, 2022	DS DP			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001					M-183	Aug 12, 2019
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002					M-183	Aug 12, 2019
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 001	9375478	Jan 30, 2035	U-1857			
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001					M-184	Aug 31, 2019
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	9278961	Dec 15, 2028	U-1825			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	9227946	Jun 15, 2027	U-1668			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	9227946	Jun 15, 2027	U-1668			
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 001					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 002					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	9265720	May 13, 2030	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	9265720	May 13, 2030	U-674			
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N 022196 001	8236285	Aug 07, 2032	DS DP U-70			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 36th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm